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(OAG) screening meets the UK National Screening
Committee criteria, to compare screening strategies
with case finding, to estimate test parameters, to
model estimates of cost and cost-effectiveness, and to
identify areas for future research.
Data sources: Major electronic databases were
searched up to December 2005.
Review methods: Screening strategies were
developed by wide consultation. Markov submodels
were developed to represent screening strategies.
Parameter estimates were determined by systematic
reviews of epidemiology, economic evaluations of
screening, and effectiveness (test accuracy, screening
and treatment). Tailored highly sensitive electronic
searches were undertaken. 
Results: Most potential screening tests reviewed had
an estimated specificity of 85% or higher. No test was
clearly most accurate, with only a few, heterogeneous
studies for each test. No randomised controlled trials
(RCTs) of screening were identified. Based on two
treatment RCTs, early treatment reduces the risk of
progression. Extrapolating from this, and assuming
accelerated progression with advancing disease
severity, without treatment the mean time to blindness
in at least one eye was approximately 23 years,
compared to 35 years with treatment. Prevalence
would have to be about 3–4% in 40 year olds with a
screening interval of 10 years to approach cost-
effectiveness. It is predicted that screening might be
cost-effective in a 50-year-old cohort at a prevalence of
4% with a 10-year screening interval. General
population screening at any age, thus, appears not to
be cost-effective. Selective screening of groups with
higher prevalence (family history, black ethnicity) might
be worthwhile, although this would only cover 6% of
the population. Extension to include other at-risk
cohorts (e.g. myopia and diabetes) would include 37%
of the general population, but the prevalence is then
too low for screening to be considered cost-effective.
Screening using a test with initial automated
classification followed by assessment by a specialised
optometrist, for test positives, was more cost-effective
than initial specialised optometric assessment. The
cost-effectiveness of the screening programme was
highly sensitive to the perspective on costs (NHS or
societal). In the base-case model, the NHS costs of
visual impairment were estimated as £669. If annual
societal costs were £8800, then screening might be
considered cost-effective for a 40-year-old cohort with
1% OAG prevalence assuming a willingness to pay of
£30,000 per quality-adjusted life-year. Of lesser
importance were changes to estimates of attendance
for sight tests, incidence of OAG, rate of progression
and utility values for each stage of OAG severity. 
Cost-effectiveness was not particularly sensitive to the
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accuracy of screening tests within the ranges observed.
However, a highly specific test is required to reduce
large numbers of false-positive referrals. The findings
that population screening is unlikely to be cost-effective
are based on an economic model whose parameter
estimates have considerable uncertainty. In particular, if
rate of progression and/or costs of visual impairment
are higher than estimated then screening could be 
cost-effective. 
Conclusions: While population screening is not cost-
effective, the targeted screening of high-risk groups
may be. Procedures for identifying those at risk, for
quality assuring the programme, as well as adequate
service provision for those screened positive would all
be needed. Glaucoma detection can be improved by
increasing attendance for eye examination, and
improving the performance of current testing by either
refining practice or adding in a technology-based first
assessment, the latter being the more cost-effective
option. This has implications for any future
organisational changes in community eye-care services.
Further research should aim to develop and provide
quality data to populate the economic model, by
conducting a feasibility study of interventions to
improve detection, by obtaining further data on costs
of blindness, risk of progression and health outcomes,
and by conducting an RCT of interventions to improve
the uptake of glaucoma testing.
AbstractHealth Technology Assessment 2007; Vol. 11: No. 41
v
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
Contents
List of abbreviations .................................. vii
Executive summary .................................... ix
1 The aim of the review ................................ 1
2 Background ................................................ 3
Introduction ............................................... 3
The condition ............................................. 4
Burden of disease in the UK ...................... 4
Current practice for glaucoma 
detection in the UK  ................................... 5
Diagnostic and treatment services  ............. 6
3 Screening tests for glaucoma .................... 7
Description of potential screening tests ..... 7
4 Overview of methods and definitions ....... 13
Developing the screening pathways and 
the economic model ................................... 13
Searching for the evidence  ........................ 21
5 Epidemiology of open angle glaucoma ...... 25
Introduction ............................................... 25
Methods ...................................................... 25
Results ........................................................ 27
Discussion ................................................... 36
Conclusions ................................................ 40
6 Screening and diagnostic tests for open 
angle glaucoma .......................................... 41
Introduction ............................................... 41
Methods ...................................................... 41
Results ........................................................ 44
Discussion of results ................................... 77
Conclusions ................................................ 83
7 Evidence of effectiveness ........................... 85
Screening for prevention of optic nerve
damage due to OAG .................................. 85
Effectiveness of glaucoma treatment  ......... 87
Probability of glaucoma deterioration from
mild disease to visual impairment ............. 89
8 Economic analysis ...................................... 95
Principles of economic evaluation  ............. 95
Systematic review of cost-effectiveness of
screening for OAG  ..................................... 95
Economic evaluation of screening for 
OAG ............................................................ 105
9 Factors relevant to the NHS, other sectors 
of the economy and patients ..................... 135
Potentially relevant target groups for 
screening .................................................... 135
Estimating the numbers eligible for 
screening .................................................... 135
Consideration of screening performance ... 136
Implications for service provision .............. 139
Implications for patients and their 
families ....................................................... 139
Summary .................................................... 141
10 Does screening for open angle glaucoma 
meet the National Screening Committee
criteria? ...................................................... 143
The condition ............................................. 143
The test  ...................................................... 144
The treatment  ............................................ 145
The screening programme  ........................ 145
Summary .................................................... 147
11 Discussion ................................................... 149
Main results ................................................ 149
Assumptions, limitations and 
uncertainties ............................................... 150
12 Conclusions ................................................ 153
Implications for healthcare ........................ 153
Acknowledgements .................................... 155
References .................................................. 157
Appendix 1 Markov model for glaucoma ... 171
Appendix 2 Literature search strategies ... 175
Appendix 3 Data extraction form:
epidemiology review of open angle 
glaucoma .................................................... 185
Appendix 4 Included studies: epidemiology
review of open angle glaucoma  ................. 191
Appendix 5 Excluded studies: epidemiology
review of open angle glaucoma  ................. 197
Appendix 6 Characteristics of included 
studies: epidemiology review of open angle
glaucoma .................................................... 205Appendix 7 Modified QUADAS quality
assessment checklist  ................................... 225
Appendix 8 Included studies: screening 
and diagnostic tests review ......................... 227
Appendix 9 Studies providing data on
reliability: screening and diagnostic tests 
review .......................................................... 235
Appendix 10 Excluded case–control studies:
screening and diagnostic tests review  ........ 241
Appendix 11 Results of the quality 
assessment for the individual studies ......... 245
Appendix 12 Characteristics of the 
included studies: screening and diagnostic 
tests review .................................................. 249
Appendix 13 Results by type of test: 
screening and diagnostic tests review  ........ 255
Appendix 14 Quality assessment of the
systematic review by Maier and colleagues 
(2005) .......................................................... 273
Appendix 15 Included studies: glaucoma
progression ................................................. 275
Appendix 16 Glaucoma progression: 
approach 1 – randomised trials ................. 277
Appendix 17 Glaucoma progression: 
approach 2 – studies  .................................. 279
Appendix 18 Included studies: 
cost-effectiveness of screening for open 
angle glaucoma  .......................................... 285
Appendix 19 Characteristics of included
studies: cost-effectiveness of screening for 
open angle glaucoma ................................. 287
Appendix 20 Complete incremental 
cost-effectiveness data for each included 
study ........................................................... 293
Appendix 21 Interim life table  ................. 299
Appendix 22 Utility scores ........................ 301
Appendix 23 Cost-effectiveness 
acceptability curves  .................................... 303
Appendix 24 The wider costs of visual
impairment ................................................. 327
Appendix 25 Further details of the 
estimation of the numbers eligible and
ineligible for screening  .............................. 329
Appendix 26 Number of people in the
observation state over time ........................ 331
Appendix 27 Costs of diagnosis and 
cases detected for the technician and 
no-screening strategies ............................... 333
Appendix 28 Diagnostic performance of 
the technician and no-screening 
strategies ..................................................... 337
Health Technology Assessment reports
published to date ....................................... 343
Health Technology Assessment 
Programme  ................................................ 359
Contents
viHealth Technology Assessment 2007; Vol. 11: No. 41
vii
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
AGIS Advanced Glaucoma Intervention
Study
ASSIA Applied Social Science Index and
Abstracts
BHPS British Household Panel Survey
C-20° central 20 degrees of visual field
CCT Current Controlled Trials
CDR cup-to-disc ratio
CDSR Cochrane Database of Systematic
Reviews
CEAC cost-effectiveness acceptability
curve
CENTRAL Cochrane Central Register of
Controlled Trials
CI confidence interval
CNTGS Collaborative Normal Tension
Glaucoma Study
CRD Centre for Reviews and
Dissemination
CrI credible interval
D dioptre
DALY disability-adjusted life-year
DARE Database of Abstracts of Reviews of
Effectiveness
DOR diagnostic odds ratio
EMGT Early Manifest Glaucoma Trial
EQ-5D EuroQol 5 Dimensions
FDT frequency doubling technology
FN false negative
FP false positive
GAT Goldmann applanation tonometry
GDx VCC GDx variable corneal
compensation
GHT glaucoma hemifield test
GO glaucoma optometrist
GPS glaucoma probability score
HbA1c glycosylated haemoglobin
HF Harrington–Flock
HMIC Health Management Information
Consortium
HRQoL health-related quality of life
HRT Heidelberg retina tomograph
HSROC hierarchical summary receiver
operating characteristic
IC incremental cost
ICER incremental cost-effectiveness ratio
IGA International Glaucoma
Association
IOP intraocular pressure 
ITT intention-to-treat
MD mean deviation
MDP motion detection perimetry
MPT  manual perimetry technique
MRA Moorfields regression analysis
continued
List of abbreviationsList of abbreviations
viii
List of abbreviations continued
NA not applicable
NCT non-contact tonometry
NEI National Eye Institute
NFI nerve fibre indicator
NFL nerve fibre layer
NHS EED NHS Economic Evaluation
Database
NICE National Institute for Health and
Clinical Excellence
NR not reported
NRR neuroretinal rim
NS not stated
NSC National Screening Committee
NTG normal tension glaucoma
OAG open angle glaucoma
OCT optical coherence tomography
OKP oculokinetic perimetry
OR odds ratio
PS partial sight
QALY quality-adjusted life-year
QAVY quality-adjusted year of vision
QUADAS Quality Assessment of Diagnostic
Accuracy Studies
RCT randomised controlled trial
RDOR relative diagnostic odds ratio
RNFL retinal nerve fibre layer
RR relative risk
RTA retinal thickness analyser
RVM relevance vector machine
SAP standard automated perimetry
SCI Science Citation Index
SD standard deviation
SE standard error
SITA Swedish interactive threshold
algorithm
SLP scanning laser polarimetry
SROC summary receiver operating
characteristic
SSCI Social Science Citation Index
STV&WS Sight Test Volume and Workforce
Survey
SWAP short-wavelength automated
perimetry
TD total deviation
TN true negative
TP true positive
VCDR vertical cup-to-disc ratio
VFQ Visual Function Questionnaire
VI visual impairment
All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or 
it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case 
the abbreviation is defined in the figure legend or at the end of the table.Health Technology Assessment 2007; Vol. 11: No. 41
ix
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
Background
Glaucoma is the leading cause of irreversible
blindness worldwide. Open angle glaucoma (OAG)
accounts for about 50% of glaucoma blindness.
Prior evaluations of screening effectiveness have
concluded that there is insufficient evidence to
recommend screening for OAG; recent treatments
appear effective in delaying progression, but long-
term health outcomes are uncertain. Screening
programmes for OAG have not been adopted in
any country. In the UK, glaucoma is detected by
opportunistic case finding, usually by community
optometrists. 
Objectives
The objectives of this systematic review were:
● to assess whether OAG screening meets the UK
National Screening Committee (NSC) criteria
● to develop a model comparing screening
strategies with case finding
● to estimate parameters through systematic
reviews
● to model estimates of cost and cost-effectiveness
● to identify areas for future research.
Methods
Screening strategies were developed by wide
consultation. In the first (‘technician’) strategy, the
cohort ‘at risk’ would be invited for examination,
based on measurement of intraocular pressure
(IOP) and a second ‘test’ (not prespecified). Screen
positives would be referred for specialised
optometrist assessment. In the second (‘glaucoma
optometrist’) strategy, the cohort would be invited
to a specialised optometrist for assessment.
Positives from either strategy would be referred for
diagnosis, by an ophthalmologist, as occurs in
current case finding (‘no screening’ strategy). 
Markov submodels were developed to represent
these strategies. Parameter estimates were
determined by systematic reviews of epidemiology,
economic evaluations of screening, and effectiveness
(test accuracy, screening and treatment). 
Tailored highly sensitive electronic searches were
undertaken. The date of last searches was 
December 2005.
Results
In the UK, the estimated prevalence of OAG is
2.1% [95% confidence interval (CI) 1.7 to 2.5],
ranging from 0.3% in people aged 40 to 3.3% in
people aged 70 years. Incidence ranges from 30 to
181 per 100,000 person-years for ages 50 and 70
years, respectively. Of an estimated half a million
people affected, 67% are undetected. Several risk
factors are identified; for ages 40–75 years,
prevalence estimates are: people with myopia 2.7%,
people with diabetes 3.3% and family history in a
first-degree relative 6.7%. The risk is four times
higher among those of African ethnicity. Insufficient
data were available to estimate prevalence in other
ethnic minority groups in the UK.
Most potential screening tests reviewed had an
estimated specificity of 85% or higher. No test
was clearly most accurate, with only a few,
heterogeneous studies for each test.
No randomised controlled trials (RCTs) of
screening were identified. Based on two treatment
RCTs, early treatment reduces the risk of
progression (hazard ratio 0.65, 95% CI 0.49 to
0.87). Extrapolating from this, and assuming
accelerated progression with advancing disease
severity, without treatment the mean time to
blindness in at least one eye was approximately
23 years, compared to 35 years with treatment. 
The main determinant of cost-effectiveness was
prevalence. Prevalence would have to be about
3–4% in 40 year olds with a screening interval of
10 years to approach cost-effectiveness. It is
predicted that screening might be cost-effective in
a 50-year-old cohort at a prevalence of 4% with a
10-year screening interval. General population
screening at any age, thus, appears not to be cost-
effective. Selective screening of groups with higher
prevalence (black ethnicity and family history)
might be worthwhile, although this would only
cover 6% of the population. Extension to include
other at-risk cohorts (e.g. myopia and diabetes)
Executive summarywould include 37% of the general population, but
the prevalence is then too low for screening to be
considered cost-effective. 
Screening using a test with initial automated
classification followed by assessment by a
specialised optometrist, for test positives, was
more cost-effective than initial specialised
optometric assessment. The cost-effectiveness of
the screening programme was highly sensitive to
the perspective on costs (NHS or societal). In the
base-case model, the NHS costs of visual
impairment were estimated as £669. If annual
societal costs were £8800, then screening might be
considered cost-effective for a 40-year-old cohort
with 1% OAG prevalence assuming a willingness to
pay of £30,000 per quality-adjusted life-year. Of
lesser importance were changes to estimates of
attendance for sight tests, incidence of OAG, rate
of progression and utility values for each stage of
OAG severity. Cost-effectiveness was not
particularly sensitive to the accuracy of screening
tests within the ranges observed. However, a
highly specific test is required to reduce large
numbers of false-positive referrals. 
The findings that population screening is unlikely
to be cost-effective are based on an economic
model whose parameter estimates have
considerable uncertainty. In particular, if rate of
progression and/or costs of visual impairment are
higher than estimated then screening could be
cost-effective. 
Conclusions
Implications for healthcare
Screening for OAG met the UK NSC criteria for
condition and treatment, but not for test or
screening. Population screening is not cost-
effective, but targeted screening of high-risk
groups may be. Measures systematically to 
identify those at risk and quality assure the
programme would be required. Adequate service
provision for those screened positive would be
needed. 
Glaucoma detection can be improved by
increasing attendance for eye examination, and
improving the performance of current testing by
either refining practice or adding in a technology-
based first assessment, the latter being the more
cost-effective option. This has implications for any
future organisational changes in community eye-
care services.
Implications for research 
Further research should aim to develop and
provide quality data to populate the economic
model, by undertaking the following, in order of
priority.
First, a feasibility study of interventions to improve
detection; input from qualitative researchers,
health economists, health psychologists and
trialists is required to evaluate components of the
care pathway:
● optimal test strategy
● acceptability of interventions to improve
attendance and the acceptability of subsequent
testing
● harms and benefits associated with enhanced
glaucoma detection strategies.
Secondly, a refinement of the parameter estimates
in the economic model. In particular, further data
on costs of blindness, risk of progression and
health outcomes are required. A value for
information analysis would inform where primary
research should be directed.
Thirdly, an RCT of interventions to improve the
uptake of glaucoma testing, informed by the
results of the prior feasibility studies.
x
Executive summaryT
his report was commissioned to evaluate the
clinical effectiveness and cost-effectiveness of
screening for open angle glaucoma (OAG) in the
UK. Specifically, secondary research with economic
modelling was required to assess the extent to
which screening for OAG would meet the National
Screening Committee (NSC) criteria for a
screening programme and to identify future
research needs.
The specific objectives were:
● to review systematically risk factors for
developing OAG, and to determine the
prevalence and incidence of OAG according to
age
● to review systematically the accuracy of
screening tests for OAG
● to review systematically treatment effectiveness
and to extrapolate these effects on long-term
visual outcome
● to identify any potential benefits and harms of
screening and subsequent management
● to determine the clinical and cost-effectiveness
of alternative screening strategies
● to assess whether screening for OAG meets
specified criteria for a national screening
programme
● to describe the impact on the NHS if a
population screening programme for OAG were
initiated
● to identify and prioritise areas for future
research.
Health Technology Assessment 2007; Vol. 11: No. 41
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Chapter 1
The aim of the reviewIntroduction
Glaucoma describes a group of eye diseases, in
which there is progressive damage to the optic
nerve leading to impaired vision and blindness if
untreated. The primary glaucomas (those that are
not a consequence of other eye or systemic
disease) can be classified as OAG or angle closure
glaucoma. These two types are distinguished by
the anatomy of the anterior segment of the eye, as
illustrated in Figure 1.
Angle closure glaucoma, although less common
than OAG, is more likely to result in bilateral
blindness and is estimated to be the cause of 50%
of glaucoma blindness worldwide.1,2 While
screening for angle closure glaucoma may be
appropriate for other country settings, it is a
different disease from OAG, with different risk
factors, and different screening tests are required
for early detection. The epidemiology of OAG is
described in detail in Chapter 5.
This report was commissioned to assess whether
screening for OAG would be worthwhile in the
UK. Screening for OAG among ‘at-risk’ target
populations with interval screening offered at
selected sites has not been adopted in any country,
but a number of ad hoc strategies exists, with
clinical guidelines for the detection and
subsequent management of glaucoma.3–7
For screening for OAG to be considered, several
criteria should be addressed. In the UK, the NSC
provides advice to government on which
population screening programmes should be
introduced. The NSC uses a set of criteria, based
on the original WHO criteria,8 but developed over
the years to take account of new scientific
developments. These criteria are available on the
NSC website.9 Not all the criteria are relevant to
OAG, but most are. In brief, the condition should
be an important public health problem, there
needs to be an acceptable test or combination of
tests that are able to detect sufficient people at risk
of visual impairment to justify testing large
numbers of people who are not at risk, early
treatment must be effective and acceptable, and
appropriate diagnostic and management facilities
to care for people with detected glaucoma must be
available. The benefits of screening must outweigh
the risks, and the programme needs to be cost-
effective and practically feasible. The NSC, in
cooperation with the Welsh Assembly, convened a
workshop on screening for glaucoma in
September 2001 and a report has been issued.10
The current NSC policy is that screening for OAG
is not yet recommended, and the topic is due for
reconsideration in 2008.11
A recent health technology assessment report for
the US Preventative Services Task Force found that
screening can detect early OAG in adults and that
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FIGURE 1 Anterior segment of the eye (open angle and closed angle)early treatment reduces the number of people
whose visual field defects progress, but that the
evidence was insufficient to determine whether a
screening programme would reduce impairment
of vision or impairment of quality of life.12
New potential screening tests for OAG are
available,13–17 and recent evidence on the
effectiveness of treatment18,19 justifies a further
evaluation of the effectiveness of screening for
OAG. 
The condition
OAG is diagnosed primarily by glaucomatous
optic neuropathy (cupping) and a compatible
visual field defect, in the presence of an open,
normal appearing, anterior chamber angle. Raised
intraocular pressure (IOP) of at least 21 mmHg
(two standard deviations above the mean) used to
be considered as a part of the definition of OAG,
but population studies have consistently found
that many people with OAG have an IOP below
this level.20–24 The risk of developing glaucoma,
and for worsening of existing glaucoma, does,
however, increase with increasing IOP.25–27 More
advanced disease at diagnosis is also associated
with a higher IOP.23,28
Typical early glaucomatous changes in the optic
disc include localised or generalised thinning of
the neuroretinal rim, with increased enlargement
of the optic cup and an increased cup-to-disc ratio
(CDR). As glaucoma advances, there is further
neuroretinal rim thinning until the cup occupies
most of the disc area (Figure 2).
Currently, the only treatment for OAG is to lower
the IOP. This can be done medically, usually with
eye drops, or surgically, by laser, or any
combination of these. The effectiveness of OAG
treatments is evaluated in a number of ongoing or
completed Cochrane reviews,18,29–31 and is
discussed in Chapter 7.
Burden of disease in the UK
Glaucoma is second to age-related macular
degeneration as the most common cause of
blindness in adults in the UK and Ireland.32–35
The statutory definition of blindness is that “a
person should be so blind as to be unable to
perform any employment”. There is no equivalent
definition for partial sight, but it refers to people
who are not blind, but who are substantially and
permanently disabled by defective vision.36
Ophthalmologists register new cases of blindness
and partial sight with the local authorities across
the UK. Registration is voluntary; it is a
prerequisite for receiving certain social security
benefits, but not for all social service concessions.
The recommendations for blind and partial sight
registration, based on the vision of the better eye,
are as described in Box 1.
The frequency of glaucoma as a cause of blindness
or partial sight is reported as incidence (new
cases) and prevalence (all cases). Registration data
are available for England, Scotland and Wales,37–39
but recent estimates of incident visual impairment
are not available for Northern Ireland. In
England, Scotland and Wales, 31,676 people were
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FIGURE 2 The optic nerve in OAG: (a) healthy optic nerve (reproduced with permission from AgingEye Times, www.agingeye.net); 
(b) advanced glaucoma damage (reproduced courtesy of A Azuara-Blanco)registered as incident visual impairment (blind
and partial sight registrations) in 2002/03,
although data were not detailed according to
causes of visual impairment. 
A detailed analysis of main causes of blindness for
England and Wales in 1990/91 found that
glaucoma was the main cause in 11.7% of incident
blind registrations and 9.6% of partial sight
registrations for all ages, and a contributing cause
in another 8% of blind and 4% of partial sight
registrations.34 People may be registered using the
specific term OAG or simply as ‘glaucoma,
unspecified’. A more recent analysis of certifications
of visual impairment in England and Wales in
1999/2000 found similar proportions, with
glaucoma accounting for 10.9% of blindness and
10.2% of partial sight registrations, although the
analysis was not detailed according to registrations
specifically for OAG.32 Applying these proportions
to registration data for 2002/03, it can be estimated
that 3108–3138 people aged over 50 years were
newly registered with visual impairment (blind and
partial sight) due to glaucoma in England and
Scotland in 2002/03. There are at least 1192 new
registrations of incident visual impairment due to
OAG as the main cause, but the true number may
be higher than this, as some OAG cases would
have been registered as glaucoma non-specified.
Data for Wales were not detailed according to age
and are not included.
Data on blind and partial sight registration may
not be accurate for several reasons. The criteria
for registration are subjective, some eligible
people do not wish to be registered and
ophthalmologists may not offer registration to
those who are eligible. Analyses of people eligible
for blind and partial sight registration from
attendees at ophthalmology departments in three
centres in the UK have estimated that up to 50%
of individuals eligible for blind or partial sight
registration are not registered.32,40,41 These studies
were consistent in their findings that people
eligible for partial sight registration were less likely
to be registered than people eligible for blind
registration. People with visual field loss alone
were less likely to be registered than people with
impaired central visual acuity, and people
undergoing long-term treatment and follow-up
were less likely to be registered or have
registration delayed compared with people with a
condition that was untreatable and not under
long-term follow-up, for example age-related
macular degeneration.32,40,41 It is therefore likely
that many more people have visual impairment
due to OAG than currently recorded in the UK
blind and partial sight registration system. 
Vision below the level that is required for driving
is a major burden of glaucoma, and is not
necessarily reflected in the visual impairment
statistics, but is of importance to those affected.
The number of people who have been forced to
surrender a driving licence on account of
glaucoma visual field loss is not captured by
national statistics, but would be an important
indicator of the burden of glaucoma.
Current practice for glaucoma
detection in the UK
In the UK, community optometrists are the key
providers of primary eye care; general medical
practitioners do not usually have access to
specialist equipment or the necessary training and
skills to detect glaucoma. The majority (90%) of
referrals to secondary care ophthalmology as
suspect glaucoma are initiated from an
optometrist.42–44 Current detection strategies are
opportunistic, based on optometrist case finding
or open access where the population tested is self-
selecting. In the UK, apart from Scotland, only
select groups qualify for a free sight test; such
groups are people aged over 40 years with a
family history of glaucoma, people aged over
60 years and those on income support. Guidelines
exist for a more detailed eye examination in 
at-risk groups; the optometrist is advised to
undertake an assessment of the optic nerve head,
perform tonometry and undertake a central visual
field assessment.45 ‘At risk’ is not, however, defined
and is at the discretion of the practitioner: a sight
test may not necessarily include testing for
glaucoma, and, as such, cases, particularly early
glaucoma, are missed.
In summary, the current service does not
constitute a formal attempt to reach and test
Health Technology Assessment 2007; Vol. 11: No. 41
5
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
Blindness
● Acuity worse than 3/60 
● Acuity better than 3/60, but below 6/60 with a very
restricted visual field 
Partial sight
● From 3/60 to 6/60 with a full visual field 
● Up to 6/24 with moderate restriction of the visual
field
● 6/18 or better with a gross visual field defect 
BOX 1 Recommendations for blind and partial sight registrationeveryone at risk in a defined population and is
opportunistic surveillance rather than screening.46
Guidelines are provided by the College of
Optometrists45 about which tests should be done
and when, but these are not mandatory, and as
such a sight test often does not detect glaucoma.
Uptake of sight testing by the population is
variable and members of more deprived
communities are less likely to seek testing.47 The
General Ophthalmic Services in Scotland have
been reviewed, and as from April 2006, provision
has been made to provide free NHS eye
examinations for all. The thrust of the new service
is to move away from the current emphasis of a
sight test on refraction to a broader eye health
assessment appropriate to the patient’s needs,
including a more extensive examination to
improve glaucoma detection. 
Diagnostic and treatment services
Current, usual practice is that suspect glaucoma
cases identified by community optometrists are
referred to secondary care for an
ophthalmologist’s opinion with treatment,
observation or discharge as required. People
requiring treatment or observation as high-risk
suspects remain under review by an
ophthalmologist. 
With an ageing population and improved
detection, the current diagnostic and management
service in secondary hospital care is likely to
become increasingly overloaded. Several schemes
are in operation in the UK, which aim to alleviate
the pressure on the hospital eye service and
improve glaucoma care, by using glaucoma-
trained optometrists, or nurse practitioners in 
co-managed shared care treatment and
monitoring schemes, which may be hospital or
community based.48–50 National initiatives to
define and develop clinical care pathways for
glaucoma are underway.51–54 These, together with
a review of general ophthalmic services55 and a
connected information technology system in the
NHS, provide the basis for a standardised
diagnostic and treatment service for glaucoma.
Background
6Description of potential screening
tests
Ideally, a screening test for OAG should be safe,
easy to administer and interpret, portable, quick,
acceptable to the people who are to be tested, and
sufficiently valid to distinguish between those who
do and do not have OAG.
Tests for glaucoma involve an assessment of
structural changes at the optic nerve head,
functional visual loss by visual field testing and the
level of the IOP. It is not always possible to make a
definitive diagnosis using these criteria. A person
could have a media opacity precluding a view of
the optic disc, or visual field testing may not be
possible, and in these circumstances diagnosis is
made on only one of these findings or severe
visual loss with raised IOP.56
Many commercial devices, particularly for
assessing structural damage, are now available.
The following sections describe candidate
screening tests for OAG. The diagnostic
performance of the candidate screening tests is
reported in Chapter 6.
Intraocular pressure
Measurement: contact and non-contact
tonometry
Contact tonometry and non-contact tonometry
(NCT) are quick, taking about 1–2 minutes per
eye.
Contact tonometry
The most widely used and generally accepted
reference standard for measuring the IOP is
Goldmann applanation tonometry (GAT). GAT
uses a prism to apply an external force to the
cornea to indent and flatten its surface.57 The two
general sources of error with Goldmann
tonometry can be categorised as those caused by
faults in the application of the technique and
those related to biological variability of the human
eye, both normal and pathological. Of particular
note is the error induced by variability in the
central corneal thickness. GAT is mounted onto a
slit-lamp, which limits its convenience, and is
usually performed by trained optometrists, nurses
and ophthalmologists. A clinical background is not
essential; with training a technician can perform
GAT. 
The Perkins tonometer is a portable device that is
similar to the Goldmann tonometer. Like the
other portable devices, it is useful in situations
where a patient cannot be seated at a slit-lamp,
such as bedside examinations, the operating 
room, nursing homes, remote areas and mass
screenings.
The Tonopen is an automated handheld
applanation tonometer based on the
MacKay–Marg tonometer.58 It is small, light and
battery operated, but may be less accurate than
GAT. 
There are potential problems with using contact
tonometry in a screening situation in that contact
with the tear film and the cornea may raise
concerns regarding transmissible disease.
Chemical disinfection is required after each test to
reduce the risk of cross-infection.
Disposable prisms for Goldmann and Perkins
tonometry or disposable covers for the Tonopen
tip avoid the risk of cross-infection but incur
additional costs. Disposable prism tonometry is,
potentially, a reliable alternative to GAT.59
Non-contact tonometry
NCTs applanate the cornea with a puff of air.60
Measurement errors are larger in patients who
squeeze their eyelids or who blink rapidly in
response to the startling jet of air, and in eyes with
moderately elevated IOPs. The advantages of
NCT include speed, no anaesthetic and low risk
for corneal abrasion (hence more suitable for
technician operation) and, since there is no direct
contact with the eye, any infection control issues
are avoided. 
Population distribution of IOP
IOP in the population is normally distributed 
with an additional tail towards higher levels of
IOP (Figure 3). The mean IOP in adult
populations is consistently estimated at
15–16 mmHg, with a standard deviation (SD) of
2.5–2.8 mmHg.20–22,61–66 Other factors (ethnicity,
diabetes, systolic blood pressure, family history of
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Screening tests for glaucomaglaucoma, myopia) influence the population IOP
distribution.67 There is a marked overlap of IOP
distributions between those with and without
glaucoma. In people with glaucoma the median
untreated IOP has been estimated to be
26 mmHg.62,68
Structural damage
Structural damage is assessed clinically by a
subjective assessment of the optic nerve head (the
optic disc) and/or by evaluating the retinal nerve
fibre layer.
Ophthalmoscopy (direct and indirect)
Direct ophthalmoscopy (i.e. with a direct
ophthalmoscope), best performed with the pupils
dilated and the room darkened, provides a
magnified view of the optic disc. The main
disadvantage is the absence of a stereoscopic view.
The examiner has to use indirect cues to allow the
interpretation of the optic disc as a tridimensional
structure. Furthermore, direct ophthalmoscopy
does not yield a permanent record, and the
examiner is required to draw the optic disc to
allow subsequent comparisons. 
Binocular ophthalmoscopy has the advantage of
stereopsis, allowing a tridimensional observation
of the optic disc. Current practice consists of the
use of a standard slit-lamp biomicroscopy
associated with non-contact lenses (60D or 78D).
The possibility of achieving stereopsis depends on
the pupil’s size, which often needs to be dilated,
the image is inverted and additional training is
required for accurate interpretation. It is also
possible to use the slit-lamp in association with a
contact lens (e.g. the Goldmann lens), but this
technique requires the use of a topical anaesthetic
and a viscoelastic substance between the lens and
the cornea. Despite being more uncomfortable,
the image provided is excellent with high
magnification and is not inverted, making for
easier interpretation. 
Optic disc photography (monoscopic and
stereoscopic)
A wide variety of digital and non-digital cameras is
available to provide colour images of the optic
disc. Photography has the advantage over
ophthalmoscopy of a permanent recording of the
optic disc, but has the same limitations of ideally
requiring a dilated pupil and clear media, that is,
no significant cataract. Monoscopic photographs
can be obtained with a standard fundus camera;
however, the tridimensional structure of the optic
disc can only be assessed by stereophotography.
Stereoscopic pictures can be obtained with
sequential photographs using a standard fundus
camera by horizontal realignment of the camera
base when photographing the same retinal image.
Alternatively, simultaneous stereoscopic fundus
photographs can be obtained using a camera with
a beam-splitting prism to capture two images of
the fundus taken simultaneously at a fixed relative
angle. Digital stereophotographs may be viewed in
a number of ways, using either stereoviewers or
flicker glasses, which rapidly alternate the image
between the left and right eye of the observer.69
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FIGURE 3 Intraocular pressure (IOP). G, glaucoma population; N, normal distribution; P , frequency of distribution of IOP in population.Population distribution of CDR
Optic disc changes typical of glaucoma include
vertical and generalised thinning of the
neuroretinal rim, localised thinning and notching,
and displacement of the retinal vessels. A
consensus definition for glaucomatous optic
neuropathy has been proposed whereby a CDR
above which 2.5% of the normal population lie
defines the upper limit of normal.56 Optic disc
parameters, particularly size of the optic disc, vary
for different populations; in European
populations, the 97.5% centile typically equates to
a vertical cup-to-disc ratio (VCDR) of 0.770 and is
generally considered to be the most useful
parameter for determining glaucoma in the
presence of a visual field defect.56 Cup disc
asymmetry of 0.2–0.3 could also be used to define
glaucoma.71,72 For subjects in whom a reliable
visual field test is not possible, a cut-off exceeding
the 99.5th percentile (i.e. a VCDR   0.9), in most
populations, would define glaucoma. Cup disc size
varies between populations with small discs having
small cups that may be pathological, and vice
versa for large discs. Thus, the division between
normal and abnormal for optic disc parameters is
not clear, and therefore a screening test based on a
subjective assessment of glaucomatous optic nerve
damage would require an experienced observer to
diagnose glaucoma accurately.
Retinal nerve fibre layer photography
The appearance of the retinal nerve fibre layer
(RNFL) may be documented using high-resolution
black and white images, where the fibre bundles
are seen as silver striations, most visible in the
superior and inferior poles of the optic disc
(Figure 4). The technique includes the use of a
green or blue filter with either standard or digital
photography. The quality of RNFL image is poor
in eyes with small pupils and media opacities.
Furthermore, the technique is subjective and
requires an experienced observer for
interpretation. A manual with a reference set of
RNFL images is available to guide technicians in
the reading of such images.73
Quantitative analysis of the optic nerve head and
RNFL
Scanning laser tomography
Confocal laser scanning imaging technology, used
by the Heidelberg retina tomograph (HRT;
Heidelberg Engineering, Heidelberg, Germany),
exploits the principle of confocal laser scanning to
allow quantitative structural information.
The topographic image is derived from multiple
optical sections at consecutive focal depth planes.
Each image consists of numerous pixels, with each
pixel corresponding to the retinal height at its
location. The device is operator dependent in that
the optic disc margin needs to be defined by a
contour line manually placed around the inner
margin of the peripapillary scleral ring. The
software calculates stereometric parameters within
this line. These parameters are computed for the
whole of the optic nerve head, and for six
predefined sectors.
The HRT II is compact and relatively easy to use,
pupil dilation is not required and cataracts do not
prevent imaging. Specific training is required in
contour line placement, which can be a source of
error in image analysis. Measurement time is
about 10 minutes per eye.13,14 HRT III is now
available and does not require manual drawing of
the contour line.
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RNFL defect
typical of glaucoma
FIGURE 4 The retinal nerve fibre layer (reproduced courtesy of A Azuara-Blanco)Population distribution of test parameters
The commercially available HRT II device reports
the Moorfields regression analysis (MRA) as a
classification system for glaucoma. This
classification is based on a normative database of
80 normal white participants, with a refractive
error of less than 6 dioptres (D).74 The
neuroretinal rim (NRR) is thinned in glaucoma,
and the MRA has derived limits for normality
based on the area of the NRR, classified for each
segment of the optic disc. Three diagnostic classes
are given: within normal limits (the NRR area lies
within the 95% prediction interval of normal),
borderline (between 95% and 99%) and outside
normal limits (beyond 99.9%). This is a statistical
classification, based on a narrowing of the NRR.
The classifications of borderline and outside
normal limits are considered as indicative of OAG,
but definitive diagnosis requires other relevant
clinical data. 
However, the normative database is based on small
numbers and may not be valid for non-white
populations, people with high refractive error and
large or tilted optic discs; as such, the results
should be interpreted with caution. The HRT III
incorporates a new, larger, race-specific database.
This new normative database consists of 733 eyes
of white people and 215 eyes of black people. The
software v3.0 calculates the glaucoma probability
score (GPS), a new, automated algorithm that
evaluates both optic disc and parapapillary RNFL
topography to estimate the probability of
glaucoma. The GPS uses a new sophisticated
version of artificial intelligence known as a
relevance vector machine (RVM) that estimates the
likelihood of glaucoma. No contour line or
reference plane is used in the GPS calculation, and
therefore it is completely an operator-independent
analysis.
Data are limited on the distribution of HRT
parameters in the general population and this is
relevant to the use of the HRT as a screening
device for OAG. In the UK, a study evaluating
screening for eye disease75 is ongoing (the
Bridlington eye assessment project), where people
aged over 65 years receive a comprehensive eye
examination by a trained optometrist, with the
examination including optic disc imaging using
the HRT II. Women were found to have
significantly larger rim volume, mean RNFL
thickness and cross-sectional area than men, and
tended to have smaller cup areas and volumes and
cup-to-disc area ratios than men. It is also worth
noting that the performance of the HRT is
dependent on the optic disc size.76,77 For HRT II
to be used in a screening situation the diagnostic
criteria for classification as normal and abnormal
need to be appropriately defined. Asymmetrical
thinning of the NRR is recognised as one of the
diagnostic criteria for OAG. In the same
Bridlington population study, a reference range
for rim to disc area asymmetry in a normal elderly
population was defined, with this measure having
the advantage over other HRT parameters of
being independent of age, gender and disc size. A
measure of between-eye NRR asymmetry could be
used to discriminate between normals and
abnormals for screening purposes.78
Scanning laser polarimetry
Scanning laser polarimetry (SLP) measures the
RNFL thickness objectively based on the
birefringent properties of the RNFL, which has its
neurotubules disposed in an organised, parallel
fashion. This peculiar anatomy leads to a rotation
of the plane of polarised light as it passes through
the RNFL, creating a retardation that is directly
proportional to its thickness. The current model
(GDx VCC) introduces variable corneal
compensation to enhance the accuracy of the
measurements. The GDx VCC is user friendly and
compact, and pupil dilation is not required. A
technician can perform the test. The disadvantage
is that eyes with optic disc abnormalities, such as
large myopic discs with peripapillary atrophy,
cannot be imaged reliably. The GDx VCC can
acquire images in less than 3 minutes for both
eyes.
Population distribution of test parameters
The normative database characterises the normal
tridimensional RNFL thickness, and individual
patient profiles are compared with the normative
database, thus indicating RNFL loss due to
disease. The database also includes data on
glaucoma subjects and is the basis of the machine
classifier, the nerve fibre indicator (NFI), for
indicating OAG damage. There is a wide range 
of RNFL thickness values among normal
individuals, with overlap between normal and eyes
with OAG. The GDx NFI is intended to supply the
clinician with a method of glaucoma diagnosis,
and the higher the NFI the greater the likelihood
that the eye has glaucoma. A score of 0–30 is
considered normal, 31–70 indicates that the eye is
suspect for glaucoma and 71–100 indicates that
the eye is glaucomatous. The GDx VCC normative
database contains 811 (540 normal, 271
glaucoma) patients. Ethnic minorities are well
represented on the database: Caucasians and
Hispanics 70%, African-Americans 18% and 
Asians 12%.79
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The RNFL thickness is also measured by optical
coherence tomography (OCT). OCT is an optical
imaging technique capable of providing high-
resolution, cross-sectional, in vivo imaging of the
human retina in a fashion analogous to B-scan
ultrasonography, but using light instead of
sound.80 The first commercial system was available
in 1996; the latest generation OCT3 system is
Stratus-OCT. Early OCT systems required a pupil
size of at least 5 mm. OCT3, however, operates
with a 3-mm pupil size, which suggests, like non-
mydriatic fundus cameras, that pupil dilation is
not required when operated in a darkened room.
Posterior subcapsular cataracts and cortical
cataracts can impair measurement.14
Population distribution of test parameters
A single score of overall RNFL thickness averaged
over 12 clock-hour thicknesses is compared with a
normative database derived from responses from
350 individuals aged between 20 and 80 years.81
An abnormal result is defined as below 5% level
compared with the normal population. The
distribution of OCT parameters has not been
described in a population setting.
Retinal thickness analyser
The retinal thickness analyser (RTA), commercially
available since 2000 (Talia), combines a colour
digital fundus camera with a laser-based system
(helium–neon laser, wavelength 543 nm) for
measuring nerve fibre layer thickness. One scan
covers 3 × 3 mm, which consists of 16 optical capital
cross-sections with the laser. Each cross-section is
187 µm apart and 3 mm long. In the posterior pole
thickness mode, five such scans at the centre, super
temporal and infer temporal, and superonasal and
inferonasal areas of the posterior pole, which cover
an area of 6 mm × 6 mm, are performed for each
measurement. The performance of the RTA is
affected by media opacities. 
Visual function tests
Frequency doubling technology
The clinical test procedure measures contrast
threshold in 19 visual field locations within the
central 20 degrees of the visual field (C-20°). It
can be used in threshold and suprathreshold
screening mode. In the suprathreshold mode it
takes about 1 minute per eye. Recently, FDT
Matrix, a 24-2 version of frequency doubling
technology (FDT), has been introduced. FDT is
portable and user friendly, and moderate
uncorrected refractive errors, a common finding
in the general population, do not appear to
interfere with FDT testing.
Population distribution of test parameters
Normative data were based on examination of 407
healthy people, aged between 14 and 85 years, to
provide a basis for establishing the probability
plots for FDT perimetry.82 Using the C-20°–1
algorithm, the initial level presented would be
detected by 99% of the normal population of a
particular age, and is therefore designed to have a
high specificity. Using the C-20°–5 algorithm the
initial level presented would be detected by 95% of
the normal population of a particular age and is
therefore a test aimed to optimise sensitivity.
Motion detection perimetry 
This test measures the ability to detect movement
in the peripheral retina, which may be impaired in
glaucoma. There are several types of stimuli that
can be used to explore motion sensitivity: a line, a
dot or a patch of dots. Motion detection perimetry
(MDP) takes longer and may be more difficult for
people to perform than standard perimetry,
although its reliability appears not to be affected
by cataract or pupil size. There is, as yet, no
commercially available instrument, and the
principle of motion detection as a screening tool
for OAG needs further evaluation.83
Oculokinetic perimetry
Oculokinetic perimetry (OKP) with the Damato
chart is a simple and inexpensive visual field test
device. Damato campimetry consists of 20
numbers located on a flat, white card within the
central 30 degrees of visual field. The subject is
required to refixate from number to number,
sequentially reporting whether the central 1.5-mm
black spot is visible. There is a 40-cm hinged piece
that serves to maintain the appropriate test
distance and occludes the non-tested eye. Any
point missed, other than the physiological blind
spot area, is confirmed once before considering it
a true missed point. A modified version is
currently available (free of charge) on the
Internet.84,85 This test, either in card form or web
based, is quick, simple and available, and if of
sufficient diagnostic validity would be valuable as a
screening test.
Short-wavelength automated perimetry
Short-wavelength automated perimetry (SWAP) is
a modification of automated static threshold
perimetry and is purported to detect very early
loss of sensitivity in the visual field. SWAP uses a
yellow background and large, blue stimuli to test
the blue cones. The blue cone system is slower and
has a low visual acuity (about 20/200). As a
consequence, the stimulus is perceived as fuzzy,
and the test is more difficult and time-consuming.
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on the thresholds determined by SWAP, but lens
opacities tend to result in profoundly depressed
fields that are difficult to interpret. 
Population distribution of test parameters
Glaucomatous visual field defects include,
classically, arcuate scotomas within the central
25 degrees, nasal step, diffuse loss of sensitivity,
hemispheric loss and eventually only a central
island of vision remaining. There are many
definitions of abnormality based on the number of
abnormal points, the pattern of visual field loss,
the depth of the defect and the glaucoma
hemifield test (GHT). Normative databases are
established for standard automated perimetry14,86
and for the more recent Swedish interactive
threshold algorithms (SITA) based on 330 people
with no evidence of OAG.87
The GHT is widely used to distinguish between
abnormal and normal results on standard
automated perimetry.88 The GHT is based on a
comparison of the expected sensitivity in the
superior hemifield to the inferior hemifield. On
standard SAP testing, the GHT is reported as
abnormally high sensitivity, within normal limits,
generalised reduction in sensitivity,
borderline/generalised reduction in sensitivity,
borderline, and outside normal limits. The latter
two classifications generally are taken as suspicious
of glaucoma.
Standard automated perimetry
Standard automated perimetry (SAP) is considered
to be the reference standard in visual field
examination of glaucomatous patients. SAP
estimates the threshold sensitivity of several points
within the visual field. The target locations remain
constant and the brightness is modified in a
staircase approach to estimate the sensitivity. SAP
is able to quantify the reliability, and compare the
actual examination with an age-matched normal
database. Examination of the visual field in
glaucoma is usually limited to the central 30- or
24-degree area, since almost all clinically relevant
defects fall within this area. The most commonly
used automated perimeter in the UK in
ophthalmology clinics is the Humphrey perimeter,
now with SITA, which speeds up the testing
process. 
Suprathreshold testing with automated perimetry
involves the use of stimuli that are of greater
intensity than the presumed threshold at each
location. This test strategy does not quantify the
depth of visual field defects, but is much quicker
than threshold testing.
The proportion of people able to undertake the
test reliably, and the need for confirmatory testing,
could limit the usefulness of standard automated
perimetry as a screening test. However, perimetry
does have the advantage of its availability, in that
most community optometric practices are
equipped with automated perimeters.
Screening tests for glaucoma
12I
n this chapter an overview of methods is
presented including the clinical pathways 
and details of the structure of the economic
model. This overview is used to provide a 
structure to the rest of this report. Data related 
to the issues and methods used are reported 
in subsequent chapters as described towards the
end of the section ‘Economic model’ (p. 15).
Developing the screening
pathways and the economic
model
Screening pathways
There are various options for a screening
programme. The options were explored by
personal communication with UK experts in the
diagnosis and management of OAG
(ophthalmologists and optometrists).
The key questions asked were:
● Who should be invited for screening and how
would these groups be identified?
● Which of the many candidate screening tests or
combinations of tests should be used to screen
for OAG? 
● Should level of IOP be used as part of a
screening strategy and, if so, what cut-off of IOP
should be used?
● Where should screening take place and who
should perform it?
● Should screen-positive people be diagnosed 
and managed in primary care by optometrists
or in secondary care either by ophthalmologists
or a supervised care glaucoma diagnostic
service?
The pathways were presented to the following
patients and professional groups for refinement: a
meeting of the European Glaucoma Society in
Brussels, October 2005; a meeting with patient
representatives from the International Glaucoma
Association (IGA) convened in Aberdeen, October
2005; and an advisory group to the NSC on
screening for OAG in the UK, convened in
November 2005. The latter group consisted of
representatives of specialist societies,
ophthalmology, optometry, nurses and a patient
group.
As described in Chapter 3, many potential
screening tests are now available. There was no
consensus on which test or combination of tests
should be recommended as a screening test. As
explained in Chapter 2, the level of IOP does not
define OAG, but the risk of OAG increases with
increasing IOP and the rate of progression may
also correlate with higher IOP. There was a
general consensus on the inclusion of IOP level to
identify people of high risk of developing severe
glaucoma, and an IOP of 26 mmHg was generally
agreed as a cut-off. There were concerns that this
would miss a significant number of cases of low-
pressure OAG and therefore an additional test or
tests for people with an IOP below 26 mmHg
should be considered. 
It was generally agreed that screening should start
at 50 years, but for higher risk groups (e.g. people
with a family history of OAG or of African
ethnicity), screening at 40 years should be
considered. It was agreed that identifying siblings
of newly diagnosed OAG was not currently
feasible. If such an approach to screening were to
be implemented a register of incident OAG cases
would be required.
The high demand on already stretched hospital
eye departments was highlighted as a concern if a
population screening programme was introduced.
However, for the purpose of this evaluation, the
advisory group to the NSC felt that this project
should evaluate the performance of the tests and
the impact on the number of cases detected, but
that this should be modelled through the existing
diagnostic pathway where suspected cases are
referred to hospital eye departments as if there
were the capacity to do this. If screening appeared
viable, further research would be needed to
evaluate the best strategy for managing the newly
diagnosed cases.
The outcomes of these discussions led to the
development of two alternative strategies for a
screening programme, and the economic model
was developed to compare these with the current
situation of opportunistic screening.
Health Technology Assessment 2007; Vol. 11: No. 41
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Chapter 4
Overview of methods and definitionsCurrent case finding
Current practice involves the opportunistic
screening of individuals presenting to community
optometrists for an eye test (Figure 5). Individuals
who test positive are referred to secondary care for
diagnosis by an ophthalmologist (i.e. the reference
diagnosis).
Screening strategies
Both potential screening strategies considered
would involve inviting a prespecified cohort of 
at-risk individuals for screening. At-risk groups
may be identified on the basis of age and another
factor such as family history of OAG or ethnicity.
Screening by invitation to a glaucoma-trained
optometrist
In the first of the screening strategies considered
testing would be performed by a glaucoma
optometrist (Figure 6). Glaucoma-trained
optometrists are optometrists who have received
additional training in glaucoma diagnosis and
management and have been accredited, usually by
assessment by a consultant ophthalmologist
specialising in glaucoma. The glaucoma
optometrist would perform a full ophthalmic
examination, measurement of the IOP, and
examination of the optic nerve and visual fields,
using the equipment available in the particular
optometric practice. People considered to have
glaucoma, or to be highly suspect of glaucoma
would be referred to an ophthalmologist for a
definitive diagnosis, as in current practice. Other
significant eye pathology might also be identified
by the glaucoma optometrist, although this
possibility has not been included in the economic
model described below. Furthermore, with this
strategy some of the cases of OAG may still be
identified by opportunistic screening. 
Screening by a technician
In the second screening strategy the population to
be screened would be invited to a primary care
setting to undergo a measure of IOP and a single
screening test by a technician or nurse, who has
received some training (Figure 7). 
This screening pathway incorporates IOP
measurement by applanation tonometry, with a
cut-off of an IOP of at least 26 mmHg being used
to identify groups at higher pretest probability of
developing serious OAG. A second test is used for
people with an IOP below 26 mmHg. The choice
of second test depends on which of the alternative
tests has the best balance of diagnostic accuracy,
the proportion of people able to do the test and
availability. People with an IOP of at least
26 mmHg, and people with an IOP below
26 mmHg and positive on the second test would
be referred for diagnostic assessment by a
glaucoma-accredited optometrist. People testing
negative on the second test are not referred for
further testing and are recalled for further
screening in the next cycle. As with the first
Overview of methods and definitions
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Opportunistic
sampling
All Optometrists
No glaucoma
Missed glaucoma
Observation
Positive Glaucoma
No glaucoma
Outcome
Opportunistic
sampling
Long-term
treatment
Reference
diagnosis
Negative
Untreated, progressive
glaucoma At least 60%
OAG undetected
At least 1200 new cases of
visual impairment due to OAG
in 2002/03 in UK
Mild
Moderate
Severe
FIGURE 5 Current case findingstrategy, other significant eye disease would be
identified and ongoing case finding by current
practice may still identify OAG cases.
Economic model
The economic model was developed to represent
the screening pathways described above. The
pathways indicate that screening would be best
considered as an event that will be repeated at
discrete time intervals. Furthermore, as glaucoma
is a chronic condition, which progresses slowly
over time, the model should reflect timing of both
screening and disease progression. For this reason
a Markov modelling approach was adopted. A
Markov model can be used to represent the logical
and temporal sequence of events following the
Health Technology Assessment 2007; Vol. 11: No. 41
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Eligibility
Cohort at risk Accept Glaucoma optometrist Positive
Reference
diagnosis
Glaucoma
Mild
Moderate
Severe
Treatment
Mild/PS/blind
Treatment
Opportunistic
detection
(mild/moderate/severe)
No glaucoma
Other eye
disease
Negative No glaucoma
Missed glaucoma
Decline
Untreated, progressive
glaucoma
Invite for screening
FIGURE 6 Screening by referral to a glaucoma accredited optometrist. PS, partial sight. 
Cohort at risk
Accept
Screen
test(s)a Positive
Glaucoma
optometrist
Positive
Reference
diagnosis
Glaucoma
Mild
Moderate
Severe No glaucoma
Opportunistic
detection
(mild/moderate/severe)
Treatment
Mild/PS/Blind
Treatment
Untreated, progressive
glaucoma
Missed glaucoma
Decline
Invite for screening
Eligibility
No glaucoma Negative
Other eye disease
FIGURE 7 Screening by a technician. aTest is IOP and technology. The reference standard is an ophthalmologist in all strategies. 
IOP  26 mmHg = screen positive; IOP < 26 mmHg + second technology test positive = screen positive; IOP < 26 mmHg+ second
technology test negative = return to standard case finding and rescreen cycle. implementation of alternative screening strategies.
In this study the model is used to provide the
estimated costs and outcomes over a selected
period of a cohort of patients for different
screening and/or non-screening strategies
adopted. Three Markov submodels were
developed and run in parallel. Each submodel
represented one of the three strategies outlined
above. The model parameters and the data are
presented in the section ‘Economic evaluation of
screening for OAG’ (p. 105). The results of these
sub-models presented in this chapter were
compared to obtain the final cost-effectiveness
results, which are presented in ‘Results of base-
case analysis and sensitivity analysis on the base’
(p. 115).
The model
Typically, Markov models have states (e.g. Markov
states) in which individuals stay for a period of
time called a ‘cycle’. The cycle must be a period
relevant to the condition considered (e.g.
6 months, 1 year). At the end of each cycle,
individuals can remain in the state in which they
started the cycle or move to a different state. The
probabilities of moving from one state to another
are called transition probabilities. In each state,
the model will assign costs and benefits for each
individual according to different interventions
and/or the time spent in the state. In these
models, there must be at least one absorbing state,
typically death, from which the person will not be
able to leave.
Figure 8 shows a simplified version of the model
used for the base-case analysis. In this figure the
states are presented as ovals while the arrows show
the possible directions in which individuals could
move at the end of each cycle, depending on the
transition probabilities. The states considered in
the model were those thought to reflect possible
paths for normal and glaucoma individuals. The
top line in Figure 8 represents the possible path for
undiagnosed individuals, while the bottom section
of the figure reflects the glaucoma progression for
treated patients. 
Glaucoma states were defined in terms of severity
of disease; namely, observation, glaucoma mild,
glaucoma moderate, glaucoma severe and visual
impairment. There is no universally agreed
staging system for OAG, and there are limited
data on utility values according to glaucoma
severity (see ‘Health state utilities’, p. 112, for
details). Therefore, an economic project
management group, including three economists
and three ophthalmologists, agreed the
classification of health states. The severity of
disease was based on binocular visual field loss.
The detailed description of binocular visual field
loss was adapted from a scoring system of the
integrated visual field, whereby uniocular visual
field analyses are integrated into a single
binocular field without additional testing, 
reported by Crabb and colleagues.89,90 The
definitions of health states are described in 
Table 1.
Overview of methods and definitions
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Dead
Disease progression
undiagnosed 
Disease progression,
treated patients
Glaucoma
moderate
Glaucoma
mild
Treatment
glaucoma mild
Glaucoma
severe
Visual
impairment
Normal
Treatment
glaucoma
moderate 
Treatment
glaucoma
severe
Observation
FIGURE 8 Markov model for OAGThe treatment states refer to treated disease at
each stage. The modality of treatment, either IOP-
lowering eye drops, laser or surgery or any
combination thereof, is not specified for a
treatment state. A treatment state refers to any
modality or combination treatment for each stage
of severity.
According to whether the individual has or has not
got glaucoma, he or she would start in the model
in a normal state or in an undiagnosed glaucoma
state. As time passes, the normal individuals could
develop glaucoma (e.g. new incident cases of
glaucoma), while those with glaucoma could
progress into further stages of the disease until
they eventually become visually impaired. These
states represent the true condition of the
individual. There are three treatment states in
Figure 8, which vary according to the severity of
glaucoma being treated. An observation state
where individuals without a definite diagnosis
remain until a further diagnosis decision is made
is also included in the model. The observation
state was built up as ‘tunnel states’; that is, a
person is observed for a definite period within
which a decision is made about whether or not
OAG is present. More details on the observation
states are provided below. 
OAG is not reversible and this is reflected in the
model (Figure 8). It is not possible to return to the
normal state or to a less severe glaucoma state
from any glaucoma state. The absorbing state in
the model is death. Any individual can move into
this state from any other state within the model.
The model allows for a cohort of the population,
some with OAG, to pass through different
strategies. The intuitive idea behind the model is
to identify the strategy that leads to the largest
proportion of individuals with OAG crossing the
bridge into treatment (Figure 8). Figures 50–52 in
Appendix 1 show complete versions of the model. 
The diagnosis of OAG within the model
Ophthalmologist involvement within the model
Four types of professional are explicitly considered
in the model. These are the technician, the
optometrist, the glaucoma optometrist (GO) and
the ophthalmologist. The main difference between
them within the model is their ability to diagnose
OAG, which varies from a simple reading of an
equipment outcome by the technician to the
assumed gold-standard assessment by the
ophthalmologist used in the base-case analysis.
Ophthalmologists are involved as the final stage of
diagnosis in all three strategies and their diagnosis
is considered to be the gold standard in the
analyses presented in this study. Nevertheless, the
model structure allows this assumption to be
relaxed if data were to become available. For any
person assessed by the ophthalmologist the
following decision structure is used (Figure 9). If
the ophthalmologist’s assessment is positive, they
will decide to treat the patient, although the
model structure allows this to be either a true or a
false positive. If the assessment is negative, there
will be two options: to discharge or to keep under
observation. The decision to place someone under
observation would be appropriate if the
ophthalmologist felt, for whatever reason, that the
individual was at high risk of developing
glaucoma.
As stated above, the final stage of the diagnosis is
always the ophthalmologist. Figure 10 shows the
possible paths for the normal state. Within the
Health Technology Assessment 2007; Vol. 11: No. 41
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TABLE 1 Definitions of glaucoma health states
No glaucomatous impairment  Under observation as suspect glaucoma but not on medication and no glaucoma visual
field defect in either eye
Mild glaucoma On treatment, no binocular visual field loss, unilateral glaucoma visual field defect
present
Moderate glaucoma Up to five missed points (<10 dB) in the binocular central 20° of visual field
Severe glaucoma Binocular visual field loss below UK driving standarda
Visual impairment (includes  As per criteria for ‘severe’, except binocular visual field loss includes both the upper 
partial sight and blind) and lower fields of vision
Adapted from Crabb et al.89,90
a Six or more adjoining missed points (<10 dB), and any additional separate missed point(s) OR a cluster of four or more
adjoining missed points (<10 dB), either of which is either wholly or partly within the central 20° superior or inferior
hemispheric field.base case all these people will be correctly
identified as negative for OAG.
Conceptually, if the diagnostic ability of the
ophthalmologist is less than perfect, then the
ophthalmologist might incorrectly identify a
person as being positive for OAG and initiate
treatment. In such a situation the person would at
the end of the cycle move into the ‘treatment
(normal)’ state or progress into ‘treatment
(glaucoma mild)’ state. If the assessment is
negative, the ophthalmologist can decide to
discharge the patient or keep the person under
observation. If the person is discharged it is
possible that over the duration of the cycle they
may go on to develop OAG. The likelihood of 
this happening would be dictated by the 
expected incidence of OAG over the cycle length
(i.e. the annual incidence of OAG). For a person
kept under observation it is possible that they will
develop OAG while under observation. The
likelihood of this happening is again dictated 
by the annual incidence of OAG. Should the
person develop OAG then this will be 
diagnosed by the ophthalmologist and treatment
started. 
Figure 11 shows a similar Markov tree layout for
the ‘glaucoma mild’ state case. In the analyses
presented in this report it has been assumed that
all people with mild glaucoma referred to the
ophthalmologist will be correctly diagnosed as
having OAG and will commence treatment.
Treatment, on average, would be expected to
delay the progression of disease, but not prevent
progression for all people. For this reason people
diagnosed with OAG may move into the states of
‘treatment (glaucoma mild)’ or ‘treatment
(glaucoma moderate)’. The likelihood of moving
to either of these two states will be determined by
Overview of methods and definitions
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Glaucoma
(true positive)
Positive
Negative
Ophthalmologist
test/assessment
No glaucoma
(false positive)
Glaucoma
(false negative)
No glaucoma
(true negative)
Treat
Treat
Not to treat
Not to treat
Observe
Observe
FIGURE 9 Decision pathways for diagnosis by the ophthalmologist
Treatment (normal)
Positive
Ophthalmologist
test/assessment
Treatment (glaucoma mild)
Normal
Discharge
Observation
Negative
Glaucoma mild
Observation (normal)
Treatment (glaucoma mild)
FIGURE 10 Ophthalmologist involvement Markov tree: normal statethe annual risk of progression from mild to
moderate disease for treated cases.
Conceptually, if the diagnostic ability of the
ophthalmologist is less than perfect then it might
be possible for a person with mild OAG to be
incorrectly diagnosed as negative. In such a
situation the ophthalmologist might discharge the
person, who would then face the risk of
progressing to more severe disease. The likelihood
of progression would be equal to the annual risk
of disease progression for untreated OAG. 
Although only considered as a hypothetical option
within the model at present, it may be possible
that individuals incorrectly diagnosed as negative
are still considered by the ophthalmologist as
being suspect of OAG. In this situation such
people would enter the state ‘observation
(glaucoma mild)’. In the initial period under
observation the patient would have the risk of the
disease progressing and moderate OAG
developing. If such progression should occur then
it might be expected to be identified by the
ophthalmologist and treatment initiated. It is for
this reason that in Figure 11 one of the branches
following observation progresses to ‘treatment
(glaucoma moderate)’ and not to ‘observation
(glaucoma moderate)’.
Observation state structure
The tree structure for this state is similar, no
matter what health state the person originates
from. These states are modelled as a 5-year tunnel
state. Figure 12 shows the structure for the
‘observation (normal)’ state. As noted above and
described in Figure 8, this is the only observation
state allowed in the analyses presented in this
report (owing to the opthalmologist gold
standard/perfect information assumption within
the model).
A person coming from a normal state, who the
ophthalmologist wishes to observe, would enter
Health Technology Assessment 2007; Vol. 11: No. 41
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Treatment (glaucoma moderate)
Positive
Ophthalmologist
test/assessment
Treatment (glaucoma mild)
Glaucoma mild Discharge
(false negative and discharge)
Observation
Negative
Glaucoma moderate
Observation (glaucoma mild)
Treatment (glaucoma moderate)
FIGURE 11 Ophthalmologist involvement Markov tree: glaucoma mild state
Normal
Judged normal
Observation 
(normal)
Glaucoma mild
Observation (normal)
Observation
No observation
(out of tunnel state)
Judgement remains
Treatment (glaucoma mild)
Normal
Glaucoma mild
FIGURE 12 Observation (normal) state Markov treethis ‘observation (normal)’ state. During the cycle
length of this state the ophthalmologist could
decide that the patient under observation does not
have OAG, or decide to keep the person under
observation. In the first situation, the person
would be discharged as ‘normal’ (i.e. no OAG).
However, they would still face the risk of
developing OAG (based on likelihood of its
incidence) and hence might progress into the state
of ‘glaucoma mild’. Should this occur then this will
not be identified unless presenting to the
ophthalmologist at some future date.
If the ophthalmologist’s judgement does not
change, the person will remain in observation for
a maximum of 5 years (five cycles of the model).
In any of these years the person would face the
risk of developing OAG. If this happens the
person will be automatically detected and
treatment initiated. 
Although this state is not possible in any of 
the analyses presented in this report, Figure 13
shows the Markov tree hypothetical situation of
people with mild OAG being observed [the
‘observation (glaucoma mild)’ state]. The
difference is that, when diagnosed, in this case as 
a glaucoma mild patient, the person will not be
discharged but will commence treatment [i.e. enter
the ‘treatment (glaucoma mild)’ state].
Furthermore, if the disease progresses to moderate
OAG [the ‘treatment (glaucoma moderate)’ state]
then this will be identified and the patient will be
treated as a glaucoma moderate patient. The rest
of the structure is similar to that depicted in
Figure 12.
The strategies considered
The model considered one current practice
strategy and the two alternative screening
strategies as described in Figures 5–7. Current
practice reflects current glaucoma detection by
opportunistic case finding. The two alternative
screening strategies vary in how screening would
be organised; for example, an invitation for a
screening examination by a glaucoma-trained
optometrist or for a simple test assessing 
either visual field loss or structural damage,
together with a measurement of the IOP by a
technician. The Markov models reflecting 
these pathways are detailed in Appendix 1 
(Figures 50–52).
As indicated above, the model has assumed that
the ophthalmologist is the gold standard and
makes a perfect diagnosis (e.g. specificity and
sensitivity equal to 1) but, as described above, the
model structure allows for the relaxation of this
assumption. If the ophthalmologist assessment
result is negative, the individual could be
discharged or remain under observation (as
described above). If positive, the ophthalmologist
initiates treatment.
For all the screening strategies, people are invited
for screening at preselected screening intervals
(e.g. every 3, 5 or 10 years) and they have the
choice of accepting or declining the invitation.
Those who accept the invitation would go through
the screening process, while those who decline the
invitation would follow similar paths to the one
they would follow in no-screening years. For the
years for which screening does not occur it is
Overview of methods and definitions
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Treatment (glaucoma mild)
Treatment
(Glaucoma moderate)
Diagnosed
Observation 
(glaucoma mild)
Treatment
(glaucoma moderate)
Observation
Glaucoma mild
Glaucoma moderate
No observation
(out of tunnel state)
Not diagnosed
Observation
(glaucoma mild)
FIGURE 13 Observation (glaucoma mild) state Markov treeassumed that people might still be diagnosed
using the same procedures outlined for current
practice (strategy 1).
Populating the model with parameter estimates
To provide estimates of relative effectiveness, cost
and cost-effectiveness data, the model requires
estimated values for a whole range of different
types of parameters. Such parameter estimates
should be derived in a systematic and reproducible
manner to avoid bias caused by the distorted 
and selective use of data.91 The assembly of such
data need not necessarily be comprehensive;
rather, effort should be focused on identifying 
the most relevant data to the decision problem,
which was in this case the comparison of
alternative screening strategies for OAG for
a UK setting. 
A series of systematic reviews and focused searches
covering the different types of data required for
the economic model was therefore conducted. The
methods and results of these are reported in detail
in subsequent chapters of this report. In brief, the
broad types of data required to populate the
economic model relate to:
● the prevalence, incidence and risk of
progression of the disease; that is, its
epidemiology and natural history (systematically
assessed in Chapter 5)
● the performance of the different strategies in
terms of the accuracy of the screening and
diagnostic tests used (systematically assessed in
Chapter 6); the effectiveness of treatments for
those identified as having OAG (systematically
reviewed in Chapter 7)
● resource use and unit costs required to estimate
the costs of alternative screening strategies; the
specific parameters and methods used to
provide estimates that are relevant to a UK
context are described in the section reporting
the detailed methods and results of the
economic evaluation (‘Economic evaluation of
screening for OAG’, p. 105)
● Health state utilities; the methods used to
identify UK-specific values are also described 
in ‘Economic evaluation of screening for OAG’
(p. 105).
In addition to these data, the structure and
conduct of the economic evaluation could be
usefully informed by any previous economic
evaluations. A review of such studies, as reported
in ‘Systematic review of cost-effectiveness of
screening for OAG’ (p. 95), should indicate
whether further assessment of cost-effectiveness is
worthwhile; it might also serve to identify an
existing model that could be readily adapted for
this study, or if the existing economic evaluations
are limited it could provide a firm justification for
a new modelling exercise. Thus, a thorough review
of the strengths and weaknesses of the existing
studies may help to ensure that a model will
provide as useful evidence as possible on cost-
effectiveness. 
Searching for the evidence
Highly sensitive electronic searches were
undertaken to identify the evidence for this report.
Initial searching was undertaken between January
and April 2005, with the major searches updated
during November and December 2005. As
prespecified in the protocol, electronic searches
were restricted to reports published in the English
language; reports published only as abstracts were
excluded. The following databases were searched:
● MEDLINE: 1966 to November week 3 2005
● EMBASE: 1980 to 2005 week 49 
● MEDLINE In Process and Non-indexed
Citations: 23 February, 6 December 2005
● Science Citation Index (SCI): 1981 to 
3 December 2005
● BIOSIS: 1985 to 30 November 2005
● Cochrane Central Register of Controlled Trials
(CENTRAL): Cochrane Library Issue 4 2005
● PsycInfo: 1967 to June week 3 2005
● Social Science Citation Index (SSCI): 1981 
to 27 June 2005
● Applied Social Science Index and Abstracts
(ASSIA): 28 June 2005
● Science Direct (American Journal of
Ophthalmology, Ophthalmology only): 1998 to
November 2005
● High Wire Journals (British Journal of
Ophthalmology, Investigative Ophthalmology and
Vision only): 1998 to November 2005
● Journal of Glaucoma: 2001 to November 2005
● NHS Economic Evaluation Database (NHS
EED): November 2005
● Health Technology Assessment Database (HTA
Database): November 2005
● Database of Abstracts of Reviews of Effectiveness
(DARE): November 2005
● Cochrane Database of Systematic Reviews
(CDSR): Cochrane Library Issue 4 2005
● Health Management Information Consortium
(HMIC): November 2005
● National Research Register: Issue 1 2006
● Current Controlled Trials (CCT): March 2006
● Clinical Trials: March 2006.
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Specific searches were undertaken separately for
each component of the report: effectiveness of
screening, accuracy and reproducibility of
diagnostic tests, patient acceptance of glaucoma
testing, effectiveness of glaucoma treatment,
epidemiology, risk factors and progression of
glaucoma, and economic evaluation. In addition,
general searches on the topic of OAG were
undertaken within the reviews and trials 
databases. Table 2 details the databases that 
were searched for each component, with the
number of reports retrieved from each search 
after deduplication against the results of the
MEDLINE/EMBASE searches. Appendix 2 
details all the search strategies that were used. 
In addition, reference lists of all included studies
were scanned to identify additional potentially
relevant studies. Web pages of appropriate
professional organisations were also searched 
for additional background material. The details 
of the main ones consulted are listed in 
Appendix 2.
The databases were searched using strategies that
were tailored to the scope of the individual
components of this report:
● Effectiveness of screening: aimed to restrict
evidence to randomised controlled trials
(RCTs), without language restriction.
● Accuracy and reproducibility of diagnostic tests:
aimed to restrict evidence to reports that assessed
diagnostic performance of a selected range of
tests. This was supplemented with full-text
searching of selected ophthalmology journals. 
● Patient acceptability of glaucoma testing:
additional social science databases were searched.
● Effectiveness of glaucoma treatment: a relevant
systematic review,19 published in 2005, was
identified, therefore searching was restricted to
updating this review.
● Epidemiology, risk and progression: included,
but was not restricted to, specific searching for
selected risk factors and known major
epidemiological studies.
● Economic evaluation of screening: aimed to
restrict evidence to cost-effectiveness and
utilities data.
All titles and abstracts identified in these ways
were assessed to identify potentially eligible
studies. Table 3 provides details of the number of
reports that were selected for full-text assessment.Introduction
The aetiology of the majority of cases of adult-
onset OAG is not known. Since OAG has no
associated symptoms and is often asymptomatic
before the development of established visual field
loss, there is a need to identify groups at a high
risk of developing glaucoma and quantify the level
of risk.
Risk factors have been identified from
epidemiological studies. These are increasing age
and IOP, ethnicity, family history of OAG in a first-
degree relative, myopia and diabetes. Identifiable
gene mutations are implicated,92–96 but account
for only about 4% of cases of adult-onset OAG.97
Although certain genetic subtypes are more likely
to progress towards severe disease, based on
current knowledge of the inheritance of OAG,
genetic screening would not detect a substantial
number of the currently undetected cases. 
The aim of this systematic review was to determine
the incidence and prevalence of OAG in the UK
population and to identify the magnitude of risk
of OAG attributable to age, ethnicity, family
history, myopia and diabetes.
Methods
Inclusion and exclusion criteria
Types of studies and participants
Population-based studies, namely cohort and
cross-sectional studies, investigating the risk of
developing OAG and the prevalence in the UK,
were included. Meta-analyses and systematic
reviews of observational population-based studies
were also included. Preliminary searches identified
few UK studies and therefore other studies
reporting similar populations, such as European,
North American, Canadian or Australasian were
sought. Studies in which the population was
defined at the hospital or clinic-based setting were
excluded, as participants were not considered to
be representative of the general population.
Studies were also excluded when it was not
possible to ascertain the type of glaucoma being
assessed. The review was restricted to English-
language publications.
Types of risk factors and outcomes
The following variables were considered as risk
factors for OAG:
● age: 40, 50, 60, 70 years
● myopia: mild/moderate ( 6 D); high (>6)
● ethnicity
● diabetes: types 1 and 2
● family history: one or more first-degree
relative(s) with OAG
● IOP.
The following outcome measures were considered:
● number of OAG cases detected
● number of mild, moderate and severe OAG
cases detected
● relative risk of OAG for each risk factor
reported
● relative risk of mild, moderate and severe OAG
for each risk factor
● time to glaucoma diagnosis (mild, moderate
and severe) according to level of IOP.
Data extraction strategy
Four reviewers screened the titles and abstracts of
all papers identified by the search strategy. Full
text copies of all potentially relevant studies were
obtained and four reviewers independently
assessed them for inclusion. Reviewers were not
masked to the names of studies’ authors,
institutions or sources of the reports. Any
uncertainties in the data were resolved by
discussion between reviewers.
A data extraction form was developed to record
details of the design of included studies, year of
publication, year of study, country of study, sample
size, participation rate, method of recruitment,
eligibility criteria, diagnostic criteria for OAG,
overall prevalence and prevalence by the risk
factors of interest, relative risk of OAG and
incidence (Appendix 3). Data were single data
extracted by the same four reviewers. 
Quality assessment strategy
Two reviewers (JB, TL) assessed the
methodological quality of the included studies.
Any disagreements were resolved by consensus or
arbitration. The included studies were assessed to
Health Technology Assessment 2007; Vol. 11: No. 41
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Chapter 5
Epidemiology of open angle glaucomasee whether they contained the elements shown in
Table 4. An acceptable diagnosis required a
glaucomatous visual field defect with or without
glaucomatous optic neuropathy. It was accepted
that the classification of glaucoma would vary
between studies, and in particular that methods
for ascertaining visual field loss would have
changed from the studies conducted in the 1960s.
A secure record for exposure (risk factor)
assessment was considered to be through a clinical
examination or the examination of records. The
overall quality of each study was summarised as
(A) no major flaws or (B) possible important flaws.
Studies were included when they rated ‘A’ in all
fields. Exceptions were made to include ‘B’ studies
when no better evidence was available. 
Data synthesis
Prevalence and incidence reported for an age
range were attributed to the age category to which
the midpoint was closest. Study estimates of
prevalence came from definite cases of OAG
excluding probable and/or possible cases. When
this information was not provided, it was assumed
that the rate presented in studies was for definite
cases.
The prevalence of glaucoma was calculated as the
number of participants diagnosed with glaucoma
divided by the number of participants screened.
The prevalence of OAG was calculated for the
whole population, and for those aged 40, 50, 60
and 70 years. For each study, a standard error (SE)
estimate was produced, using the large sample
normal approximation. Prevalence estimates were
pooled using the DerSimonian and Laird random
effects method.98 A pooled estimate of the
proportion of undetected OAG was produced
using the same methods. Since only one study99
reported the prevalence of undetected OAG by
age, the overall estimate of undetected OAG was
applied to each age category to produce crude
age-specific estimates. A crude age-specific
estimate of the prevalence of undetected OAG was
calculated by multiplying the pooled prevalence
estimate at that age by the pooled estimate of the
proportion of previously undetected cases.
Incidence was summarised for each age category
as the mean and range for cases per 100,000 years
at risk. No formal pooling was undertaken. No
studies provided data with which to estimate
incidence for 40 year olds and therefore the values
for 50 year olds were used. Incidence estimates for
the UK were determined by dividing the number
of cases newly diagnosed by the number of people
at risk (population data were obtained from the
2001 UK Census). 
Crude and adjusted relative risks (or odds ratios
depending on study design) of OAG for the risk
factors under investigation were abstracted. Where
two or more studies contributed data, a random
effects meta-analysis was undertaken using the
DerSimonian and Laird method. If both an
unadjusted and adjusted ratio were reported in a
study, an age- and gender-adjusted odds ratio was
used in the meta-analysis. A relative risk was
generated when an adjusted odds ratio was not
reported and raw data were available. 
A pooled prevalence was also calculated for the
prevalence of OAG in the high-risk group under
each risk factor. The number at risk in the UK
population for each risk factor was determined by
applying the pooled estimate to the 2001 UK
Census. Data obtained from the A-rated studies
contributed to the pooled estimates. Where no 
A-rated studies were available B-rated studies were
used.
High IOP was defined as one or more
measurements with readings equal to or above
26 mmHg. Other IOP cut-offs were also
investigated. Participants with myopia were
defined as having one or more measurements with
refractive errors greater than 0.5 D, ascertained by
either measurement of present spectacles or a
Epidemiology of open angle glaucoma
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TABLE 4 Quality assessment criteria
Criterion Type of bias
Were participants sampled adequately? Selection
(Random sample obtained from a representative population)
Was exposure (risk factor) status obtained from a secure record?  Detection
(Clinical examination or examination records)
Was the criterion used in the diagnostic classification thorough? Detection
(Glaucomatous visual field defect with or without glaucomatous optic neuropathy)
Was the response rate greater than 75%? Attritionrefraction examination. Family history of OAG was
defined as participants having any first-degree
relative affected by OAG confirmed by clinical
examination. Diabetes was defined as people on
treatment for diabetes (type 1 or 2) or those
testing positive on urinalysis, glycosylated
haemoglobin (HbA1c) or a glucose tolerance test.
Results
Number and type of studies included
The study selection process is summarised in
Figure 14. In total, 4383 reports were identified
from the search for studies on epidemiology, risk
and disease progression, of which 285 were
selected for full assessment for this review. Ninety-
two reports describing 27 studies met the inclusion
criteria for the review. In addition, one meta-
analysis was identified. The included studies and
associated references are listed in Appendix 4.
Number and type of studies excluded,
with reasons for specific exclusions
A total of 192 reports was obtained but
subsequently excluded because they failed to meet
one or more of the inclusion criteria (Figure 14).
The majority of the exclusions were not
population-based studies or the population was
not defined at the geographical level. (See
Appendix 5 for further details.)
Study quality and characteristics of
included studies
Quality of available evidence
The results of the quality assessment of the
included studies are summarised in Table 5. In
most studies (81%), participants were sampled
adequately and selected from a relevant
population. Suboptimal approaches to diagnose
OAG (e.g. high IOP, absence of a visual test,
baring of the blind spot, case records,
unstandardised criteria) were used in five studies
(19%).100–104 IOP, diabetes and myopia status were
obtained from a secure record (examination or
examination records) in most studies. However,
only one (20%)105 obtained family history status
from a secure source, by examination of first-
degree relatives of detected cases. Sixteen (59%)
included studies specified the participation rate to
be greater than 75%; however, this information
was unclear in seven (26%) studies.
Health Technology Assessment 2007; Vol. 11: No. 41
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4383 initial search
285 selected for full assessment
4098 reports excluded
93 reports included
92 population-based reports 
(describing 27 studies)
1 meta-analysis
192 reports excluded
119 – not population-based reports or population not defined at the geographical level
  41 – subjects not similar to those in the UK:
      3 Latino
      9 African
    16 Asian
    13 West Indies
28 – no usable results
1 glaucoma was self-reported
1 reported number of eyes rather than number of subjects 
1 fatally flawed
1 authors did not report separate data for OAG and CAG
FIGURE 14 Study selection processCharacteristics of included studies
Appendix 6 provides details of the characteristics
of all included studies. Only A-rated studies are
described in this section
(n = 19).21,22,28,63,64,99,105–117 All but one of the
included studies105 described a population-based
cross-sectional study. The remaining eight
studies100–104,118–120 are also described in
Appendix 6.
Studies included in the review presented variations
in relation to study settings, age of participants,
types of exposures measured and the definition of
OAG (Tables 6 and 7). Of the 19 eligible studies,
four took place in the UK,21,64,113,116 three in 
the USA,111,114,122 two each in Australia,63,115
Italy,106,107 Iceland110,117 and Sweden,28,109 and
one each in Ireland,108 Spain,99 Greece,112
and The Netherlands.105
The participation rate ranged from 67%121 to
92%.21 Four studies did not provide information
on participation rate. Sample size ranged from
207116 to 32,918.28
All 19 studies gave details of participants’ age.
Eight studies included participants aged 40 years
old and all but seven studies did not have an
upper age limit. Most studies involved mainly
white populations. However, in one study 45%
(n = 2394) of included participants were of black
ethnicity.114
The majority of studies selected participants from
a population register (census in eight, municipal
register in three and electoral register in one).
One study took participants from another
population-based study.121 Two additional studies
drew participants from general medical practice
groups113,116 and one recruited participants after
delivering preliminary publicity campaign cards
inviting people over 40 years of age in Bedford,
UK, for a screening examination.64
All studies ascertained glaucoma status by means
of a clinical examination. Questionnaires were
used to ascertain exposure status of participants in
three studies.63,99,114
Disease prevalence
Data on prevalence was grouped as undetected
OAG and overall OAG. Undetected OAG refers to
participants being newly diagnosed at screening.
Overall OAG refers to both previously detected
and undetected glaucoma. All 19 studies provided
information on the prevalence of OAG with the
majority reporting undetected prevalence as well
as the overall prevalence (Table 7). Estimates of the
overall prevalence of OAG varied across studies,
ranging from 0.421 to 6.6%.117 The pooled
prevalence rate from 19 studies was estimated to
be 2.1% [95% confidence interval (CI) 1.7 to 2.5].
For previously undetected OAG, the pooled
prevalence rate was 1.4% (95% CI 1.0 to 1.9).
Fifteen studies contributed to this estimation and
values ranged from 0.3108 to 3.3%.109 By applying
the pooled prevalence estimates to the UK
population over 40 years of age, it was estimated
that there are approximately 569,000 people
affected by OAG, of which 380,000 are undetected
cases (Table 7, Figure 15). (The proportion of
people with undetected glaucoma across the
studies can be found in Appendix 6.)
Disease incidence 
The incidence of OAG was investigated in three
studies (Table 8).123–125 Two of the studies
estimated the incidence of OAG by conducting a
population-based cohort study with an observation
period of 5 years. The other study estimated the
incidence of OAG from age-specific prevalence
data. Based on these studies, the incidence rate
Epidemiology of open angle glaucoma
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TABLE 5 Summary of quality assessment of papers (n = 27) reporting cross-sectional studies
Criterion A B Unclear
Were participants sampled adequately and selected from a relevant population? 22 (81%) 5 (19%) 0
Were the criteria used in the diagnostic classification thorough? 22 (81%) 5 (19%) 0
Was IOP status obtained from a secure record?a 9 (90%) 1 (10%) 0
Was family history status obtained from a secure record?a 1 (20%) 4 (80%) 0
Was diabetes status obtained from a secure record?a 3 (75%) 1 (25%) 0
Was myopia status obtained from a secure record?a 3 (100%) 0 (0%) 0
Was the response rate greater than 75%? 16 (59%) 4 (15%) 7 (26%)
aAs not all studies report all risk factors, the total number of studies does not add up to 26.Health Technology Assessment 2007; Vol. 11: No. 41
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TABLE 6 Characteristics of included studies (only A-rated studies)
Study Country Participants  Age range  No. of  Ethnicity (%) Exposures
selection (years) participants
(% uptake) White Black
Anton, 200499 Spain Census 40–79 510 (90) NR  NR IOP; family 
Segovia Study history, age
Bankes, 196864 UK All population 40+ 5,941 NR NR IOP , age
Bedford Glaucoma 
Survey
Bonomi, 2001106 Italy National register 40–80+ 4,297 NR NR Age 
Egna–Neumarkt 
Glaucoma Study
Cedrone, 1997107 Italy Census 40–80+ 1,034 NR NR IOP , age 
Coffey, 1993108 Ireland Electoral register 50–80+ 2,186 NR NR IOP , age
Dielemans, 1996105 Netherlands Municipal registry 55–75+ 3,062 (72) 98 NR IOP , family 
Rotterdam Study history,
diabetes, age
Ekstrom, 1996109 Sweden Municipal registry 60–74 760 (91) NR NR
Tierp Glaucoma 
Survey
Grodum, 200228 Sweden All population 57–79 32,918 (77) NR NR
Leibowitz, 198022 US Other population- 55–84 2,631 (67) 100 Age
Framingham Eye  based study
Study
Hollows, 196621 UK Census 40–75 4,231  (92) NR NR
Jonasson, 1987117 Iceland Census 43–83+ 751 (81) NR NR Age
Jonasson, 2003110 Iceland Census 50–80+ 1,045 (76) NR NR Age
Reykjavik Eye 
Study
Klein, 1992111 US Census 43–84 4,926 (83) 100 0 IOP , myopia 
Beaver Dam Eye  diabetes
Study
Kozobolis, 2000112 Greece Municipal registry 40–80+ 1,107 (85) NR NR IOP , age
Mitchell, 1997122 Australia Census 49–80+ 3,654 (88) 100 0 IOP , age, family 
Blue Mountains Eye  history, myopia
Study
Reidy, 1998113 UK General medical  65–100 1,547 (84) NR NR Age
practice groups
Tielsch, 1991114 US Census 40–80+ 5,308 (79) 54.9 45.1 IOP , diabetes, 
Baltimore Eye  family history, 
Survey ethnicity, age
Weih, 2001115 Australia Census 40–90+ 4,498 (86) 100 0 IOP , family 
Visual Impairment  history, myopia, 
Project ethnicity, age
Wormald, 1992116 UK Age–gender 65+ 207  (72) NR NR
register
NR, not reported.Epidemiology of open angle glaucoma
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TABLE 7 Prevalence of OAG in population-based studies
Study ID Diagnostic criteria for OAG Participants Prevalence OAG (%)
Undetected Overall
Anton, 200499 Glaucomatous optic disc stereographs,  510 2.1 2.1
Segovia Study suprathreshold field and open angle 
Bankes, 196864 Disc, semi-automated field, open angle slit-lamp  5,941 NR 0.76
Bedford Glaucoma  examination on suspects
Survey
Bonomi, 2001106 Disc (direct ophthalmoscopy), suprathreshold  4,297 1.5 1.95
Egna-Neumarkt  field, slit-lamp examination
Glaucoma Study
Cedrone, 1997107 Suprathreshold field, and one of IOP positive or  1,034 2.3 2.5
disc positive
Coffey, 1993108 Disc and slit-lamp, suprathreshold field only in  2,186 0.3 1.0
suspects
Dielemans, 1996105 Threshold field, open angle and one of positive  3,062 0.6 1.1
The Rotterdam Study disc or IOP positive
Ekstrom, 1996109 Disc, threshold field, open angle on slit-lamp 760 3.2 5.7
Tierp Glaucoma 
Survey
Grodum, 200228 Threshold field, disc, open angle on slit-lamp  32,918 1.2 1.5
examination
Leibowitz, 198022 Glaucoma visual field defect and any of positive  2,631 NR 1.0
The Framingham Eye  IOP , or disc or glaucoma history
Study
Hollows, 196621 Disc, field, slit-lamp (open angle) 4,231 0.3 0.4
Jonasson, 1987117 Glaucoma visual field defect and any of positive  751 NR 6.6
IOP , or disc or glaucoma history
Jonasson, 2003110 Disc, IOP , threshold fields (two out of three) 1,045 2.4 4.0
Reykjavik Eye Study
Klein, 1992111 Disc (stereoscopic photograph), suprathreshold field 4,926 1.9 2.1
Beaver Dam Eye Study
Kozobolis, 2000112 Open angle (slit-lamp examination), disc, nerve  1,107 2.0 2.8
fibre defect and visual field defect
Mitchell, 1997122 Disc, open angle, suprathreshold field 3,654 1.2 2.4
Blue Mountains Eye 
Study
Reidy, 1998113 Suprathreshold field, disc 1,547 2.3 3.0
Tielsch, 1991114
Baltimore Eye Survey
Slit-lamp examination (open angles), disc,  5,308 1.2 2.5
(stereoscopic photography), field
Weih, 2001115 Disc, threshold visual field  4,498 1.1 1.8
Visual Impairment 
Project
Wormald, 1992116 Disc, suprathreshold fields 207 0.5 4.4
Pooled estimate 1.4 2.1
(95% CI) (1.0 to 1.9) (1.7 to 2.5)
UK estimate Number Number 
Denominator: affected affected
Total population over 40 (2001 Census): 27,116,127 379,626 569,439for OAG increases with age (Table 9). Incidence of
OAG ranged from 30 to 181 cases per 100,000
people per year at 40 and 70 years of age,
respectively. By applying the pooled estimate for
each age to the 2001 UK census population, the
number of new cases in the UK is estimated to
range from 263 to 880 new cases for 40 and 
70 year olds per calendar year, respectively. It is
noteworthy that sample sizes in the older age
cohorts are usually quite small and therefore the
estimates presented in Table 9 may not reflect the
true incidence among older people. In addition,
the ageing population in the studies may not be
representative of the general ageing population.
For those reasons, these incidence estimates
should be interpreted with caution.
Disease severity 
Five studies provided information on disease
severity for participants; however, information was
not provided separately for the newly detected
cases, and in the majority of cases disease status
was unclear (Table 10).71,108,114,117,126 In these
cross-sectional studies the percentage of people
with moderate disease varies from approximately
9%114 to 15.4%.126 Mild disease was reported in
only one study and was estimated to be 12.1%.114
Severe disease was reported in three studies,
varying from 4%117 to 14.6%.108 Blind from
glaucoma was reported in four studies, varying
from 3%71 to 10.6%.114 There appeared to be
heterogeneity between the studies regarding
severity definition and therefore these results
should be interpreted with caution. 
Demographic risk factors
Age
The prevalence of OAG by age was reported in 16
studies (Table 11). There was no standardisation of
age intervals across studies and therefore direct
comparisons were difficult. For the purpose of this
review, the focus was on age 40, 50, 60 and
70 years as cut-offs. All studies consistently showed
that the prevalence of OAG increases with older
age. The overall prevalence of OAG by age was 0.3
(95% CI 0.1 to 0.5) in people aged 40 years and
increased steeply with age to 3.3% (95% CI 2.5 to
4.0) in people aged 70 years. As the prevalence of
undetected cases stratified by age was not reported
in any of the included studies, it was assumed that
the proportion of undetected OAG does not vary
across age groups. The prevalence of undetected
OAG was then estimated to range from 0.2 to
2.1% in people aged 40 and 70 years, respectively
(Table 11). Figure 15 shows the estimated number
of people with undetected OAG in the UK,
steadily rising from 1761 at 40 years to 11,000
people at 70 years of age.
Health Technology Assessment 2007; Vol. 11: No. 41
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TABLE 8 Incidence estimates stratified by age
Age (years) Study Incidence rate (per 100,000 per year)
40 Mukesh, 2002125 0
50 Mukesh, 2002125 20
Podgor, 1983123 40
60 Mukesh, 2002125 120
Podgor, 1983123 60
de Voogd, 2005124 60
70 Mukesh, 2002125 280
Podgor, 1983123 140
de Voogd, 2005124 124
TABLE 9 Estimated new OAG cases per year by age cohorta
Age (years) UK population at risk  Mean  Range UK estimate  Range
(n) (per 100,000 per year)  (population)
40 878,257 30b 20–40 263 176–351
50 717,088 30 20–40 215 144–287
60 556,794 80 60–120 445 334–668
70 486,614 181 124–280 880 603–1408
a Population estimate for all people aged 40–70: 11,054 new cases per year in the UK.
b Same incidence as 50 year olds was assumed.Ethnicity
The relationship between ethnicity and OAG was
evaluated in only one study.114 This study
provided a direct comparison of prevalence
between black and white ethnicity. Age-specific
prevalence rates for OAG among African-
Americans ranged from 1.23% (95% CI 0.23 to
2.24) in those aged 40–49 years to 9.15% 
(95% CI 5.83 to 12.48) in those aged 70–79 years.
The relative risk of OAG among the Baltimore
over-40 years black population compared with
whites is estimated to be 3.80 (95% CI 2.56 to
5.64). The onset of disease appears to be earlier
for blacks as the number of cases identified for
those aged between 40 and 59 was considerably
higher than that observed in whites (2.3% and
Epidemiology of open angle glaucoma
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TABLE 10 Severity of glaucoma (newly detected and established cases)
Study Severity (%) Definition of severity
Mild Moderate Severe Blind Unclear
n (%) n (%) n (%) n (%) n (%)
Coffey, 1993108 NR NR NR NR 3 (15) 1 (7) 37 (78) Severe: low vision
(<6/18)
Blind: not reported
Dielemans, 199471 NR NR 2 (6a) NR NR 1 (3) 31 (91) Moderate: advanced 
Rotterdam Study visual field loss in at least
one eye
Blind: visual acuity
 20/200 in the better
eye
Jonasson, 1987117 NR NR NR NR 2 (4) 3 (6) 45 (90) Severe: visual field loss
Blind: visual acuity  6/60
in the better eye or
visual field less than 10°
(legally blind)
Lee, 2003126 NR NR 16 (15a) 6 (6) NR NR 82 (79) Moderate: advanced 
Blue Mountains  visual field loss in at least 
Eye Study one eye
Severe: bilateral
advanced visual field loss
Tielsch, 1991114 16 (12) 12 (9) NR NR 14 (11) 90 (68) Mild: one visual field 
Baltimore Eye  either typically abnormal 
Survey or compatible with
glaucoma and cupping or
nerve fibre layer loss
Moderate: at least one
abnormal visual field with
some but not perfect
congruence between
fields and a C/D  0.8 or
a difference between the
two eyes of  0.3
Blind: end-stage disease
with visual acuity
 20/200 and 100%
cupping
a No details of the other eye were given, so disease severity was assumed to be moderate because it was presumed that the
authors would have reported it as bilateral visual field loss (severe disease). Health Technology Assessment 2007; Vol. 11: No. 41
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TABLE 11 Pooled prevalence estimate stratified by age
Age (years) Study Prevalence (%) (95% CI)
Undetected Overall
40 Anton, 200499 00
Bankes, 196864 NR 2.0 (0 to 0.4)
Bonomi, 2001106 NR 0.4 (0 to 0.8)
Cedrone, 1997107 NR 1.4 (0 to 2.9)
Kozobolis, 2000112 NR 0
Tielsch, 1991114 NR 0.6 (0.1 to 1.0)
Weih, 2001115 NR 0.1 (0 to 0.2)
Pooled prevalence  0.2 (0.1 to 0.4)a 0.3 (0.1 to 0.5)
50 Anton, 200499 2.2 (0 to 5.2) 2.2 (0 to 5.2)
Bankes, 196864 NR 0.3 (0.1 to 0.5)
Bonomi, 2001106 NR 1.4 (0.7 to 2.0)
Cedrone, 1997107 NR 1.3 (0 to 2.8)
Coffey, 1993108 NR 0.7 (0 to 1.3)
Jonasson, 1987117 NR 0.9 (0 to 2.1)
Jonasson, 2003110 NR 0.6 (0 to 1.3)
Klein, 1992111 NR 1.0 (0.5 to 1.5)
Kozobolis, 2000112 NR 2.8 (0.4 to 5.1)
Mitchell, 1997122 NR 0.4 (0 to 0.7)
Tielsch, 1991114 NR 2.1 (1.3 to 2.8)
Weih, 2001115 NR 0.8 (0.3 to 1.3)
Pooled prevalence 0.6 (0.3 to 1.0)a 0.9 (0.6 to 1.3)
60 Anton, 200499 2.2 (0 to 4.7) 2.2 (0 to 4.7)
Bankes, 196864 NR 0.9 (0.4 to 1.4)
Bonomi, 2001106 NR 2.3 (1.4 to 3.1)
Cedrone, 1997107 NR 2.5 (0.8 to 4.3)
Coffey, 2003108 NR 1.8 (0.8 to 2.7)
Dielemans, 1996105 NR 0.2 (0 to 0.4)
Jonasson, 1987117 NR 3.0 (0.6 to 5.3)
Jonasson, 2003110 NR 2.8 (1.1 to 4.5)
Klein, 1992111 NR 1.1 (0.5 to 1.6)
Kozobolis, 2000112 NR 2.5 (0.9 to 4.2)
Leibowitz, 198022 NR 0.6 (0.1 to 1.0)
Mitchell, 1997122 NR 1.1 (0.5 to 1.6)
Tielsch, 1991114 NR 1.3 (0.9 to 1.8)
Weih, 2001115 NR 1.9 (1.1 to 2.6)
Pooled prevalence 0.9 (0.5 to 1.4)a 1.4 (1.0 to 1.9)
70 Anton, 200499 3.3 (0.4 to 6.1) 3.3 (0.4 to 6.1)
Bankes, 196864 NR 2.8 (1.5 to 4.2)
Bonomi, 2001106 NR 4.6 (3.0 to 6.3)
Cedrone, 1997107 NR 4.3 (1.7 to 6.9)
Coffey, 2003108 NR 3.2 (1.7 to 4.7)
Dielemans, 1996105 NR 1.3 (0.7 to 2.0)
Jonasson, 1987117 NR 6.1 (2.6 to 9.6)
Jonasson, 2003110 NR 8.0 (4.6 to 11.3)
Klein, 1992111 NR 2.8 (1.9 to 3.7)
Kozobolis, 2000112 NR 2.6 (1.1 to 4.1)
Leibowitz, 198022 NR 1.3 (0.5 to 2.1)
Mitchell, 1997122 NR 4.2 (2.9 to 5.4)
Reidy, 1998113 NR 2.0 (1.0 to 2.9)
Tielsch, 1991114 NR 4.6 (3.3 to 5.9)
Weih, 2001115 NR 4.2 (2.7 to 5.6)
Wormald, 1992116 NR 2.0 (0 to 4.7)
Pooled prevalence 2.1 (1.4 to 3.0)a 3.3 (2.5 to 4.0)
a Owing to the limited evidence on the prevalence of undetected OAG by age, the overall estimate of undetected OAG was
applied to each age category to produce crude age-specific estimates.0.25%, respectively). The number of people of
black ethnicity (Caribbean, African, other and
mixed) with OAG in the UK is estimated to be
approximately 9000 for those aged between 40
and 75 years. No studies reported data for other
ethnic populations.
Ocular risk factors
IOP
Seven studies described the prevalence of OAG by
a range of IOP levels.63,99,107,108,111,112,127 Across
the studies, the proportion of people with OAG
who had an IOP above 21 mmHg was consistently
higher than those who had an IOP of 21 mmHg
or less (Table 12). The proportion of people with
high IOP varied widely across studies. However, all
but one99 included cases with previously detected
OAG, and thus already under glaucoma therapy,
and therefore underestimate the true prevalence
of OAG in people with high IOP. The reason for
the study by Coffey108 reporting such a low
prevalence of glaucoma among those with high
IOP was unclear, although the authors did not
report IOP measurements in 12 of the 36 OAG
cases. Prevalence of IOP by higher IOP levels
( 26 mmHg) was also investigated. The risk of
having glaucoma for those with IOP
measurements 26 mmHg or greater is estimated
to be 13 times higher than that for those with
lower IOP [relative risk (RR) 12.58, 95% CI 5.07
to 31.24]; of note was that only newly detected
cases contributed to the estimation of this relative
risk.127
Myopia
Prevalence rates of OAG for those with and
without myopia were available from four studies
(Table 13).128–131 The proportion of people with
OAG appeared to be higher in participants with
myopia than in those without myopia. The
prevalence of OAG among people with myopia
ranged from 1.4 to 4.3%, with a pooled estimate
of 2.7% (95% CI 1.5 to 3.9). The pooled relative
risk of OAG among participants with myopia (any
definition) compared with non-myopes was
estimated to be 1.88 (95% CI 1.53 to 2.31). This
result should be treated with caution as there was
no standardisation on the definition of myopia
across the studies and therefore the risk for low
(<–6 D) and moderate (>–6 D) could not be
determined. 
Non-ocular risk factors
Diabetes
The prevalence of OAG by diabetes status was
reported in four studies that established diabetes
Epidemiology of open angle glaucoma
34
0
2000
4000
6000
8000
10,000
12,000
14,000
16,000
18,000
40 50 60 70
N
u
m
b
e
r
 
w
i
t
h
 
O
A
G
Overall OAG
Undetected OAG
Age (years)
FIGURE 15 Estimated number of people with OAG in the UK at specific agesby clinical tests.22,105,122,132 Three of those provided
adjusted estimates for odds ratios105,122,132 (Table
14). The prevalence of OAG among participants
with diabetes varied from 1.2%105 to 5.5%,122 with
a pooled estimate of 3.3% (95% CI 1.8 to 4.8%). As
shown in Table 14, this investigation demonstrated
almost twice the risk of OAG onset among people
with diabetes when compared with people without
diabetes (RR 1.93, 95% CI 1.38 to 2.69). The
number of those with diabetes with OAG in the UK
is estimated to be approximately 49,300 for those
aged over 45 years.
Family history
The relationship between family history of
glaucoma and OAG was investigated in five
studies.99,130,133–135 Only four presented data
sufficiently similar to allow for quantitative
synthesis.130,133–135 However, the Rotterdam
Study135 was removed from the analysis because
their uptake rate was low (<75%). The included
studies reported adjusted odds ratios estimates
(Table 15). The prevalence of OAG among
participants with a positive family history varied
from 4.2 to 8.6%, with a pooled estimate of 6.7%
(95% CI 5.0 to 8.4). The meta-analysis showed
that a family history of glaucoma is associated with
a three-fold excess age-adjusted risk of OAG
(RR 3.14, 95% CI 2.32 to 4.25) (Table 16). These
results should be interpreted with caution, as these
studies are methodologically weak because family
history of glaucoma was based solely on
Health Technology Assessment 2007; Vol. 11: No. 41
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TABLE 12 Prevalence of OAG stratified by IOP
Study Age (years) IOP > 21 mmHg (n/N) IOP     21 mmHg (n/N) Undetected OAG (%)
Anton, 200499 40–79 0.37 (3/8) 0.014 (7/497) 100
Cedrone, 1997107 40+ 0.34 (21/62) 0.005 (5/1002) 19.2
Coffey, 1993108 50+ 0.09 (6/65) 0.0087 (15/1734) 66.7
Klein, 1992111 43–84 0.31 (71/232) 0.007 (33/4694) 90
Kozobolis, 2000112 40+ 0.28 (28/101) 0.003 (3/1006) 70
Mitchell, 199663 49+ 0.2 (27/135) 0.022 (81/3654) 51
Tielsch, 1994127 40+ 0.1 (80/775) 0.011 (114/9669) 61
TABLE 13 Univariate and multivariate odds ratios (OR) reported by studies describing the relationship between glaucoma and myopes
Study Crude OR 95% CI Adjusted OR 95% CI Comments 
Grodum, 2001128 1.85  1.4 to 2.4 NR NR Myopia:  –2.0 D
Mitchell, 1999129 2.1a 1.2 to 3.8 2.4 1.3 to 4.1 Adjusted for age, gender, family history
of glaucoma, diabetes, hypertension,
typical migraine history, steroid use and
presence of pseudoexfoliation; myopia:
 1.0 to 3.0 D
Weih, 2001130 NR NR 1.6 0.9 to 6.7 Adjusted for age; myopia:  –0.5 D
Wong 2003131 NR NR 1.6 0.9 to 2.6 Adjusted for age and gender; myopia:
 –1.0 D
a Gender adjusted.
TABLE 14 Univariate and multivariate odds ratios reported by studies describing the relationship between glaucoma and diabetes
Study Crude OR 95% CI Adjusted OR 95% CI Comments 
Dielemans, 1996105 NR NR 3.11 1.12 to 8.66 Adjusted for age, gender and body mass
index
Klein, 1994132 NR NR 1.84 1.09 to 3.11 Adjusted for age and gender
Leibowitz, 198022 1.27 0.5 to 2.9 NR NR
Mitchell, 1997122 2.07 1.5 to 4.7 2.12 1.18 to 3.79 Adjusted for age and genderparticipant self-report of family history. This
method is suboptimal as it relies on the imperfect
knowledge among participants (a form of recall
bias).
This association remained statistically significant
when data from the Rotterdam Study135 were also
considered (RR 3.23, 95% CI 2.40 to 4.37). This
study investigated the relationship of OAG with
family history by means of a nested case–control
study and was initially excluded from this analysis
because of the high degree of uncertainty
surrounding the results owing to its small sample
size. However, it was the only study that
ascertained a positive family history by examining
first-degree relatives of patients with glaucoma
and control subjects from the population-based
Rotterdam Study.
Discussion
In this chapter a systematic review has provided
the basis for estimates of the prevalence of OAG in
Western countries and associated risk factors were
evaluated. The results support an association
between OAG and raised IOP, myopia, diabetes,
age, family history and black ethnicity. There were
insufficient data to estimate the risk of OAG for
other ethnic minority groups in the UK.
Inclusion criteria
Given the aetiological focus of this systematic
review, study designs such as population-based
cross-sectional and cohort studies were considered
the most appropriate sources of evidence on the
prevalence and incidence of OAG. As Beral136 and
Dickersin137 pointed out, if associations detected
by those studies are causal, even small increased
risks are likely to have a large public health impact
when exposure is common.136,137 Study designs
such as these are, however, subject to many
alternative interpretations because of the scope for
the results to be biased or confounded.138 In
addition, the published epidemiological literature
is unquestionably heterogeneous.137 Studies
naturally vary in terms of participants’
characteristics or on the methods used to assess
exposure and outcomes. The presence of major
heterogeneity among studies in a systematic review
means that the results of any statistical synthesis
should be treated with caution. 
Only 19 of the 26 studies identified in this review
were considered to be similar enough to allow for
meaningful pooling. This selection was based on
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TABLE 15 Univariate and multivariate odds ratios reported by studies describing the relationship between glaucoma and family history
Study Crude OR 95% CI Adjusted OR 95% CI Comments 
Mitchell, 2002133 2.7a 1.5 to 4.7 3.18 1.8 to 5.6 Adjusted for age, myopia, ocular
hypertension, diabetes and IOP
Tielsch, 1994134 2.48 1.6 to 3.9 2.85 1.8 to 4.5 Adjusted for age and race
Weih, 2001130 NR NR 3.7 2.0 to 6.7 Adjusted for age
Wolfs, 1998135 14.7a 1.7 to 130 16.6 1.9 to 147 Adjusted for age, gender, and the
presence of diabetes or hypertension
a Age and gender adjusted.
TABLE 16 Pooled prevalence estimates and respective adjusted relative risks stratified by ethnicity, IOP , myopia, diabetes and family
history
Risk factor Pooled prevalence (%)  Pooled adjusted  95% CI Number of studies
(95% CI) relative risk
Black ethnicitya – 3.80 2.56 to 5.64 1114
IOP  26 mmHg – 12.58 5.07 to 31.24 1127
Myopia 2.7 (1.5 to 3.9) 1.88 1.53 to 2.31 4128–131
Diabetes 3.3 (1.8 to 4.8) 2.08 1.44 to 2.99 3105,122,132
Family history 6.7 (5.0 to 8.4) 3.14 2.32 to 4.25 3130,133,134
a African-American.the consideration that reasonable quality studies
that might contribute usable data for evidence
synthesis should have an adequate sampling
method, an acceptable glaucoma definition, an
exposure status obtained from a high-quality data
source, and a response rate greater than or equal
to 75%.
This systematic review attempted to estimate the
current prevalence and incidence of OAG in the
UK by applying the pooled estimates to the 2001
UK Census population. There are numerous
epidemiological surveys assessing the prevalence
of glaucoma, but there are few cohort studies that
provide estimates of incidence. Only three studies
have been identified to report 5-year incidence
rates for a cohort of people. Incidence studies are
important to identify the risk of developing OAG
and the number of new cases among a population
of individuals previously unaffected. Prevalence
studies only measure the risk of having the
disease. To overcome this problem, some studies
derived the incidence from already available
prevalence data.139,140 Using this method,
Minassian and colleagues140 in the UK estimated a
higher incidence than that observed in this study
(approximately 14,000 as opposed to 11,000).
This difference may be because their estimate is
based on a much smaller population, including
only those aged above 65 years. 
The systematic review includes the results of 14
studies conducted in eight different European
countries, as well as three in the USA and two in
Australia. The breadth of coverage across
geographical areas facilitates the consideration of
generalisability, although this limited the data
available on the risk of glaucoma by ethnicity.
Included studies
Only four UK surveys21,64,113,116 met the inclusion
criteria, two of which were performed during the
1960s. For these two, the level of risk, population
structure, disease definition and methods of
diagnosis used may no longer be applicable to the
current situation. In addition, the results of studies
performed outside the UK may not be
generalisable to a UK population owing to
differences in aetiological and cultural factors.
Further studies would be useful to assess directly
the prevalence of OAG overall and by the different
risk factors deemed important for the UK. 
The results of the review may be biased if the
participation rates in the included studies are low.
In this review, six of the 19 studies included did
not provide information on participation rates. In
addition, the majority of studies that provided this
information did not give details about the
characteristics of those who did not participate.
This provides a potential for bias if the risk of
glaucoma among responders is systematically
different from that of non-responders. If non-
responders were to be more likely to be glaucoma
cases (perhaps because they do not see the benefit
of entering the study), then this would lead to
underestimation of the prevalence of OAG in the
population. 
The results of this systematic review must also be
interpreted in light of the quality of the included
observational studies. A validated checklist was not
used to assess the quality of the included studies;
instead, a set of fields had to be satisfied in order
for a study to be considered good quality with no
major flaws. The reason for this is that there are
no validated checklists available to assess the
quality of cross-sectional studies. Some may find
this checklist compact and oversimplified.
However, studies failing to provide details on
eligibility criteria or where the credibility of 
study designs was questionable were excluded
before the quality assessment stage. For example, 
a cohort study that did not demonstrate the
outcome of interest would have been excluded
with no further quality assessment conducted.
Nevertheless, despite efforts to focus only on 
the best available data for some outcomes (e.g.
risk of OAG by family history) B-rated studies had
to be included because of the lack of available
evidence. Furthermore, even where data were
available they were not always reported in a 
format suitable for inclusion in the meta-analysis.
For example, Anton and colleagues99 evaluated
the relationship of OAG to family history of
glaucoma, but results were presented as a
proportion of those with OAG who had a positive
family history. No data were provided on the
proportion of people with family history in the
total sample and, hence, a relative risk could not
be estimated. 
One of the main difficulties in ascertaining an
estimate of population prevalence and risk factors
for developing OAG is the lack of a reference
standard definition of OAG. Raised IOP is a risk
factor for developing OAG, but does not define its
presence or absence. In this review, studies were
included using a definition of OAG based on
glaucomatous visual field loss, but the definition of
a glaucomatous visual field defect varied
considerably across the studies. Perimetric
methods for ascertaining glaucomatous visual field
loss have evolved over time. The review included
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studies used a range of criteria to define a positive
test; therefore, the definition of a positive case
may vary between observers and studies and
account for some of the variation in prevalence
rates between studies. Differential verification bias
was likely in some of the included
studies28,64,106–108,110,112 in that only suspects on
the initial screen went on to a more extensive
reference standard examination, and therefore
some of the cases may have been missed.
Therefore, the prevalence may have been
underestimated by these studies.
OAG and age
The association between OAG and age is very
robust. All included studies show that the
prevalence of OAG is higher in older age groups.
One of the limitations in the calculation of a
pooled estimate of prevalence in this review is the
fact that the age cut-offs used were different to
those reported in the included studies. In
addition, specific age points (40, 50, 60, 70) were
chosen rather than age ranges, and therefore the
assumption that the prevalence is constant across a
particular age range may not be a true
representation.
OAG and ethnicity
Only one study included in the review reported
data on the relationship between ethnicity and
OAG.114 The risk of having OAG for African-
Americans was found to be approximately four
times that for whites. OAG is not only more
prevalent but also appears to be more severe in
black than in white people. This is possibly
because the onset of disease is earlier for black
people than it is for white people.114 The relative
risk was not adjusted for other risk factors and
should therefore be treated with caution. In
addition, the UK African Caribbean Eye Survey
reported that not only darker skin but also place
of origin in Africa are associated with a
significantly increased risk of disease.120 The risk
of glaucoma among black Africans was
significantly higher than that in black Caribbeans.
This study was, however, a B-rated study, in that it
was based on a volunteer sample rather than a
random sample of the population. 
Studies conducted in Africa, South America and
Asia were not included, as it was felt that the level
of risk in these settings would not necessarily be
representative of the risk observed in the same
ethnic groups living in the UK. Prevalence rates as
high as 13% and 16% have been observed in
Congo141 and Barbados.142
The increased risk associated with black ethnicity
may be a function of the excess co-morbidities in
these populations, including sickle cell disease,
systemic hypertension and diabetes.143 There may
also be ethnic differences in optic disc
morphology and an increased susceptibility at a
given IOP level. However, there is likely to be
heterogeneity within an ethnic population, and a
common level of attributable risk to being of black
ethnicity may not be appropriate for different
geographical areas and subgroups within an ethnic
group.144
People of Hispanic ethnicity are also at increased
risk. In a large US population-based study of
definite OAG in Latinos of Mexican ancestry,
including more than 6000 participants who
underwent a complete ophthalmic examination
for determining glaucoma, the prevalence pattern
of OAG was similar to that observed in those of
black ethnic origin in the USA and significantly
higher than in non-Hispanic whites.145
OAG and IOP
Across the included studies the proportion of
people with OAG who had an IOP greater than
21 mmHg was consistently higher than among
those who had an IOP less than 21 mmHg. Even
though a clear association was found between
OAG and high IOP, it is possible that this
relationship could be stronger. The reason for this
is that the included studies did not provide a
separate IOP measurement for those participants
who had previously detected glaucoma. It is very
likely that these participants will be receiving
pressure-lowering therapy, hence the possible
underestimation of the prevalence of OAG among
those with high IOP. One study provided sufficient
data to calculate the relative risk based on
previous undiagnosed cases.127 The sample was
small and the estimate was unadjusted for other
risk factors and should therefore be treated with
caution.
OAG and myopia
There is evidence that people with myopia are
more likely to develop OAG. One of the greatest
limitations in assessing the relationship between
these two conditions is the lack of a consensus
across the included studies on the definition of
myopia. For example, in the Visual Impairment
Project,115 participants were classified as myopes
when they had a refractive error worse than
–0.5 D, whereas Grodum and colleagues28 used a
refractive error equal or worse than –2.0 D to
classify myopes. In addition, differences in the
definition of glaucoma may lead to an
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people with myopia. However, overdiagnosis of
glaucoma among people with myopia may also be
responsible for this association, because myopia is
associated with a number of non-glaucomatous
visual field defects and myopic discs can be
difficult to assess for glaucomatous damage.131
Owing to limited evidence it was not possible to
estimate the risk of glaucoma in people with low
and moderate myopia and therefore the pooled
estimates should be treated with caution. 
Structural differences in the myopic optic nerve
may make myopic eyes more susceptible to
glaucomatous damage.129,131,146 Furthermore,
glaucoma and myopia have a strong familial basis
and therefore they may share a common genetic
link.129 A dose–response relationship between
OAG and myopia has been postulated (the higher
the myopia the more likely an individual would be
to develop OAG). This relationship can be
observed in the Blue Mountains Eye Study,
reporting an odds ratio of 3.3 for those with
moderate to high myopia ( –3.0 D) compared
with 2.3 in those with low myopia ( –1.0 to
<–3.0 D).129
OAG and diabetes
Currently available evidence suggests that there is a
positive association between people with diabetes
and OAG. The present study identified an
increased risk of OAG in those with diabetes. These
results are consistent with those of a meta-analysis
performed in 2004 (OR 1.57; 95% CI 1.13 to
2.20).147 This meta-analysis had variations in the
eligibility criteria used to select studies compared
with the present study. Bonovas and colleagues147
included studies that did not establish diabetes
through a clinical examination as well as studies
that were conducted in African countries. These
were excluded in the review reported in this chapter
because, in order to avoid detection bias, exposure
should be obtained from a secure record, and also
because it is believed that the level of risk of OAG
in people in countries of African descent is very
different from that observed in other populations. 
The results reported in this chapter are consistent
with one population-based cohort study
performed in Scotland,102 and with one
population-based cross-sectional study performed
in England.116 Ellis and colleagues102 reported a
risk ratio of 1.57 for diabetes, although this result
was not statistically significant. This study was
excluded from the analysis owing to inadequate
methods used to select cases of glaucoma.
Wormald and colleagues120 reported a risk ratio of
2.2 for diabetes, but this result was also not
statistically significant (95% CI 0.9 to 5.6). This
study was excluded from the analysis because a
volunteer sample was used rather than a random
sample and therefore it is likely that a healthy
volunteer effect was present in the results. The
method of sampling is crucial to the avoidance of
selection bias, and the observed increased risk in
people with diabetes and myopia may reflect this
type of bias, in that these groups may be more likely
to be tested for glaucoma because they have regular
eye tests for diabetic eye disease and for spectacle
care for myopia. The impact of this bias would be
to elevate artificially the relative risk of OAG. 
OAG and family history 
All studies identified indicated that an association
exists between OAG and a positive family history.
However, none of the included studies proved to
be high quality (i.e. none was rated as ‘A’ in the
quality assessment). There was no standardisation
on the type of family history reported across the
four included studies.115,133–135 It is possible that
the level of risk varies according to the type of
family history. For example, Tielsch and
colleagues134 and Mitchell and colleagues133 found
some variability in the strength of the association
by the type of family member, in which the
strongest association was observed between
siblings. 
Most of the studies relied on verbal reporting of
family history of glaucoma rather than a clinical
examination of relatives of glaucoma cases,
making results prone to misclassification. Such
misclassification may be due to an
underascertainment of glaucoma cases since the
diagnostic criteria used for relatives may have
been different from those used to diagnose the
cases. Moreover, those who had a previous
diagnosis of glaucoma are more likely to recall and
therefore report a positive family history.133,134 In
the Rotterdam Study, attempts were made to
minimise some of these biases by examining
relatives of glaucoma cases. However, a small
sample size led to wide confidence intervals
surrounding the estimates, giving rise to a high
degree of uncertainty.135
Even though an increased risk of glaucoma among
people with a positive family history has been
observed, the population attributable risk is low.
This was estimated in two studies.133,135 Both
estimated a population attributable risk of
approximately 16%, suggesting that other risk
factors largely determine the occurrence of
glaucoma in the population.
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Key points:
● This systematic review estimates the prevalence
of OAG in a predominantly white population
aged over 40 years to be 2.1% (95% CI 1.7 to
2.5). An estimated 67% of cases are not
currently detected; a prevalence rate of 1.4%
(95% CI 1.0 to 1.9) is estimated for those with
previously undiagnosed disease.
● The overall prevalence of OAG by age ranges
from 0.3 (95% CI 0.1 to 0.5) in people aged
40 years, increasing steeply to 3.3% (95% CI 
2.5 to 4.0) in people aged 70 years. 
● The incidence of glaucoma is estimated as
ranging from 30 to 181 per 100,000 person-
years for people aged 50 and 70 years,
respectively.
● Approximately 569,000 people are affected by
OAG, of whom 380,000 are undetected cases.
The number of people with undetected disease
steadily rises from 1800 at 40 years, reaching
approximately 11,000 at 70 years of age. One
can estimate that there are approximately
11,000 new cases of OAG per year. 
● The risk of having glaucoma for those with IOP
measurements 26 mmHg or greater is estimated
to be 13 times higher than that for those with
lower IOP.
● The onset of disease appears to be earlier for
black people and the relative risk of OAG for
people of black ethnicity compared with white
people is estimated to be 3.80 (95% CI 2.56 to
5.64).
● There is almost twice the risk of OAG onset in
people with diabetes compared with those
without diabetes (RR 1.93, 95% CI 1.38 to 2.69).
● A positive family history of glaucoma is
associated with OAG (RR 3.14, 95% CI 2.32 to
4.25). The strongest association is for siblings of
an affected case. 
● The proportion of people with OAG appeared
to be higher in participants with myopia
compared with those without myopia. The
combined relative risk of OAG among
participants with myopia compared with those
without myopia was estimated to be 1.88 
(95% CI 1.53 to 2.31).
Strengths and limitations:
● This comprehensive systematic review identified
19 eligible studies. Data were sparse for some of
the review outcomes. For example, only one
study provided data on the relationship between
OAG and ethnicity. There were few data for the
assessment of disease severity. Even though a
number of studies reported family history, none
of the included studies that contributed to an
overall estimate was of high quality. Therefore,
more accurate risk information is necessary for
better estimates to be developed in relation to
family history and ethnicity.
● An extensive literature search was conducted,
but only published data in English were sought.
It is possible that unpublished and non-English-
language studies were missed, with the direction
of effect in these studies being unknown. 
● Strong associations between OAG and increased
age, black ethnicity, high IOP, myopia, diabetes
and family history are highlighted. However,
the prevalence of glaucoma by certain risk
factors may be overestimated, in particular
when assessing family history, myopia and
diabetes as potential risk factors, as these
groups are more likely to have sight tests, and
therefore may be more likely to have glaucoma
diagnosed. Also, some studies did not adjust
relative risk estimates to other risk factor
variables. 
● Risk factor and OAG definitions varied
considerably, causing the exclusion of several
studies because of poor reporting and
inadequate criteria. 
For future epidemiological studies, a standardised
definition of OAG and improved reporting on how
the suspects and definite cases received the
reference standard diagnostic assessment are
required. Efforts should be directed to create a
collaborative group with the aim of standardising
data such that the results can be presented and
pooled with similar case definitions for similar
populations. Ideally, prevalence studies should
report IOP measurements for participants with
newly diagnosed (i.e. untreated) glaucoma, to allow
the determination of appropriate cut-offs for IOP
as a diagnostic or prognostic indicator of OAG.
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There are many potential tests or combinations of
tests for detecting glaucoma (see Chapter 3). To
date, no single test or combination of tests has
been identified as a definitive screening test for
glaucoma. 
The aim of this systematic review was to evaluate
the accuracy of candidate screening tests and to
provide details of the reliability of the tests and
the proportion of people able to complete each
test.
Methods
Inclusion and exclusion criteria
Types of study
The following types of study were included:
● direct (head-to-head) studies in which both
index test(s), comparator test(s) and reference
standard test are done independently in the
same group of people
● RCTs in which people are randomised to the
index and comparator test(s) and all receive the
reference standard test. 
Where there was insufficient evidence from direct
studies and RCTs, indirect (between-study)
comparisons were considered by meta-analysing
studies that compared each single test or
combination of tests with the reference standard
test, and comparing the meta-analyses of the
different tests. This type of study design, however,
is less reliable than direct studies as differences in
test accuracy are susceptible to confounding factors
between studies. The following types of study were
considered for the indirect comparisons:
● observational studies, including cohort studies,
with analysis data on at least 100 participants,
in which the sample is created by identifying all
people presenting at the point of testing
(without any reference to the test results)
● case–control studies in which two groups are
created, one known to have the target disease
and one known not to have the target disease,
where it was reasonable to assume that all
included had undergone the index and
reference standard tests.
Population-based studies and studies in a primary
care or hospital-based setting were considered
where the participants were likely to be
representative of a screening situation or of a
glaucoma suspect population referred from a GP
or an optometric practice. Case–control studies
where the inclusion criteria were different for cases
and controls were excluded; that is, studies
comparing severely diseased people with very
healthy controls or studies excluding people with
other ocular disease such that the spectrum of
disease and non-disease was unlike that to be
encountered in a screening situation. Also
excluded were case reports and studies
investigating technical aspects of a test. 
Target condition
The target condition was OAG (early, moderate or
severe).
Participants
People over 40 years of age and those in the
following higher risk subgroups were included:
● family history of glaucoma
● black race
● people with myopia
● people with diabetes.
The criteria for defining myopia and diabetes
were loosely applied and definitions used by study
authors for these conditions were considered
acceptable.
Index and comparator test(s)
The tests to be considered fell within three broad
categories:
● structure
– ophthalmoscopy
– optic disc photography (including non-digital
and digital monoscopic and stereoscopic
photography, and planimetric)
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Chapter 6
Screening and diagnostic tests for open 
angle glaucoma– RNFL photography
– HRT version II
– GDx VCC RNFL analyser (scanning laser
polarimetry)
– OCT
–R T A
● function:
– FDT
– MDP
– OKP
–S W A P
– white-on-white SAP, including suprathreshold
and threshold
● IOP:
–G A T
– NCT
– tonopen.
Comparisons both of individual and combinations
of tests were considered.
Reference standard test
There is no optimal reference standard for the
diagnosis of OAG or the classification of its
severity. OAG is a clinical diagnosis, based on
structural abnormalities of the optic disc and an
associated glaucomatous visual field defect.
Progressive structural optic neuropathy has been
proposed as a reference standard.148
Either of two reference standard tests was
considered. The primary reference standard test
was confirmed OAG on follow-up. This was
considered the best reference standard, although it
was anticipated that few studies would use it.
Therefore, also considered were studies where the
reference standard was ophthalmologist-diagnosed
OAG requiring treatment. This diagnosis can be
based on an assessment of the visual field and/or
the optic disc, but without follow-up confirmation.
Each reference standard might include one or
more of the screening tests against which it was
being compared.
Studies using a technology-based diagnostic test(s)
result alone as a reference standard were excluded. 
Types of outcome
To be included, studies had to report relevant and
interpretable data on one of more of the following
types of outcome:
● the absolute numbers of true positives, false
positives, false negatives and true negatives, or
numbers from which they could be computed,
such as the sensitivity and specificity values
● adverse events
● acceptability of the tests to those who receive
them
● reliability of the tests.
If the evidence allowed, it was planned to assess
test performance in early, moderate and severe
glaucoma.
Data extraction strategy
Two reviewers (GM, MARS) screened the titles
(and abstracts if available) of all reports identified
by the search strategy. Full text copies of all studies
deemed to be potentially relevant were obtained
and two reviewers (GM, MARS) independently
assessed them for inclusion. Any disagreements
were resolved by consensus or arbitration by a
third party (JB).
A data extraction form was developed and piloted.
One reviewer (GM or MARS) extracted details of
study design, participants, index, comparator and
reference standard tests, participant flow and
outcome data. In the event of any uncertainty, a
second reviewer (GM or MARS) provided advice
and validated the data extraction.
Quality assessment strategy
Quality assessment was performed using the
QUADAS tool. QUADAS is a recently developed
quality assessment tool for use in systematic
reviews of diagnostic studies.149 It was developed
through a formal consensus method and was
based on empirical evidence. The original
QUADAS checklist contained 14 questions. The
QUADAS tool was adapted to make it more
applicable to assessing the quality of studies of
tests for detecting OAG. (See Appendix 7 for an
example of the modified checklist.)
Question 1 concerns the representativeness of the
spectrum of people assessed by the test (question
1 of the original QUADAS checklist). This was
split into two parts, depending on whether the
study sample was (1) taken from an unscreened
population with a glaucoma prevalence between
>0 and 20% or (2) constructed from previously
undiagnosed glaucoma patients but representative
of those referred from primary care as suspect
glaucoma. Case–control studies were assessed on
the basis of whether the cases and controls could
be regarded as representative of those detected in
primary care. 
Question 2, concerning the reference standard
(question 3 of the original QUADAS checklist),
was reworded to ask whether the reference
standard was follow-up confirmation of glaucoma
Screening and diagnostic tests for open angle glaucoma
42(i.e. glaucoma confirmed clinically by the
longitudinal follow-up of the patient), considered
to be the best reference standard against which to
measure tests for detecting OAG. Given the nature
of the reference standard, the QUADAS question
on whether the period between reference standard
and index test was short enough to be reasonably
sure that the target condition did not change
between the two tests was omitted (question 4 of
the original QUADAS checklist).
Questions 3 (partial verification bias), 
4 (differential verification bias), 5 (incorporation
bias), 6 (test review bias), 7 (diagnostic review bias)
and 10 (withdrawals from the study) remained
unchanged (questions 5, 6, 7, 10, 11 and 14 of the
original QUADAS checklist). Partial verification
bias occurs when not all of the study participants
are verified by a reference standard. Differential
verification bias happens when some of the
patients receiving the index test are verified by a
different reference standard. Incorporation bias
occurs when the index test also forms part of the
reference standard. Test review bias and diagnostic
review bias happen when interpretation of the
results of the index test is influenced by
knowledge of the results of the reference standard,
and vice versa.
It should be noted that in relation to
incorporation bias (question 5), in glaucoma a
situation may occur whereby the index test may be
a test of visual function (e.g. FDT) and the
reference standard may include a different test of
visual function (e.g. SAP). In such cases question 5
was marked as incorporation bias avoided, taking
the view that although both tests were of visual
function they were actually different tests.
However, in a situation such as this the sensitivity
and specificity of the index test may be
overestimated as the tests are measuring similar
outcomes. The same situation may occur with
different tests that assess the structure of the eye
when one is the index test and one forms part of
the reference standard, e.g. HRT II and
ophthalmoscopy. 
Question 8 is concerned with whether the same
clinical data were available when the test results
were interpreted as would be available when the
test is used in practice (question 12 of the original
QUADAS checklist). This question was split into
two parts, depending on whether the study was a
screening or diagnostic accuracy study. It was
assumed that in a screening situation in practice
the index test results alone would be used, but that
for studies of diagnostic test accuracy (cohort or
case–control) in practice information from
ophthalmic examination and/or information on
co-morbidity might be used.
Question 9 concerns the reporting of numbers 
of uninterpretable/intermediate test results
(question 13 of the original QUADAS checklist). 
If uninterpretable/intermediate results occur 
but are not reported then this may lead to a
biased assessment of the test characteristics.
Therefore, this question was retained and also
amended to include whether incomplete tests 
were reported. 
Items relating to the quality of reporting in terms
of the description of the selection criteria, the
execution of the index test, and the execution of
the reference standard test were omitted
(questions 2, 8 and 9 of the original QUADAS
checklist). Three questions were added to the
checklist on whether the technology of the index
test was still current (question 11), whether the
study provided a clear definition of what was
considered a positive result (question 12), and
whether the definition of a positive test result was
determined before the study was carried out
(question 13).
Two reviewers (GM, MARS) independently
assessed the quality of all included studies using
the modified version of QUADAS. Each of the 13
questions was checked as ‘Yes’, ‘No’ or ‘Unclear’.
Each item was worded so that a rating of ‘Yes’ was
always optimal in terms of methodological quality.
Any disagreements were resolved by consensus or
arbitration by a third party (JB). A ‘higher quality’
study was considered to be one that was checked
as ‘Yes’ to questions 1 (patient spectrum
representative), 3 and 4 (partial and differential
verification bias avoided) and 6 and 7 (test review
bias and diagnostic review bias avoided).
Sensitivity analysis was planned to assess whether
the results for higher quality studies differed
systematically from those of the other included
studies.
Data analysis 
The results of the individual studies were
tabulated and sensitivity, specificity, and diagnostic
odds ratios (DORs) calculated. A DOR combines
sensitivity and specificity into a single summary of
diagnostic performance. If more than one
threshold level was reported in a given study a
separate 2 × 2 table was derived for each
threshold. Separate 2 × 2 tables were also
produced for relevant subgroups considered in the
studies.
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calculated for studies comparing two or more tests
in the same participants. A 95% confidence
interval was calculated under the assumption of
two independent groups which will be conservative.
Insufficient data were reported, however, to allow
a paired analysis to be undertaken.
Summary performance of each test
Summary receiver operating characteristic (SROC)
curves were produced for each test where two or
more studies reported estimates of sensitivity and
specificity. A second set of SROC curves was also
produced for a test-specific common cut-off. From
each study reporting each test, a cut-off was
chosen (the common cut-off) from among the
various cut-offs reported. The aim was to select a
cut-off that was broadly similar across studies
reporting that test. The decision on which cut-off
to select was made following discussion by two
ophthalmologists (JB and RS). Owing to the
limited number of studies identified, statistical
investigation of the potential sources of
heterogeneity was not undertaken. The F
distribution method was used for calculating the
confidence intervals for sensitivity and specificity
for individual studies,150 which were produced
using Metadisc software.151
Meta-analysis models were fitted using the
hierarchical summary receiver operating
characteristic (HSROC) model152 in WinBUGS
1.4.153 This model takes proper account of the
diseased and non-diseased sample sizes in each
study, and allows estimation of random effects for
the threshold and accuracy effects. The SROC
curves from the HSROC models were produced on
the corresponding SROC plots. Summary
sensitivity, specificity and DORs for each model
were reported as median and 95% credible interval
(CrI). Credible intervals are the Bayesian equivalent
of confidence intervals. Where two or more higher
quality studies were available for a test, a model
using only these studies was also fitted. A
simplified model, which assumed a symmetrical
SROC shape, was used where limited data caused
convergence problems under the full model.
Indirect comparison between tests
All tests with two or more included studies were
modelled together in a single HSROC model to
compare formally the performance of the tests. A
symmetrical SROC model was assumed for all the
tests. Pairwise differences in sensitivity and
specificity between tests were assessed from the
median difference and the corresponding 95%
credible interval.
Results
Number and type of studies included 
Appendix 8 lists the 82 studies published in 93
reports that were included.
Accuracy
Forty studies, published in 46 reports, met the
inclusion criteria for the screening and diagnostic
accuracy review. There were 20 population-based
studies representative of a screening
setting.21,72,99,100,106,112,115,154–170 Twenty studies
were representative of a glaucoma suspect
population referred from primary care, of which
eight were cohort studies22,171–177 and 12 were
case–control studies.178–191
Uptake, interpretability, time taken to do test
and reliability of test
In addition to the studies included in the review of
screening and diagnostic test accuracy that
contributed information on uptake,
interpretability of tests, time taken to do the test
and reliability of the test, 47 reports also provided
data on these aspects. These studies did not
provide usable outcome data in terms of test
accuracy, but otherwise met the review’s inclusion
criteria.107,109,110,132,192–234 Information on uptake,
interpretability and time taken to do the test is
given in the results section for each test, while
those studies reporting reliability are listed in
Appendix 9. 
Number and type of studies excluded,
with reasons for specific exclusions
For the screening and diagnostic accuracy review,
5918 titles and abstracts from the specific and
general searches were screened, from which 877
were selected for full-text assessment. Articles were
excluded because they failed to meet one or more
of the specified inclusion criteria in terms of study
design, participants, index tests, reference
standard or outcomes reported. Fifty-seven of the
full-text reports excluded were case–control studies
whose participants were considered to be
unrepresentative of those who would attend for
screening and are listed in Appendix 10. 
Tabulation of quality of studies,
characteristics of studies and evidence
rating
Quality of studies
The results of the quality assessment for the
individual studies are shown in Appendix 11. The
quality assessment of studies reporting the various
tests is discussed in the results section for each
test.
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Appendix 12 provides details of the characteristics
of the included studies. 
The 40 studies enrolled over 48,000 people, with
over 39,000 included in the analysis. The earliest
study took place in 196321 and the latest in
2003/04,156,176 while 21 studies gave no indication
of the period in which they were carried out.
Thirteen studies took place in the
USA,22,158,159,162,166,168,170,172,175,181,187–189 nine in
the UK,21,164,176,177,180,182,186,190,191 four in
Australia,115,157,163,173 two each in Italy,106,174 The
Netherlands,169,183 Spain99,179 and Sweden,100,171
one each in Belgium,155 Canada,156 Greece,112
India161 and Norway,154 and one in Canada and
Finland.178 Twenty-six studies gave details of the
gender of their participants, 51% of whom were
women.21,22,99,106,112,115,154–157,159,161–164,166,168,170,171,
173–176,183,186,188 The median age of the
participants across studies was 60.5 years, with an
age range from 13 years183 to 97 years.155,157
The reports included a number of major
population-based prevalence surveys, such as the
Baltimore Eye Survey,72,159 the Blue Mountains
Eye Study,157 the Crete, Greece Glaucoma
Study,112 the Dalby Population Survey,100 the
Egna–Neumarkt Study,106 the Framingham Eye
Study,22 the Glaucoma Screening Study
(GLASS),158,160 the Groningen Longitudinal
Glaucoma Study,183–185 the Rhondda Valley
Study,21 the Rotterdam Study,169 the Segovia
Study99 and the Visual Impairment Project.115
The included studies reported the following 
tests: ophthalmoscopy,115,163,164,168,172,177,191
optic disc photography,166,169,175,188–190 RNFL
photography,167,178,188,189 HRT II,156,163,186
OKP,154,170,180,182
SAP,157–159,162–164,166,168,174,176,179,181,182,186
FDT,155,161,163,170,173,176,183–185,187
GAT,21,22,99,100,106,112,157,168,171 and NCT.164,165 No
studies of GDx VCC, OCT, RTA, SWAP, MDP or
Tonopen met the inclusion criteria in terms of
reporting of test accuracy outcomes. 
Eighteen population-based studies reported
uptake (the percentage of those eligible for
screening who actually attended).21,22,99,100,106,107,
109,110,112,115,132,154,157,159,163,164,168,169 Out of a total
of 58,708 eligible people, 44,653 (76.1%) attended
for screening (median 82.8%, range 28.3–99.5%)
(Table 17). Fifteen of these studies are included in
the screening and diagnostic accuracy review.
Three others failed to meet the review’s inclusion
criteria in terms of test accuracy outcomes, but as
they provided data on uptake they have also been
included in the table.107,110,132
Tabulation of results
Tests of structure
Ophthalmoscopy
Quality assessment
Seven studies enrolling 7279 people reported the
test accuracy of ophthalmoscopy, including four
population-based studies,115,163,164,168 two cohort
studies172,177 and one case–control study.191
Figure 16 summarises the quality assessment for
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TABLE 17 Uptake reported by population-based studies
Study Eligible Attended %
Anton, 200499 (Segovia Study) 569 510 89.6
Bengtsson, 1980100 (Dalby Population Survey) 1,938 1,511 78.0
Bonomi, 2001106 (Egna–Neumarkt Study) 5,816 4,237 72.9
Cedrone, 1997107 1,226 1,034 84.3
Christoffersen, 1995154 196 195 99.5
Ekstrom, 1996109 (Tierp Glaucoma Survey) 838 760 90.7
Hollows, 196621 (Rhondda Valley Study) 4,608 4,231 91.8
Ivers, 2001157 (Blue Mountains Eye Study) 4,433 3,654 82.4
Jonasson, 2003110 (Reykjavik Eye Study) 1,379 1,045 75.8
Katz, 1993159 (Baltimore Eye Survey) 6,705 5,308 79.2
Klein, 1994132 (Beaver Dam Eye Study) 5,924 4,926 83.2
Kozobolis, 2000112 (Crete, Greece Glaucoma Study) 1,300 1,107 85.2
Leibowitz, 198022 (Framingham Eye Study) 3,977 2,631 66.2
Robin, 2005163 2,486 704 28.3
Vernon, 1990164 988 874 88.5
Wang, 1998168 530 405 76.4
Weih, 2001115 (Visual Impairment Project) 5,520 4,744 85.9
Wolfs, 1999169 (Rotterdam Study) 10,275 6,777 66.0
Total 58,708 44,653 76.1these studies. In four of the seven studies the
participants were considered to be representative
of a screening setting.115,163,164,168 Four studies
were judged to be free from both partial and
differential verification bias.163,172,177,191 In three
of the seven studies both the index test and the
reference standard test were interpreted without
knowledge of each other’s results.115,163,191 Only
the study by Robin and colleagues163 met all
criteria specified for higher quality studies.
Accuracy
Figure 17(c) shows the sensitivity and specificity,
with 95% confidence intervals, for the five studies
reporting ophthalmoscopy at a common cut-off
(for details of the common cut-off selected for
ophthalmoscopy see Appendix 13). There was
statistically significant heterogeneity across the
studies, most obviously due to the study by
Theodossiades and colleagues in terms of
sensitivity177 and Theodossiades and colleagues177
and Wood and colleagues191 in terms of specificity.
Both were small studies using subjective criteria to
detect suspect discs in an already suspect
population, one being a cohort study177 and the
other a case–control study.191 In both studies it was
unclear whether the spectrum of people was
representative of those who would be encountered
in primary care. The study by Wood and
colleagues191 was specifically aimed at identifying
people with early/moderate glaucoma.
Figure 17(a) and (b) show, respectively, the SROC
plots for all cut-offs for all studies, and the
common cut-off. For all cut-offs, sensitivity ranged
from 11% (cut-off of VCDR   0.9)163 to 100% (cut-
off of VCDR   0.4),163 while specificity ranged
from 57% (cut-off of VCDR   0.4)163 to 99% (discs
subjectively graded as normal or suspicious).164 For
the common cut-off, sensitivity ranged from 41%115
to 91%,177 while specificity ranged from 74%177 to
99%.164 The pooled sensitivity, specificity and
DOR from the meta-analysis models for the
common cut-off were 60% (95% CrI 34 to 82%),
94% (95% CrI 76 to 99%) and 25.70 (95% CrI
5.79 to 109.50), respectively (Figure 17d).
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46
0% 20% 40% 60% 80% 100%
Spectrum representative
Reference standard confirmed follow-up
Partial verification bias avoided
Differential verification bias avoided
Incorporation bias avoided
Test review bias avoided
Diagnostic review bias avoided
Clinical review bias avoided
Uninterpretable results reported
Withdrawals explained
Index test technology current
Positive result clearly defined
Positive result defined prior to study
Yes
No
Unclear
FIGURE 16 Ophthalmoscopy: summary of quality assessmentHealth Technology Assessment 2007; Vol. 11: No. 41
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 Table 18 shows, where this information was
reported, the type of ophthalmoscopy undertaken,
whether or not participants’ pupils were dilated and
the clinical experience of those giving the tests.
Interpretable results
Ten population-based studies reported that 13,341
(98.0%) of 13,620 participants provided
interpretable test results for
ophthalmoscopy,22,100,107,109,112,115,161,163,164,168
while three prospective cohort studies reported
that 278 (90.0%) of 309 participants provided
interpretable test results,172,177,200 giving an overall
rate of 97.8% for all studies. None of the studies
gave details of the time taken to perform the test. 
Optic disc photography
Quality assessment
Six studies enrolling over 7800 people reported
the test accuracy of optic disc photography,
including two population-based studies,166,169 one
cohort study175 and three case–control
studies.188–190 Figure 18 summarises the quality
assessment for these studies. In four of the six
studies the participants were considered to be
representative of a screening setting166,169 or
diagnostic setting175,188 (i.e. people referred from
primary care with suspect glaucoma). Five of the
six studies were judged to be free from both
partial and differential verification
bias.166,169,175,188,189 In four studies both the index
test and the reference standard test were
interpreted without knowledge of each other’s
results.166,169,175,190 The studies by Vitale and
colleagues,166 Wolfs and colleagues169 and Schultz
and colleagues175 met all of the above criteria
specified for higher quality studies.
Accuracy
Figure 19(c) shows the sensitivity and specificity,
with 95% confidence intervals, for the six studies
reporting optic disc photography at a common
cut-off (for details of the common cut-off selected
for optic disc photography see Appendix 13). The
study by Wollstein and colleagues190 aimed to
detect early-stage glaucoma.
Figure 19(a) and (b) show, respectively, the SROC
plots for all cut-offs for all studies, and the
common cut-off. For all cut-offs, sensitivity ranged
from 35% (cut-off of concave slopes and 
CDR   0.05 in the vertical than horizontal
direction)189 to 86% (cut-off of VCDR   0.5),175
while specificity ranged from 59% (cutoff of
VCDR   0.59)166 to 99.5% (cut-off of concave
slopes and CDR   0.05 in the vertical than
horizontal direction).189 For the common cutoff,
sensitivity ranged from 65%175 to 77%,166,188 while
specificity ranged from 59%166 to 98%.175 The
pooled sensitivity, specificity and DOR from the
meta-analysis models for the common cut-off were
73% (95% CrI 61 to 83%), 89% (95% CrI 50 to
99%) and 21.74 (95% CrI 3.07 to 148.30),
respectively (Figure 19d).
Table 19 shows, where this information was
reported, details of the optic disc photography,
whether or not participants’ pupils were dilated
and the clinical experience of those giving the
tests.
Interpretable results
Seven population-based studies reported that
16,957 (85.0%) of 19,950 participants provided
interpretable test results for optic disc
photography,110,155,157,159,166,168,169 while four
prospective cohort studies reported that 499
(89.7%) of 556 participants provided interpretable
test results,175,202,207,209 giving an overall rate for
all studies of 85.1%. One study reported that the
average test duration was 16 minutes per eye
(image acquisition and recording requiring
Screening and diagnostic tests for open angle glaucoma
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TABLE 18 Type of ophthalmoscopy used
Study Type of  Pupils dilated? Clinical experience of those 
ophthalmoscopy giving/interpreting the tests
Robin, 2005163 Slit-lamp biomicroscopy Not stated Not stated
Vernon, 1990164 Direct ophthalmoscopy Undilated Experienced ophthalmologist
Wang, 1998168 Direct ophthalmoscopy Dilated Not stated
Weih, 2001115 Slit-lamp Dilated Trained clinician
Hammond, 1979172 Direct ophthalmoscopy Undilated Nurses skilled in the use of the
ophthalmoscope
Theodossiades, 2001177 Direct ophthalmoscopy Undilated Not stated (optometrists)
Wood, 1987191 Direct ophthalmoscopy Dilated Not stated (ophthalmologists)Health Technology Assessment 2007; Vol. 11: No. 41
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0% 20% 40% 60% 80% 100%
Spectrum representative
Reference standard confirmed follow-up
Partial verification bias avoided
Differential verification bias avoided
Incorporation bias avoided
Test review bias avoided
Diagnostic review bias avoided
Clinical review bias avoided
Uninterpretable results reported
Withdrawals explained
Index test technology current
Positive result clearly defined
Positive result defined prior to study
Yes
No
Unclear
FIGURE 18 Optic disc photography: summary of quality assessment
TABLE 19 Details of optic disc photography
Study Type of optic disc photography Pupils dilated? Experience of those
giving/interpreting the tests
Vitale, 2000166 Topcon ImageNet simultaneous  Dilated Technicians with considerable 
stereophotography experience carried out the tests
Wolfs, 1999169 Topcon TRC-SS2 simultaneous  Dilated Transparencies digitised and analysed by 
stereophotography technicians
Quigley, 1980188 Colour stereophotographs placed in a  Not stated Not stated
stereoviewer
Schultz, 1995175 NIDEK fundus camera for  Dilated Photographs examined by third-year 
stereophotographs using Kodak Gold  ophthalmology residents
100 35-mm negative film. Also stereo 
slide transparencies obtained using 
35-mm Ektachrome 100 film and 
examined through a stereoviewer
Sommer, 1979189 Colour stereophotographs  Not stated Not stated
Wollstein, 2000190 Canon CF6OU colour non-simultaneous  Not stated Taken by trained technicians, interpreted 
stereophotographs using 35-mm Kodak  by experienced observers (glaucoma 
Ektachrome 150 film consultants, glaucoma fellow, clinical
glaucoma technician)Screening and diagnostic tests for open angle glaucoma
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.
 approximately 4 minutes per eye, after which time
the presence of the patient was no longer
required, with subsequent calculations of
topographical and pallor parameters requiring
approximately 12 minutes per eye).197
RNFL photography
Quality assessment
Four studies enrolling over 700 people reported
the test accuracy of RNFL photography, including
one population-based study167 and three
case–control studies.178,188,189 Figure 20 summarises
the quality assessment for these studies. In two of
the four studies the participants were considered
to be representative of a screening167 or
diagnostic188 setting. Three studies were judged to
be free from both partial and differential
verification bias.178,188,189 In one study both the
index test and the reference standard test were
interpreted without knowledge of each other’s
results.178 No study met all the criteria specified
for higher quality studies. 
Accuracy
Figure 21(c) shows the sensitivity and specificity,
with 95% confidence intervals, for the four studies
reporting RNFL photography at a common cut-off
(for details of the common cut-off selected for
RNFL photography see Appendix 13). Three
studies were set in the USA.167,188,189 The study by
Airaksinen and colleagues178 appeared to have a
joint setting of Canada and Finland and it was
unclear whether the spectrum of people was
representative of those who would be encountered
in primary care.
Figure 21(a) and (b) show, respectively, the SROC
plots for all cut-offs for all studies, and the
common cut-off. Both for all cut-offs and the
common cut-off, sensitivity ranged from 59%189 to
94%,178 while specificity ranged from 60%178 to
98%.189 The pooled sensitivity, specificity and
DOR from the meta-analysis models for the
common cut-off were 75% (95% CrI 46 to 92%),
88% (95% CrI 53 to 98%) and 23.10 (95% CrI
4.41 to 123.50), respectively (Figure 21d).
Interpretable results
One population-based study reported that 136
(79.5%) of 171 participants provided interpretable
test results for RNFL photography.167 None of the
studies reported the time taken to perform the
test, but it is likely to be similar to optic disc
photography.
Health Technology Assessment 2007; Vol. 11: No. 41
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0% 20% 40% 60% 80% 100%
Spectrum representative
Reference standard confirmed follow-up
Partial verification bias avoided
Differential verification bias avoided
Incorporation bias avoided
Test review bias avoided
Diagnostic review bias avoided
Clinical review bias avoided
Uninterpretable results reported
Withdrawals explained
Index test technology current
Positive result clearly defined
Positive result defined prior to study
Yes
No
Unclear
FIGURE 20 RNFL: summary of quality assessmentScreening and diagnostic tests for open angle glaucoma
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.HRT II
Quality assessment
Three studies enrolling 1073 people reported the
test accuracy of HRT II, including two population-
based studies,156,163 and one case–control study.186
Figure 22 summarises the quality assessment for
these studies. In the studies by Harasymowycz and
colleagues156 and Robin and colleagues163 the
participants were considered to be representative
of a screening setting. All three studies were
judged to be free from both partial and
differential verification bias.156,163,186 In all three
studies the index test and the reference standard
test were interpreted without knowledge of each
other’s results.156,163,186 The studies by
Harasymowycz and colleagues156 and Robin and
colleagues163 met the criteria specified for higher
quality studies. 
Accuracy
Figure 23(c) shows the sensitivity and specificity,
with 95% confidence intervals, for the three
studies reporting HRT II at a common cut-off (for
details of the common cut-off selected for HRT II
see Appendix 13). In the population-based studies
by Harasymowycz and colleagues156 and Robin
and colleagues163 the tests were carried out by an
ophthalmic photographer and “appropriately
trained staff ”, respectively, while in the
case–control study by Ieong and colleagues186 the
tests were carried out by optometrists and early-
stage glaucoma was targeted. The study by
Harasymowycz and colleagues156 focused on
groups at high risk of developing glaucoma
(people of Caribbean or African descent, or older
than 50 years of age, or with a family history of
OAG).
Figure 23(a) and (b) show, respectively, the SROC
plots for all cut-offs for all studies, and the
common cut-off. For all cut-offs, sensitivity ranged
from 69%186 to 100%,156 while specificity ranged
from 81%163 to 95%.186 For the common cut-off,
sensitivity ranged from 69%186 to 95%,163 while
specificity ranged from 81%163 to 95%.186 The
pooled sensitivity, specificity and DOR from the
meta-analysis models for the common cut-off were
86% (95% CrI 55 to 97%), 89% (95% CrI 66 to
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0% 20% 40% 60% 80% 100%
Spectrum representative
Reference standard confirmed follow-up
Partial verification bias avoided
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Incorporation bias avoided
Test review bias avoided
Diagnostic review bias avoided
Clinical review bias avoided
Uninterpretable results reported
Withdrawals explained
Index test technology current
Positive result clearly defined
Positive result defined prior to study
Yes
No
Unclear
FIGURE 22 HRT II: summary of quality assessmentScreening and diagnostic tests for open angle glaucoma
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.98%) and 50.93 (95% CrI 11.48 to 246.30),
respectively (Figure 23d).
Interpretable results
Two population-based studies reported that 536
(94.2%) of 569 participants provided interpretable
test results for HRT II.156,163 None of the studies
reported the time taken to perform the test. 
Tests of function
FDT (C-20-1) 
Quality assessment
Three studies involving 575 people reported the
test accuracy of the FDT C-20-1 test, including
one population-based study170 and two
case–control studies.185,187 Figure 24 summarises
the quality assessment for these studies. In two of
the three studies the participants were considered
to be representative of a screening170 or
diagnostic185 setting. The study by Yamada and
colleagues170 was the only one judged to be free
from both partial and differential verification bias
and also the only one in which both the index test
and the reference standard test were interpreted
without knowledge of each other’s results, thereby
meeting the criteria specified for higher quality
studies. 
Accuracy
Figure 25(c) shows the sensitivity and specificity,
with 95% confidence intervals, for the three
studies reporting FDT C-20-1 at a common cut-off
(for details of the common cut-off selected for
FDT C-20-1 see Appendix 13). The heterogeneity
in terms of specificity is mainly due to the high
value reported by Johnson and colleagues.187 In
this study both eyes of normal participants (mean
age 46 years) and one eye of participants with
glaucoma (mean age 64 years) were tested. 
Figure 25(a) and (b) show, respectively, the SROC
plots for all cut-offs with multiple abnormal test
points for all studies, and the common cut-off. For
all cut-offs, sensitivity ranged from 65% at five
abnormal test points185 to 93% at one abnormal
test point,187 while specificity ranged from 86% at
one abnormal test point170 to 100% at one
abnormal test point, two abnormal test points or
two clustered abnormal test points.187 For a
common cut-off of one abnormal test point,
sensitivity ranged from 91%185 to 93%,187 while
specificity ranged from 86%170 to 100%.187 The
pooled sensitivity, specificity and DOR from the
meta-analysis models for the common cut-off were
92% (95% CrI 65 to 95%), 94% (95% CrI 73 to
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FIGURE 24 FDT C-20-1: summary of quality assessmentScreening and diagnostic tests for open angle glaucoma
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 99%) and 181.20 (95% CrI 25.49 to 2139.00),
respectively (Figure 25d).
Interpretable results
Two population-based studies reported that
14,569 (96.8%) of 15,057 participants provided
interpretable test results for FDT C-20-1,170,210
while one prospective cohort study reported that
27 (87.1%) of 31 participants provided
interpretable test results,214 giving an overall rate
of 96.7% for all studies. Four studies reported the
time taken to perform the test,170,185,187,214 which
ranged from less than 45 seconds per eye for
normal participants to approximately 2 minutes
per eye for those with advanced glaucoma.187
FDT (C-20-5)
Quality assessment
Five studies involving 2956 people reported the
test accuracy of the FDT C-20-5 test, including
three population-based studies155,161,163 and two
case–control studies.173,187 Figure 26 summarises
the quality assessment for these studies. In two of
the five studies the participants were considered to
be representative of a screening setting.155,163 Four
of the five studies were judged to be free from
both partial and differential verification
bias.155,161,163,173 In three of five studies155,161,163
both the index test and the reference standard test
were interpreted without knowledge of each
other’s results. Two of five studies met the criteria
specified for higher quality studies.155,163
Accuracy
Figure 27(c) shows the sensitivity and specificity,
with 95% confidence intervals, for the five studies
reporting FDT C-20-5 at a common cut-off (for
details of the common cut-off selected for 
FDT C-20-5 see Appendix 13). There was marked
statistically significant heterogeneity across the
studies. In particular, the study by Mansberger and
colleagues161 reported extremely low sensitivity
(7%) compared with the other studies. The setting
for this study was rural villages in India.
Ophthalmological diagnosis was based on review
of optic disc photographs and this may have
overdiagnosed glaucoma.
Figure 27(a) and (b) show, respectively, the
hierarchical SROC plots for all cut-offs with
multiple abnormal test points for all studies, and
the common cut-off. For all cut-offs, sensitivity
ranged from 7% at one abnormal test point161 to
100% at one abnormal test point on repeat
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FIGURE 26 FDT C-20-5: summary of quality assessmentScreening and diagnostic tests for open angle glaucoma
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.
 testing,173 while specificity ranged from 55% at
one abnormal test point163 to 95% at two clustered
abnormal test points.187 For a common cut-off of
one abnormal test point, sensitivity ranged from
7%161 to 100%,173 while specificity ranged from
55%163 to 89%.187 The pooled sensitivity,
specificity and DOR from the meta-analysis
models for the common cut-off were 78% (95%
CrI 19 to 99%), 75% (95% CrI 57 to 87%) and
10.14 (95% CrI 0.72 to 249.00), respectively
(Figure 27d).
Interpretable results
Three population-based studies reported that
2164 (91.8%) of 2357 participants provided
interpretable test results for FDT C-20-5,155,161,163
while one prospective cohort study173 reported
that 223 (97.8%) of 228 participants provided
interpretable test results, giving an overall rate of
92.3% for all studies. Two studies155,187 reported
the time taken to perform the test, which ranged
from less than 45 seconds per eye for normal
participants to approximately 2 minutes per eye
for those with advanced glaucoma.187
FDT (C-20 full threshold and C-20 matrix)
Heeg and colleagues,183,184 in a case–control 
study set in The Netherlands, reported the
accuracy of the FDT C-20 full threshold test. An
abnormal test result was defined as more than one
depressed test point, p < 0.01, in the total
deviation probability plot (TD > 1). Table 20
shows the sensitivity and specificity of the FDT C-
20 full threshold test, both for all participants and
for a subgroup excluding those with early
glaucoma, at cut-offs of TD greater than 1, 2 and
3. As would be expected, for both the whole 
group and also the subgroup, sensitivity was
highest (90% and 100%, respectively) at a cut-off
of TD greater than 1, while specificity was highest
(both 88%) at TD greater than 3. In terms of
quality assessment, the cases and controls were
judged as being representative of a diagnostic
setting.
Spry and colleagues,176 in a cohort study set in the
UK, reported the test accuracy of the FDT C-20
matrix (Humphrey matrix 24-2). An abnormal test
result was defined as a GHT outside the normal
limit and/or p < 0.05 with the pattern standard
deviation global index in one or both eyes. The
study reported sensitivity of 100% and specificity
of 27%. In terms of the quality of the study, the
spectrum of people was considered to be
representative of a diagnostic setting, it was
judged to be free from both partial and
differential verification bias, and both the index
test and the reference standard test were
interpreted without knowledge of each other’s
results, thereby meeting the criteria specified for
higher quality studies. 
OKP
Quality assessment
Four studies enrolling 768 people reported the
test accuracy of OKP, including two population-
based studies,154,170 and two case–control
studies.180,182 Figure 28 summarises the quality
assessment for these studies. In three of the four
studies the participants were considered to be
representative of a screening154,170 or diagnostic182
setting. The study by Yamada and colleagues170
was the only one judged to be free from both
partial and differential verification bias and was
also the only study in which both the index test
and the reference standard test were interpreted
without knowledge of each other’s results, thereby
meeting the criteria specified for higher quality
studies. 
Accuracy
Figure 29(c) shows the sensitivity and specificity,
with 95% confidence intervals, for the four studies
reporting OKP at a common cut-off (for details of
the common cut-off selected for OKP see
Appendix 13). There was statistically significant
heterogeneity, in terms of sensitivity, mainly due to
the study by Harper and colleagues.182 There was
no obvious explanation for this heterogeneity in
Health Technology Assessment 2007; Vol. 11: No. 41
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TABLE 20 Sensitivity and specificity of FDT C-20 full threshold for whole group and subgroup excluding patients with early glaucoma
Cut-off TD Sensitivity (%) Specificity (%)
>1 All participants 90 81
Early glaucoma excluded 100 81
>2 All participants 86 85
Early glaucoma excluded 99 85
>3 All participants 82 88
Early glaucoma excluded 97 88terms of the spectrum of people. In three of the
four studies, including the study by Harper and
colleagues, the participants were considered to be
representative of a screening154,170 or diagnostic182
setting, while the representativeness of the
participants was unclear in the case-control study
by Damato and colleagues.180 However, in contrast
to the other three studies, in the study by Harper
and colleagues182 there was minimal instruction
and supervision. In preparation for the test, the
participants were asked to read the test
instructions with no further assistance given,
following which they self-administered the test,
unsupervised.182
Figure 29(a) and (b) show, respectively, the SROC
plots for all cut-offs for all studies and the
common cut-off. For both all cut-offs and the
common cut-off, sensitivity ranged from 25%182 to
100%,154 while specificity ranged from 78%170 to
94%.154,182 One reason for the high sensitivity
reported by Christoffersen and colleagues154 was
that test negatives did not receive a reference
standard test to confirm this but were assumed to
be true negatives, so that the study reported no
false negatives and therefore a sensitivity of 100%.
Yamada and colleagues170 also reported a high
sensitivity rate (95%). However, this study
contained a higher than average prevalence of
glaucoma (10.7%) and it would be expected that
the sensitivity of the test would therefore be higher
in such a population compared with an average
prevalence population. The pooled sensitivity,
specificity and DOR from the meta-analysis
models for the common cut-off were 86% (95%
CrI 29 to 100%), 90% (95% CrI 79 to 96%) and
57.54 (95% CrI 4.42 to 1585.00), respectively
(Figure 29d).
Interpretable results
Two population-based studies reported that 362
(97.1%) of 373 participants provided interpretable
test results for OKP,154,170 while one prospective
cohort study reported that 16 (94.1%) of 17
participants provided interpretable test results,212
giving an overall rate of 96.9% for all studies.
Three studies reported the time taken to perform
the test,154,170,212 which ranged from
approximately 3 minutes170 to 4 minutes212 per eye.
SAP (suprathreshold)
Quality assessment
Nine studies enrolling over 10,200 people
reported the test accuracy of the SAP
Screening and diagnostic tests for open angle glaucoma
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.suprathreshold test, including six population-
based studies,157,159,162,164,166,168 one cohort
study174 and two case–control studies.182,186
Figure 30 summarises the quality assessment for
these studies. In eight of nine studies the
participants were considered to be representative
of a screening157,159,162,164,166,168 or diagnostic174,182
setting. Four of the nine studies were judged to be
free from both partial and differential verification
bias.162,166,174,186 In two of the nine studies both
the index test and the reference standard test were
interpreted without knowledge of each other’s
results.166,186 Only the study by Vitale and
colleagues166 met the criteria specified for higher
quality studies. 
Accuracy
Figure 31(c) shows the sensitivity and specificity,
with 95% confidence intervals, for the nine studies
reporting SAP suprathreshold at a common cut-off
(for details of the common cut-off selected for SAP
suprathreshold see Appendix 13). There was
statistically significant heterogeneity across the
studies that could not be explained by differences
in study design, participants or equipment used.
However, the two largest population-based studies,
the Blue Mountains Eye Study157 and the
Baltimore Eye Survey,159 involving more than
3600 and 4700 people, respectively, reported
similar sensitivities and specificities. Of note in the
study by Vernon and colleagues,164 is that the
definition of glaucoma excluded people with IOP
of 22 mmHg or below.
Figure 31(a) and (b) show, respectively, the SROC
plots for all cut-offs for all studies, and the
common cut-off. For all cut-offs, sensitivity ranged
from 25% (sufficient points to drop the indicator
into the suspicious zone or below)164 to 100% (one
or more points missing),157 while specificity
ranged from 50% (one or more points missing)157
to 96% (sufficient points to drop the indicator into
the suspicious zone or below).164 For the common
cut-off, sensitivity ranged from 25% (sufficient
points to drop the indicator into the suspicious
zone or below)164 to 90% (at least four abnormal
points in any single quadrant),162 while specificity
ranged from 67% (absolute or relative defects
 17)168 to 96% (sufficient points to drop the
indicator into the suspicious zone or below).164
The pooled sensitivity, specificity and DOR from
the meta-analysis models for the common cut-off
Screening and diagnostic tests for open angle glaucoma
62
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FIGURE 30 SAP: summary of quality assessmentHealth Technology Assessment 2007; Vol. 11: No. 41
63
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
(
c
)
(
d
)
C
o
m
m
o
n
 
c
u
t
-
o
f
f
 
N
u
m
b
e
r
 
o
f
 
s
t
u
d
i
e
s
 
 
9
S
e
n
s
i
t
i
v
i
t
y
 
(
%
)
 
(
9
5
%
 
C
r
I
)
 
 
7
1
 
(
5
1
 
t
o
 
8
6
)
S
p
e
c
i
f
i
c
i
t
y
 
(
%
)
 
(
9
5
%
 
C
r
I
)
 
 
8
5
 
(
7
3
 
t
o
 
9
3
)
D
O
R
 
(
9
5
%
 
C
r
I
)
 
 
1
4
.
4
2
 
(
6
.
3
9
 
t
o
 
3
3
.
7
3
)
 
 
H
i
g
h
-
q
u
a
l
i
t
y
 
s
t
u
d
i
e
s
 
N
u
m
b
e
r
 
o
f
 
s
t
u
d
i
e
s
 
 
1
S
e
n
s
i
t
i
v
i
t
y
 
(
%
)
 
(
9
5
%
 
C
r
I
)
 
 
5
0
 
(
3
7
 
t
o
 
6
3
)
S
p
e
c
i
f
i
c
i
t
y
 
(
%
)
 
(
9
5
%
 
C
r
I
)
 
 
8
3
 
(
7
6
 
t
o
 
8
8
)
D
O
R
 
(
9
5
%
 
C
r
I
)
 
 
4
.
8
6
 
(
2
.
5
3
 
t
o
 
9
.
3
3
)
(
a
)
(
b
)
0
0
.
1
0
.
2
0
.
3
0
.
4
0
.
5
0
.
6
0
.
7
0
.
8
0
.
9
1
.
0
0
0
.
1
0
.
2
0
.
3
0
.
4
0
.
5
0
.
6
0
.
7
0
.
8
0
.
9
1
.
0
1
 
–
 
S
p
e
c
i
f
i
c
i
t
y
S
e
n
s
i
t
i
v
i
t
y
H
a
r
p
e
r
,
 
1
9
9
4
1
8
2
I
e
o
n
g
,
 
2
0
0
3
1
8
6
I
v
e
r
s
,
 
2
0
0
1
1
5
7
 
K
a
t
z
,
 
1
9
9
3
1
5
9
M
a
r
r
a
f
f
a
,
 
1
9
8
9
1
7
4
M
u
n
d
o
r
f
,
 
1
9
8
9
1
6
2
V
e
r
n
o
n
,
 
1
9
9
0
1
6
4
V
i
t
a
l
e
,
 
2
0
0
0
1
6
6
W
a
n
g
,
 
1
9
9
8
1
6
8
0
0
.
1
0
.
2
0
.
3
0
.
4
0
.
5
0
.
6
0
.
7
0
.
8
0
.
9
1
.
0
0
0
.
1
0
.
2
0
.
3
0
.
4
0
.
5
0
.
6
0
.
7
0
.
8
0
.
9
1
.
0
1
 
–
 
S
p
e
c
i
f
i
c
i
t
y
S
e
n
s
i
t
i
v
i
t
y
I
v
e
r
s
,
 
2
0
0
1
1
5
7
 
 
K
a
t
z
,
 
1
9
9
3
1
5
9
 
M
u
n
d
o
r
f
,
 
1
9
8
9
1
6
2
V
e
r
n
o
n
,
 
1
9
9
0
1
6
4
W
a
n
g
 
1
9
9
8
1
6
8
H
a
r
p
e
r
,
 
1
9
9
4
1
8
2
I
e
o
n
g
,
 
2
0
0
3
1
8
6
M
a
r
r
a
f
f
a
,
 
1
9
8
9
1
7
4
V
i
t
a
l
e
 
2
0
0
0
1
6
6
 
 
 
7
7
/
8
7
1
2
2
/
1
4
6
 
 
 
 
9
/
1
0
 
 
 
 
3
/
1
2
 
 
4
8
/
6
9
 
 
5
7
/
6
7
 
 
2
1
/
2
9
 
 
7
2
/
1
4
0
 
 
2
9
/
5
8
S
t
u
d
y
T
P
/
T
P
+
F
N
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
S
e
n
s
i
t
i
v
i
t
y
2
5
8
7
/
3
5
6
7
3
4
3
9
/
4
5
8
7
 
 
 
 
9
5
/
1
3
5
 
 
8
1
3
/
8
4
3
 
 
 
 
9
7
/
1
4
5
 
 
1
3
6
/
1
4
5
 
 
 
 
3
5
/
3
7
 
 
 
 
3
7
/
4
2
 
 
1
4
1
/
1
7
0
T
N
/
T
N
+
F
P
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
S
p
e
c
i
f
i
c
i
t
y
H
a
r
p
e
r
,
 
1
9
9
4
1
8
2
I
e
o
n
g
,
 
2
0
0
3
1
8
6
I
v
e
r
s
,
 
2
0
0
1
1
5
7
 
K
a
t
z
,
 
1
9
9
3
1
5
9
M
a
r
r
a
f
f
a
,
 
1
9
8
9
1
7
4
M
u
n
d
o
r
f
,
 
1
9
8
9
1
6
2
V
e
r
n
o
n
,
 
1
9
9
0
1
6
4
V
i
t
a
l
e
,
 
2
0
0
0
1
6
6
W
a
n
g
,
 
1
9
9
8
1
6
8
F
I
G
U
R
E
 
3
1
S
A
P
 
s
u
p
r
a
t
h
r
e
s
h
o
l
d
:
 
(
a
)
 
S
R
O
C
 
p
l
o
t
:
 
a
l
l
 
s
t
u
d
i
e
s
,
 
a
l
l
 
c
u
t
-
o
f
f
s
;
 
(
b
)
 
S
R
O
C
 
p
l
o
t
:
 
c
o
m
m
o
n
 
c
u
t
-
o
f
f
;
 
(
c
)
 
s
e
n
s
i
t
i
v
i
t
y
 
a
n
d
 
s
p
e
c
i
f
i
c
i
t
y
 
a
t
 
c
o
m
m
o
n
 
c
u
t
-
o
f
f
;
 
(
d
)
 
p
o
o
l
e
d
 
e
s
t
i
m
a
t
e
s
.
 
F
N
,
 
f
a
l
s
e
 
n
e
g
a
t
i
v
e
;
F
P
,
 
f
a
l
s
e
 
p
o
s
i
t
i
v
e
;
 
T
N
,
 
t
r
u
e
 
n
e
g
a
t
i
v
e
;
 
T
P
,
 
t
r
u
e
 
p
o
s
i
t
i
v
e
.were 71% (95% CrI 51 to 86%), 85% (95% CrI 73
to 93%) and 14.42 (95% CrI 6.39 to 33.73),
respectively (Figure 31d).
Interpretable results
Six population-based studies reported that 8368
(80.1%) of 10,444 participants provided
interpretable test results for SAP
suprathreshold,157,159,162,164,166,168 while two
prospective cohort studies involving 504
participants reported that all provided
interpretable test results,174,208 giving an overall
rate of 81.0% for all studies. Four studies reported
the time taken to perform the test,159,162,164,174
which ranged from approximately 3 minutes164 to
15 minutes157,159,162,164,166,168 for both eyes.
SAP (threshold)
Quality assessment
Five studies enrolling 1457 people reported the
test accuracy of the SAP threshold test, including
two population-based studies,158,163 one cohort
study176 and two case–control studies.179,181
Figure 32 summarises the quality assessment for
these studies. In three of the five studies the
participants were considered to be representative
of a screening163 or diagnostic176,179 setting. Four
of the five studies were judged to be free from
both partial and differential verification
bias.158,163,176,179 In one study both the index test
and the reference standard test were interpreted
without knowledge of each other’s results.163 Only
the study by Robin and colleagues163 met the
criteria specified for higher quality studies.
Accuracy
Figure 33(c) shows the sensitivity and specificity,
with 95% confidence intervals, for the five studies
reporting SAP threshold at a common cut-off (for
details of the common cut-off selected for SAP
threshold see Appendix 13). There was statistically
significant heterogeneity across the studies. There
was no obvious explanation for the heterogeneity,
although there were differences across the studies
in terms of study design and setting. The same
types of study (population-based,158,163
case–control179,181) appeared to be homogeneous
in terms of specificity but not sensitivity. 
Figure 33(a) and (b) show, respectively, the SROC
plots for all cut-offs for all studies, and the
common cut-off. For all cut-offs for all studies,
sensitivity ranged from 58% [mean deviation +
pattern SD (least significant), significance level
cut-off 0.005] to 97% (mirror image method),181
(clusters, Low Tension Glaucoma Study, 
Screening and diagnostic tests for open angle glaucoma
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FIGURE 32 SAP threshold: summary of quality assessmentHealth Technology Assessment 2007; Vol. 11: No. 41
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 p-values),158 while specificity ranged from 52%
(GHT “outside normal limit” and/or pattern SD
p < 0.05 in one or both eyes)176 to 98% [mean
deviation + pattern SD (least significant),
significance level cut-off 0.005].181 For the
common cut-off, sensitivity ranged from 63%
[Advanced Glaucoma Intervention Study (AGIS)
score  3]158,163 to 97% (mirror image method),181
while specificity ranged from 52% (GHT “outside
normal limit” and/or pattern SD p < 0.05 in one
or both eyes)176 to 92% (logistic discriminant
analysis applied to 59 points).179 The pooled
sensitivity, specificity and DOR from the meta-
analysis models for the common cut-off were 88%
(95% CrI 65 to 97%), 80% (95% CrI 55 to 93%)
and 29.87 (95% CrI 5.59 to 159.30), respectively
(Figure 33d).
Interpretable results
Seven population-based studies reported that
4459 (98.7%) of 4520 participants provided
interpretable test results for SAP
threshold,100,107,109,112,158,163,164 while seven
prospective cohort studies involving 940
participants reported that all provided
interpretable test results,176,192,194,195,198,201,206
giving an overall rate of 98.9% for all studies. Four
studies reported the time taken to perform the
test,176,195,198,206 which ranged from approximately
5 minutes176 to 18 minutes206 for both eyes. All
four studies used SITA standard or SITA fast.
Tests of IOP
GAT
Quality assessment
Nine studies involving 20,308 people reported the
test accuracy of GAT for detecting OAG, including
seven population-based studies21,99,100,106,112,157,168
and two cohort studies.22,171 Figure 34 summarises
the quality assessment for these studies. In eight of
the nine studies the participants were considered
to be representative of a
screening21,99,100,106,112,157,168 or diagnostic22
setting. Two of the nine studies were judged to be
free from both partial and differential verification
bias.21,100 In no study were both the index test and
the reference standard test interpreted without
knowledge of each other’s results and no study
met the criteria specified for higher quality studies. 
Accuracy
Figure 35(c) shows the sensitivity and specificity,
with 95% confidence intervals, for the nine studies
reporting GAT at a common cut-off (for details of
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.the common cut-off selected for GAT see
Appendix 13). There was statistically significant
heterogeneity across the studies, especially for
sensitivity, with no obvious explanation. 
Figure 35(a) and (b) show, respectively, the SROC
plots for all cut-offs for all studies, and for the
common cut-off. For all cut-offs, sensitivity ranged
from 3% (IOP > 28 mmHg)157 to 90% (IOP >
21 mmHg),112 while specificity ranged from 81%
(IOP   21 mmHg)171 to 99% (IOP > 21 mmHg,99
IOP > 28 mmHg).157 For the common cut-off,
sensitivity ranged from 10% (IOP > 21 mmHg)22
to 90% (IOP > 21 mmHg),112 while specificity
ranged from 81% (IOP   21 mmHg)171 to 99%
(IOP > 21 mmHg).99 The pooled sensitivity,
specificity and DOR from the meta-analysis
models for the common cut-off of above
21 mmHg were 46% (95% CrI 22 to 71%), 95%
(95% CrI 89 to 97%) and 14.95 (95% CrI 4.48 to
48.95), respectively (Figure 35d). 
Interpretable results
Thirteen population-based studies reported that
25,422 (99.1%) of 25,650 participants provided
interpretable test results for
GAT,21,22,99,100,106,107,109,112,157,159,168,199,205 while
two prospective cohort studies193,204 involving 135
participants reported that all provided
interpretable test results, giving an overall rate of
99.1% for all studies. None of the studies reported
the time taken to perform the test. 
NCT
Quality assessment
One population-based study involving 874 people
reported NCT for detecting OAG.164,165 Figure 36
summarises the quality assessment for this study.
The participants were considered to be
representative of a screening setting. The study
was judged to be free from partial verification bias
but not differential verification bias. Furthermore,
the index test was interpreted without knowledge
of the results of the reference standard test, but
not vice versa. It should be noted that the
reference standard was suboptimal for several
reasons: the authors’ definition of glaucoma
excluded people with IOP of 22 mmHg or below
and included people with IOP above 30 mmHg
and ‘required treatment’ without other evidence of
glaucoma damage, and optic nerve evaluation was
based on direct ophthalmoscopy through
undilated pupils. This study did not meet the
criteria required for a higher quality study. 
Screening and diagnostic tests for open angle glaucoma
68
0% 20% 40% 60% 80% 100%
Spectrum representative
Reference standard confirmed follow-up
Partial verification bias avoided
Differential verification bias avoided
Incorporation bias avoided
Test review bias avoided
Diagnostic review bias avoided
Clinical review bias avoided
Uninterpretable results reported
Withdrawals explained
Index test technology current
Positive result clearly defined
Positive result defined prior to study
Yes
No
Unclear
FIGURE 36 NCT: summary of quality assessmentAccuracy
Vernon and colleagues164,165 reported IOP at a
range of cut-offs from above 21 mmHg to 
above 26 mmHg and from one to four pulses 
per eye. Figure 37(a) and (b) show, respectively, 
the SROC plots for all cut-offs, and a common
cut-off (for details of the common cut-off selected
for NCT see Appendix 13). For all cut-offs,
sensitivity ranged from 42% (IOP > 26 mmHg,
four pulses per eye) to 92% (IOP > 21 mmHg,
IOP > 22 mmHg, both four pulses per eye), 
while specificity ranged from 93% 
(IOP > 21 mmHg, one pulse per eye) to 99.7%
(IOP > 26 mmHg, four pulses per eye). For the
common cut-off of >21 mmHg, sensitivity was
92% (95% CrI 62 to 100%), specificity was 
92% (95% CrI 90 to 94%) and the DOR was
134.88 (95% CrI 17.15 to 1061.10) (Figure 37c
and d). 
Interpretable results
In addition to the study by Vernon and
colleagues,164 five population-based studies,
although not providing usable data for NCT in
terms of test accuracy, otherwise met the review’s
inclusion criteria and provided information on
interpretable results.110,155,161,196,203 The six studies
reported that 6126 (97.1%) of 6308 participants
provided interpretable test results for NCT, while
one prospective cohort study211 involving 105
participants reported that all provided
interpretable test results, giving an overall rate of
97.2% for all studies. One study reported that it
took approximately 2 minutes to perform the test
for both eyes.164
Summary
Table 21 shows the summary performance for each
test at the common cut-off. Sensitivity and
specificity are derived from the 40 included
studies, while the information on interpretable
results and time taken to perform the test also
includes data, where reported, from other
population-based studies and prospective cohort
studies that did not report usable outcomes in
terms of accuracy, but otherwise met the review’s
inclusion criteria. Appendix 13 provides details of
the sensitivity and specificity for each study, by
type of test. 
Only one study reporting true and false positives
and negatives for NCT met the inclusion criteria.
Vernon and colleagues164 reported 92% sensitivity
and also 92% specificity for NCT at a cut-off of
IOP above 21 mmHg. However, the high
sensitivity reported was influenced by the fact that
the authors’ definition of glaucoma excluded
normal tension glaucoma (NTG). The
performance estimates should be viewed with
caution as the reference standard was suboptimal.
Interpretable results were provided by 97% of
those taking the test, while the time taken to
perform the test averaged 2 minutes for both 
eyes.
In many of the tests there was statistical
heterogeneity across studies. The FDT C-20-1 test
was associated with the highest sensitivity (92%)
and was among the tests with the highest
specificity (94%) (ophthalmoscopy 94%; GAT
95%), as well as being associated with a relatively
high percentage (97%) of interpretable test results
and short length of time taken to perform the test
(<1–2 minutes per eye).
Higher quality studies
Eight studies met the criteria for higher quality
studies, including six population-based
studies155,156,163,166,169,170 and two cohort
studies.175,176 Sensitivity analysis was undertaken
by examining separately the results of the higher
quality studies, using HSROC analysis where more
than one higher quality study reported the same
test (Table 22). For both SAP threshold and FDT
C-20-5, the higher quality studies reported lower
values for both sensitivity and specificity when
compared with all studies, while two FDT C-20-5
studies not meeting the criteria for higher
quality173,187 reported very high sensitivity values
(98% and 100%, respectively). For optic disc
photography, compared with all studies, the
higher quality studies reported similar sensitivity
(74% versus 73%), with slightly lower specificity
(82% versus 89%). For HRT II, compared with all
studies, the higher quality studies reported higher
sensitivity (93% versus 86%) but slightly lower
specificity (85% versus 89%). 
Studies reporting combinations of tests
Two population-based studies reported the
sensitivity and specificity of combinations of tests
for detecting OAG.163,164 Robin and colleagues163
compared the sensitivity and specificity of
sequential testing with FDT C-20-5 followed by
HRT II in a population-based study set in
Australia involving 261 people. For FDT,
participants with any miss of any severity repeated
the test. Three definitions of abnormal HRT II
were assessed: one or more borderline or severe
abnormalities, two or more borderline or one or
more severe abnormalities, or three or more
borderline or one or more severe abnormalities.
The definitions were based on MRA, which takes
into account the global and sectorial rim area
Health Technology Assessment 2007; Vol. 11: No. 41
69
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.Screening and diagnostic tests for open angle glaucoma
70
(
c
)
(
d
)
C
o
m
m
o
n
 
c
u
t
-
o
f
f
 
N
u
m
b
e
r
 
o
f
 
s
t
u
d
i
e
s
 
 
1
S
e
n
s
i
t
i
v
i
t
y
 
(
%
)
 
(
9
5
%
 
C
r
I
)
 
 
9
2
 
(
6
2
 
t
o
 
1
0
0
)
S
p
e
c
i
f
i
c
i
t
y
 
(
%
)
 
(
9
5
%
 
C
r
I
)
 
 
9
2
 
(
9
0
 
t
o
 
9
4
)
D
O
R
 
(
9
5
%
 
C
r
I
)
 
 
1
3
4
.
8
8
 
(
1
7
.
1
5
 
t
o
 
1
0
6
1
.
1
0
)
 
 
H
i
g
h
-
q
u
a
l
i
t
y
 
s
t
u
d
i
e
s
 
N
u
m
b
e
r
 
o
f
 
s
t
u
d
i
e
s
 
0
(
a
)
(
b
)
0
0
.
1
0
.
2
0
.
3
0
.
4
0
.
5
0
.
6
0
.
7
0
.
8
0
.
9
1
.
0
0
0
.
1
0
.
2
0
.
3
0
.
4
0
.
5
0
.
6
0
.
7
0
.
8
0
.
9
1
.
0
1
 
–
 
S
p
e
c
i
f
i
c
i
t
y
S
e
n
s
i
t
i
v
i
t
y
V
e
r
n
o
n
,
 
1
9
9
0
1
6
4
V
e
r
n
o
n
,
 
1
9
9
0
1
6
4
0
0
.
1
0
.
2
0
.
3
0
.
4
0
.
5
0
.
6
0
.
7
0
.
8
0
.
9
1
.
0
0
0
.
1
0
0
.
2
0
0
.
3
0
0
.
4
0
0
.
5
0
0
.
6
0
0
.
7
0
0
.
8
0
0
.
9
0
1
.
0
0
1
 
–
 
S
p
e
c
i
f
i
c
i
t
y
S
e
n
s
i
t
i
v
i
t
y
V
e
r
n
o
n
,
 
1
9
9
0
1
6
4
1
1
/
1
2
S
t
u
d
y
T
P
/
T
P
+
F
N
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
S
e
n
s
i
t
i
v
i
t
y
7
9
7
/
8
6
2
T
N
/
T
N
+
F
P
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
S
p
e
c
i
f
i
c
i
t
y
F
I
G
U
R
E
 
3
7
N
C
T
:
 
(
a
)
 
S
R
O
C
 
p
l
o
t
:
 
a
l
l
 
s
t
u
d
i
e
s
,
 
a
l
l
 
c
u
t
-
o
f
f
s
;
 
(
b
)
 
S
R
O
C
 
p
l
o
t
:
 
c
o
m
m
o
n
 
c
u
t
-
o
f
f
;
 
(
c
)
 
s
e
n
s
i
t
i
v
i
t
y
 
a
n
d
 
s
p
e
c
i
f
i
c
i
t
y
 
a
t
 
c
o
m
m
o
n
 
c
u
t
-
o
f
f
;
 
(
d
)
 
p
o
o
l
e
d
 
e
s
t
i
m
a
t
e
s
.
 
F
N
,
 
f
a
l
s
e
 
n
e
g
a
t
i
v
e
;
 
F
P
,
 
f
a
l
s
e
p
o
s
i
t
i
v
e
;
 
T
N
,
 
t
r
u
e
 
n
e
g
a
t
i
v
e
;
 
T
P
,
 
t
r
u
e
 
p
o
s
i
t
i
v
e
.Health Technology Assessment 2007; Vol. 11: No. 41
71
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
T
A
B
L
E
 
2
1
S
u
m
m
a
r
y
 
i
n
f
o
r
m
a
t
i
o
n
 
f
o
r
 
t
e
s
t
s
 
i
n
c
l
u
d
e
d
 
i
n
 
t
h
e
 
H
S
R
O
C
 
m
e
t
a
-
a
n
a
l
y
s
i
s
 
m
o
d
e
l
s
a
T
e
s
t
N
o
.
 
o
f
 
S
e
n
s
i
t
i
v
i
t
y
 
(
%
)
 
S
p
e
c
i
f
i
c
i
t
y
 
(
%
)
 
D
O
R
c
(
9
5
%
 
C
I
)
M
e
a
n
 
%
 
i
n
t
e
r
p
r
e
t
a
b
l
e
 
T
i
m
e
 
t
a
k
e
n
 
t
o
 
p
e
r
f
o
r
m
 
s
t
u
d
i
e
s
(
9
5
%
 
C
r
I
)
(
9
5
%
 
C
r
I
)
r
e
s
u
l
t
s
 
(
r
a
n
g
e
)
t
e
s
t
,
 
p
e
r
 
e
y
e
 
(
m
i
n
u
t
e
s
)
 
(
r
a
n
g
e
)
O
p
h
t
h
a
l
m
o
s
c
o
p
y
5
6
0
 
(
3
4
 
t
o
 
8
2
)
9
4
 
(
7
6
 
t
o
 
9
9
)
2
6
 
(
6
 
t
o
 
1
1
0
)
9
8
 
(
8
6
 
t
o
 
1
0
0
)
N
o
t
 
s
t
a
t
e
d
O
p
t
i
c
 
d
i
s
c
 
p
h
o
t
o
g
r
a
p
h
y
6
7
3
 
(
6
1
 
t
o
 
8
3
)
8
9
 
(
5
0
 
t
o
 
9
9
)
2
2
 
(
3
 
t
o
 
1
4
8
)
8
5
 
(
7
3
 
t
o
 
1
0
0
)
1
6
R
N
F
L
 
p
h
o
t
o
g
r
a
p
h
y
b
4
7
5
 
(
4
6
 
t
o
 
9
2
)
8
8
 
(
5
3
 
t
o
 
9
8
)
2
3
 
(
4
 
t
o
 
1
2
4
)
8
0
N
o
t
 
s
t
a
t
e
d
H
R
T
 
I
I
3
8
6
 
(
5
5
t
o
 
9
7
)
8
9
 
(
6
6
 
t
o
 
9
8
)
5
1
 
(
1
1
 
t
o
 
2
4
6
)
9
4
 
(
9
1
 
t
o
 
9
7
)
 
N
o
t
 
s
t
a
t
e
d
F
D
T
 
C
-
2
0
-
1
3
9
2
 
(
6
5
 
t
o
 
9
9
)
9
4
 
(
7
3
 
t
o
 
9
9
)
1
8
1
 
(
2
5
 
t
o
 
2
1
3
9
)
9
7
 
(
8
7
 
t
o
 
9
9
)
<
1
 
t
o
 
2
F
D
T
 
C
-
2
0
-
5
5
7
8
 
(
1
9
 
t
o
 
9
9
)
7
5
 
(
5
7
 
t
o
 
8
7
)
1
0
 
(
0
.
7
 
t
o
 
2
4
9
)
9
2
 
(
8
6
 
t
o
 
9
8
)
<
1
 
t
o
 
2
O
K
P
4
8
6
 
(
2
9
 
t
o
 
1
0
0
)
9
0
 
(
7
9
 
t
o
 
9
6
)
5
8
 
(
4
 
t
o
 
1
5
8
5
)
9
7
 
(
9
4
 
t
o
 
9
8
)
3
 
t
o
 
4
 
S
A
P
 
s
u
p
r
a
t
h
r
e
s
h
o
l
d
9
7
1
 
(
5
1
 
t
o
 
8
6
)
8
5
 
(
7
3
 
t
o
 
9
3
)
1
4
 
(
6
 
t
o
 
3
4
)
8
1
 
(
6
0
 
t
o
 
1
0
0
)
2
 
t
o
 
8
S
A
P
 
t
h
r
e
s
h
o
l
d
d
5
8
8
 
(
6
5
 
t
o
 
9
7
)
8
0
 
(
5
5
 
t
o
 
9
3
)
3
0
 
(
6
 
t
o
 
1
5
9
)
9
9
 
(
9
1
 
t
o
 
1
0
0
)
3
 
t
o
 
9
G
A
T
9
4
6
 
(
2
2
 
t
o
 
7
1
)
9
5
 
(
8
9
 
t
o
 
9
7
)
1
5
 
(
4
 
t
o
 
4
9
)
9
9
 
(
9
7
 
t
o
 
1
0
0
)
N
o
t
 
s
t
a
t
e
d
N
C
T
1
9
2
 
(
6
2
 
t
o
 
1
0
0
)
9
2
 
(
9
0
 
t
o
 
9
4
)
1
3
5
 
(
1
7
 
t
o
 
1
0
6
1
)
9
7
 
(
9
0
 
t
o
 
1
0
0
)
1
a
S
u
m
m
a
r
y
 
d
a
t
a
 
a
c
r
o
s
s
 
a
l
l
 
s
t
u
d
i
e
s
 
i
r
r
e
s
p
e
c
t
i
v
e
 
o
f
 
q
u
a
l
i
t
y
.
b
O
n
e
 
s
t
u
d
y
 
p
r
o
v
i
d
e
d
 
d
a
t
a
 
o
n
 
i
n
t
e
r
p
r
e
t
a
b
l
e
 
r
e
s
u
l
t
s
.
1
6
7
c
D
O
R
s
 
a
r
e
 
b
a
s
e
d
 
o
n
 
a
l
l
 
s
t
u
d
i
e
s
 
u
s
i
n
g
 
a
 
c
o
m
m
o
n
 
c
u
t
-
o
f
f
.
d
F
o
u
r
 
s
t
u
d
i
e
s
 
r
e
p
o
r
t
e
d
 
t
h
e
 
t
i
m
e
 
t
a
k
e
n
 
t
o
 
p
e
r
f
o
r
m
 
t
h
e
 
t
e
s
t
,
 
a
l
l
 
o
f
 
w
h
i
c
h
 
u
s
e
d
 
S
I
T
A
 
s
t
a
n
d
a
r
d
 
o
r
 
S
I
T
A
 
f
a
s
t
.
1
7
6
,
1
9
5
,
1
9
8
,
2
0
6
T
A
B
L
E
 
2
2
H
S
R
O
C
 
a
n
a
l
y
s
i
s
:
 
a
l
l
 
s
t
u
d
i
e
s
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
h
i
g
h
e
r
 
q
u
a
l
i
t
y
 
s
t
u
d
i
e
s
O
p
t
i
c
 
d
i
s
c
 
p
h
o
t
o
g
r
a
p
h
y
H
R
T
 
I
I
F
D
T
 
C
-
2
0
-
5
S
A
P
 
t
h
r
e
s
h
o
l
d
S
e
n
s
i
t
i
v
i
t
y
 
S
p
e
c
i
f
i
c
i
t
y
S
e
n
s
i
t
i
v
i
t
y
S
p
e
c
i
f
i
c
i
t
y
S
e
n
s
i
t
i
v
i
t
y
 
S
p
e
c
i
f
i
c
i
t
y
 
S
e
n
s
i
t
i
v
i
t
y
 
S
p
e
c
i
f
i
c
i
t
y
 
(
%
)
(
%
)
(
%
)
(
%
)
(
%
)
(
%
)
(
%
)
(
%
)
A
l
l
 
s
t
u
d
i
e
s
 
7
3
8
9
8
6
8
9
7
8
7
5
8
8
8
0
H
i
g
h
e
r
 
q
u
a
l
i
t
y
 
7
4
8
2
9
3
8
5
7
2
6
0
7
3
6
4corrected for global and sectorial disc area and
uses three grades: ‘normal’ if all of the
measurements fall within the 95% confidence
intervals, ‘borderline’ if at least one falls 
between the lower 95% and 99.9% confidence
intervals, and ‘outside normal limits’ if at 
least one rim area measurement is less than 
the lower 99.9% confidence interval. The
reference standard consisted of a full clinical
ophthalmic examination by an ophthalmologist; 
a panel of nine glaucoma experts determined 
the final diagnosis of glaucoma. The 
combinations of tests reported were: (a) FDT (at
least one abnormality) then HRT II (at least one
abnormality); (b) FDT (at least one abnormality)
then HRT II (at least two abnormalities); (c) FDT
(at least two abnormalities) then HRT II (at 
least one abnormality); and (d) FDT (at least 
two abnormalities) then HRT II (at least two
abnormalities). The highest sensitivity, 79%, was
reported for both (a) and (b) with specificities of
88% and 93%, respectively, while the highest
specificity, 95%, was reported for (d) with a
sensitivity of 74%. 
The study by Vernon and colleagues164 also
reported the sensitivity and specificity of
sequential testing of NCT (Keeler Pulsair)
followed by SAP (Henson CFS 2000 26-point
suprathreshold screening programme) for
detecting OAG. For NCT, the criterion used to
define a positive result was mean IOP of at least
22 mmHg. For SAP, a missed point on the 
26-point suprathreshold programme required the
operator to extend to a 66-point test. A failed test
was defined as occurring when sufficient points
had been missed to drop the indicator on the
screen into the suspicious zone or below. The
reference standard consisted of all participants
having their optic discs graded by an experienced
ophthalmologist. There was verification bias in
that those who tested positive on the index tests
had a more extensive evaluation. Glaucoma was
defined as IOP greater than 22 mmHg plus
pathologically cupped disc with field loss, or 
IOP greater than 22 mmHg on two occasions in
association with two or more of six pathological
disc parameters despite normal fields, or IOP
greater than 30 mmHg on two occasions. The
authors reported a sensitivity of 92% and
specificity of 93% for sequential testing of IOP
followed by the Henson 26-point suprathreshold
screening programme. It should be noted,
however, that the reference standard is 
suboptimal as reported for this study when
reporting the accuracy of NCT alone in the
previous section.
Studies assessing accuracy for different stages of
glaucoma
One population-based study158 and six
case–control studies181,182,184,186,190,191 reported the
accuracy of tests for detecting glaucoma at
different stages of the disease. Although some of
these studies did not specifically state this as an
aim, they were considered to do so by either
including or excluding people with certain stages
of glaucoma. While the present review’s inclusion
criteria aimed to ensure that study participants
would be representative of a screening population,
some studies were accepted that excluded very
severe loss, for example hemispheric loss, or
hemianopia or that applied exclusion criteria on
vision that were not judged as being unduly
restrictive. These studies were accepted on the
basis that they were in effect providing
information on test accuracy for different stages of
glaucoma and that the categories of people
excluded would generally have already been
detected owing to the severity of their vision loss.
For example, Katz and colleagues158 excluded
people with hemispheric or greater loss, Enger
and colleagues181 excluded those with advanced
glaucoma and Harper and colleagues182 excluded
people with more advanced glaucomatous visual
field defects, while all participants with glaucoma
in the study by Wood and colleagues191 possessed
early/moderate visual field defects. Ieong and
colleagues186 included people with minimal
glaucomatous field loss, while Wollstein and
colleagues190 included those with visual field
defects defined as ‘mild glaucoma’. 
As these studies aimed to assess test accuracy in
different stages of glaucoma, their participants
were representative of a specific severity rather
than a broad spectrum of disease. Table 23
provides details of those studies assessing the
accuracy of tests for different stages of glaucoma,
the tests used, the sensitivity and specificity
reported by the individual studies, and the pooled
sensitivity and specificity from the meta-analysis
models for all studies reporting the tests (for all
stages of glaucoma) at the common cut-off (as
shown in Table 21). 
In two studies186,190 assessing early-stage glaucoma
and reporting optic disc photography, HRT II and
SAP suprathreshold, sensitivity ranged from 69%
(HRT II) to 72% (SAP suprathreshold), while
specificity ranged from 94% (optic disc
photography) to 95% (HRT II; SAP
suprathreshold). Sensitivity was similar for SAP
suprathreshold (72% versus 71%) and optic disc
photography (71% versus 73%), but lower for
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.HRT II (69% versus 86%), when compared with
the pooled data from the meta-analysis models for
all studies reporting the tests at a common cut-off.
The specificities reported by the individual studies
for each test were higher compared with the
pooled data.
In four studies158,181,182,191 assessing
early/moderate-stage glaucoma and reporting
ophthalmoscopy, OKP and SAP threshold,
sensitivity ranged from 25% (OKP) to 97% (SAP
threshold), while specificity ranged from 78%
(ophthalmoscopy) to 98% (SAP threshold). In
these studies, compared with the pooled data from
the meta-analysis models, sensitivity was higher
for SAP threshold (97% versus 88%) but lower for
ophthalmoscopy (56% versus 60%) and especially
for OKP (25% versus 86%), while specificity was
higher for OKP (94% versus 90%) and SAP
threshold (98% and 94% versus 80%), but lower
for ophthalmoscopy (78% versus 94%). One
possible explanation for the low sensitivity of OKP
put forward by the study authors was that the test
was self-administered and unsupervised, and
relied on self-assessment by the participants.182
In the one study184 reporting a subgroup of the
study population with moderate/severe-stage
glaucoma, sensitivity for the FDT C-20 full
threshold test was higher (100% versus 90%) with
similar specificity (both 81%) when compared with
the whole study group.
Studies directly comparing tests
Overview
Six studies directly compared two or more of the
following tests that were considered to be
potentially feasible for use in a screening
programme for detection of OAG: optic disc
photography, HRT II, SAP, FDT and
GAT.157,163,166,168,176,186 All of the studies compared
SAP with one or more of the other tests (Table 24).
SAP compared with optic disc photography
Vitale and colleagues166 compared SAP
(suprathreshold programme 1 of the Dicon LD
400 Autoperimeter) with optic disc photography
(Topcon ImageNet) in a case–control study set in
the USA involving 249 people. The participants
were selected from survivors of a population-based
sample included in the Baltimore Eye Survey
Follow-up Study.235 Three definitions of an
abnormal SAP test were assessed: two adjacent
points missed, three adjacent points missed, or
two or more points missed in any location. Criteria
used to define a positive test result for optic disc
photography were VCDR greater than 0.59 or rim
area/disc area less than 0.66. Overall, optic disc
photography performed better than SAP in terms
of sensitivity but worse in terms of specificity.
Sensitivity for SAP ranged from 50% [three
adjacent points missed (common cut-off)] to 71%
(two or more points missed, any location), while
specificity ranged from 58% (two or more points
missed, any location) to 83% [three adjacent
points missed (common cut-off)]. Sensitivity for
optic disc photography ranged from 73% (rim
area/disc area <0.66) to 77% [VCDR > 0.59
(common cut-off)], while specificity ranged from
59% [VCDR > 0.59 (common cut-off)] to 62% (rim
area/disc area <0.66). In terms of the
methodological quality of the study, the spectrum
of people was seen as representative of those who
would attend for screening, there was no evidence
of partial or differential verification bias, and the
results of the index tests were interpreted without
knowledge of the results of the reference standard
test, and vice versa. The reference standard for
this study was glaucoma expert opinion based on
slit-lamp examination, and dilated
ophthalmoscopy to assess the optic disc and nerve
fibre layer. Therefore, the estimates for the
accuracy of optic disc photography as the index
test may overestimate the accuracy of the test, as
the reference standard, although a different test, is
also a test of structure.
SAP compared with HRT II
Two studies compared SAP with HRT II, with
Robin and colleagues163 reporting HRT II as the
better test, and Ieong and colleagues186 reporting
broadly similar results for both tests. Robin and
Screening and diagnostic tests for open angle glaucoma
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TABLE 24 Studies directly comparing two or more of: optic disc photography, HRT II, FDT, SAP and GAT
Study Optic disc photography HRT II FDT  SAP GAT
Ivers, 2001157 ✕✕
Ieong, 2003186 ✕✕
Robin, 2005163 ✕✕✕
Spry, 2005176 ✕✕
Vitale, 2000166 ✕✕
Wang, 1998168 ✕✕colleagues163 compared SAP (Central 24-2
threshold screening programme of the Humphrey
field analyser) with HRT II in a population-based
study set in Australia involving 261 people. The
SAP test was analysed using the AGIS visual field
test scoring method. Three definitions of
abnormal HRT II were assessed: one or more
borderline or severe abnormalities, two or more
borderline or one or more severe abnormalities, or
three or more borderline or one or more severe
abnormalities. The reference standard was a full
clinical ophthalmic examination and a panel of
nine glaucoma experts determined the final
diagnosis of glaucoma. Overall, HRT II
performed better than SAP in terms of both
sensitivity and specificity. Sensitivity for HRT II
ranged from 90% (at least two borderline or one
severe abnormality; at least three borderline or
one severe abnormality) to 95% [at least one
borderline or one severe abnormality (common
cut-off)], while specificity ranged from 81% [at
least one borderline or one severe abnormality
(common cut-off)] to 91% (at least three
borderline or one severe abnormality). Sensitivity
for SAP ranged from 63% [AGIS score  3
(common cut-off)] to 90% (AGIS score  1), while
specificity ranged from 58% (AGIS score  1) to
74% [AGIS score  3 (common cut-off)]. In this
study the spectrum of people was seen as
representative of those who would attend for
screening, there was no evidence of partial or
differential verification bias, and the results of the
index tests were interpreted without knowledge of
the results of the reference standard test, and vice
versa. The accuracy of both SAP and HRT II as
index tests may have been overestimated as visual
field testing and estimates of CDRs also formed
part of the reference standard.
Ieong and colleagues186 compared SAP
suprathreshold (DICON) with HRT II in a
case–control study set in the UK involving 29
participants with OAG (including 15 NTG) and 37
normal participants, with the tests being carried
out by eight optometrists. This study aimed to
target those with early-stage glaucoma. OAG
participants with minimal field loss were recruited
through glaucoma clinics at Moorfields Eye
Hospital. Normal participants were spouses or
partners of those with OAG. The reference
standard was glaucoma expert opinion. In terms
of the criteria used to define a positive result, for
SAP, decisions on whether visual plots were truly
defective were left to the optometrists’ judgement,
while for HRT II if either the global or one of six
segments was flagged abnormal the optic disc was
regarded as suspicious, with borderline
classifications taken as normal. The less affected
eye of OAG participants was analysed, while for
normal participants the eyes analysed alternated
right then left in order of presentation. At the
common cut-off, sensitivity for SAP and HRT II
was 72% and 69%, respectively, while specificity for
both tests was 95%. In terms of quality, the
spectrum of people was not regarded as
representative of screening or diagnosis in that
only early disease was targeted, there was no
evidence of partial or differential verification bias,
and the results of the index tests were interpreted
without knowledge of the results of the reference
standard test, and vice versa. The accuracy of both
SAP and HRT II as index tests may have been
overestimated, as both visual field testing and
optic nerve examination formed part of the
reference standard. 
SAP compared with FDT
Two studies compared SAP with FDT, with both
Robin and colleagues163 and Spry and
colleagues176 reporting FDT as better than SAP in
terms of sensitivity, but worse in terms of
specificity. Robin and colleagues163 compared SAP
(Central 24-2 threshold screening programme of
the Humphrey field analyser) with FDT C-20-5 in
a population-based study set in Australia involving
261 people. The SAP test was analysed using the
AGIS visual field test scoring method. Four
definitions of abnormal FDT C-20-5 were
assessed: one abnormal point, two abnormal
points, three abnormal points and one abnormal
point at moderate or severe level. The reference
standard was a full clinical ophthalmic
examination and a panel of nine glaucoma experts
determined the final diagnosis of glaucoma.
Overall, FDT C-20-5 performed better than SAP
in terms of sensitivity but worse in terms of
specificity. Sensitivity for FDT C-20-5 ranged from
68% (one abnormal point at moderate or severe
level) to 84% [one abnormal point (common cut-
off)], while specificity ranged from 55% [one
abnormal point (common cut-off)] to 76% (one
abnormal point at moderate or severe level).
Sensitivity for SAP ranged from 63% [AGIS score
 3 (common cut-off)] to 90% (AGIS score  1),
while specificity ranged from 58% (AGIS score  1)
to 74% [AGIS score  3 (common cut-off)]. In this
study the spectrum of people was seen as
representative of those who would attend for
screening, there was no evidence of partial or
differential verification bias, and the results of the
index tests were interpreted without knowledge of
the results of the reference standard test, and vice
versa. The accuracy of both SAP and FDT C-20-5
as index tests may have been overestimated as
Health Technology Assessment 2007; Vol. 11: No. 41
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reference standard.
Spry and colleagues176 compared SAP threshold
(SITA fast) with FDT C-20 matrix (Humphrey
matrix 24-2) in a cohort study set in the UK
involving 48 people. The reference standard
consisted of an ophthalmic examination including
the SAP threshold test. The definition of an
abnormal test for both SAP and FDT was a GHT
outside the normal limit and/or p < 0.05 with the
pattern standard deviation global index in one or
both eyes. At the common cut-off, the study
reported sensitivity for SAP and FDT of 80% and
100%, respectively, while specificity was 52% and
27%, respectively. In terms of the quality of the
study, the spectrum of people was considered
representative of a diagnostic setting, there was no
evidence of partial or differential verification bias,
and the results of the index tests were interpreted
without knowledge of the results of the reference
standard. The results of the reference standard
were interpreted without knowledge of the FDT
test results, but with knowledge of the SAP test
results as this test formed part of the reference
standard. Sensitivity and specificity may be
overestimated as both index tests were visual field
tests, with one (SAP) also forming part of the
reference standard, resulting in incorporation bias
for this test.
SAP compared with GAT
Two studies157,168 compared SAP suprathreshold
with GAT, with both reporting that SAP performed
better than GAT in terms of sensitivity but worse
in terms of specificity. Ivers and colleagues157
compared SAP (Humphrey 76-point
suprathreshold screening test) with GAT in a
population-based study set in Australia (Blue
Mountains Eye Study) involving 3654 people.
Criteria for a positive SAP test included one,
three, five or ten or more points missing, while
GAT was assessed at IOP greater than 22 mmHg
and IOP greater than 28 mmHg. The reference
standard for all participants was a detailed eye
examination and a screening visual field test.
Glaucoma suspects received a more thorough
reference standard consisting of a full threshold
visual field test. Sensitivity for SAP ranged from
37% (ten or more points missing) to 100% (one or
more points missing), while specificity ranged
from 50% (one or more points missing) to 92%
(ten or more points missing). At the common cut-
off sensitivity and specificity for SAP was 89% and
73%, respectively. Sensitivity for GAT ranged from
3% (IOP > 28 mmHg) to 14% [IOP > 22 mmHg
(common cut-off)], while specificity ranged from
98% [IOP > 22 mmHg (common cut-off)] to 99%
(IOP > 28 mmHg). In terms of the quality of the
study, the spectrum of people was seen as
representative of those who would attend for
screening, there was no evidence of partial
verification bias in that everyone received a
reference standard test, but there was evidence of
differential verification bias in that only test
positives on the index tests went on to receive a
more thorough reference standard. Although the
results of the index tests were interpreted without
knowledge of the results of the reference standard
test, thereby avoiding test review bias, diagnostic
review bias may have occurred in that the final
diagnosis of glaucoma was made with knowledge
of the results of the SAP and GAT index tests,
potentially biasing the assessment of glaucoma
status. The accuracy of both SAP and GAT as
index tests may have been overestimated, as visual
field testing and IOP measurement formed part of
the reference standard, so that it was not wholly
independent of the index tests, leading to
incorporation bias.
Wang and colleagues168 compared SAP
suprathreshold (Humphrey full field 120
screening programme) with GAT in a population-
based study set in the USA involving 510 people.
The participants were selected from those
attending an adult primary care clinic at the Johns
Hopkins Hospital. SAP was assessed at 17 or more
absolute or relative defects, while GAT was
assessed at IOP above 21 mmHg. The reference
standard for all participants was a full
ophthalmological examination. Only screen
positives were referred for a further definite
diagnosis of glaucoma. At the common cut-off, the
study reported sensitivity for SAP and GAT of 70%
and 28%, respectively, while specificity was 67%
and 96%, respectively. In terms of the quality of
the study, the spectrum of people was seen as
representative of those who would attend for
screening, there was no evidence of partial
verification bias in that all participants received a
reference standard test, but there was evidence of
differential verification bias in that only test
positives on the index tests went on to receive a
more thorough reference standard. Although the
results of the index tests were interpreted without
knowledge of the results of the reference standard
test, avoiding test review bias, it was unclear
whether the reference standard test was
interpreted without knowledge of the results of the
index tests. The accuracy of both SAP and GAT as
index tests may have been overestimated, as visual
field testing and IOP measurement formed part of
the reference standard, so that it was not wholly
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incorporation bias.
Summary
Table 25 shows the sensitivity, specificity, DOR and
relative RDOR at the common cut-off for the tests
being compared directly within studies. In terms
of sensitivity, SAP performed better than
GAT,157,168 broadly similar186 or worse163 than
HRT II and worse than optic disc photography,166
FDT C-20-5163 or FDT C-20 matrix.176 In terms of
specificity, SAP performed better than optic disc
photography,166 FDT C-20-5163 or FDT C-20
matrix,176 broadly similar186 or worse than HRT
II163 and worse than GAT.157,168 DORs for the tests
ranged from 4 for SAP threshold176 to 75 for HRT
II,163 with higher DORs indicating more
convincing diagnostic evidence. 
In terms of RDORs, compared with SAP, GAT
performed better168 or worse,157 HRT II
performed better163 or worse,186 FDT C-20-5163
and FDT C-20 matrix176 performed better, while
optic disc photography166 showed a broadly
similar performance. The RDORs in the study by
Ivers and colleagues157 were statistically significant
in favour of SAP suprathreshold over GAT, while
those in the study by Robin and colleagues163 were
statistically significant in favour of HRT II over
SAP threshold.
The studies by Robin and colleagues,163 Vitale and
colleagues166 and Spry and colleagues176 met the
criteria specified for higher quality studies.
However, incorporation bias occurred in the study
by Robin and colleagues163 and Spry and
colleagues176 as the SAP test also formed part of
the reference standard. There was a possibility of
incorporation bias in the study by Vitale and
colleagues166 as one index test (optic disc
photography) and tests that formed part of the
reference standard (slit-lamp biomicroscopy) were
tests of structure. 
Indirect comparisons in a single HSROC model
The results of the indirect comparison of the ten
tests are given in Table 26. Out of the large
number of comparisons only four for sensitivity
and two for specificity showed a statistically
significant difference between tests. There was
evidence that the sensitivity of FDT C-20-1 was
higher than ophthalmoscopy (–30, 95% CrI –62 to
–0.01) and GAT (45, 95% CrI 17 to 68), and that
SAP threshold (41, 95% CrI 14 to 64) and HRT II
(39, 95% CrI 3 to 64) had a higher sensitivity than
GAT. For specificity, there was evidence of a higher
level for GAT than for FDT C-20-5 (–19, 95% CrI
–53 to –0.2) and SAP threshold (–14, 95% CrI 
–37 to –1). Several other comparisons were close to
being statistically significant. No one test (or group
of tests) was clearly more accurate than the others.
Discussion of results
Main findings
The included studies reported tests of structure
(ophthalmoscopy; optic disc photography, RNFL
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TABLE 25 Sensitivity, specificity, DOR and RDOR at the common cut-off for studies directly comparing tests
Study Test Sensitivity (%) Specificity (%)  DOR  RDOR 
(95% CI) (95% CI) (95% CI) (95% CI)
Ivers, 2001157 SAP suprathreshold 89 (80 to 94) 73 (71 to 74) 20 (10 to 39) 1
GAT 14 (7 to 23) 98 (97 to 98) 6 (3 to 12) 0.31 (0.12 to 0.78)
Ieong, 2003186 SAP suprathreshold 72 (53 to 87) 95 (82 to 99) 46 (9 to 237) 1
HRT II 69 (49 to 85) 95 (82 to 99) 39 (8 to 198) 0.85 (0.08 to 8.54)
Robin, 2005163 SAP threshold 63 (38 to 84) 74 (68 to 80) 5 (2 to 13) 1
HRT II 95 (74 to 100) 81 (75 to 85) 75 (10 to 574) 15.01 (1.57 to 143.82)
FDT C-20-5 84 (60 to 97) 55 (49 to 61) 7 (2 to 23) 1.31 (0.27 to 6.43)
Spry, 2005176 SAP threshold 80 (52 to 96) 52 (34 to 69) 4 (1 to 18) 1
FDT C-20 matrix 100 (78 to 100) 27 (13 to 46) 12 (1 to 222)  2.83 (0.11 to 72.91)
Vitale, 2000166 SAP suprathreshold 50 (37 to 63) 83 (76 to 88) 5 (3 to 9) 1
Optic disc photography 77 (62 to 89) 59 (50 to 67) 5 (2 to 11) 0.99 (0.36 to 2.75)
Wang, 1998168 SAP suprathreshold 70 (57 to 80) 67 (59 to 74) 5 (2 to 9) 1
GAT 28 (17 to 40) 96 (93 to 98) 9 (4 to 19) 1.89 (0.70 to 5.13)
RDOR = index test DOR/SAP DOR. RDOR calculated as all direct studies had SAP as one of the tests. Values of 
RDOR > 1 indicate that the test performed better than SAP in the study and values < 1 indicate that the test performed
worse than SAP .
For details of the common cut-off selected for each test see Appendix 13.Screening and diagnostic tests for open angle glaucoma
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TABLE 26 Pairwise indirect comparisons of the 10 tests
Comparisona Difference between tests
Sensitivity, median (95% CrI) Specificity, median (95% CrI)
Ophthalmoscopy versus
Optic disc photography –12 (–46 to 20) 6 (–7 to 21)
RNFL photography –14 (–50 to 26) 6 (–7 to 30)
HRT II –24 (–57 to 14) 5 (–9 to 30)
FDT C-20-1 –30 (–62 to –0.01)* 0.3 (–11 to 18)
FDT C-20-5 –11 (–49 to 32) 19 (–2 to 53)
OKP –20 (–54 to 19) 4 (–9 to 26)
SAP suprathreshold –10 (–43 to 20) 9 (–4 to 22)
SAP threshold –26 (–58 to 2) 14 (–2 to 37)
GAT 15 (–22 to 47) –0.06 (–12 to 7)
Optic disc photography versus
RNFL photography –2 (–31 to 34) –0.05 (–17 to 24)
HRT II –12 (–38 to 22) –1 (–18 to 24)
FDT C-20-1 –18 (–42 to 6) –6 (–21 to 12)
FDT C-20-5 1 (–30 to 40) 12 (–10 to 47)
OKP –8 (–35 to 27) –2 (–18 to 21)
SAP suprathreshold 2 (–23 to 25) 3 (–13 to 17)
SAP threshold –14 (–38 to 7) 8 (–11 to 31)
GAT 27 (–4 to 53) –6 (–21 to 3)
RNFL photography versus
HRT II –10 (–45 to 25) –1 (–25 to 24)
FDT C-20-1 –16 (–50 to 10) –5 (–29 to 13)
FDT C-20-5 3 (–36 to 44) 12 (–16 to 47)
OKP –6 (–43 to 30) –1 (–26 to 22)
SAP suprathreshold 4 (–31 to 29) 3 (–21 to 18)
SAP threshold –12 (–46 to 12) 8 (–17 to 32)
GAT 29 (–10 to 57) –6 (–30 to 4)
HRT II versus
OKP 4 (–29 to 38) –1 (–26 to 22)
FDT C-20-1 –6 (–38 to 17) –4 (–29 to 14)
FDT C-20-5 12 (–23 to 52) 13 (–16 to 49)
SAP suprathreshold 14 (–18 to 36) 4 (–21 to 19)
SAP threshold –2 (–34 to 18) 9 (–18 to 33)
GAT 39 (3 to 64)* –5 (–30 to 5)
OKP versus
FDT C-20-1 –10 (–42 to 14) –3 (–26 to 14)
FDT C-20-5 9 (–29 to 49) 14 (–13 to 49)
SAP suprathreshold 10 (–24 to 34) 5 (–18 to 19)
SAP threshold –6 (–39 to 16) 10 (–15 to 34)
GAT 35 (–2 to 62) –4 (–26 to 5)
SAP suprathreshold versus
FDT C-20-1 –20 (–40 to 3) –8 (–22 to 9)
FDT C-20-5 –1 (–29 to 38) 10 (–12 to 45)
SAP threshold –16 (–37 to 5) 5 (-12 to 28)
GAT 25 (–2 to 50) –9 (–22 to 0.3)
SAP threshold versus
FDT C-20-1 –4 (–23 to 18) –13 (–36 to 6)
FDT C-20-5 15 (–11 to 53) 5 (–23 to 41)
GAT 41 (14 to 64)* –14 (–37 to –1)*
FDT C-20-1 versus
FDT C-20-5 19 (–10 to 57) 18 (–6 to 53)
GAT 45 (17 to 68)* –0.4 (–18 to 8)
FDT C-20-5 versus GAT 26 (–16 to 57) –19 (–53 to –0.2)*
a A versus B = A – B.
* Statistically significant difference.photography, HRT II), visual function (FDT, OKP,
SAP) and IOP (GAT, NCT). Other tests were
considered, including those of structure (GDx
VCC, OCT, RTA), visual function (SWAP, MDP) or
using Tonopen to measure IOP. However, no
studies using these tests met the inclusion criteria
in terms of reporting of test accuracy outcomes.
Despite the huge volume of literature, no good-
quality studies were found providing a positive
response to all questions on the modified QUADAS
checklist. Eight studies were rated as higher quality
in that the spectrum of people was considered
representative of a screening or diagnostic setting,
and partial and differential verification bias and
test and diagnostic review bias were avoided. 
Analyses were performed at a number of different
levels:
● HSROC model for each test at all cut-offs and a
common cut-off
● HSROC model for tests reported by two or
more higher quality studies at a common cut-off
● analysis of studies reporting combinations of
tests
● analysis of studies reporting the accuracy of
tests for stages of glaucoma
● analysis of studies directly comparing two or
more tests in the same population
● indirect comparison of all tests from all
included studies at a common cut-off. 
From the available data, the following tests were
considered to be potentially feasible for use in a
screening programme for detection of OAG: optic
disc photography, HRT II, FDT, SAP and GAT.
Direct comparison studies provide the most robust
estimates of comparative test accuracy. Only six
studies directly compared two or more of these
tests, with all studies including SAP as one of the
tests.157,163,166,168,176,186 In these studies, at the
common cut-off, in terms of sensitivity, SAP
performed better than GAT,157,168 broadly
similar186 or worse163 than HRT II and worse than
optic disc photography,166 FDT C-20-5163 or FDT
C-20 matrix.176 At the common cut-off, in terms of
specificity, SAP performed better than optic disc
photography,166 FDT C-20-5163 or FDT C-20
matrix,176 broadly similar186 or worse than HRT
II163 and worse than GAT.157,168 Three direct
comparison studies met the criteria for higher
quality studies.163,166,176
The pooled estimate of the sensitivity of the tests
in detecting OAG ranged from 46% (GAT) to 92%
(FDT C-20-1), while specificity ranged from 75%
(FDT C-20-5) to 95% (GAT). The FDT C-20-1 test
was associated with the highest sensitivity (92%)
and was one of the tests associated with the highest
specificity (94%), along with ophthalmoscopy (94%)
and GAT (95%). The pooled estimate for FDT C-
20-1 showed higher sensitivity and specificity than
the pooled estimate for FDT C-20-5 and also the
single FDT C-20 full threshold study. This is
unexpected (i.e. better sensitivity of C-20-1 than 
C-20-5). These findings were based on only three
FDT C-20-1 studies, five FDT C-20-5 studies and
one FDT C-20 full threshold study, with
heterogeneity evident especially in the FDT C-20-5
studies. Forest plots showing sensitivity and
specificity with 95% confidence intervals revealed
statistical heterogeneity across studies for most
tests, other than for the sensitivity of optic disc
photography (number of studies, n = 6), sensitivity
and specificity of HRT II (n = 3), and sensitivity of
FDT C-20-1 (n = 3). Empirically, there was no
obvious single cause for the heterogeneity, but
potential contributory factors include differences in
populations, study design, setting, prevalence and
severity of glaucoma within studies. Other factors
include differences in reference standard, and in
tests included within the same category (e.g.
different types of perimetry and ophthalmoscopy
have a large number of variants, potentially
leading to heterogeneity in discriminatory power
across studies reporting those tests), and the extent
to which studies were affected by other potential
biases (e.g. partial and differential verification bias,
incorporation bias, test and diagnostic review bias).
Owing to the imprecision in the estimates from the
pooled meta-analysis models for the diagnostic
performance of each test it was not possible to
identify a single test (or even a group of tests) as
the most accurate. 
Based on the pairwise indirect comparisons, in
terms of statistically significant differences in test
performance, there was evidence that GAT had a
lower sensitivity than HRT II, SAP threshold and
FDT C-20-1, but a higher specificity than SAP
threshold and FDT C-20-5. FDT C-20-1 also
seemed to have a better sensitivity than
ophthalmoscopy. Other differences in accuracy
between tests may well exist which could not be
detected because of the high level of uncertainty.
The wide credible intervals reflected the small
number of studies reporting each test and the
generally high level of heterogeneity. 
Potential biases
Reference standard
OAG is a clinical diagnosis, based on structural
abnormalities of the optic disc and an associated
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universally agreed optimal reference standard for
the diagnosis of OAG, although progressive
structural optic neuropathy has been proposed as
the best possible reference standard.148,236
Variations in the reference standard used to define
OAG directly affect the estimates of test
accuracy.237,238 In addition, the different tests
become abnormal at different stages of the disease
and at a single time-point agreement between tests
is likely to be poor owing to these differences.
In this review either of two reference standard
tests was considered. The primary reference
standard was confirmed OAG on follow-up and
was considered to be the best reference standard
although, as anticipated, few studies used it.
Therefore, another reference standard, cross-
sectional ophthalmologist-diagnosed OAG, was
also considered. The diagnosis from this second
reference standard could be based on assessment
of the visual field and/or the optic disc without
requiring follow-up confirmation. Of the 40
studies included in this review, seven used a
reference standard of follow-up confirmation of
glaucoma.22,106,166,171,174,178,189 However, there was
no obvious pattern in terms of the sensitivity and
specificity of the tests reported by studies using a
reference standard of follow-up confirmation of
glaucoma compared with those studies using a
reference standard of ophthalmologist-diagnosed
glaucoma. 
Severity of the disease
The majority of the studies did not stratify test
accuracy on the basis of disease severity. In
general, tests become more sensitive as the disease
becomes more severe. Hence, a study including
participants with advanced disease should report
better sensitivity. However, unless the distribution
of disease severity in the examined population is
explicitly reported in primary studies, it is not
possible to evaluate the impact of any spectrum
bias that might have occurred. In addition, if an
adequate sample size for subgroups is not
achieved, within-study comparisons of test
performance may result in a loss of power to
detect significant differences.239 Seven studies
reporting test accuracy in different stages of
glaucoma were included in this
review.158,181,182,184,186,190,191 However, no
consistent pattern of sensitivities and specificities
for different stages of glaucoma emerged from the
studies. One reason for this was that the studies
mostly reported different tests. Of those reporting
the same tests for different stages of glaucoma,
Ieong and colleagues186 reported a sensitivity of
72% for SAP suprathreshold for early-stage
glaucoma, while Enger and Sommer181 and Katz
and colleagues158 both reported a sensitivity of
97% for early/moderate-stage glaucoma. It is not
unexpected that a visual field test such as SAP
would increase in sensitivity as the disease
progresses. Variations in the results between other
studies can be explained by the use of non-
uniform and non-standardised definitions for
various stages of glaucoma. Some studies used
structural damage to define these stages (early,
moderate, severe), while others used functional
damage. However, it could be argued that once
functional damage is detectable on standard
perimetry, then by definition the disease has
progressed beyond early stage.229,240,241
Incorporation bias
In glaucoma diagnosis the concept of incorporation
bias is complex. For example, it has been
suggested that inclusion of any optic disc criteria
in the reference standard when evaluating another
optic disc test (e.g. HRT) introduces incorporation
bias.242 In such studies it may seem logical to use
only visual field examination as a reference
standard test. This, however, assumes that
structural (e.g. optic disc) and functional (e.g.
visual field) damage occur simultaneously in
glaucoma pathogenesis, whereas there is evidence
that disc damage precedes manifest visual field
loss.229,240,241 Up to 30% of optic nerve fibre
damage occurs before visual field damage becomes
detectable. Hence, using visual field assessment
alone as a reference standard may report an
unfairly low accuracy of an imaging test, especially
if more people with early glaucoma are included
in the study. For example, if visual field damage
alone is used as a reference standard and a study is
conducted at time-point A (Figure 38) to evaluate
an imaging test, it will report many false positives,
as detectable visual field damage has not yet
occurred. However, if a similar study is performed
at time-point B, there will be greater agreement
between reference standard and index test and
hence the test accuracy will be much higher.
Hospital-based studies (including case–control
studies)
Twenty of the 40 studies included in this review
were hospital based. A hospital population is, by
nature, an enriched population and the
prevalence of the disease will be higher than that
in the community. This population may also
include a disproportionate number of patients
with high IOP and a disproportionately small
number of patients with small optic discs,
potentially leading to overoptimistic performance
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generally recruit participants from glaucoma
clinics who have previous experience of tests and
therefore these studies cannot account for the
learning effect in those unfamiliar with such tests,
unlike the case in a screening situation.243–246
However, only hospital-based studies whose
participants were considered to be representative
of those referred from primary care were included
in the review. 
Diagnostic case–control studies are useful at the
initial stages of validating a test. To test the
applicability of a new test it should be applied
directly to the population of its intended use.
Case–control studies recruit participants with a
clear disease status, that is, either with or without
the target disease. Indeterminate and
intermediate results are common, and often
coexisting disease produces a positive test result.
The majority of the case–control studies identified
applied stringent criteria for inclusion such as
visual acuity of 6/9, or no other ocular disease.
Rutjes and colleagues247 evaluated various
potential sources of bias in diagnostic studies. The
factor with the highest impact on estimates of test
accuracy was a case–control study design with
severely diseased cases and healthy controls. Fifty-
seven case–control studies where the participants
were considered unrepresentative of a case-mix
found in a general population where OAG
screening would be carried out were excluded
from the review (see Appendix 10). 
Prevalence of the disease
The accuracy of a test may vary according to the
population in which it is performed. Although
absolute sensitivity and specificity of a diagnostic
test are independent of the prevalence of a
disease, a diverse spectrum of the disease is
encountered in different prevalence levels. With
increasing prevalence more cases of moderate to
severe disease are expected, and since it is easier
to differentiate between severely diseased and
non-diseased people, a test would be expected to
report improved (apparent) sensitivity and
specificity. Therefore, studies with a significantly
higher prevalence than the UK estimates should
be interpreted with this limitation in
mind.156,161–163,168,170 These studies tended to
recruit their participants through media
advertising rather than contacting individuals in a
predefined population. These studies, including
two that met the criteria for higher quality
studies,163,170 may be considered to be more
representative of screening in higher risk
populations.
Higher quality studies
Only eight studies met the criteria specified for
higher quality studies, of which six were
population based155,156,163,166,169,170 and two were
cohort studies.175,176 For FDT C-20-5 and SAP
threshold, the higher quality studies reported
lower values for both sensitivity and specificity
compared with all studies, while two studies not
meeting the criteria for higher quality173,187
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FIGURE 38 Structural versus functional damage and effect on cross-sectional diagnostic studiesreported very high sensitivity values. For optic disc
photography, compared with all studies, the
higher quality studies reported similar sensitivity,
with slightly lower specificity. For HRT II,
compared with all studies, the higher quality
studies reported higher sensitivity but slightly
lower specificity. 
Issues relevant to screening
Uptake and time taken to perform the test
In addition to the sensitivity and specificity of the
test(s), other factors may impact on the success of
a screening programme, including the percentage
of people invited who attend for screening
(uptake), the percentage of those taking part who
provide interpretable test results and the time
taken to perform the test. Uptake levels ranged
from 28.3163 to 99.5%,154 with a median rate
across studies of 82.8%. The difference may be
explained at least in part by differences in the way
in which the studies made their targeted audience
aware of the screening programme. For example,
Robin and colleagues163 advertised their
programme through the media, while other
studies with greater uptake adopted a more
proactive approach in identifying their target
population and inviting them to attend for
screening.21,99 The percentage of participants
providing interpretable test results ranged from
79.5% for RNFL photography to 99.1% for GAT,
with ophthalmoscopy (97.8%), OKP (96.9%), SAP
threshold (98.9%), FDT C-20-1 (96.7%) and NCT
(97.2%) all reporting rates of interpretable test
results greater than 95%. 
Few included studies gave details of the time taken
to perform the test (see Table 21). None of the
included studies of ophthalmoscopy, RNFL
photography, HRT II or GAT reported the time
taken to perform the test. One study reported this
information for optic disc photography,197 three
for OKP,154,170,212 four for SAP
suprathreshold,159,162,164,174 four for SAP
threshold, all of which used SITA standard or
SITA fast,176,195,198,206 four for FDT 
C-20-1,170,185,187,214 two for FDT C-20-5155,187 and
one for NCT.164 The information provided on
time taken to perform the test should be
interpreted with this limitation in mind.
What stage of glaucoma should be targeted for
screening?
It is important to determine the severity of
glaucoma that screening should detect. This is
important as tests that perform better in moderate
to severe disease but have low diagnostic yield in
early glaucoma could have an overall superior
diagnostic utility as screening tests. Identifying
large numbers of people with early disease that
may never progress to significant visual
impairment or reduction in quality of life may
result in greater harm than benefit from
screening.
Damage caused by OAG typically occurs slowly
and over a long period. Many people diagnosed
with glaucoma will never develop a significant
visual impairment during their lifetime. Current
case detection identifies only around half the
number of people with OAG and thus prevents
only a limited number from progressing to
significant visual impairment. Introducing OAG
screening with a test that is sensitive for moderate
disease will prevent significant visual impairment
in an additional number of people but will still
miss some cases. Using a highly sensitive test for
OAG will identify all those who are at risk of
developing significant visual field loss and
blindness; however, it will also identify a large
proportion of people who are not at risk of
developing severe glaucoma during their lifetime.
Treating these otherwise asymptomatic individuals
could result in the unnecessary use of limited
healthcare resources. In addition, labelling
asymptomatic individuals as ‘diseased’ may well
cause unnecessary anxiety.
Most of the visual disability in glaucoma is related
to visual field loss. Therefore, it is reasonable to
target glaucoma with early visual field loss (i.e.
perimetric glaucoma) in OAG screening. It is
worth noting that this does not rule out structural
tests from glaucoma screening. A structural test
such as HRT may have a better diagnostic
performance than a functional test such as SAP in
the perimetric stage of glaucoma because, in this
stage, the disc damage would have progressed
beyond early stage and would therefore be easier
to detect.
Strengths and limitations of the review
The field of systematic reviews of diagnostic tests
is a nascent one and the methodology for these
complex reviews is currently still evolving. 
Bearing these limitations in mind, this review is
one of the largest systematic reviews of screening
and diagnostic tests in glaucoma. Several 
levels of analyses were undertaken, including
HSROC analysis on all studies and higher quality
studies, analysis of studies reporting combinations
of tests, studies reporting accuracy of tests for
detecting stages of glaucoma and studies directly
comparing two or more tests. In addition, all the
tests were modelled simultaneously (in one model)
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estimates of differences in sensitivities and
specificities to be calculated. To be included,
studies had to meet specific inclusion criteria. The
validity of indirect comparisons does depend on
assumptions regarding the characteristics of the
included studies; however, the indirect method is
formally performing the comparison that users of
the report are likely to make when assessing the
pooled results for the individual tests. As such, this
method of indirect comparisons serves an
important purpose and reaffirms the lack of
certainty about which test is indeed the best. 
In terms of limitations, relatively few studies were
identified for each test and it was not possible to
perform sensitivity analysis based on study design.
Owing to the small number of studies for each
test, different study designs (population-based
studies and studies including an already suspect
population) were pooled together in the HSROC
meta-analysis models. Only six of the 40 studies
directly compared two or more of the tests that
were considered to be potentially feasible for use
in a screening programme. There were too few
studies on the individual tests for the indirect
comparison to identify what was the best test. Only
eight studies met the criteria for higher quality
studies. The studies were lacking in evidence of
test accuracy in high-risk groups and those most
likely to be targeted for OAG screening. There is a
lack of a generally agreed reference standard test
for OAG against which other tests can be
evaluated. Studies not providing sufficient
information to allow the calculation of 2 × 2 tables
were excluded, although they may have
contributed information in terms of sensitivity and
specificity. Case–control studies where the
participants were not considered representative of
a screening population were also excluded, even if
the same inclusion and exclusion criteria were
applied to both cases and controls, although they
may have contributed information on test accuracy
in a clinic situation.
Conclusions
Implications for practice
For a low-prevalence disease a screening test needs
to be highly specific. In the meta-analysis models
the following tests provided a specificity of 85% or
higher: ophthalmoscopy (94%), optic disc
photography (89%), RNFL photography (88%),
HRT II (89%), FDT C-20-1 (94%), OKP (90%),
SAP suprathreshold (85%) and GAT (95%). In this
review the FDT C-20-1 test was associated with the
highest combination of sensitivity and specificity
for detecting OAG. As pointed out earlier, there
was a wide variation in the reference standards
among included studies. Variations in the reference
standards may partly account for varied diagnostic
accuracies: a stricter reference standard within a
study will lead to a higher specificity and vice versa.
However, owing to the strongly heterogeneous
nature of the data overall and the relatively small
number of studies, it was not possible to conclude
with certainty whether any one test was definitely
superior in terms of accuracy. 
Implications for future research
Future research should focus on a consensus OAG
definition and reference standard. As a significant
proportion of visual morbidity in glaucoma is
directly related to visual field loss, a definition
with emphasis on visual field damage may be
more appropriate. The possibility of a consensus
reference standard test should also be explored.
The definition of different severities of glaucoma
is important, and the stage of glaucoma that is
important to be detected by screening should be
agreed. There is a need for high-quality primary
studies comparing candidate screening tests in an
appropriate population.
The accuracy of the various screening tests should
be evaluated in a sufficiently large population-
based study. Initially, a cross-sectional study to
evaluate the relative accuracies of comparator tests
would be preferable. The main advantage of a
cross-sectional study is a quick outcome. A
diagnostic cross-sectional study could be an RCT
where patients are randomised to one or the other
test(s), or it may be a paired study where each
patient receives both (several/all) tests. The
advantage of a paired study is that a smaller
sample size is required. However, for logistical
reasons, it may not be practical for every
participant to receive all tests. The study should
have a predetermined sample size for assessment
of test accuracies in high-risk subgroups and for
populations in whom glaucoma screening is
thought to be cost-effective. Different combination
algorithms combining structural and functional
tests need further exploration. In this review the
common cut-off chosen for each test was the one
most frequently reported by the studies, which
may not necessarily be the most appropriate. For
example, IOP testing was considered an integral
part of a screening strategy, but studies generally
reported data only for a cut-off of above
21 mmHg, although also providing data for other,
additional, cut-offs would have been more
informative.
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nerve damage due to OAG
Introduction
A Cochrane systematic review of screening for
OAG, led by the Cochrane Eyes and Vision group,
is in the final stages of completion248 (and
Cochrane Collaboration Eyes and Vision Group:
personal communication, 2006). A summary is
provided in this section.
The aim of this review was to determine the
impact of screening, in terms of benefits and
harms, compared with opportunistic case finding.
Effectiveness of screening can be assessed by the
prevalence of and degree of optic nerve damage
due to OAG in screened and unscreened
populations, assuming that successful detection
and subsequent treatment of OAG lead to lower
prevalence of advanced optic nerve damage in
screened versus unscreened populations.
Methods
Inclusion and exclusion criteria
RCTs of screening versus no screening for 
OAG were eligible for inclusion. The reference
strategy of no screening included case finding;
that is, opportunistic detection. Trials comparing
different screening strategies were not included.
Any method of randomisation was considered,
including that in which individuals, locations or
practices were randomised, and differences in
study quality were taken into account in the
analysis. Ideally, trials should have analysed data
on an intention-to-treat (ITT) basis. It was
planned to include other types of analysis
provided all randomised patients were 
accounted for and to use an available case-based
analysis.
Types of participant
Studies from any population were considered, but
major differences in the populations studied such
as age at screen and race would be reported when
analysing the results. People already known to
have glaucoma or already under the care of an eye
specialist, or known to be visually impaired for
other reasons were not expected to be included in
routine screening. Screening is likely to detect
other degenerative eye conditions and other forms
of glaucoma, although these were not included as
the primary outcome of the review.
Types of intervention
Studies of any screening modality for OAG were
eligible. 
Types of outcome measure
Primary outcomes
Any or all of the following three primary outcomes
were considered for this review:
● Prevalence of any degree of characteristic visual
field loss in screened and non-screened
populations as diagnosed by any method of
visual field assessment (excluding
confrontation). The proportion of people with a
predetermined severity of field loss (attributable
to glaucoma) was to be compared in the
screened and unscreened populations.
● Prevalence of optic nerve damage in screened
and non-screened populations as diagnosed 
by any method of imaging. The difference in
the prevalence of a prespecified degree of
structural optic nerve damage would have been
examined in screened and unscreened
populations.
● Prevalence of visual impairment in screened
and non-screened populations as defined by
number of subjects certified or registered
according to national or regional standards
(where the study was conducted) as:
– blind 
– partially sighted
– vision below standard for driving. 
Secondary outcomes
Screening may lead to more treatment and
subsequently a lower mean IOP in screened than
in unscreened populations. IOP is a surrogate
outcome but, nevertheless, indirect evidence of
effectiveness of screening might be derived from
the reduction in the severity of the most well-
established and modifiable risk factor. Reporting
of any differences in mean IOP in screened and
unscreened populations was planned.
Adverse effects
False negatives are people with glaucoma who 
pass screening and go on to lose vision. False
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Chapter 7
Evidence of effectivenesspositives are people without glaucoma who fail
screening and are referred for further
investigation but who do not undergo any
treatment. Referral causes excess burden on health
services and unnecessary inconvenience and
anxiety for the patient.
Quality of life measures
Reporting of any measures of quality of life or
health status attributable to the screening or OAG
was planned.
Economic data
Reporting of any economic data on the costs and
cost-effectiveness of programme implementation,
cost per case identified or other costs relating to
the screening programme was planned. 
Other outcomes
The technical differences between the screening
and control interventions, the quality of the
intervention including any quality control
measures, rates of participation, contamination
and follow-up were measured among screening
and control arms.
Follow-up
A minimum follow-up of 1 year postscreening was
required for all studies.
Search strategy for identification of studies
Any RCTs evaluating population-based screening
programmes for OAG with a minimum 1-year
follow-up were included. 
Electronic searches
The searches outlined in Chapter 4 were used;
however, for this review no language or date
restrictions were applied, according to Cochrane
methodology. No manual searches were
undertaken for this review.
Results
The search generated 1191 records of studies
relevant to the search criteria, but none was an
RCT of screening and hence no data extraction or
analysis was conducted.
Discussion
No RCTS were identified, the applied search
strategy (detailed in Appendix 2) was
comprehensive, with in this case no language
restrictions, and as such it is very unlikely to have
missed any existing trials. Two major sources of
bias that will otherwise distort the findings of
observational studies can only be dealt with by
randomised trials of screening.
Lead-time bias occurs when the condition is
detected at an earlier stage through screening,
although no influence on ultimate outcome is
achieved as a result of that earlier detection. The
survival is apparently greater because the
condition is known about for longer, but an
otherwise similar unscreened individual goes blind
at the same rate, although spending less time
being aware of the problem. In such a
circumstance, it is fair to conclude that screening
has done harm.
Length bias occurs because interval screening is
more likely to detect slowly progressive and
indolent disease than aggressive, rapidly
progressing glaucoma. Apparently, screening has
led to more people with early-stage disease being
identified who are at much lower risk of blindness.
This apparent benefit may actually be harmful if
the risk of the adverse effects of disease in these
mild cases is very low, and the number of people
with aggressive, blinding glaucoma may remain
the same and the blindness rates unchanged.
Hence, this review specifically searched for RCTs of
screening in that it is the only study design that can
adequately deal with these two sources of bias.
However, the organisation and conduct of such
studies is demanding and long-term follow-up is
required on large numbers of people if there is to
be any likelihood of detecting an effect. It is
perhaps not surprising that no such trials were
identified. Justification for such a study will depend
on refinement of screening test strategies and
economic modelling of potential benefit and cost.
Conclusions
Effectiveness of screening for OAG can only be
established by high-quality randomised trials.
Some preliminary issues need to be dealt with
before such trials can be undertaken. A better
understanding of testing technologies is needed
and high-quality studies in different populations
are required to delineate optimum screening
strategies in terms of individuals, tests,
combinations of tests and test frequency. It is
recognised that 1-year follow-up, included as a
minimum in this review, is extremely short in the
course of glaucoma. Ideally, much longer follow-
up is required; however, surrogate outcomes such
as IOP at 1 year can be indicators of prognosis.
Modelling alongside a trial can be used to predict
long-term costs and benefits. Better monitoring of
health outcomes in large populations using
registers of blindness by cause can provide
surveillance for the observation of the impact of
prevention strategies over time.
Evidence of effectiveness
86Effectiveness of glaucoma
treatment
Introduction
Treatment aims to prevent visual disability and
preserve overall wellbeing for patients with
glaucoma. The visual loss in glaucoma is due to
the death of retinal ganglion cells. Vascular and/or
mechanical factors at the optic nerve head may
precipitate cell death and IOP may be implicated
in either or both of these mechanisms.249
Currently, IOP is the only risk factor that can be
treated.
Medical treatment, to lower IOP, is administered
topically as eye drops. These treatments are
commonly topical  -blockers, and more recently
newer topical agents including carbonic anhydrase
inhibitors,  2-agonists and prostaglandin
analogues have been introduced.  -Blockers and
prostaglandin analogues are the most commonly
used medications. Reduced rates of surgery for
glaucoma are felt to be a consequence of the
introduction of these new eye drops.250 An
alternative or additive treatment to the use of
medications is laser trabeculoplasty with discrete
laser ablation to the trabecular meshwork of the
drainage angle. The effectiveness of alternative
medical interventions for OAG and of laser
trabeculoplasty is being assessed in two Cochrane
reviews that are currently in progress.30,31
Glaucoma drainage surgery aims to lower the IOP
by creating an alternative route for aqueous
humour outflow. Trabeculectomy is the most
common glaucoma surgical procedure. In a
Cochrane review of medical versus surgical
interventions for OAG, evidence from one trial
suggests, for mild OAG, that visual field
deterioration up to 5 years is not significantly
different whether treatment is initiated with
medication or trabeculectomy. There was no
evidence to determine the effectiveness of
contemporary medication (prostaglandin
analogues,  2-agonists and topical carbonic
anhydrase inhibitors) compared with surgery in
severe OAG.29
The aim of this part of the project was to
undertake a systematic review to determine the
effectiveness of any IOP-lowering treatment
(medical, laser or surgery or any combination
thereof), compared with no treatment in
preventing glaucoma progression in terms of
reduced visual field loss and progressive optic
nerve damage (a surrogate outcome for visual
field loss), and on patient-reported health status.
Methods
Inclusion and exclusion criteria
Systematic reviews and RCTs of treatment versus
no treatment for participants with OAG were
included. Studies where the participants had
ocular hypertension (i.e. raised IOP but no
evidence of glaucoma damage) were excluded.
Data extraction
One reviewer screened the titles and abstracts of
the identified reports.
Quality assessment
A previously validated ten-item checklist
developed by Oxman was used to assess the
methodological quality of systematic reviews
meeting the inclusion criteria.251,252 The checklist
contains nine criteria, scored as ‘Yes’, ‘Partially’ or
‘No’, depending on the extent to which they are
met. The checklist also provides one summary
criterion for overall scientific quality, scored on a
seven-point scale, where 1 indicates ‘extensive
flaws’ and 7 indicates ‘minimal flaws’.
Results
Number and type of studies included
In total, 323 reports were identified, and 15 full-
text papers were selected for assessment. One
systematic review of RCTs of treatment versus no
treatment for ocular hypertension and OAG was
identified.19 No further RCTs of treatment
effectiveness for OAG: other than those included
in the systematic review and also separately
identified by the search strategy, were identified.
One additional RCT253 was identified where
participants had ocular hypertension, but this did
not meet the inclusion criteria of this specific
review and was excluded.
Characteristics of included study 
The systematic review by Maier and colleagues19
included seven studies; however, five of these
related to the treatment of ocular hypertension
and therefore are not relevant to this review. Thus,
this review reports the results of the two included
trials of treatment versus no treatment for
participants with OAG: the Early Manifest
Glaucoma Trial (EMGT),27 where participants had
been identified as having manifest OAG with or
without raised IOP, and the Collaborative Normal
Tension Glaucoma Study (CNTGS),254 where
participants had OAG but the IOP had not been
recorded as over 24 mmHg in either eye. 
The CNTGS was a 5-year study in the 1990s across
24 centres in the USA, Canada, The Netherlands
and Finland. One eye of 145 participants with
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no treatment. In the treatment arm, treatment
could be medical or surgical and aimed for a 30%
reduction in IOP. The end-point of the study was
documented progression either in terms of visual
field or optic disc changes compatible with
progression. The rate of development of cataracts
in the untreated participants was significantly
lower than in the surgically treated group. In a
survival analysis there was no significant difference
in the risk of progression between the two groups;
however, after censoring for cataract development
the treated group had a significantly lower risk of
progression. The mean survival time to
progression in the treated arm was 6 years, and
5 years in the no-treatment arm.
The EMGT had a different spectrum of
participants from CNTGS, recruiting newly
detected OAG cases identified from a population-
screening programme with 255 participants
randomised to treatment or no treatment.
Participants with very high IOPs (mean IOP 
>30 mmHg) were excluded. All eyes randomised
to treatment received a full 360-degree
trabeculoplasty plus a selective  -blocker eye drop
(Betaxalol). Additional therapy was added if the
IOP exceeded 25 mmHg on two consecutive
occasions. At the final analysis (median follow-up
of 6 years), 78 (62%) of the 126 control eyes versus
58 (45%) of the 129 treated eyes progressed (log-
rank p = 0.007). The median time to progression
was 5.5 years in the treated patients and 4 years in
the no-treatment group. More patients in the
treatment arm developed cataract than in the 
no-treatment group (p = 0.004). Health-related
quality of life (HRQoL) was measured using a
Swedish translation of the 25-item National Eye
Institute Visual Function Questionnaire (NEI VFQ-
25), but was not measured at baseline, as the
questionnaire was not available at that time. There
was no significant difference in composite scores
between the treated and untreated group at 6-year
follow-up. The results of this study therefore
suggest that treatment, whether by randomisation
or received during follow-up, was not related to
vision-targeted HRQoL. However, the analysis of
the HRQoL data was not an ITT analysis.
Quality assessment
The systematic review was assessed as having only
minor flaws, in that the criteria used to assess the
methodological quality of the included trials were
not stated, the search strategy was deemed to be
reasonably comprehensive in that there were no
language restrictions, reference lists were searched
and authors were contacted for further details if
required, but there was no handsearching (see
Appendix 14 for the detailed results of the quality
assessment of the systematic review). As the
systematic review had not assessed the
methodological quality of the included trials, the
quality of the two included RCTs was assessed
according to criteria developed by the Cochrane
Collaboration Eyes and Vision Group. These
criteria assess quality in terms of likelihood of
selection, performance, detection and attrition
bias. In CNTGS it was unclear whether allocation
was adequately concealed, participants and
clinicians were not masked to treatment
assignment, the person assessing outcomes was
unaware of the assigned treatment, it was unclear
whether follow-up rates were similar in
comparison groups, and the analysis was ITT.
Thus, this study can be considered as potentially
prone to selection, performance and possibly
attrition bias. EMGT was graded as low risk of bias
for selection, detection and attrition bias (except
for the HRQoL outcome), but there was a
possibility of performance bias in that clinicians
and participants were not masked to treatment
allocation. The nature of the study was such that
clinicians needed to be aware of treatment
allocation to decide on clinical management
during the study. 
Assessment of effectiveness
The analysis by Maier and colleagues19 combined
the results of these two studies using a DeSimonian
and Laird random effects model and showed a
significant pooled treatment effect of lowering
IOP to prevent glaucoma progression (hazard
ratio 0.65, 95% CI 0.49 to 0.87, p = 0.003). There
was no significant statistical heterogeneity between
the studies ( 2 = 0.13, p = 0.72).
Discussion
In both studies the definition of glaucoma
progression was based on either or both of
progressive glaucomomatous optic disc changes or
progressive visual field loss and progression was
determined by a reading committee masked to the
intervention. The criteria defining progression of
visual field loss and optic disc changes differed
between studies but in both studies there was a
strict definition of progression, visual field
assessment was on automated perimetry and in
both studies visual field loss had to be confirmed
on repeat testing. In both studies, of those
participants progressing, the majority were based
on progressive visual field loss with all bar one
participant in the EMGT, and three participants in
the CNTGS, progressing on optic disc criteria
alone.
Evidence of effectiveness
88The results suggest a beneficial treatment effect;
however, neither study was graded as high quality
on all criteria, and as such the effects may be
subject to bias, and the results should be
interpreted with this in mind.
Conclusions 
Evidence from the included, good-quality,
systematic review suggests that treatment is
effective at slowing the rate of progression of
OAG. It is less certain as to how this translates into
the effectiveness of treatment on reducing long-
term visual impairment and maintaining quality 
of life. 
Probability of glaucoma
deterioration from mild disease to
visual impairment
Introduction
As described in the previous section, OAG is
typically a slowly progressive disease. The purpose
of this section is not systematically to describe all
issues and studies that have investigated
progression per se, but to describe specifically for
the purposes of the economic modelling the
approximate probability of progressing from mild
disease to visual impairment. OAG was defined
using a visual field glaucoma staging system that
had four stages: mild, moderate, severe and
visually impaired (partial sight and blind). The
details are described below. Progression was
assumed to follow a linear course, implying that a
newly diagnosed glaucoma patient would start
with mild disease and progress through every
stage until visually impaired. 
The aim of this component of the study was to
estimate the yearly probability of progressing from
mild to moderate, moderate to severe and severe
to visually impaired.
Grading of disease severity
There is no accepted scale of glaucoma severity.
Automated threshold perimetry is a widely
accepted method of assessing uniocular glaucoma
severity and for monitoring progression in each
eye, but there is no standardised definition of
severity and progression on automated perimetry.
There is also limited evidence on the correlation
between the severity of visual field loss and
patient-reported visual disability and quality 
of life. 
RCTs for OAG27,255,256 each developed different
scoring systems for defining severity and
progression. These scoring systems were event
based, in that progression was confirmed when a
preset threshold was exceeded. When each of
these scales was applied to the same cohort of
patients the rates of apparent progression varied
according to which scoring scale and definition of
progression were used.257,258
A modified version of the glaucoma severity scale
used by a study group examining the costs of
glaucoma treatment by stage in Europe and the
USA was used for this study259,260 (Table 27). This
scale itself was a modification of the
Hodapp–Anderson–Parrish scale.261 For the
purposes of this study a commonly reported
measure of the depth of the glaucomatous visual
field defect was used; this was the mean defect or
mean deviation (MD) on standard automated
perimetry. The MD refers to the average deviation
in decibels (dB) of the measured threshold values
from the age-corrected normal value. One
problem with using the MD alone to classify
severity is that other non-glaucomatous disease,
mainly the presence of cataract, affects the MD.
Other glaucoma severity scales are based on the
MD, but also take into account other
characteristics of visual field loss such as the
location and clustering of the defect, the pattern
deviation and the corrected pattern standard
deviation to categorise the extent of the focal loss
of visual field (i.e. correcting for diffuse loss that
may be caused by the presence of cataract). After
preliminary searching of the literature, it became
clear that the pattern deviation and the corrected
pattern standard deviation could not be
incorporated into the severity scale used, since
studies rarely reported these items in detail. 
Methods
To estimate the rate of glaucoma progression, a
study would require a random sample of people
with glaucoma, and who have not been treated.
This sample would be prospectively followed up
without treatment for many years and visual field
tested at regular intervals. Recognising that such
an approach is ethically and practically difficult, it
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TABLE 27 Visual field-based glaucoma staging system 
common cut-off for studies directly comparing tests
MD score (dB)
Mild glaucoma –0.01 to –6.00 
Moderate glaucoma –6.01 to –12.00
Severe glaucoma –12.01 to –20.00
Visual impairment (partial sight/blind) –20.01 or worsewas decided to use two complementary approaches
to estimating progression:
● Approach 1: systematically identify RCTs 
of OAG treatment versus control and 
predict yearly progression rates (by stage of
OAG) beyond the current trial follow-up 
period. 
● Approach 2: partially validate approach 1
estimates and systematically identify any studies
that provide yearly estimates of progressing to
each of the defined stages of OAG for treated
patients.
Inclusion and exclusion criteria
Types of study
The following types of study were included:
● Approach 1: RCTs in which people diagnosed
with OAG are randomised to either treatment
or no-treatment control groups. 
● Approach 2: any comparative or observational
studies, including cohort studies, with analysis
data on at least 100 participants.
To be considered for inclusion in approach 1, the
study had to report the group average baseline
MD and follow-up MD measure for treated
patients, or to have categorised progression in
terms of the present grading system. For approach
2, the study should have categorised progression
in terms of the grading system used in this study
(or provided enough information to be
categorised into the grading system).
Target condition
The target condition was OAG (mild, moderate or
severe).
Participants
People over 40 years of age were included.
Outcomes
Studies reporting relevant and interpretable data
on the following outcomes were considered:
● average MD in decibels at study entry
● average MD in decibels at follow-up
● average yearly MD reduction
● probability of progressing from mild to
moderate disease
● probability of progressing from moderate to
severe disease
● probability of progressing from severe disease to
visual impairment
● probability of progressing to unilateral
blindness.
Data extraction strategy
Two reviewers screened the titles (and abstracts if
available) of all reports identified by the search
strategy. Full-text copies of all studies deemed to
be potentially relevant were obtained and one
reviewer assessed them for inclusion. One reviewer
extracted details of study design, participants and
outcome data. In the event of any uncertainty, a
second reviewer provided advice and validated the
data extraction. A list of the included studies is
given in Appendix 15.
Data analysis
Approach 1
The baseline MD score was used to categorise
study participants into mild, moderate or severe
disease. The reduction in MD score at follow-up
was used to approximate a yearly rate of
reduction. The yearly reduction was applied to
each follow-up year. At each follow-up year, the
current stage of glaucoma was determined by the
MD score as given in the present grading system.
The probability of progression per year was
estimated by 1 divided by the number of years in
the same grade of OAG. For example, if baseline
average MD score was –4.0 dB the group would be
considered mild disease. If the group were to
progress at –0.5 dB per year, it would take 5 years
for the group to progress to moderate disease
(<–6.0 dB). The probability of yearly progression
from mild to moderate disease would be 1/5 = 0.2
for this cohort of patients. The average MD at
diagnosis was assumed to be –4.0 dB in the
projections.
Approach 2
Study participants were categorised into mild,
moderate or severe disease according to either
baseline MD scores or study reported severity. The
percentage of people progressing was converted
into an approximate yearly probability of
progressing by dividing the percentage by the
average length of follow-up.
Results
Approach 1
As described in the section ‘Effectiveness of
glaucoma treatment’ (p. 87), two randomised trials
were identified that compared a treated group
with a no-treatment control group.27,254 Table 28
describes the type of participants in each group,
progression in terms of MD changes and
percentage who progressed according to each
study definition of progression. Further details can
be found in Appendix 16. The results from the
EMGT suggested that the average rate (treated
and untreated) of progression was approximately
Evidence of effectiveness
90–0.4 dB per year (12 × –0.03 dB per month) for
mild OAG patients and the CNTGS suggested that
the average rate in moderate OAG patients might
be –0.45 dB per year (average of two groups).
There were no included studies within a severe
disease OAG population, therefore it was assumed
that the rate of MD progression in a severe
population was –0.5 dB year (a linear projection
from the mild and moderate estimates). The three
estimates of MD progression per year for treated
patients were used to derive a probability of
progressing between mild to moderate, moderate
to severe and severe to visual impairment using
methods described previously (Table 29).
Interpretation
The average treated patient population would
progress from mild OAG disease to moderate
disease in 5 years, resulting in a yearly probability
of progression of 0.2. The population would be
moderate OAG for 14 years and remain with
severe disease for a further 16 years, resulting in a
cumulative time to become visually impaired of
35 years.
Reflecting the uncertainty in these estimates, 
for the economic modelling, a triangular
distribution was used and assumes the rate of
progression may be half this rate or as much as
triple this rate.
Approach 2
Two additional randomised trials255,262 and seven
cohort studies259,263–268 met the inclusion criteria
and were included. Table 30 describes the type of
participants in each group, and progression
percentage who progressed according to each
study definition of progression. Further details can
be found in Appendix 17.
From the results presented in Table 30, it was
possible to estimate the yearly probability of
progressing from the various OAG stages.
● the yearly probability of progressing from mild
to moderate disease from five studies was
0.028,255 0.05,268 0.066,265 0.10266 and 0.11263
(median = 0.066)
● the yearly probability of progressing from
moderate to severe disease from six studies was
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TABLE 28 Studies included in approach 1
Study Treatment Visual field at baseline  Length of  Visual field at follow-up (dB)
(dB) follow-up
CNTGS254 Treated (n = 61)  Mean (SD): –8.38 (5.26) 5 years Mean defects, mean (SD) (slope per year): 
Control (n = 79) Mean (SD): –7.54 (4.31) –0.4992 (1.97)
(moderate) –0.4018 (3.65)
Progressed at end of follow-up
22 (33%) = 6.6% per year
31 (39%) = 7.8% per year
EMGT27 Treated (n = 129) Mean (SD): –5.0 (3.7) 6 years Mean defects, mean (SD) (dB change 
Control (n = 126) Mean (SD): –4.4 (3.3) per month):
(mild) –0.03 (0.05)
–0.05 (0.07)
Progressed at end of follow-up
58 (45%) = 7.5% per year
78 (62%) = 10.3% per year
TABLE 29 Estimates of probability of progressing per year for treated and untreated patients
No. of years  Probability progressing  No. of years  Probability progressing 
(treated) per year (treated) (untreated) per year (untreated)
Mild to moderate 5 0.2 4 0.25
Moderate to severe 14 0.07 9 0.11
Severe to visually impaired 16 0.06 10 0.10
Total number of years from  35 23
diagnosis to visual impairmentEvidence of effectiveness
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TABLE 30 Studies included in approach 2
Study Treatment Visual field at baseline  Length of  Visual field at follow-up (dB)
(dB) follow-up
CIGTS255 Medicine (n = 307) Mean (SD): 4.6 (4.2) 5 years Mean: 5.0 (SE 0.4)
Surgery (n = 300) Mean (SD): 5 (4.3) Mean: 5.2 (SE 0.4)
Visual field scoring scale 63% had  Visual field scoring scale
(mild) data at 
Progressed at end of follow-up (visits not  5 years
patients):
314 (10.7%) = 2.1% per year
372 (13.5%) = 2.8% per year
Nouri- AGIS study subset  AGIS study patients had  Mean =  –2.07 (SD 0.86) dB per year in those that 
Mahdavi, (n = 591,  mean of 9 on VF scale 7.4 years  progressed only (conservatively assuming 
2005  eyes = 789) with  (moderate) (SD 1.7) that all non-progressed patients had 0-dB 
(AGIS)262 a number of  per year slopes, the population 
different types of  mean = –0.6 dB per year)
progression criteria  Progressed at end of follow-up 
compared 30% = 4% per year
Sponsel,  Beaver Dam Study;  (Moderate) 5 years Mild/moderate and no progression: 11/120
2001267 120 treated  Progressed a category: 44/120
patients Improved a category: 22/120
Severe and stayed severe: 43/120
Progressed at end of follow-up
44 (37%) = 7.5% per year
Eid, 2003263 102 treated patients Stage at presentation Mild to  Stable: 19/102
Grade I: 45 moderate:   1 stage loss: 83
Grade II: 31 7 years  2 stages lost: 39
Grade III: 17 Moderate  3 stages lost: 9
Grade IV: 9 to severe:  Mild to moderate: (36/45): 11% per year
(mild/moderate) 6 years Moderate to severe: (32/48): 11% per year
Severe to  Severe to visually impaired: (4/9): 3% per 
visually  year
impaired: 
14 years
Hattenhauer,  Olmsted county  (Mild/moderate) 15 years  Taking only ‘classic’ glaucoma patients
1998264 Study: (SD 8) Bilateral blindness: 22% (8–38%)
114 ‘classic’  Unilateral blindness: 54% (42–72%)
glaucoma cases
Quigley,  151 patients from  (Mild/moderate) Progression was 0.23 of a grading scale 
1996266 the Baltimore Eye  per year 95% CI (0.04 to 0.50) (i.e. two 
Study used to  grades progressed in 10 years)
develop a model  Using the present criteria the probability of
of progression progressing would be 10% per year for 
each stage
Traverso,  194 patients across  Stage 0: 33/194 5 years 29.6% progressed at least one stage = 6% 
2005259 Europe Stage 1: 32/194 per year
Stage 2: 34/194
Stage 3: 33/194
Stage 4: 31/194
Stage 5: 31/194
(moderate)
continued0.04,262 0.06,259 0.075,267 0.10,266 0.11263 and
0.12265 (median = 0.087)
● the yearly probability of progressing from severe
to visually impaired disease from three studies
was 0.03,263 0.10266 and 0.16265 (median=0.10). 
The Olmsted County study264 suggested that
unilateral blindness in a treated population at 
15-year follow-up was 54%. Applying a simple
linear progression assumption, it would take
28 years (15/0.54, 95% CI 21 to 36 years) for the
entire population to progress to blindness.
Interpretation
There was significant heterogeneity between study
probabilities. The study-estimated probabilities of
yearly progression for moderate to severe and for
severe to visually impaired provided no evidence
that approach 1 estimates were clearly wrong.
Indeed, the median estimates were within 0.02.
The approach 1 estimated probability for mild to
moderate progression was significantly higher
than for approach 2. This difference may be partly
explained by the assumption of severity of mild
disease at diagnosis. On the grading scale used in
this review, assuming a baseline MD of –4 dB
implied that the eye needed to progress by –2 dB
to become moderate. Clearly, if more mild disease
were diagnosed, the probability of progression to
moderate disease would decrease (e.g. –3 dB would
decrease the probability of progression to 12%).
Discussion
Approximate estimates for the probability of
progression from mild to moderate, moderate to
severe and severe to visually impaired were
derived. Approach 1 used a simple linear
extrapolation of the results from the CNTGS and
EMGT studies. The model suggested that it would
take 35 years for a treated population to progress
to unilateral blindness. Such an estimate is
plausible if the Olmsted County study is
extrapolated to the entire population264 (35 years
is contained within the Olmsted County study 95%
confidence interval) and is similar to the estimate
derived by Quigley and colleagues,266 which
suggested that progression to blindness would take
approximately 40 years.
Strengths and limitations
Extrapolating trial outcomes from short-term
follow-up to longer term outcome risks serious
underestimation or overestimation if the
assumption of linear progression is incorrect.
Using two complementary approaches enabled
partial validation of the extrapolation in this study.
There is, therefore, some confidence that the
estimated probabilities of progression between
stages for the entire population of glaucoma
patients are approximately correct. The risk of
blindness is based on risk estimates for one eye,
driven by the available primary data, and is
therefore not necessarily representative of the risk
of bilateral blindness. 
A ‘black box’ approach was taken to estimate
progression. That is, a ‘precise’ treatment path was
not formulated for different stages of glaucoma and
differing presenting prognostic factors. Therefore,
it is recognised that there may be some inaccuracy
in the estimates for specific subgroups of glaucoma
patients. This imprecision has been partially taken
into account in the economic modelling by
assuming that the rate of progression may be as
little as half the estimated rates or as much as triple
this rate. Using these assumptions, the modelling
considered probabilities of progression that were
bigger and smaller than any published estimates.
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TABLE 30 Studies included in approach 2 (cont’d)
Study Treatment Visual field at baseline  Length of  Visual field at follow-up (dB)
(dB) follow-up
Spry, 2005268 108 patients AGIS score = 3.3 3.6 years  19% progressed = 5% per year
(mild cases) (SD 1.3)
Olivius,  160 eyes  Grade I: 27 5 years Mild to moderate (20/61 = 6.6% per year)
1978265 (119 patients) Grade II: 34 Moderate to severe (19/31 = 12% per 
Grade III: 39 year)
Grade IV: 24 Severe to blind
Grade V: 16 (13/16 = 16% per year)
Grade VI: 5
Grade VII: 12
Grade VIII: 3
(mild/moderate)Some studies269–272 have tried to predict
progression using various prognostic factors.
There is some evidence that rate of progression
increases with age (e.g. an odds ratio of 1.3 has
been suggested for every 5-year increase in
age),270 but it is conflicting and some prospective
studies have not found such a relationship.273 A
similar scenario has also been observed for
IOP.274,275 It was decided to ignore such estimates
within the economic model. The rationale for this
was that one aspect of the economic modelling was
to identify which components of the economic
model had the most significant impact on the
results before adding any further complexities to
the model.
Using MD to classify progression was not entirely
satisfactory. It is known that other non-
glaucomatous disease, such as the presence of
cataract, affects the MD. MD was used in this study
because a continuous measure of progression was
desirable, but studies rarely reported progression
on a continuous scale. The more commonly used
stage models (event-based models) for progression
have a major limitation: all patients within a
specific stage are considered to be at the same
severity of disease and therefore stage models fail
to identify eyes that may be progressing but have
not yet reached the threshold to change a stage.
The stage approach gives little information on the
rate and magnitude of change within patients.276
A better approach to estimating progression might
be trend-based approaches where progression rate
is examined on individual visual field points using
regression analysis. Some studies have suggested
that such an approach is more sensitive than
event-based methods.256,258,262
Conclusions
Main findings 
Using RCTs of treatment versus no treatment, the
pooled hazard ratio of progression for treatment
versus no treatment was 0.65 (95% CI 0.49 to
0.87). Extrapolating the trial results predicted that
a treated person would progress from mild to at
least unilateral blindness in approximately
35 years. Untreated, the time to progression is
estimated as 23 years.
Future research
The lack of consensus on an appropriate
definition of ‘progression’ is a major impediment
to understanding the rate and magnitude of
change in glaucoma patients and consequently the
long-term effects of various treatments. A
comparison of event-based and trend-based
scoring systems needs to be undertaken in a large
prospective cohort of glaucoma patients who
represent the spectrum of glaucoma disease.
Evidence of effectiveness
94T
his chapter has three main sections: an outline
of the principles of economic evaluation, a
systematic review reporting economic evaluations
of OAG screening strategies and a final section
reporting the economic evaluation, using a
Markov model, the structure of which was outlined
in the section ‘Economic model’ (p. 15), to assess
the cost-effectiveness of screening for OAG.
Principles of economic evaluation
The decision to use resources to provide one
method of identifying OAG would mean that the
opportunity to use them in other desirable ways
(either to provide another method of identification
or to meet an entirely different health need) is
given up. The cost of this decision is the benefits
(health gains, etc.) that could have been obtained
had the resources been used another desirable way.
This is the economic notion of ‘opportunity cost’.
Strictly speaking, the opportunity cost of a decision
to use resources in one way is equivalent to the
benefits forgone in the next best alternative use of
these resources. Economic evaluation is a method
of providing decision-makers with information
about the opportunity cost of the decisions that
could be made. It is the comparative analysis of
alternative courses of action in terms of both their
costs (resource use) and effectiveness (health
effects).277 An economic evaluation, in this context,
would involve assessing the relative costs and
benefits associated with alternative identification
strategies, including screening, for OAG. The
objective of such an economic evaluation would be
to provide information to assist decision-makers in
the allocation of the available resources so that
benefits can be maximised. How an economic
evaluation brings together information on costs
and effects is illustrated in Figure 39. The vertical
axis represents the difference in costs between an
experimental (e.g. screening for OAG) and a
control treatment (e.g. no formal screening for
OAG). An evaluation of alternative strategies for
identifying OAG cost estimates might typically be
expected to include the value of the resources used
to provide the strategy as well as the resource
consequences of that strategy (e.g. the costs of
treatment). The horizontal axis represents
differences in effectiveness between the two
approaches. The effectiveness of the alternative
strategies might be measured in clinical terms (e.g.
reductions in IOP), natural terms (e.g. cases of
visual impairment avoided) or more economic
measures, such as quality-adjusted life-years
(QALYs). The latter combines estimates of both
quality of life and length of life. The wider the
definition of benefit used, the more likely it is to
measure outcomes of importance to individuals.
In the north-west and south-east quadrants of
Figure 39 a clear decision about which treatment
should be preferred is provided because one or
other treatment dominates. In the north-west
quadrant the experimental treatment is more
costly and provides less benefit and therefore the
control treatment is more efficient (is dominant).
In the south-east quadrant the opposite situation
occurs and the experimental treatment is more
efficient (is dominant) as it is less costly and
provides more benefit. The circle in the centre of
the figure represents the possibility that no
meaningful differences in costs or benefits exist
between the treatments and for practical purposes
the two interventions are equally efficient. In the
two remaining areas of the figure, the north-east
and south-west quadrants, a judgement is required
as to whether the more effective treatment is worth
the extra cost. To aid these judgements,
information can be provided in terms of an
incremental cost-effectiveness ratio (ICER). The
higher the ICER of one intervention compared
with another, the less likely it is that this
intervention will be considered efficient. 
Systematic review of cost-
effectiveness of screening for OAG
Aims and objectives
The aim of this systematic review is to address the
following research questions. From the perspective
of the UK NHS, is screening for OAG cost-
effective and which method of screening is most
likely to be cost-effective? These questions were
addressed by:
● systematically identifying and quality assessing
all the economic evaluations comparing
alternative methods of screening for OAG
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Chapter 8
Economic analysis● summarising the evidence from the review of
these studies for and against the alternative
interventions. 
Methods
Inclusion and exclusion criteria
Types of study
Studies that compare both costs and outcomes for
OAG screening were included. Studies were
excluded if they did not attempt to relate cost to
outcome data. The following types of paper were
also excluded: methodological papers, papers that
reviewed economic evaluations (although their
reference lists were checked), discursive analysis of
costs/benefits, partial evaluation studies such as
cost analyses, efficacy or effectiveness evaluations
and cost of treatment/burden of illness papers. 
Study population
Studies had to be performed in adult populations.
Types of intervention
Any intervention used for the screening of OAG.
Types of outcome
The outcomes of the review were costs (regardless
of how estimated) and effects (no matter how
these had been specified). Additional, more
specific, secondary outcomes of the review were:
● incremental costs per case of visual impairment
(e.g. loss of vision below driving standard)
prevented
● incremental costs per year of visual impairment
(e.g. loss of vision below driving standard)
prevented
● incremental costs per case of blindness
prevented
● incremental costs per additional QALY gained
● incremental costs per number of case of OAG
detected.
Search strategy
The search strategy used to identify relevant
studies is described in detail in Chapter 4.
Data extraction strategy
One reviewer extracted the data according to the
guidelines produced by the Centre for Reviews
and Dissemination (CRD) for the critical appraisal
of economic evaluations.91,278 Data extraction
focused on two key areas: the results of the
economic evaluations in terms of estimates of costs
and effects, and the methods used to derive the
Economic analysis
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Experimental 
intervention more costly
Control
intervention more costly
Control intervention 
more effective
Experimental intervention
more effective
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FIGURE 39 Relationship between the difference in costs and effects between a new (experimental) intervention and a standard
(control) interventionresults and their interpretation. Where the
economic evaluation had been based on a
modelling exercise, additional data extraction was
performed to describe the source of parameter
estimates and the methods used to combine these
estimates in the economic model. The criteria
used were based on those developed by Philips
and colleagues.91 Where included studies had
previously been included in NHS EED, these
abstracts were also used to inform the review.
Examples of the type of data extracted from the
included studies are described below. 
● study characteristics
– the research question
– the study design
– the comparison
– the setting
– the time-horizon of the study
– the basis of costing
● characteristics of the study population
– numbers receiving or randomised to each
intervention
– other systematic differences in clinical
management
– inclusion/exclusion criteria
– dates to which data on effectiveness and costs
related
● duration of follow-up for both costs and
effectiveness
● results
– summary of effectiveness and costs (point
estimate and if reported range or standard
deviation)
– summary of cost-effectiveness/utility (point
estimate and if reported range or standard
deviation)
– sensitivity analysis
● conclusions as reported by the authors.
To estimate the secondary outcomes described
above, data were also extracted for each
intervention considered on:
● number of cases of visual impairment (e.g. loss
of driving vision) prevented
● average number of years of visual impairment
(e.g. loss of driving vision) prevented
● number of cases of blindness prevented
● average total cost per person screened
● number of cases of OAG
● average number of QALYs.
Quality assessment strategy
The quality of the studies was assessed using
Figures 1–11 of the CRD report.278 Study quality
was summarised in terms of how the literature on
effectiveness was retrieved, how the effectiveness
data were derived from the studies, justification
provided for the strategies assessed, how costs
were determined, whether all relevant costs were
included, the perspective of the analysis (i.e.
whose costs and benefits were considered
important to the decision-maker), the measures
used to determine cost-effectiveness and the
nature of the sensitivity analysis performed. 
Data synthesis
No attempt was made to synthesise quantitatively
the studies that were identified. Data from the
included studies were summarised to identify
common results, variations and weaknesses across
studies. If a study only reported average cost-
effectiveness ratios then, where possible, the data
were reanalysed to provide estimates of
incremental cost-effectiveness. The ICERs were
obtained by calculating the difference in costs (∆C)
between one non-dominated strategy and its
preceding non-dominated strategy, and dividing it
by the difference in effectiveness (∆E) between
these two strategies. It is important to note that
the strategies were compared only for the same
age groups. It was considered likely that the
identified studies would provide data for different
patient groups (e.g. those aged 45 and over, those
aged 65 and over), a range of pretesting risks (e.g.
general population risk, strong pretest suspicion
of OAG) and a range of screening and diagnostic
interventions. Therefore, separate summaries were
developed for each set of studies that considered
the same patient group, pretesting risk and
diagnostic intervention. Where possible, the data
extracted from the included studies were used to
provide estimates of the secondary outcomes
described above. 
Results
Number of studies identified
As described in Chapter 4, a total of 431 titles or
abstracts were identified by the searches conducted
for the economic evaluation of screening (Table 2)
and a further 65 titles or abstracts were identified
from the general search of databases such as
Health Management Information Consortium and
HTA. Sixty-seven full-text papers were retrieved
for assessment. From these, five eligible reports
were identified.279–283 One study was reported in
two separate reports279,280 and the journal version
was used as the primary publication.280 The four
eligible studies used modelling techniques of
varying levels of complexity to arrive at estimates
of cost-effectiveness. These studies are listed in 
Appendix 18 and summarised in Appendix 19.
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the included studies. 
Characteristics of the included studies 
All four studies assessed cost-effectiveness of
screening for primary OAG. There was one study
each from the USA,282 and Canada280 and two
studies from the UK.281,283 The analysis by
Gottlieb and colleagues compared hypothetical
screening programmes for a population of one
million individuals aged between 40 and
79 years.282 Boivin and colleagues considered the
introduction of screening programmes for those
aged 40 and 79 years in the Province of Quebec in
Canada.280 In 1991 the population of this
province was estimated to be 2.6 million.280
Gooder considered the implications of adopting
screening for a 100,000 cohort of the UK general
population aged 40 years or more.281 In the final
study, by Tuck and Crick, the screening strategies
were compared for a hypothetical cohort of 10,000
Caucasians aged 40 years and above.283 In all four
studies the screening strategies considered would
be implemented in a community setting. The
characteristics of the included studies are
summarised in Appendix 19.
Screening strategies considered in the studies
A description of the strategies considered by each
of the studies is provided in Appendix 19 and
summarised in Table 31. In only one of these
studies was screening compared with current, no
screening, practice.281
Gottlieb and colleagues considered seven different
screening strategies: ophthalmoscopy, tonometry
(at two different thresholds of >21 mmHg and
>24 mmHg), manual perimetry (using HF, MPT,
Globuck or Goldmann fields) and automated
perimetry.282 Boivin and colleagues considered
Economic analysis
98
TABLE 31 Description of screening strategies considered by each of the studies
Study Strategy Screening interval
Gottlieb, 1983282 Ophthalmoscopy, with positives referred to ophthalmology Once only
Tonometry  21 mmHg, with positives referred to ophthalmology Once only
Tonometry  24 mmHg, with positives referred to ophthalmology Once only
HF fields, with positives referred to ophthalmology Once only
MPT fields, with positives referred to ophthalmology Once only
Globuck fields, with positives referred to ophthalmology Once only
Goldmann fields, with positives referred to ophthalmology Once only
Boivin, 1996280 Tonometry (cut-off not stated), fundoscopy, with positives for either getting  1, 3 or 5 years
gonioscopy and perimetry
Tonometry (cut-off not stated), with positives getting fundoscopy, gonioscopy  1, 3 or 5 years
and perimetry
Gooder, 1995281 Opportunistic screening at the time of a routine eye test Once only
Tonometry Once only
Tuck, 1997283 Tonometry and Henson fields Once only
Tonometry and perimetry if IOP > 20 mmHg Once only
Tonometry and perimetry if IOP > 22 mmHg Once only
Tonometry at thresholds of IOP > 22 mmHg Once only
Ophthalmoscopy (sv) Once only
Perimetry Once only
Ophthalmoscopy and tonometry (sv) Once only
Ophthalmoscopy and tonometry, positives referred to perimetry (sv) Once only
Ophthalmoscopy and tonometry, positives referred to perimetry (lx) Once only
Ophthalmoscopy and perimetry (sv) Once only
Ophthalmoscopy and tonometry (lx) Once only
Ophthalmoscopy and tonometry, ‘high-risk’ candidates referred to perimetry (sv) Once only
Tonometry at thresholds of IOP > 20 mmHg Once only
Ophthalmoscopy and tonometry, ‘high-risk’ candidates referred to perimetry (lx) Once only
Ophthalmoscopy and perimetry (lx) Once only
Ophthalmoscopy and tonometry and perimetry (sv) Once only
Ophthalmoscopy and tonometry and perimetry (lx) Once only
Ophthalmoscopy (lx) Once only
HF, Harrington–Flock; lx, lax referral criteria; MPT, manual perimetry technique; sv, severe referral criteria.two main strategies.280 In the first, initial
screening was with tonometry (although the cut-off
values were not stated) and fundoscopy, and if
there were abnormal findings in either, individuals
were then investigated with gonioscopy and
perimetry. The second strategy was to screen the
population initially with tonometry alone followed
by gonioscopy, fundoscopy and perimetry in those
with abnormal IOP. A total of 12 scenarios was
assessed by varying the age range, participation,
compliance and treatment efficacy rates for these
two main strategies.280 Gooder compared two
active screening strategies with opportunistic
screening performed at the time of a routine eye
test (current standard UK practice). The first
screening strategy considered was tonometry and
the second involved non-contact tonometry and
field tests. People testing positive were then
referred on to hospital services.281 Tuck and Crick
considered 18 different screening strategies.283
These strategies varied in terms of the tests used
(ophthalmoscopy, tonometry and perimetry), the
cut-off values used for tonometry (IOP > 20 or
IOP > 22 mmHg) and the severity of referral
criteria. Referral criteria depended on IOP, visual
field defects (defined as “a failure on the 66-point
test, suspicious zone or below, of a Henson
suprathreshold field”), CDRs, an assessment of
risk based on family history of glaucoma or high
myopia. Severity was defined as relatively lax or
severe. An example of severe criteria for referral
would be that patients with IOP between 26 and
30 mmHg would only be referred if the CDR was
>0.4 or if there was a visual field defect. Lax
referral criteria would refer all patients with an
IOP between 26 and 30 mmHg regardless of the
results of the other tests.
As described in Table 31, only Boivin and
colleagues assessed cost-effectiveness based on a
cyclical screening mode (i.e. once every year, every
3 years or every 5 years).280 The other studies
assumed that the screening was to be done only
once.281–283
Quality of included studies
All studies were based on models, but none
specified the type of model used. Two studies dealt
with cost-effectiveness of diagnosis and treatment
combined280,282 and one study reported the results
in terms of two different measures of cost-
effectiveness as well as one measure of
cost–utility.281 The final study considered the costs
and effects of diagnosis only (i.e. it excluded the
costs and effects consequent on diagnosis).283
None of the studies implicitly or explicitly justified
the screening strategies compared. 
All the included studies derived their literature on
effectiveness from ad hoc searching, rather than
from a systematic review. The estimates of
effectiveness of diagnostic and treatment measures
were arbitrarily determined in all four studies by
assumptions made from data from previous studies
and on expert opinion. None of the studies clearly
stated how they derived estimates of effectiveness
from the included studies. Three studies clearly
stated the sensitivities and specificities of the
diagnostic tests used in their modelling,281–283
whereas one did not.280
The measures used to determine the effectiveness
of the different strategies compared varied
between studies. The measures included quality-
adjusted years of vision (QAVYs) saved (with
quality adjustment based on a subjective
assessment of the number of years of vision that
someone would forgo to avoid the side-effects of
treatment),282 disability-adjusted life-years
(DALYs),281 years of blindness prevented
(although in the study by Boivin and colleagues it
was unclear how these were calculated: no values
were reported, but number of years of blindness
appeared to be the same as the number of cases of
blindness avoided)280,281 and number of true
positives identified.281,283
All four studies reported detailed data on how the
costs were derived and the price year to which
costs related (Table 32). One study reported costs
in Canadian dollars,280 and two others reported
costs in US dollars, one for the year 1980282 and
one for 1995.283 The fourth study reported costs
in 1995 UK pounds sterling.281 In the study by
Tuck and Crick costs were expressed in US dollars
but were originally calculated in UK pounds
sterling and converted to US dollars using an
exchange rate of £1 to US$1.55.283 Only Boivin
and colleagues reported resource quantities and
costs separately.280
Although there were variations between the
studies, the type of resource use considered
relevant to include in the costing was generally
similar. However, none of the studies included the
costs of the organisation of the screening
programme such as personnel costs and costs for
inviting the participants. 
In the study by Gottlieb and colleagues, the costs
for diagnosis and treatment in this analysis were
estimated from the Massachusetts Blue Cross/Blue
Shields average daily hospital reimbursement rates
in Massachusetts in the year 1980.282 The average
cost of medications was estimated by doubling
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ntheir wholesale prices. The costs included those of
screening tests, drugs, diagnostic evaluation,
physician visits with and without treatment,
surgery for glaucoma and surgery for cataracts as a
complication of glaucoma treatment. Indirect
societal costs were not taken into account in the
analysis. The analysis by Boivin and colleagues
included costs for diagnostic tests and treatment
(by both the clinician and optometrist), societal
costs for the blind in terms of aids (reading,
writing and mobility) and disability pensions.280
The clinician costs were based on fees for
procedures performed in a private healthcare
setting. Societal costs for blindness were obtained
from the budgets for the ten rehabilitation
agencies in the Quebec provinces and disability
pension costs were obtained from the Régie des
rentes du Quebec. The costs were not adjusted for
inflation. Treatment costs were based on a
hypothetical model of disease progression, which
was based on data from selected studies. Gooder
included the cost of standard optometrist cost for
an eye test and assumed costs for the other tests
performed.281 The only other cost included was
the cost of a first outpatient visit. Tuck and Crick
assumed that the costs were based on screening
conducted as part of a general eye examination by
an ophthalmologist or optometrist, usually in
conjunction with prescribing lenses.283 The main
assumption was that the initial screening of 10,000
people would be performed by a single
professional examiner over a 6-year period. The
cost analysis covered cost per hour of optometrist
(including all overheads for premises, etc.), capital
costs (tonometer and field screener) and cost of
secondary examination at a clinic per patient visit
(before diagnosis). The cost analysis only covered
the costs of diagnosis and not the costs of
subsequent treatment and monitoring. The
authors of the economic analysis did not take
indirect (societal) costs into account.
Only two studies performed discounting,282,283
although it was relevant to all. In one study future
costs were discounted at a rate of 5% per
annum282 and in the other, reusable equipment
costs were annualised using a 6% discount
rate.282,283 Only one of the studies clearly stated
the time-horizon of the analysis.281
In all four studies the assessment of cost-
effectiveness was presented from a government
perspective. Two studies reported average cost 
per year of blindness avoided280,281 and one the
average cost per true positive case found.281,283
Gottlieb and colleagues reported average and
incremental cost per quality-adjusted year of 
vision saved282 and Gooder reported incremental
(versus current practice) cost per DALY 
saved.281
Three studies performed some form of sensitivity
analysis, although this was limited to simple one-
way analysis (i.e. changing only one parameter at
a time; such an approach ignores interactions
between different parameters).280,282,283 Sensitivity
analyses were performed around age, disease
prevalence and treatment effectiveness rates. The
specifics of the sensitivity analyses varied between
studies reflecting the different data, outcome
measures and model structure used. For example,
Gottlieb and colleagues assessed the impact of
varying the prevalence of raised IOP, disease
progression, treatment effectiveness, variations in
surgery refusal rate and proportion of patients
controlled with primary medications or surgery
alone.282 In the study by Boivin and colleagues
sensitivity analysis was performed with variations
in patient age range, frequency of screening, tests
used, participation rate and the rate of
effectiveness.280 Tuck and Crick, in their sensitivity
analysis, considered varying the prevalence of
primary OAG, sensitivity values, predictive values,
the costs of examination and the definition of
true-positive cases.283
Summary of the results of the included studies
As described above the included studies were
broadly similar with respect to population,
screening and treatment costs and their results are
summarised in Tables 33–38 (and reported in more
detail in Appendix 20). Where necessary, the
ICERs presented in the tables were calculated, by
the reviewers, from data provided in the included
studies. Nevertheless, data were not reported in
sufficient detail to reinterpret the results of the
studies in terms of a common outcome measure.
Tables 33 and 34 report the results of the
cost–utility analysis conducted. Table 33 reports the
findings from Gottlieb and colleagues.282 In this
table the results are only presented for three of the
seven age groups considered and all screening
strategies that were dominated (i.e. less effective
than less costly alternatives) have been omitted.
Ophthalmoscopy was the least costly but least
effective strategy for all age groups except for the
70–74 year olds (Table 33). As the table shows, out
of the seven strategies considered (see Table 31)
only between three and four strategies were not
dominated. The ordering of the interventions
varied between age groups and this indicates the
likely importance of age on estimates of cost-
effectiveness. It also indicates that the optimal
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.choice of strategy might vary by age at screening.
Gooder found that both screening strategies
considered were more effective but more costly
than current practice.281 However, screening with
tonometry might not be considered cost-effective
while screening using NCT and fields might be
considered worthwhile (the incremental cost per
DALY saved compared with current practice was
estimated to be approximately £22,000). 
The values reported for the cost–utility analyses
are difficult to interpret because of the different
years and countries to which the data relate as well
as differences in the technologies considered and
outcome measures used. Presenting the relative
difference in costs and effects provides more
comparative information. For example, in Gottlieb
and colleagues the cost of screening with
tonometry with a threshold IOP of 24 mmHg is
155% of the cost of ophthalmoscopy.282 These
estimates put into context the increases in costs
and effects that accrue from adopting a more
effective but more costly screening strategy. 
The results in terms of incremental cost per year
of blindness avoided are presented using the 
same approach as those described for the
cost–utility analyses described above. Using the
data from Boivin and colleagues, the incremental
costs per year of blindness were estimated
(Table 35).280 With these data it is unclear whether
any of the more costly but effective strategies are
worthwhile compared with the strategy of
tonometry or tonometry and fundoscopy as initial
tests followed by fundoscopy, gonioscopy and
perimetry. The data from Gooder suggest lower
incremental costs per year of blindness avoided
(Table 36),281 and indicate that screening is more
likely to be cost-effective compared with data from
Boivin and colleagues.280 However, the data are
more difficult to interpret because of the
differences between the two studies, in terms of
comparators, methods and source data. Without
further information it is not possible to
disentangle which factor or factors is most
important.
In terms of incremental cost per case detected
data were available from two studies.281,283 Both
screening strategies considered by Gooder were
considerably more effective than current practice,
but also more costly (Table 37).281 Tonometry was
the least effective and least costly of the two active
strategies considered, but as it was compared with
the relatively inexpensive current practice the cost
per case detected was relatively high. In contrast,
the incremental cost per case detected for NCT
and field testing strategy compared with
tonometry was relatively modest. The data from
Tuck and Crick also suggest that tonometry was
the least costly but also least effective screening
strategy test (Table 38). This is because it was
associated with a poor sensitivity (69% at an IOP
cut-off of 20 mmHg).283 Screening strategies
involving ophthalmoscopy alone or in
combination with either tonometry or perimetry
were dominated (i.e. less effective and more costly)
and have not been included in Table 38, although
they are presented in Appendix 20. The use of
either tonometry followed by perimetry or
ophthalmoscopy followed by tonometry and
perimetry was more effective than tonometry
alone. However, the cost rapidly increased and it
would require society to pay an additional US
$18,500 per additional case detected associated
with adopting a strategy of ophthalmoscopy,
tonometry and perimetry for referral candidates
with lax referral criteria for further evaluation
compared with a screening strategy of perimetry
alone.
Discussion
Despite an extensive systematic search of the
literature only four studies that assessed the cost-
effectiveness of screening strategies for glaucoma
were identified. The latest of the included studies
was published in 1997 and it analysed costs based
on 1995 prices.283 As a basis for decision-making
about the desirability of adopting screening for
OAG, our judgement is that this evidence base is
insufficient: the diagnostic tests and treatment
interventions available for primary OAG have
changed since the identified studies were
conducted and the tests and treatment
interventions used in routine clinical practice now
may have different effects from those that were
assessed in the included studies. It is quite
possible that the cost-effectiveness of glaucoma
screening, using currently available tests and
treatment options, may differ markedly from the
estimates provided by the studies described in this
review. Moreover, some of the screening tests used
in the studies, such as manual perimetry
techniques (HF, MPT and Globuck field tests), are
no longer routinely used in clinical practice. There
have been developments in diagnostic tests such as
SAP, which is currently the choice for visual field
testing. Only Gottlieb and colleagues and Gooder
included an automated perimetry test in their
assessment.281,282 New treatments are available,
with the introduction of prostaglandin analogues,
 2 agonists and topical carbonic anhydrase
inhibitors. These were not treatments considered
in the reviewed studies. 
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A further limitation of the four studies is that only
one included a ‘no-screening’ strategy.281
Unfortunately, the method of assembling data for
use in this economic evaluation was flawed as it
was not based on any systematic assembly and
relied on indirect comparisons. Therefore, none of
the studies was able reliably to address the
question as to whether any form of screening
would be worthwhile. 
It is also important to be aware of the
methodological limitations of the included studies.
First, it is unclear whether the studies used the
best available evidence for the diagnostic
performance of the tests and the effectiveness of
treatments. The methods used to derive estimates
of sensitivity and specificity of screening tests as
well as the effectiveness of treatment interventions
used in the economic model were poor. They were
based on ad hoc searching, rather than on a
systematic review. Such an approach has been
recognised to be subjective and therefore prone to
bias and error.284 Hence, it is possible that the
selection of evidence in the included studies may
have been biased. This is a weakness observed in
economic evaluations of other treatment
conditions.285 Furthermore, all the studies
considered different measures of effectiveness 
for the cost-effectiveness analysis. Again, this
makes it difficult to draw comparisons between
studies.
Two of the studies considered screening in
countries other than the UK and differences in
reimbursement strategies and costs complicate the
interpretation from a UK perspective.280,282
Current UK prices are markedly different from the
prices quoted in the two included UK studies.
While all four studies explained in detail how the
costs for the different strategies were derived, only
one study presented resource use and costs
separately.280 This makes it difficult to judge
whether these data are applicable to the UK. Only
one study considered a cyclical screening strategy
(i.e. once every 3 years, etc.),280 and the failure of
the others to consider such an approach is
unrealistic as the incidence of glaucoma increases
with age (see Chapter 5). 
The effectiveness of screening is not just
dependent on the sensitivity and specificity of the
test used. It also depends on a range of other
parameters, such as acceptance of screening,
treatment efficacy rate and compliance. A variety
of different values was used across the studies and
these values were either implicit (e.g. assuming
100% compliance with treatment) or explicit (e.g.
Boivin and colleagues assumed a 75% compliance
rate with treatment).280
The uncertainty surrounding estimates of cost-
effectiveness was also very poorly addressed by all
four studies. The simple one-way sensitivity
analysis used in three studies is unlikely to have
fully explored the full extent of the uncertainty
present in each evaluation.280,282,283
Conclusions
Very few economic evaluations comparing
alternative screening strategies (including no
screening) for OAG are available. Those studies
that were identified suffered from numerous
weaknesses that would limit their usefulness for
decision-making in the UK at this time.
Furthermore, the differences between the studies
in terms of tests, populations, assumed
effectiveness of tests and treatment as well as costs
makes it difficult to disentangle which factors are
the key determinants of cost-effectiveness. On the
basis of the data summarised in this review there is
an insufficient evidence base for judging whether
screening for OAG should take place, and if it
should take place, how it should be performed.
These findings confirm that further research is
required on the cost-effectiveness of alternative
screening strategies and such work should be
based on the systematic consideration of the
evidence on acceptability, effectiveness and cost of
alternative screening strategies relevant to current
practice. This evaluation is described in the next
section.
Economic evaluation of screening
for OAG
The cost-effectiveness of screening for OAG was
assessed using a Markov model. The structure of
the model was described in the section ‘Economic
model’ (p. 15). The interventions compared within
the model are first briefly described, before the
methods used to obtain the necessary data to
populate the model are presented. The methods
used to present estimates of cost-effectiveness for
the base-case analysis and the key areas of
uncertainty addressed by sensitivity analysis on the
base case are then described. Further sensitivity
analysis focused on situations where it is believed
screening may possibly be cost-effective is next
described. The following two subsections report
the results of the base case and its associated
sensitivity analysis, as well as the results of the
further focused sensitivity analyses. Finally, the
implications of these results are discussed.Economic analysis
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.Interventions considered within the
model
Screening and diagnostic interventions
The screening and diagnostic interventions are
described in detail elsewhere (see the section
‘Economic model’, p. 15). In brief, three strategies
have been considered: one representing current
practice and the two alternative screening
strategies (see Figures 5–7, pp. 14–15). Current
practice reflects current glaucoma detection by
case finding by a community optometrist as part
of a routine eye test. The two alternative screening
strategies vary in how screening would be
organised. In one strategy individuals are invited
for a screening examination by a glaucoma-trained
optometrist. In the second strategy individuals are
invited for a simple test assessing either visual
field loss or structural damage, together with a
measurement of the IOP by a technician.
Individuals identified as at risk or positive by these
technician tests would then be seen by a glaucoma
optometrist. In all three strategies any individual
identified as positive at the end of screening or
case finding would be referred to an
ophthalmologist for definitive diagnosis and, if
necessary, treatment. 
With respect to the actual test used in the various
strategies it was concluded that for the purposes of
the economic evaluation the IOP test used by the
technician is Goldmann applanation tonometry
with disposable tips and a slit-lamp microscope.
For the second assessment within the ‘technician
screening’ strategy, there is a number of possible
screening tests available; details of the tests and
their performance are described in Chapters 3
and 6. The model included a range of sensitivity
and specificity values, rather than modelling the
performance of one test or combination of tests as
none of the candidate tests, or combinations of
tests was clearly superior (Chapter 6).
The glaucoma optometrist assessment was
assumed to be the same test combination as
ophthalmologist diagnosis. This diagnostic test 
is a combination of IOP measurement by GAT, 
slit-lamp examination, fundoscopy and a visual
field test. 
Management of glaucoma
Should the ophthalmologist diagnose OAG, it has
been assumed that treatment would be initiated.
The following treatment pathway has been
assumed in the model. Initial medical treatment
would be with a topical treatment  -blocker or
prostaglandin analogue). If that failed, this would
be followed by an additional drop of another class
of medications. For those patients for whom this
fails, argon laser trabeculoplasty (ALT) or surgery
(trabeculectomy) is the next treatment step. In
addition to medications, treatment would involve
visits to the ophthalmologist every 6 weeks at the
beginning of treatment and a full assessment every
6 months. After surgery the patient would be seen
at an ophthalmology outpatient clinic at 1, 2, 4, 8,
12 and 26 weeks after surgery. 
Parameter estimates used in the model
Parameter estimates required to populate the
model were obtained from the systematic reviews
of test accuracy, OAG epidemiology, treatment
effectiveness and cost-effectiveness, as well as other
systematic, focused searches of the literature. The
following sections give details on the probabilities,
costs and utility data used, as well as the probability
distributions adopted within the model.
Probabilities
Table 39 shows data on prevalence, incidence and
progression of glaucoma used in the model.
Within the model, prevalence was not formally
based on data from the literature, as there were
many different subgroups for which screening
could be determined. The model was run for a
range of prevalence values, informed by the
review, aiming to identify those prevalences where
screening strategies might be considered
worthwhile. Once these were determined they
were related to relevant subgroups to which the
results might apply.
The proportion of OAG subjects with each severity
of disease was informed by the systematic review of
epidemiology (see Table 10, p. 32, for details).
However, data were limited, as the majority of
studies reporting severity did not report severity
status for newly detected cases, and for the
majority of participants severity status was not
reported. Estimation was therefore based on
expert opinion from ophthalmologists (RW, AAB
and JB), and the included studies informed the
distribution around these estimates. Limited data
were obtained for incidence and progression of
glaucoma. Incidence data were obtained as
described in Chapter 5. Progression data, as well
as the relative rate of progression between treated
and untreated individuals, were based on a review
of randomised and non-randomised evidence
reported in Chapter 7. For the probabilistic
sensitivity analysis triangular distributions were
chosen for incidence and progression, and a log-
normal distribution for the relative risk of
progression for treated compared with untreated
individuals.
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presented in Table 40. Data on these were scarce. It
is plausible, for instance, that the annual
probabilities of having an eye test differ between a
general population and an OAG population, or
between the same population in a screening or
non-screening strategy. Moreover, these
probabilities might also depend on the period
between screening waves. The model structure
allowed the incorporation of such differences.
Unfortunately, data were not available at the level
of detail required. Data on eye test, gender and
age were obtained from the British Household
Panel Survey (BHPS).286 The total sample size for
the BHPS was approximately 10,000 households
from across the UK. Individuals in the included
households are interviewed yearly. A probit
regression model was used to obtain the
probabilities of having an eye test. Alternative data
were retrieved from the Sight Test Volume and
Workforce Survey 2003/04 (STV&WS) and other
published studies.47,113 The results of the
regression analysis of the BHPS data, consistent
with the STV&WS and published studies, were
used in the model for the probability of having an
eye test (by a community optometrist) in the
current practice strategy. Normal probability
distributions were attached to the mean values for
probabilistic analysis. Screening acceptance data
were obtained from the epidemiology review
(Chapter 5). Triangular distribution was attached
to this parameter with upper and lower limits
obtained from Hollows and Graham21 and Wolfs
and colleagues,169 respectively.
Table 41 shows data on test performances. Seven
reports provided information on the accuracy of
referrals by community-based optometrists for
people with suspected glaucoma.287–293 However,
no studies were identified that reported the
diagnostic accuracy of the test strategy of
community optometrists or glaucoma-trained
Economic analysis
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TABLE 39 Prevalence, incidence and progression of glaucoma
Probability Value Source Distribution (values used to
define the distribution)
Cohort start age  40 Base-case assumption 60 and 75 years old
Prevalence of glaucoma 0 to 0.2
Proportion of glaucoma mild 0.50 Expert opinion/Chapter 5 0.475 and 0.45 for 60 and 75 years
old, respectively
Proportion of glaucoma moderate 0.30 Expert opinion/Chapter 5
Proportion of glaucoma severe 0.15 Expert opinion/Chapter 5
Proportion of visual impaired 0.05 Expert opinion/Chapter 5 0.075 and 0.10 for 60 and 75 years
old, respectively
Incidence of glaucoma Chapter 5
40 years old 0.0003 Chapter 5 Triangular (min. = 0.0001, 
likeliest = 0.0003, max. = 0.0008)
50 years old 0.0003 Chapter 5 Triangular (min. = 0.0001, 
likeliest = 0.0003, max. = 0.0008)
60 years old 0.0008 Chapter 5 Triangular (min. = 0.0002, 
likeliest = 0.0008, max. = 0.0022)
70 years old 0.00181 Chapter 5 Triangular (min. = 0.00068, 
likeliest = 0.00181, max. =
0.0044)
80 years old 0.00141 Chapter 5 Triangular (min. = 0.00097, 
likeliest = 0.00141, max. = 0.01)
Progression to glaucoma moderate 0.25 ‘Probability of glaucoma  Triangular (min. = 0.125, 
deterioration from mild disease  likeliest = 0.25, max. = 0.75)
to visual impairment’ (p. 89)
Progression to glaucoma severe 0.11 ‘Probability of glaucoma  Triangular (min. = 0.055, 
deterioration from mild disease to  likeliest = 0.11, max. = 0.33)
visual impairment’ (p. 89)
Progression to visual impaired 0.1 ‘Probability of glaucoma  Triangular (min. = 0.05, 
deterioration from mild disease to  likeliest = 0.1, max. = 0.30)
visual impairment’ (p. 89)
RR treated–non-treated 0.65 ‘Effectiveness of glaucoma  Log-normal, (mean = –0.43, 
treatment’ (p. 87) SD = 0.148)
Mortality Various See Appendix 21 for interim life tableoptometrists, or included sufficient data to
produce a 2 × 2 table to calculate sensitivity and
specificity. Sensitivity and specificity for
optometrist testing were derived from Tuck.293
This study reported a survey conducted on behalf
of the IGA involving 241 optometrists in England
and Wales who, mainly commencing between
November 1988 and February 1989, carried out
275,600 sight tests over a 6-month period
(equivalent to 5% of the national total). The
optometrists referred 1505 patients for suspected
OAG. A diagnosis was confirmed and known for
1048, of whom 436 (41.6%) had a diagnosis of
OAG confirmed by a consultant ophthalmologist.
This allowed the calculation of true positives 
(n = 436), false positives (n = 612), total testing
positive (n = 1048) and total testing negative 
(n = 274,552). As those testing negative did not
receive confirmation of this by way of examination
by a consultant ophthalmologist, there was no
information on those who tested negative but
actually had glaucoma (false negatives) or indeed
did not have OAG (true negatives). Of the three
studies considered, this one was the most
appropriate (in terms of geographical coverage,
number of patients seen and number of
Health Technology Assessment 2007; Vol. 11: No. 41
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TABLE 40 Probabilities of having an eye test in current practice and screening acceptance for screening strategies
Age group (years) Value Source Distribution (values used to define the
distribution)
40–59 0.248 Regression analysis on BHPS data Normal, (mean 0.248, SE 0.0019142)
60–75 0.3769 Regression analysis on BHPS data Normal (mean 0.3769, SE 0.0046524)
 75 0.42 Regression analysis on BHPS data Normal (mean 0.42, SE 0.0051359)
Screening acceptance; 
all groups 0.78 Epidemiology review. Range: min.  Triangular (min. = 0.66, likeliest = 0.78, 
from Wolfs 1999169 (Rotterdam  max. = 0.918)
Study); Max from Hollows 196621
(Rhondda Valley Study)
TABLE 41 Data on tests and test performance
Probability Value Source Distribution (values used to
define the distribution)
Optometrist test sensitivity 0.32 Tuck, 1991293 Beta (n = 1378, r = 436)
Optometrist test specificity 0.99 Tuck, 1991293 Beta (n = 274,228, r = 273,614)
Glaucoma optometrist test sensitivity 0.73 Grampian optometry study  Beta (n = 33, r = 24)
(Burr J: personal communication)
Glaucoma optometrist test specificity 0.96 Grampian optometry study  Beta (n = 67, r = 64)
(Burr J: personal communication)
Proportion of normal with IOP < 26 0.96 Sommer, 199123 (Baltimore Eye  Beta (n = 5682, r = 5455)
Survey, see Chapter 5)
Proportion of glaucoma with IOP   26 0.35 Sommer, 199123 (Baltimore Eye  Beta (n = 20, r = 7)
Survey, see Chapter 5)
Technician further test indeterminacy 0.1 Systematic review data,  Uniform (0.06–0.20)
diagnostic (Chapter 6)
Technician further test sensitivity 0.8 Assumption Uniform (0.8–1)
Technician further test specificity 0.8 Assumption Uniform (0.8–1)
Ophthalmologist test sensitivity 1 Assumption None defined
Ophthalmologist test specificity 1 Assumption None defined
Ophthalmologist proportion diagnosed  0.43 Henson. Manchester Glaucoma  Uniform (0.39–0.47)
as ‘observation’ state Optometry scheme 2005 data 
(Henson D, Aberdeen: personal 
communication, 2006)participating optometrists) for estimating OAG
prevalence and hence arriving at an
approximation of sensitivity and specificity. A 0.5%
prevalence of undetected glaucoma was assumed
(1378 patients out of the total of 275,600 seen).
This allowed the calculation of false negatives 
(n = 942) and true negatives (n = 273,610) to
complete a 2 x 2 table and provide an estimated
sensitivity and specificity for community-based
optometrist referrals for OAG glaucoma of 31.6%
and 99.8%, respectively. 
To estimate the diagnostic accuracy of glaucoma-
trained optometrists, data were used from a study
in Grampian evaluating a pilot community
optometry glaucoma service, the Grampian
Optometrist Study. The purpose of this study was
to assess the diagnostic accuracy of the
management decision made by accredited
glaucoma optometrists. The optometrist decision
was compared with two reference standards: an
ophthalmologist with a special interest in glaucoma,
and management decision made in usual care in
the hospital-based new patient clinic. The study
was completed in January 2006 and a publication
is in preparation (Burr JM, Azuara-Blanco A,
Thomas R, McLennan G, University of Aberdeen:
personal communication, 2006). For the purpose
of this analysis, disease was classified as OAG or
ocular hypertension requiring treatment. The
categories normal and discharged, and suspect
requiring optometric review were classified as no
disease. The consultant ophthalmologist with a
special interest in glaucoma was the reference
standard. The sensitivity of the glaucoma
optometrist was 0.73 (95% CI 0.56 to 0.85), with a
specificity of 0.96 (95% CI 0.88 to 0.99). 
Data from the Baltimore Eye Survey were used for
the estimation of the proportion of normal or
OAG patients with IOP of at least 26 mmHg.23
Details of this study can be found in Chapter 5.
Estimation of the proportion of people able to
perform the test (rate of indeterminancy) as part
of the ‘technician’ screening strategy was obtained
from the systematic review of screening tests (see
Chapter 6). In summary, for the tests the
percentage of interpretable results ranged from
80% for RNFL photography to 99% for SAP
(threshold) and GAT, with a median rate across all
tests of 97%. The number of studies contributing
data for each test was very small, although the
rates were very similar across tests.
The model used sensitivity and specificity values
for the technician tests equal to or greater than
0.8. For the ophthalmologist assessment an
assumption was made that this was the gold
standard and that the sensitivity and specificity
were equal to 1.
Beta distributions were used in the probabilistic
sensitivity analysis for the accuracy of the
optometrist in the current practice case-finding
strategy, and for the glaucoma optometrist test
sensitivities and specificities. Beta distributions
were also used for the proportion of OAG
individuals with IOP of at least 26 mmHg and
proportion of normal individuals with IOP below
26 mmHg. Uniform distributions were used for
technician further test indeterminacy, and for
sensitivity and specificity. Finally, a uniform
distribution was assumed for the proportion of
people classified as glaucoma suspects
(observation state) following diagnostic assessment
by an ophthalmologist.
Costs
Tables 42 and 43 show the cost estimates used in the
model. All figures are reported in 2006 pounds
sterling. Where costs had to be adjusted into a
common price year, a 2% inflation rate was
assumed where no inflation rate indices were
available. Table 42 shows the costs for the current
optometrist case-finding strategy. The cost for the
optometrist test was obtained from the NHS fee for
an eye test paid to an optometrist.294 A triangular
distribution was assumed for this variable. No
information on ranges was available, and as a
consequence rates of 0.5 and 1.5 times the likeliest
value were used as lower and upper limits. The cost
for the ophthalmologist diagnosis was calculated
using data from Scottish National Statistics for April
2004 to March 2005 (source: www.isdscotland.org).
The average reported cost for an ophthalmologist
outpatient visit was £65. This value was inflated by
the assumed 2% inflation rate for 2005/06. It was
also assumed, based on the likely need for visual
field testing to be performed as an additional
outpatient visit, that the ophthalmological diagnosis
would be equivalent to the cost of two standard
ophthalmology department outpatient
consultations. A triangular distribution was 
assumed for this parameter. The minimum and
maximum limits values were developed in the 
same way as the likeliest mean value, but with the
Scottish NHS Board lowest and highest average
cost for an ophthalmologist outpatient visit 
(i.e. £38 and £195, respectively). This cost was 
also used for cost of the observation state within 
the model where it was assumed that patients
judged to be at risk would be seen yearly for a
maximum of 5 years in this state or until OAG was
diagnosed.
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and colleagues.259 This is a Europe-based study
and includes data for the UK by severity of
glaucoma. In this study, the authors obtained
records for 194 patients. Unfortunately, the
sample sizes per country were not reported and
the figures might be subject to ‘small numbers’
bias. The study reported costs in euros. The price
year used was not reported in the study so it was
assumed to be 2004. Costs in the common price
year were estimated using the average 2004
exchange rate from euros into pounds sterling
(e.g. 0.6787; source: http://www.oanda.com/
convert/fxhistory), and a 2% annual inflation rate
was assumed. Triangular distributions were
attached to treatment costs. No additional data
were available to allow for construction of a 
range, so the assumption of 0.5 and 1.5 times the
likeliest value was applied. The exception to this
was the annual cost for visual impairment. The
likeliest value for the cost of visual impairment
used in this model was based on the mean value of
the last two disease stages reported in Traverso
and colleagues, as these corresponded to the
visual impairment category used in this study. A
triangular distribution was assumed for this cost,
with the minimum value being equal to the mean
value of the less costly of the last two disease
stages from Traverso and the maximum being
equal to the mean value of the more costly of
these stages.
Table 43 shows costs used for the screening
strategies. Screening invitation costs were obtained
from Facey and colleagues.295 This was a study on
the organisation of the diabetic retinopathy
screening programme for Scotland. These figures
include the cost for national coordination, local
health board coordination, screening offices and
call and recall operation, development and
maintenance of call and recall software, and
development and maintenance of image capture
software. It also assumed around 125,000 people
are screened. New NHS fees for optometrists in
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TABLE 42 Current practice costs
Costs Value (£) Source Distribution (values used to define the
distribution)
Optometrist test 18.39 Department of Health294 Triangular (min. = 9.20, likeliest = 18.39, 
max. = 27.59)
Ophthalmologist diagnosis tests 133 Scotland National Statisticsa Triangular (min. = 77, likeliest = 133, 
max. = 397)
Glaucoma mild treatment 420 Traverso, 2005259 Triangular (min. = 210, likeliest = 420, 
max. = 630)
Glaucoma moderate treatment 473 Traverso, 2005259 Triangular (min. = 236.5, likeliest = 473, 
max. = 709.5)
Glaucoma severe treatment 376 Traverso, 2005259 Triangular (min. = 188, likeliest = 376, 
max. = 564)
Visual impairment annual cost 669 Traverso, 2005259 Triangular (min. = 585.41, likeliest = 669, 
max. = 752.06)
a Source: ISD Scotland (www.isdscotland.org).
TABLE 43 Screening strategy costs
Costs Value (£) Source Distribution (values used to
define the distribution)
Screening invitation 10.45 NHS Quality Improvement Scotland295 Triangular (min. = 5.23, 
likeliest = 10.45, max. = 15.68)
Glaucoma optometrist test 46.50 Scottish Executive296 Triangular (min. = 23.25, 
likeliest = 46.50, max. = 69.75)
Technician IOP tests 10.63 NHS Quality Improvement Scotland295 Triangular (min. = 5.32, 
likeliest = 10.63, max. = 15.95)
Technician second test 10.63 NHS Quality Improvement Scotland295 Triangular (min. = 5.32, 
likeliest = 10.63, max. = 15.95)Scotland were used for glaucoma optometrist
assessment.296 The new Scottish eye examination
would include a full examination of the eye, visual
field and IOP (e.g. with NCT), and supplementary
exams if clinically indicated (e.g. applanation
pressures and threshold fields). For the technician
screening strategy, the technician IOP test and
second round test costs were obtained from the
Scottish Diabetic Retinopathy Screening study.295
The costs were based on the variable costs for non-
mydriatic camera, hospital-based, one technical
staff screening estimated by this study. Triangular
distributions were attached to the costs in Table 43
with the assumption of 0.5 and 1.5 times the
likeliest value used to estimate minimum and
maximum values.
Data for treatment costs and ophthalmologist
diagnosis were the same as in the no-screening
strategy.
Health state utilities
The primary purpose of the economic model was
to inform decision making in a UK setting. Recent
guidance suggests that estimates of QALYs should
ideally be based on generic health state valuation
methods using UK population values,297 and
therefore a focused search of the literature and
other relevant sources such as the Harvard
cost–utility database for relevant utility data was
conducted. A number of studies reporting health
state utilities was identified. These studies used a
wide variety of health state valuation techniques
and utilities were obtained from a variety of
different settings and respondents. However, none
of these studies reported utilities applicable to a
UK decision-making setting. 
For this reason the results of an ongoing study
were used to provide relevant utility estimates.
This study is attempting to develop a glaucoma-
specific measure of quality of life suitable for use
in economic evaluations. The study involved the
administration of a participant self-completed
questionnaire to people with glaucoma attending
the ophthalmology outpatient departments of
Aberdeen Royal Infirmary and the United Leeds
Teaching Hospital Trust (Leeds General Infirmary,
St James’ Hospital and St George’s Community
Eye Centre). UK members of the IGA also
participated. All participants were asked to
complete a questionnaire that included
information on self-rating of glaucoma severity
(mild, moderate or severe), a discrete choice
experiment and the EuroQol 5 Dimensions 
(EQ-5D). A subsample of patients from Aberdeen
underwent an objective assessment of glaucoma
severity. This was by a grading of the binocular
visual field using the integrated visual field
method as described by Crabb and colleagues (see
Table 1, p. 17).89 The responses to the EQ-5D were
converted to health state utilities using UK
population tariffs and analysed according to the
objective and subjective assessment of glaucoma
severity (Kilonzo M, University of Aberdeen:
personal communication, 2006). Table 44 shows
the estimates of utility for those people with an
objective assessment of their glaucoma severity.
Although these data are based on a subsample
they were chosen from the larger sample available
from the two hospitals and the IGA owing to the
relatively poor concordance between objective and
subjective assessments of glaucoma severity
(Appendix 22). Nevertheless, due to the
uncertainty surrounding which data to use, the
estimates provided by the whole data set (reported
in Appendix 22) have been used as part of a
sensitivity analysis. 
The estimates used in the model, using these data,
are detailed in Table 45. A value of 1 was assumed
for normal and observation states, while the
corresponding mean values of Table 44 were used
as utility weights for OAG states mild, moderate
and severe. The visual impaired utility state was
developed using data from Table 44 and from
Gupta and colleagues.298 This study presented
utility values for categories that matched glaucoma
severe and visual impaired states in the present
study. Then, the relative difference between these
Economic analysis
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TABLE 44 Estimated health state utilities for the different levels of severity
Value  Mild severity Moderate severity Severe severity
(n = 37) (n = 14) (n = 9)
Mean 0.8015 0.7471 0.7133
Median 0.7960 0.7435 0.7960
SD 0.1254 0.1881 0.2549
Minimum 0.29 0.20 0.09
Maximum 0.92 0.90 0.92two glaucoma states from Gupta and colleagues
was used to obtain the utility score for visual
impaired in Table 45. Beta distributions were
attached to these glaucoma utility weight
parameters (Table 45). It was assumed that there
were no differences in the utility between
undiagnosed OAG and treated OAG at each level
of severity. 
Base-case and sensitivity analysis
Base-case analysis
The base-case analysis was run for a cohort of 40-,
60- and 75-year-old males with screening
occurring every 3 years. The choice of these ages
and a 3-year screening interval was arbitrary. It
was felt that the age groups covered the range
over which screening might be considered and a
3-year screening interval was considered a
plausible starting point for the analysis (the
impact of using other screening intervals was
considered). Gender-specific variables were not
available for any of the model parameters except
for mortality, and a decision was made to use male
mortality rates in the base-case analysis, consistent
with good modelling practice, as they are a
conservative assumption for screening.
The model was run for a range of possible OAG
prevalence values and for a lifetime horizon.
Cycles length was set at 1 year. Costs are presented
in 2006 pounds sterling and effectiveness in
QALYs. A discount rate of 3.5% for costs and
benefits was used following guidelines for
technology assessment by the National Institute
for Health and Clinical Excellence (NICE).297
Results are presented in ICERs. This measure is a
ratio of the difference in costs divided by the
difference in the effectiveness between two
alternative strategies. These data can be
interpreted as how much society would have to
pay for an extra unit of effectiveness. Probabilistic
analysis results are presented for society’s
willingness to pay values of £10,000, £20,000,
£30,000 and £50,000. Cost-effectiveness
acceptability curves (CEACs) for these analyses are
presented in Appendix 23. These plot the
probability of each strategy being the optimal
decision against a range of values for society’s
willingness to pay for an extra unit of
effectiveness. Central to the assessment of 
cost-effectiveness is the value that society would
put on gaining an additional QALY. NICE 
states that “Below a most plausible ICER of
£20,000 per QALY, judgements about the
acceptability of a technology as an effective 
use of NHS resources are based primarily on 
the cost-effectiveness estimate. Above a most
plausible ICER of £20,000 per QALY, judgements
about the acceptability of the technology as 
an effective use of NHS resources are more likely
to make more explicit reference to factors
including:
● the degree of uncertainty surrounding the
calculation of ICERs;
● the innovative nature of the technology;
● the particular features of the condition and
population receiving the technology; and
● where appropriate, the wider societal costs and
benefits.
Above an ICER of £30,000 per QALY, the case 
for supporting the technology on these factors 
has to be increasingly strong.”297(p. 33). In the
absence of a more definitive statement this report
focuses on a willingness to pay of £30,000 for a
QALY.
The main results of the base-case analysis are
presented in the section ‘Results of base-case
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TABLE 45 Health state utility estimates used in the model
Quality of life Utility weight Source Distribution (values used to define
the distribution)
Normal 1   Assumption None
Glaucoma mild 0.8015 (Kilonzo M, University of Aberdeen:  Beta (alpha = 8.2, beta = 2)
personal communication, 2006)
Glaucoma moderate 0.7471 (Kilonzo M, University of Aberdeen:  Beta (alpha = 11.4, beta = 3.5)
personal communication, 2006)
Glaucoma severe 0.7133 (Kilonzo M, University of Aberdeen:  Beta (alpha = 1.2, beta = 0.4)
personal communication, 2006)
Visually impaired 0.5350 Developed using data from Gupta,  Log-normal (u = –0.31029, 
2005298 sigma = 0.16631)analysis and sensitivity analysis on the base-case’
(p. 115). Full probabilistic analyses were carried
out for the three cohort groups and rates of OAG
prevalence from 0.1% and 20%. 
Sensitivity analysis
Sensitivity analysis was carried out to explore
uncertainties within the model. As described
below, deterministic (one-way, two-way and
multiway) sensitivity analyses were carried out for
the main parameters within the model.
Probabilistic sensitivity analyses were developed to
address further parameter uncertainty in the
model. 
Changes to the screening interval
The effects of longer screening intervals (e.g. 
5 and 10 years) were explored using one-way
sensitivity analysis, as well as part of the
probabilistic sensitivity analysis. 
Changes to the probability of having an eye test
Deterministic analyses were conducted for the
probability of having an eye test with a 
community optometrist assuming low, medium
and high uptake rates. These were defined as 
an annual probability of an eye test of 2%, 13%
and 37%. The rationale for these figures was 
based on discussion among the members of the
study steering group. It was agreed that it was
likely that a part of the population would have
lower utilisation (caused by either lower access 
or the exercise of choice) to a community
optometrist test. Moreover, some people may 
have almost no access to these services. The 
values adopted would give approximately 10%,
50% and 90% of the cohort receiving an eye 
test in the community setting over a 5-year 
period.
Changes to the sensitivity and specificity of the
technician tests
In the base-case analysis it was assumed that the
sensitivity and specificity of this test was 0.8 and
0.8. In this sensitivity analysis the sensitivity and
specificity were varied between plausible ranges of
0.5 to 1.0 for sensitivity and 0.8 to 1.0 for
specificity. 
Further targeted sensitivity analyses for
potentially cost-effective scenarios
Further sensitivity analyses were carried out for
the combinations of the cohort, prevalence rate
and screening interval that seemed to be most
likely to be cost-effective. Specifically, the 
following sensitivity analyses were conducted for
the 40-year-old cohort, at a 5% (except where
otherwise stated) OAG prevalence rate and a 10-
year screening interval. 
Changes to the uptake of the community
optometrist
It is likely that the cohort of individuals with
higher OAG prevalence rates would have a higher
probability of going for an eye test, for example
people with a family history of OAG or people
with myopia. Conversely, ethnic minority groups
may have a lower probability of attending for an
eye test. Additional sensitivity analysis was
completed assuming 1.5 times and twice the
probability of having an eye test for the 
no-screening strategy. 
Changes to incidence and progression of
glaucoma
Although considerable efforts were made to
identify the estimates for incidence and
progression, few data were available. Within the
base-case analysis distributions were defined to
reflect the variability surrounding these estimates.
Despite this it was felt possible that the values
used might have been substantially lower or
higher than those used in the base case. In the
first of these sensitivity analyses the incidence of
OAG was assumed to be equal to the maximum
for incidence reported in Table 39. A triangular
distribution was attached, where the maximum was
assumed to be twice the maximum used in the
base case (truncated if necessary at 1) and the
minimum value was assumed to be equal to the
likeliest value from the base case. 
For the second of these analyses the incidence of
OAG was assumed to be equal to the minimum for
incidence reported in Table 39. A triangular
distribution was attached, where the maximum was
assumed to be the likeliest value from the base
case (truncated if necessary at 1) and the
minimum value was assumed to be equal to zero. 
With respect to progression in the ‘high’ analyses,
the maximum values for the rates of progression
were used. Likewise, in the ‘low’ analyses, the
minimum values for the rates of progression were
used. A triangular distribution around the likeliest
values used in the analyses was defined using the
same methods as described above. 
Further sensitivity analysis was carried out based
on time to progression, rather than average risk 
of progression (Chapter 7), for untreated patients
for each corresponding glaucoma state by
applying the treatment effect of 0.65 to the
number of years until progression occurred. Using
Economic analysis
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untreated were 0.31 for progression to glaucoma
moderate, 0.11 for progression to glaucoma severe
and 0.09 for progression to visually impaired.
Triangular distributions were attached to these
parameters’ mean values using the same
methodology described above. 
Changes to the sensitivity and specificity of the
technician tests
In this sensitivity analysis the same methods as
described in the section ‘Base-case and sensitivity
analysis’ (p. 113) were used to explore how the
results changed as the sensitivity and specificity 
of the second test performed by the technician 
in the ‘technician screening’ strategy were
changed. 
Sensitivity analysis on health state utilities
In previous analyses health state utilities were
based on objective assessment of the severity of
OAG. In this sensitivity analysis a larger data set
where the severity of OAG was based on the
subjective assessment of severity was used. The
data used in this analysis were described in
Appendix 22. As noted in Appendix 22, objective
and subjective assessments did not always agree.
The main difference between the utility values
based on subjective and objective assessments was
the difference in utility weights between states. For
example, in the base-case analysis, a loss of around
7% and 5% in quality of life would occur when
moving from glaucoma mild to glaucoma
moderate and from glaucoma moderate to
glaucoma severe, respectively. These changes are
approximately 2.5% and 10%, respectively, for this
analysis. 
Sensitivity analysis on costs
Costs of screening, diagnosis and treatment
As described in ‘Parameter estimates used in the
model’ (p. 107), the data available on costs were
limited and consideration was given to variations
in the costs used in the model. In this sensitivity
analysis low and high estimates were derived. For
the cost of diagnosis by the ophthalmologist low
and high values were developed using data from
Scotland National Statistics (see Table 42). For
example, in this situation, the high value was
almost three times the base-case value used. 
The treatment costs of the different disease states
were also varied in a further treatment cost
scenario. In this scenario the costs for each 
disease state were assumed to be either half or
twice the costs used in the base-case analysis
(Table 42). 
A third scenario was also considered for sensitivity
analysis around cost estimates. In this scenario the
costs of the screening invitation and the tests
performed during screening were varied. Each
cost was assumed to be either half or twice the
values used in the base-case analysis (Table 43). 
Changes to the cost of visual impairment
The perspective taken for the estimate of costs was
that of the NHS. In this sensitivity analysis the
effect of widening the perspective to include other
sectors of the economy such as Personal Social
Services and the patient was explored. The effect
of this wider perspective was assumed to affect the
costs of visual impairment alone. This analysis was
conducted for a 40-year-old cohort undergoing
screening every 10 years, but with a prevalence of
OAG of either 1% or 5%. For both prevalence
rates one-way sensitivity analysis was used to
identify threshold values for the annual cost of
visual impairment. To interpret these thresholds it
should be borne in mind that, based on the data
reported by Meads and Hyde,299 the annual cost
of a year of visual impairment can be calculated as
£7851 for the first year of visual impairment and
£7657 for subsequent years (details as to how
these estimates were derived are described in
Appendix 24).
Results of base-case analysis and
sensitivity analysis on the base case
Estimates of costs and QALYs for the base case 
Tables 46–48 report the estimated relative cost-
effectiveness by screening strategy at different
levels of prevalence of OAG for cohorts aged 40,
60 and 75 years, respectively. These results are
based on a screening interval of 3 years.
In each of these analyses, as prevalence increases
cost also increases and QALYs fall for all three
strategies and all age cohorts. Costs increase as
prevalence increases because a larger proportion
of individuals in the cohort incurs the costs of
diagnosis and the continuing costs of treating the
OAG. The mean cost per person is higher for the
40-year-old cohort than the older cohorts because
they are less likely to die during the time-horizon
of the model and thus have more opportunity to
incur costs. Estimated mean QALYs fall as
prevalence increases. This is because a greater
proportion of the cohort experience the adverse
health effects of OAG. Estimated mean QALYs are
greater for the younger age group than the older
age groups at each prevalence level, primarily
because members of the younger age group are
less likely to die during the time-horizon of the
model.
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age group considered, ‘no screening’ (i.e. the
current strategy of opportunistic case finding by
the community optometrist) is the least costly 
but also the least effective of the three 
strategies considered. Adopting a strategy 
where a technician performs the initial screening
tests is more effective but more costly than a 
no-screening strategy, and a strategy of screening
by a glaucoma optometrist is more effective but
more costly than the ‘technician’ screening
strategy.
Estimated cost-effectiveness
For each age group considered the incremental
cost per QALY gained from adopting ‘technician’
screening compared with ‘no screening’ falls as
prevalence increases. The incremental cost per
QALY gained indicates how well the extra costs of
a more expensive but more effective treatment are
converted into additional benefits. As the
incremental cost per QALY gained falls the more
likely it becomes that technician screening will be
considered cost-effective compared with no
screening. Similarly, for each age group
considered, the incremental cost per QALY gained
from adopting glaucoma optometrist screening
compared with technician screening falls as
prevalence increases. This indicates that as
prevalence increases it is more likely that
technician screening will be considered cost-
effective compared with no screening.
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TABLE 46 Incremental cost-effectiveness for the 40-year-old cohort by different prevalence rates
Prevalence Strategy Cost (£) QALYs ICER
1% No screening 257.40 19.231
Technician 520.36 19.233 107,938
GO 617.34 19.234 398,881
2% No screening 333.89 19.166
Technician 608.76 19.170 65,924
GO 705.86 19.171 240,717
4% No screening 486.85 19.036
Technician 785.57 19.044 39,118
GO 882.89 19.045 134,460
6% No screening 639.82 18.906
Technician 962.38 18.918 29,051
GO 1,059.93 18.919 93,416
8% No screening 792.79 18.777
Technician 1,139.19 18.791 23,775
GO 1,236.97 18.793 71,648
10% No screening 945.76 18.647
Technician 1,316.00 18.665 20,527
GO 1,414.00 18.667 58,158
12% No screening 1,098.72 18.517
Technician 1,492.80 18.539 18,326
GO 1,591.04 18.541 48,979
14% No screening 1,251.69 18.387
Technician 1,669.61 18.412 16,737
GO 1,768.07 18.415 42,330
16% No screening 1,404.66 18.258
Technician 1,846.42 18.286 15,535
GO 1,945.11 18.289 37,290
18% No screening 1,557.63 18.128
Technician 2,023.23 18.160 14,594
GO 2,122.15 18.163 33,339
20% No screening 1,710.59 17.998
Technician 2,200.04 18.033 13,838
GO 2,299.18 18.037 30,159
GO, ‘glaucoma optometrist’ strategy.The base-case model suggests that for a 
40-year-old cohort a technician screening strategy
compared with a no-screening strategy is
associated with an incremental cost per QALY that
society might be willing to pay at a prevalence
somewhere between approximately 6 and 10%
(Table 46). For a 60-year-old cohort a technician
screening strategy compared with a no-screening
strategy might be considered cost-effective at a
prevalence between approximately 12 and 20%
(Table 47). For a 75-year-old cohort, a no-screening
strategy has an incremental cost per QALY gained
at any of the prevalence levels considered
(Table 48). Furthermore, for no age cohort and no
prevalence level is screening by the glaucoma
optometrist instead of screening by the technician
associated with an incremental cost per QALY
gained that society might typically be willing 
to pay.
Tables 46–48 present mean costs, QALYs and
incremental costs per QALY gained. Such data do
not represent the imprecision surrounding the
parameter estimates used in the model. This
uncertainty was addressed by the probabilistic
sensitivity analyses conducted. These show the
likelihood that each screening strategy would be
considered cost-effective at different threshold
values for society’s willingness to pay for a QALY
(Tables 49–51).
Tables 49 indicates for a 40-year-old cohort that at
prevalence levels of 1% or less there is very little
likelihood that any screening strategy would be
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TABLE 47 Incremental cost-effectiveness for the 60-year-old cohort by different prevalence rates
Prevalence Strategy Cost (£) QALYs ICER
1% No screening 187.10 12.477
Technician 364.37 12.479 134,060
GO 430.42 12.479 409,416
2% No screening 232.42 12.438
Technician 418.47 12.440 88,094
GO 484.79 12.440 264,869
4% No screening 323.06 12.360
Technician 526.67 12.363 55,160
GO 593.52 12.364 156,016
6% No screening 413.71 12.281
Technician 634.87 12.286 41,963
GO 702.25 12.287 111,083
8% No screening 504.35 12.203
Technician 743.07 12.209 34,851
GO 810.98 12.210 86,547
10% No screening 594.99 12.124
Technician 851.27 12.132 30,405
GO 919.71 12.133 71,088
12% No screening 685.64 12.045
Technician 959.47 12.055 27,361
GO 1,028.44 12.057 60,456
14% No screening 776.28 11.967
Technician 1,067.67 11.979 25,147
GO 1,137.17 11.980 52,695
16% No screening 866.92 11.888
Technician 1,175.87 11.902 23,464
GO 1,245.90 11.903 46,781
18% No screening 957.57 11.810
Technician 1,284.07 11.825 22,142
GO 1,354.63 11.826 42,124
20% No screening 1,048.21 11.731
Technician 1,392.27 11.748 21,076
GO 1,463.36 11.750 38,362more cost-effective than no screening. At a 5%
prevalence level there is just over 40% likelihood
that technician screening would be considered
cost-effective if society’s willingness to pay for a
QALY was £30,000. This climbs to 56% when the
prevalence is 10%. Screening by a glaucoma
optometrist is unlikely to be considered cost-
effective at any of the prevalence levels or cost per
QALY thresholds considered. 
For a 60-year-old cohort there is less than a 50%
chance that technician screening would be
considered cost-effective when society’s willingness
to pay for a QALY is £30,000 (Tables 50) for all
prevalences up to 20%. Again, screening by a
glaucoma optometrist is unlikely to be considered
cost-effective at any of the prevalence levels or cost
per QALY thresholds considered. 
There is only a low likelihood that any strategy
other than no screening would be considered cost-
effective for the 75-year-old cohort at any of the
prevalence levels considered if society’s maximum
willingness to pay for a QALY is £30,000. Should
society’s willingness to pay for a QALY be higher
than £30,000 then the likelihood that the
technician or glaucoma optometrist screening
strategy would be considered cost-effective
increases. Nevertheless, even at a willingness to
pay for a QALY of £50,000, no screening is most
likely to be the most cost-effective strategy.
Sensitivity analysis performed around the base
case
Changes to the screening interval
The base-case analysis has assumed that screening
will take place every 3 years. In this analysis the
Economic analysis
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TABLE 48 Incremental cost-effectiveness for the 75-year-old cohort by different prevalence rates
Prevalence Strategy Cost (£) QALYs ICER
1% No Screening 103.47 6.905
Technician 210.76 6.905 200,028
GO 250.74 6.905 521,062
2% No screening 125.01 6.884
Technician 238.87 6.885 137,032
GO 279.22 6.885 350,449
4% No screening 168.11 6.843
Technician 295.11 6.845 89,440
GO 336.17 6.845 213,985
6% No screening 211.20 6.802
Technician 351.35 6.804 69,757
GO 393.12 6.804 155,507
8% No screening 254.30 6.761
Technician 407.58 6.764 58,999
GO 450.08 6.764 123,022
10% No screening 297.39 6.720
Technician 463.82 6.723 52,218
GO 507.03 6.723 102,350
12% No screening 340.49 6.679
Technician 520.06 6.683 47,552
GO 563.98 6.683 88,039
14% No screening 383.59 6.638
Technician 576.30 6.642 44,146
GO 620.94 6.643 77,544
16% No screening 426.68 6.597
Technician 632.53 6.601 41,550
GO 677.89 6.602 69,519
18% No screening 469.78 6.555
Technician 688.77 6.561 39,505
GO 734.84 6.562 63,183
20% No screening 512.87 6.514
Technician 745.01 6.520 37,853
GO 791.80 6.521 58,055impact of changing the screening interval to 5 or
10 years has been explored (Figures 40–42). These
data indicate that as the screening interval
increases the incremental cost per QALY gained
reduces. This is because it has been assumed that
OAG progresses relatively slowly and any
reduction in total QALYs is more than
compensated for by a reduction in costs.
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TABLE 49 Probabilistic sensitivity analysis for 40-year-old cohort: probability of being the optimal strategy at different threshold levels
for society’s willingness to pay for a QALY
Prevalence Strategy Cost (£) QALYs ICER Probability that intervention is cost-effective 
for different threshold values for 
society’s willingness to pay for a QALY (%)
£10,000 £20,000 £30,000 £50,000
1% No Screening 257.40 19.231 100.0 98.8 93.9 78.5
Technician 520.36 19.233 107,938 0.0 1.20 5.9 21.0
GO 617.34 19.234 398,881 0.0 0.0 0.2 0.5
5% No screening 563.34 18.971 94.4 71.5 50.8 34.9
Technician 873.97 18.981 33,153 5.4 27.9 48.0 61.3
GO 971.41 18.982 110,218 0.2 0.6 1.2 3.8
10% No screening 945.76 18.647 79.6 48.6 35.0 24.2
Technician 1,316.00 18.665 20,527 19.9 49.6 60.0 62.3
GO 1,414.00 18.667 58,158 0.5 1.8 5.0 13.5
15% No screening 1,328.17 18.323 68.9 39.6 29.2 20.6
Technician 1,758.02 18.349 16,097 30.1 55.3 59.4 56.7
GO 1,856.59 18.352 39,648 1.0 5.1 11.4 22.7
20% No screening 1,710.59 17.998 59.9 34.9 26.8 18.9
Technician 2,200.04 18.033 13,838 38.5 55.9 54.3 48.0
GO 2,299.18 18.037 30,159 1.6 9.2 18.9 33.1
See Appendix 23, Figures 53–57, for CEACs.
TABLE 50 Probabilistic sensitivity analysis for 60-year-old cohort: probability of being the optimal strategy at different threshold levels
for society’s willingness to pay for a QALY
Prevalence Strategy Cost (£) QALYs ICER Probability that intervention is cost-effective 
for different threshold values for society’s 
willingness to pay for a QALY (%)
£10,000 £20,000 £30,000 £50,000
1% No screening 187.10 12.477 100.0 98.4 92.9 79.2
Technician 364.37 12.479 134,060 0.0 1.5 6.9 20.2
GO 430.42 12.479 409,416 0.0 0.1 0.2 0.6
5% No screening 368.38 12.320 96.4 79.3 64.0 46.1
Technician 580.77 12.325 47,399 3.5 20.1 34.7 50.5
GO 647.88 12.325 129,684 0.1 0.6 1.3 3.4
10% No screening 594.99 12.124 87.6 63.0 48.4 34.3
Technician 851.27 12.132 30,405 12.0 35.3 46.7 53.0
GO 919.71 12.133 71,088 0.4 1.7 4.9 12.7
15% No screening 821.60 11.928 81.3 53.2 41.2 30.3
Technician 1,121.77 11.940 24,252 17.8 42.3 49.0 49.1
GO 1,191.54 11.941 49,551 0.9 4.5 9.8 20.6
20% No screening 1,048.21 11.731 76.7 49.4 36.2 27.8
Technician 1,392.27 11.748 21,076 22.0 42.4 47.5 43.5
GO 1,463.36 11.750 38,362 1.3 8.2 16.3 28.7
See Appendix 23, Figures 58–62, for CEACs.Economic analysis
120
TABLE 51 Probabilistic sensitivity analysis for 75-year-old cohort: probability of being the optimal strategy at different threshold levels
for society’s willingness to pay for a QALY
Prevalence Strategy Cost (£) QALYs ICER Probability that intervention is cost-effective for 
different threshold values for society’s 
willingness to pay for a QALY (%)
£10,000 £20,000 £30,000 £50,000
1% No screening 103.47 6.905 100.0 99.6 96.1 88.1
Technician 210.76 6.905 200,028 0.0 0.4 3.7 11.5
GO 250.74 6.905 521,062 0.0 0.0 0.2 0.4
5% No screening 189.66 6.823 99.1 89.8 78.7 64.0
Technician 323.23 6.824 77,908 0.9 9.9 20.4 33.8
GO 364.65 6.825 179,873 0.0 0.3 0.9 2.2
10% No screening 297.39 6.720 95.5 79.3 67.5 50.7
Technician 463.82 6.723 52,218 4.3 19.6 30.0 40.0
GO 507.03 6.723 102,350 0.2 1.1 2.5 9.3
15% No screening 405.13 6.617 91.7 74.3 62.1 46.2
Technician 604.41 6.622 42,766 7.9 23.5 31.1 38.9
GO 649.41 6.622 73,281 0.4 2.2 6.8 14.9
20% No screening 512.87 6.514 89.7 70.0 57.0 43.6
Technician 745.01 6.520 37,853 9.5 25.2 31.9 35.8
GO 791.80 6.521 58,055 0.8 4.8 11.1 20.6
See Appendix 23, Figures 63–67 for CEACs.
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FIGURE 40 Incremental cost per QALY gained by prevalence rate and at 3-, 5- and 10-year screening intervals for the 40-year-old
cohort. Incremental cost per QALY for ‘technician’ strategy is for the comparison of ‘technician’ strategy with ‘no screening’ strategy.
Incremental cost per QALY for ‘glaucoma optometrist’ strategy (GO) is for the comparison of ‘glaucoma optometrist’ strategy with
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FIGURE 41 Incremental cost per QALY gained by prevalence rate and at 3-, 5- and 10-year screening intervals for the 60-year-old
cohort. Incremental cost per QALY for ‘technician’ strategy is for the comparison of ‘technician’ strategy with ‘no screening’ strategy.
Incremental cost per QALY for ‘glaucoma optometrist’ strategy (GO) is for the comparison of ‘glaucoma optometrist’ strategy with
‘technician’ strategy. 
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FIGURE 42 Incremental cost per QALY gained by prevalence rate and at 3-, 5- and 10-year screening intervals for the 75-year-old
cohort. Incremental cost per QALY for ‘technician’ strategy is for the comparison of ‘technician’ strategy with ‘no screening’ strategy.
Incremental cost per QALY for ‘glaucoma optometrist’ strategy (GO) is for the comparison of ‘glaucoma optometrist’ strategy with
‘technician’ strategy. For the 40-year-old cohort, adopting the
technician strategy in preference to a no-screening
strategy would be associated with an incremental
cost per QALY that society might consider
acceptable at a prevalence of approximately 4% 
(5-year screening interval) and just less than 4%
(10-year screening interval). Furthermore, at a
prevalence of approximately 12% adopting the
screening by a glaucoma optometrist would be
associated with an incremental cost per QALY that
society might consider acceptable. For the 
60-year-old age group similar prevalences for the
cost-effectiveness of technician screening are 8% 
(5-year screening interval) and 6% (10-year
screening interval). Screening by a glaucoma
optometrist would be associated with an
incremental cost per QALY that society might
consider acceptable at approximately 20%
prevalence. At none of the screening intervals or
prevalences considered for 75 year olds would
either technician screening or the screening by the
glaucoma optometrist be considered cost-effective.
Figures 40–42 do not reflect the statistical
imprecision surrounding the parameter estimates
used in the calculation of the estimates of the
incremental cost per QALY gained. The
probabilistic sensitivity analyses reported in
Tables 52–54 show the likelihood that each of the
strategies might be considered cost-effective at
different threshold values for willingness to pay for
a QALY at 3-, 5- and 10-year screening intervals.
Table 52 shows these data when the prevalence is
1%, Table 53 shows the results for a 5% prevalence
level and Table 54 shows the results for a 10%
prevalence level. As these tables show, the
Economic analysis
122
TABLE 52 Likelihood of a strategy being cost-effective for different age cohorts and screening intervals: 1% prevalence of OAG
Cohort Screening interval Strategy Probabilistic cost-effectiveness for different 
threshold values for society’s willingness to pay 
for a QALY (%)
£10,000 £20,000 £30,000 £50,000
40 years old 3 years No screening 100.0 98.8 93.9 78.5
(base case) Technician 0.0 1.2 5.9 21.0
GO 0.0 0.0 0.2 0.5
5 years No screening 100.0 97.1 88.2 69.2
Technician 0.0 2.7 11.5 30.1
GO 0.0 0.2 0.3 0.7
10 years No screening 99.8 92.1 79.1 56.2
Technician 0.2 7.7 20.3 42.5
GO 0.0 0.2 0.6 1.3
60 years old 3 years No screening 100.0 98.4 92.9 79.2
(base case) Technician 0.0 1.5 6.9 20.2
GO 0.0 0.1 0.2 0.6
5 years No screening 100.0 97.2 90.0 74.4
Technician 0.0 2.7 9.6 24.7
GO 0.0 0.1 0.4 0.9
10 years No screening 100.0 95.1 86.9 69.3
Technician 0.0 4.8 12.7 29.5
GO 0.0 0.1 0.4 1.2
75 years old 3 years No screening 100.0 99.6 96.1 88.1
(base case) Technician 0.0 0.4 3.7 11.5
GO 0.0 0.0 0.2 0.4
5 years No screening 100.0 99.6 96.5 88.1
Technician 0.0 0.4 3.5 11.9
GO 0.0 0.0 0.0 0.0
10 years No screening 100.0 99.1 94.6 84.3
Technician 0.0 0.9 5.2 15.1
GO 0.0 0.0 0.2 0.6
See Appendix 23, Figures 68–73, for CEACs.likelihood that either the technician or the
glaucoma optometrist strategy would be
considered cost-effective increases as prevalence
and screening interval increase for all three age
cohorts. Again, the likelihood of the glaucoma
optometrist strategy being cost-effective is rarely
greater than 20%.
Changes in the probability of having an eye test
with a community optometrist
It was discussed and agreed in the steering group
meeting that part of the population would have a
lower attendance for a sight test by a community
optometrist. In this analysis 2%, 13% and 37%
community optometrist test uptake rates were
assumed. The rationale for these figures was that
they would result in about 10%, 50% and 90% of
the cohort having an eye test in 5 years’ time.
Tables 55–57 show the results for the 40-, 60- and
75-year-old cohorts, respectively. As expected, the
cost and QALY rise when uptake rates for
attendance at a community optometrist are higher.
The higher the uptake rate, the better the no-
screening strategy performs. For instance, the
incremental cost per QALY for a 1% prevalence
rate of OAG for the comparison of the technician
with the no-screening strategy was £107,938
(Table 46), whereas the incremental cost per QALY
when there was a low uptake rate of the
community optometrist was £59,191 (Table 55).
Moreover, if there is a group of individuals within
the cohort that do not access a community
optometrist service, the screening strategies
become more cost-effective the bigger the
deprived group is. The assumption within the
model is that this group will attend screening.
Health Technology Assessment 2007; Vol. 11: No. 41
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TABLE 53 Likelihood of a strategy being cost-effective for different age cohorts and screening intervals: 5% prevalence of OAG
Cohort Screening interval Strategy Probabilistic cost-effectiveness for different 
threshold values for society’s willingness to pay
for a QALY (%)
£10,000 £20,000 £30,000 £50,000
40 years old 3 years No screening 94.4 71.5 50.8 34.9
(base case) Technician 5.4 27.9 48.0 61.3
GO 0.2 0.6 1.2 3.8
5 years No screening 87.6 58.6 43.2 29.2
Technician 12.2 40.2 53.3 60.4
GO 0.2 1.2 3.5 10.4
10 years No screening 82.5 54.3 40.2 29.6
Technician 16.7 42.3 51.4 51.1
GO 0.8 3.4 8.4 19.3
60 years old  3 years No screening 96.4 79.3 64.0 46.1
(base case) Technician 3.5 20.1 34.7 50.5
GO 0.1 0.6 1.3 3.4
5 years No screening 93.1 73.3 56.7 40.3
Technician 6.7 25.7 40.5 50.8
GO 0.2 1.0 2.8 8.9
10 years No screening 88.1 63.9 49.3 34.9
Technician 11.5 33.6 44.0 48.4
GO 0.4 2.5 6.7 16.7
75 years old  3 years No screening 99.1 89.8 78.7 64.0
(base case) Technician 0.9 9.9 20.4 33.8
GO 0.0 0.3 0.9 2.2
5 years No screening 98.2 86.9 74.5 59.9
Technician 1.7 12.4 24.2 34.9
GO 0.1 0.7 1.3 5.2
10 years No screening 96.1 82.2 69.7 53.8
Technician 3.8 16.9 27.9 37.5
GO 0.1 0.9 2.4 8.7
See Appendix 23, Figures 74–79 for CEACs.Changes to the sensitivity and specificity of the
test following the measurement of IOP in the
‘technician’ strategy
Overall, the results of the analysis indicate that the
incremental cost per QALY is relatively insensitive
to changes to either the specificity or sensitivity of
this test. Figures 43–45 illustrate this. These figures
show that as specificity increases the incremental
cost per QALY of the technician testing strategy
falls. Likewise, as sensitivity increases the
incremental cost also falls. The figures also
illustrate that changes in specificity are more
important than changes in sensitivity and that the
importance of changes in specificity and sensitivity
declines as prevalence increases. The impact of
changes in sensitivity and specificity does not
appear to be greatly influenced by the age of the
cohort screened.
As would be expected, as the sensitivity and 
the specificity of tests in the glaucoma 
optometrist strategy were not changed, any
increase in the performance of tests performed 
as part of the technician strategy would make 
the glaucoma optometrist strategy less 
cost-effective compared with the technician
strategy. 
Results of further targeted sensitivity
analysis
As indicated above, the results of the base-case
analysis and its associated sensitivity analysis have
indicated that the following are likely to increase
the cost-effectiveness of screening:
● starting to screen at a younger age rather than
an older age (e.g. screening at 40 is more likely
Economic analysis
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TABLE 54 Likelihood of a strategy being cost-effective for different age cohorts and screening intervals: 10% prevalence of OAG
Cohort Screening interval Strategy Probabilistic cost-effectiveness for different 
threshold values for society’s willingness to pay 
for a QALY (%)
£10,000 £20,000 £30,000 £50,000
40 years old 3 years No screening 79.6 48.6 35.0 24.2
(base case) Technician 19.9 49.6 60.0 62.3
GO 0.5 1.8 5.0 13.5
5 years No screening 72.9 42.7 30.1 22.0
Technician 26.1 51.4 57.1 53.3
GO 1.0 5.9 12.8 24.7
10 years No screening 61.2 36.3 27.7 19.6
Technician 36.1 49.8 48.2 39.5
GO 2.7 13.9 24.1 40.9
60 years old 3 years No screening 87.6 63.0 48.4 34.3
(base case) Technician 12.0 35.3 46.7 53.0
GO 0.4 1.7 4.9 12.7
5 years No screening 83.0 56.3 43.3 31.7
Technician 16.1 39.4 46.7 47.9
GO 0.9 4.3 10.0 20.4
10 years No screening 77.5 50.9 38.7 29.1
Technician 21.1 39.3 43.1 39.1
GO 1.4 9.8 18.2 31.8
75 years old 3 years No screening 95.5 79.3 67.5 50.7
(base case) Technician 4.3 19.6 30.0 40.0
GO 0.2 1.1 2.5 9.3
5 years No screening 93.3 76.0 64.2 48.5
Technician 6.4 22.3 30.1 37.6
GO 0.3 1.7 5.7 13.9
10 years No screening 90.7 72.0 60.7 45.3
Technician 8.7 24.0 29.8 35.6
GO 0.6 4.0 9.5 19.1
See Appendix 23, Figures 80–85 for CEACs.Health Technology Assessment 2007; Vol. 11: No. 41
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TABLE 55 ICERs for different annual community optometrist test uptake rates: 40-year-old cohort
Low Medium High
Prevalence Strategy Cost (£) QALYs ICER Cost (£) QALYs ICER Cost (£) QALYs ICER
1% No screening 85.30 19.227 148.80 19.229 268.80 19.231
Technician 419.90 19.233 59,191 453.90 19.233 75,830 527.10 19.233 121,443
GO 518.60 19.233 292,714 551.90 19.233 331,257 623.90 19.234 424,490
2% No screening 144.24 19.160 217.54 19.163 348.36 19.167
Technician 507.76 19.169 38,559 542.18 19.170 48,474 616.03 19.170 75,528
GO 606.92 19.170 181,346 640.49 19.170 204,316 712.82 19.171 259,384
4% No screening 262.11 19.026 354.96 19.031 507.51 19.038
Technician 683.39 19.043 24,817 718.72 19.043 30,200 793.88 19.044 44,903
GO 783.51 19.044 103,626 817.62 19.044 116,122 890.68 19.045 145,898
6% No screening 379.97 18.892 492.37 18.899 666.65 18.909
Technician 859.02 18.916 19,534 895.25 18.917 23,163 971.74 18.918 33,121
GO 960.09 18.917 72,953 994.75 18.918 81,404 1,068.54 18.919 101,495
8% No screening 497.83 18.757 629.78 18.768 825.80 18.780
Technician 1,034.65 18.789 16,738 1,071.79 18.790 19,436 1,149.60 18.792 26,882
GO 1,136.68 18.791 56,533 1,171.88 18.792 62,840 1,246.40 18.793 77,815
10% No screening 615.70 18.623 767.20 18.636 984.94 18.651
Technician 1,210.28 18.663 15,007 1,248.32 18.664 17,129 1,327.46 18.666 23,020
GO 1,313.27 18.665 46,305 1,349.01 18.666 51,283 1,424.26 18.667 63,096
Low = 2%, medium = 13%, high = 37%.
TABLE 56 ICERs for different annual community optometrist test uptake rates: 60-year-old cohort
Low Medium High
Prevalence Strategy Cost (£) QALYs ICER Cost (£) QALYs ICER Cost (£) QALYs ICER
1% No screening 45.60 12.475 90.99 12.476 176.50 12.477
Technician 285.90 12.478 75,671 308.85 12.478 90,207 357.90 12.479 129,517
GO 353.90 12.479 288,783 376.15 12.479 321,553 424.00 12.479 400,583
2% No screening 74.61 12.435 127.08 12.436 221.48 12.438
Technician 338.74 12.440 52,500 362.15 12.440 61,530 411.99 12.440 85,921
GO 407.36 12.440 190,446 429.99 12.440 211,082 478.44 12.440 260,427
4% No screening 132.70 12.354 199.24 12.356 311.43 12.359
Technician 444.34 12.362 35,656 468.76 12.363 40,642 520.23 12.363 54,217
GO 514.36 12.363 114,688 537.68 12.363 126,330 587.23 12.364 153,998
6% No screening 190.80 12.273 271.40 12.276 401.38 12.281
Technician 549.93 12.285 28,849 575.36 12.286 32,191 628.47 12.286 41,401
GO 621.36 12.286 82,979 645.37 12.286 90,946 696.02 12.287 109,843
8% No screening 248.90 12.192 343.57 12.196 491.32 12.202
Technician 655.53 12.208 25,166 681.97 12.208 27,617 736.70 12.209 34,468
GO 728.36 12.209 65,553 753.06 12.209 71,524 804.81 12.210 85,676
10% No screening 306.99 12.111 415.73 12.116 581.27 12.124
Technician 761.13 12.131 22,859 788.57 12.131 24,750 844.94 12.132 30,123
GO 835.37 12.132 54,535 860.76 12.132 59,251 913.60 12.133 70,430
Low = 2%, medium = 13%, high = 37%.Economic analysis
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TABLE 57 ICERs for different annual community optometrist test uptake rates: 75-year-old cohort
Low Medium High
Prevalence Strategy Cost (£) QALYs ICER Cost (£) QALYs ICER Cost (£) QALYs ICER
1% No screening 18.80 6.904 44.20 6.904 93.90 6.905
Technician 163.90 6.905 131,756 177.00 6.905 147,916 205.00 6.905 189,980
GO 205.30 6.905 391,271 218.00 6.905 424,562 245.20 6.905 503,522
2% No screening 30.66 6.883 59.65 6.883 114.60 6.884
Technician 190.75 6.885 94,169 204.30 6.885 104,328 233.01 6.885 130,740
GO 232.76 6.885 267,262 245.78 6.885 288,725 273.53 6.885 339,283
4% No screening 54.46 6.841 90.56 6.842 156.08 6.843
Technician 244.40 6.844 65,574 258.79 6.844 71,193 288.99 6.845 85,921
GO 287.76 6.844 166,618 301.42 6.845 178,888 330.29 6.845 207,657
6% No screening 78.25 6.799 121.47 6.800 197.57 6.802
Technician 298.04 6.803 53,697 313.28 6.804 57,436 344.97 6.804 67,367
GO 342.77 6.804 123,087 357.06 6.804 131,494 387.05 6.804 151,182
8% No screening 102.05 6.758 152.38 6.759 239.06 6.761
Technician 351.69 6.763 47,193 367.77 6.763 49,905 400.95 6.763 57,223
GO 397.77 6.763 98,799 412.71 6.763 105,080 443.81 6.764 119,790
10% No screening 125.85 6.716 183.29 6.717 280.54 6.719
Technician 405.33 6.722 43,089 422.27 6.722 45,153 456.93 6.723 50,827
GO 452.78 6.723 83,303 468.35 6.723 88,239 500.57 6.723 99,808
Low = 2%, medium = 13%, high = 37%.
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FIGURE 44 Influence of changes in sensitivity and specificity of the second test in the technician strategy in a 60-year-old cohort by
prevalence level
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FIGURE 45 Influence of changes in sensitivity and specificity of the second test in the technician strategy in a 75-year-old cohort by
prevalence levelto be cost-effective than screening at 60 years of
age)
● increasing the screening interval from 3 to
10 years
● screening cohorts with a higher expected
prevalence of OAG.
In this section further sensitivity analyses were
undertaken for a specific cohort which reflected
the above factors. In these sensitivity analyses it
has been assumed that screening will be
performed in a 40-year-old cohort with a 10-year
screening interval and a 5% OAG prevalence rate,
except where specifically stated otherwise. 
The results of the comparison between the
alternative screening strategies are shown in
Table 58. The deterministic results indicate that
screening with the technician strategy might be
considered worthwhile. The probabilistic
sensitivity analysis shows that the considerable
uncertainty around the parameter estimates which
are used within the model is important. For
example, even though the point estimate of
incremental cost-effectiveness for the comparison
of the technician with the no-screening strategy is
£20,571, there is only a 42% likelihood that the
cost per QALY would be less than £20,000
(Figure 75 in Appendix 23 shows the cost-
effectiveness acceptability curves for this analysis).
Changes to the uptake rates of the community
optometrist
In this sensitivity analysis the probability of
receiving an eye test in the community varied
(Table 59). As the probability of receiving an eye
test in the community increased, both the costs
and outcomes associated with the no-screening
Economic analysis
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TABLE 58 Deterministic and probabilistic analysis results: base case 40-year-old cohort, 10-year screening interval, 5% OAG
prevalence rate
Strategy Cost (£) QALYs ICER £10,000 £20,000 £30,000 £50,000
No screening 563.34 18.971 82.5% 54.3% 40.2% 29.6%
Technician 703.24 18.978 20,571 16.7% 42.3% 51.4% 51.1%
GO 744.38 18.979 42,188 0.8% 3.4% 8.4% 19.3%
TABLE 59 Changes to the chance of receiving an eye test in the community for a 40-year-old cohort and a 10-year screening interval
for various prevalence levels
Prevalence Strategy 1.5 times the rate in base case 2 times the rate in base case
Cost (£) QALYs Incremental cost  Cost (£) QALYs Incremental cost 
per QALY per QALY
2.0% No screening 417.15 19.167 495.70 19.168
Technician 513.60 19.170 46,307 581.28 19.170 53,889
GO 550.88 19.170 111,051 617.93 19.170 130,021
2.6% No screening 465.33 19.129 545.29 19.130
Technician 566.13 19.132 37,781 634.19 19.132 43,550
GO 603.85 19.132 88,125 671.17 19.132 102,582
3.2% No screening 513.50 19.090 594.88 19.092
Technician 618.65 19.094 32,322 687.10 19.094 36,968
GO 656.82 19.094 73,337 724.42 19.095 84,972
3.8% No screening 561.67 19.052 644.46 19.053
Technician 671.18 19.055 28,528 740.01 19.056 32,410
GO 709.79 19.056 63,006 777.67 19.057 72,712
4.4% No screening 609.84 19.013 694.05 19.015
Technician 723.71 19.017 25,738 792.92 19.018 29,068
GO 762.76 19.018 55,382 830.91 19.019 63,685
5.0% No screening 658.01 18.974 743.64 18.977
Technician 776.23 18.979 23,600 845.83 18.980 26,511
GO 815.72 18.980 49,523 884.16 18.981 56,761strategy increased. The gain in QALYs for the no-
screening strategy more than compensates for the
increase in cost of this strategy. As a consequence,
the incremental cost per QALY of the technician
strategy compared with no screening increased
(for comparison, for a 40-year-old cohort screened
at 10-year intervals the incremental cost per QALY
was £38,456 at a 2% prevalence level and £15,808
at an 8% prevalence level; Figure 40). The
incremental cost per QALY for the comparison of
the glaucoma optometrist strategy compared with
the technician strategy also increased (the
incremental cost per QALY was £91,906 at a 2%
prevalence level and £28,749 at an 8% prevalence
level; Figure 40).
Changes to incidence and progression of
glaucoma
Table 60 describes the results of the sensitivity
analyses for changes in the incidence and
progression of OAG. The likelihood of either of
the two screening strategies being considered cost-
effective did not greatly alter when either lower or
higher rates of incidence of OAG were used in the
analysis. 
Sensitivity analysis was also conducted around
changes to the rate of progression. As the rate of
progression increases (i.e. the ’high’ analyses), the
likelihood that either the technician or glaucoma
optometrist strategy would be considered cost-
Health Technology Assessment 2007; Vol. 11: No. 41
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TABLE 60 Likelihood of a strategy being cost-effective for different incidence and progression parameters: analysis for a 40-year-old
cohort with a 10-year screening interval and 5% prevalence of OAG
Cohort Probability  Strategy Probabilistic cost-effectiveness for different threshold
distribution values for society’s willingness to pay for a QALY (%)
parameters
£10,000 £20,000 £30,000 £50,000
Base case No screening 82.5 54.3 40.2 29.6
Technician 16.7 42.3 51.4 51.1
GO 0.8 3.4 8.4 19.3
Incidence High No screening 82.0 53.9 40.0 29.6
Technician 17.0 42.4 50.7 50.0
GO 1.0 3.7 9.3 20.4
Low No screening 83.6 55.7 42.6 30.6
Technician 15.5 40.6 48.2 49.3
GO 0.9 3.7 9.2 20.1
Progression mild  High No screening 78.8 48.0 35.2 23.8
Technician 20.5 48.3 55.3 54.8
GO 0.7 3.7 9.5 21.4
Low No screening 82.2 54.6 39.2 27.8
Technician 16.9 42.4 51.3 53.2
GO 0.9 3.0 9.5 19.0
Progression moderate  High No screening 77.4 41.2 28.2 18.1
Technician 21.9 55.2 62.2 59.2
GO 0.7 3.6 9.6 22.7
Low No screening 89.6 68.2 52.3 36.2
Technician 10.1 30.2 42.0 50.8
GO 0.3 1.6 5.7 13.0
Progression severe  High No screening 75.8 46.2 32.8 22.3
Technician 23.2 49.8 57.4 55.4
GO 1.0 4.0 9.8 22.3
Low No screening 86.9 66.2 53.1 41.6
Technician 12.5 31.4 39.9 42.6
GO 0.6 2.4 7.0 15.8
Alternative analysis:  No screening 79.9 49.5 35.8 25.3
time to progression  Technician 19.3 46.8 54.9 53.7
mean values GO 0.8 3.7 9.3 21.0effective increases. This is as would be expected, as
screening is likely to detect more cases and hence
delay progression. In this situation the gain in
QALYs resulting from earlier detection and
treatment more than offsets any increase in cost.
Changing the rate of progression from moderate
to severe disease appears to have a greater impact
than changing the risk of progression from mild to
moderate or severe state to visually impaired. This
is caused by the interplay of the effect on QALYs,
cost and the number of people in the state. Using
alternative mean progression values, based on
applying the relative risk of progression following
treatment to estimates of the time to progression,
rather than to the annual risk of progression as
adopted for the rest of the analysis, results in a
slightly better case for screening. The CEACs are
presented in Appendix 23 (Figures 86–94).
Sensitivity and specificity of the second test
performed by the technician
In this sensitivity analysis the sensitivity and
specificity of the second test performed by the
technician and the screening interval were varied
(Figure 46). As the screening interval increases, the
‘technician’ strategy is more likely to be considered
cost-effective. The effects of changes in sensitivity
and specificity are relatively modest in comparison
to the changes in the screening interval.
Changes in the sources of health state utilities
In this sensitivity analysis the results of the
economic evaluation were revised using the health
state valuations based on the subjective assessment
of disease severity rather than the objective
assessment of disease severity used in the base-
case analysis. Using these valuations both the
technician and the glaucoma optometrist
Economic analysis
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FIGURE 46 Influence of changes in sensitivity and specificity of the second test in the technician strategy in a 40-year-old cohort by
screening interval (Int)
TABLE 61 Sensitivity analyses around utilities: 40-year-old cohort, 10-year screening interval, 5% OAG prevalence rate
Strategy Cost (£) QALYs ICER £10,000 £20,000 £30,000 £50,000
No screening 563.34 19.007 74.1% 38.2% 23.8% 14.5%
Technician 703.24 19.015 17,762 24.7% 55.0% 63.9% 58.2%
GO 744.38 19.016 36,403 1.2% 6.8% 12.3% 27.3%strategies are more likely to be considered cost-
effective. For example, the likelihood for the
technician strategy of being considered optimal
rose from less than 50% (Table 58) to about 55%
and over 60% for society’s willingness to pay for
an extra QALY of £20,000 and £30,000,
respectively (Table 61). The CEACs that illustrate
this more fully are presented in Appendix 23
(Figure 75–95).
Sensitivity analysis on costs
Table 62 shows the results for sensitivity analysis
performed on the cost estimates used within the
model. Varying the cost of diagnosis by the
ophthalmologist did not have a great impact on
the cost-effectiveness of the technician strategy.
There was rather more effect on the cost-
effectiveness of the glaucoma optometrist strategy,
but this was not of sufficient magnitude to change
conclusions about the cost-effectiveness of this
strategy. The cost-effectiveness of the technician
strategy compared with no screening was more
sensitive to changes in the costs of treatment or
the costs of inviting people to be screened or their
subsequent tests. Changes to these costs had less
effect on the cost-effectiveness of the glaucoma
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TABLE 62 Sensitivity analyses around costs: 40-year-old cohort, 10-year screening interval, 5% OAG prevalence rate
Low High
Strategy Cost (£) QALY ICER Cost (£) QALY ICER
Ophthalmologist diagnosis  No screening 555.89 18.971 598.98 18.971
Technician 693.27 18.978 20,200 750.96 18.978 23,172
GO 728.73 18.979 36,369 819.25 18.979 117,457
Treatment costs No screening 478.85 18.971 732.31 18.971
Technician 581.82 18.978 15,140 946.08 18.978 31,432
GO 617.66 18.979 36,761 997.80 18.979 53,041
Tests and screening invitation  No screening 501.88 18.971 686.33 18.971
Technician 601.93 18.978 14,712 905.98 18.978 32,297
GO 633.17 18.979 32,044 966.86 18.979 62,438
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FIGURE 47 Value of ICERs for alternative visually impaired annual costs: 40-year-old cohort, 10-year screening interval, 1% OAG
prevalence rateoptometrist strategy compared with the technician
strategy for the usual values of society’s willingness
to pay for an extra QALY. 
Changes to the cost of visual impairment
Figure 47 shows the results of this threshold
analysis for the cost of visual impairment when the
prevalence of OAG was 1%. In this case, the
technician strategy dominates the no-screening
strategy when the annual cost for visual
impairment is around £16,000. The cost of visual
impairment would need to be £8800 for the
incremental cost per QALY for the technician
compared with the no-screening strategy to be
£30,000. The glaucoma optometrist strategy
would dominate the technician strategy at high
values of annual cost for visual impairment (e.g.
over £59,000; not shown) and it needs the annual
cost of visual impairment to be greater than
£40,000 for the incremental cost per QALY to be
£30,000 or less.
When the prevalence of OAG is changed to 5%
and the annual costs of visual impairment are
approximately £5700 and £15,000, the technician
strategy dominates the no-screening strategy, and
glaucoma optometrist dominates the technician
strategy, respectively (Figure 48). 
Discussion
At the beginning of this chapter, the paucity and
limitations of existing evidence on the cost-
effectiveness of screening for OAG were
highlighted. Only one previous study was
identified that attempted to compare an active
screening strategy with current practice.281 This
study concluded that screening for OAG was not
cost-effective. In the economic evaluation reported
in this section some evidence has been provided
that screening might be cost-effective for selected
at-risk subgroups. It is, however, supportive of the
earlier study in that screening at prevalence levels
likely to be seen in the general population is
unlikely to be cost-effective. The results presented
in the analysis do not address precisely for which
specific cohorts of individuals screening might be
considered as cost-effective; this will be considered
later. 
The evidence on cost-effectiveness should be
treated cautiously. In part, this is due to the
inherent problems in combining data, even when
they have been systematically assembled, from
multiple sources. Caution must also be exercised
as it is currently unknown whether any of the
parameter estimates (e.g. uptake of screening,
diagnostic performance, disease progression,
Economic analysis
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FIGURE 48 Value of ICERs for alternative visually impaired annual costs: 40-year-old cohort, 10-year screening interval, 5% OAG
prevalence ratetreatment effectiveness, costs or utilities) would be
applicable to any of the groups for which the
model provides some evidence that screening
might possibly be cost-effective. Nevertheless,
despite the limitations of the analysis, the results
indicate some patient groups where the
organisation of a screening service might be given
further consideration. In situations where it may
be feasible to organise a service for the target
patient group, further primary research on the
effectiveness and cost-effectiveness of screening for
OAG would be required. 
As described in the section ‘Results of further
targeted sensitivity analysis’ (p. 124), a
probabilistic sensitivity analysis has been
conducted to address the statistical imprecision
surrounding the point estimates used within the
model. In this analysis each parameter estimate
has an associated statistical distribution which
provides information on the likelihood of the
parameter estimate taking any particular value.
The type of distribution for each parameter is
itself a cause of some uncertainty for any economic
evaluation. In this study the type of distribution
varied by parameter, but was consistent with prior
experience about which type of distribution would
be appropriate for the type and nature of the data
available.91,300 Despite these efforts, the precise
definition of parameter distributions for some
variables was limited, as in some cases it was
difficult to fit a distribution to the few data
available. 
Further strengths and limitations of many of the
parameter estimates have been expanded upon in
the preceding chapters. These issues do not need
to be reiterated, except to emphasise that any
limitations identified in earlier chapters are equally
applicable when these data are used for the
economic model. An assumption of the model is
that no one in the cohorts is receiving treatment
prior to screening or opportunistic case detection.
Relaxing this assumption would result in screening
being less likely to be considered cost-effective.
This is because the number of cases of OAG who
could potentially benefit from screening would be
reduced. It is also possible that screening might
identify people for whom it is recommended that
treatment should be stopped, but who subsequently
go on to develop glaucoma; the net effect is
unclear. Two sets of variables that were not the
focus of previous chapters are costs and utilities.
Only very limited data on the costs of diagnosis
and treatment were available, and although efforts
were made to identify the best data applicable to
the UK these are sparse. The model estimates
would be more robust if further data were to
become available and consideration should be
given as to whether further primary research is
needed. The model also proved to be very sensitive
to the costs assumed for visual impairment. In the
base-case analysis the perspective taken for the
assessment of costs was the NHS. In a threshold
analysis the effect of considering those costs that
fall on other groups was also considered. The
inclusion of these costs improves the cost-
effectiveness of the screening strategies and the
thresholds identified are not dissimilar to the
annual costs of visual impairment estimated by
Meads and Hyde,299 whose data suggest an annual
cost of visual impairment of approximately £7900
for the first year of visual impairment and £7700
for subsequent years (see Appendix 24 for details). 
Data with respect to health state utilities were also
very sparse. Few data reporting utilities were
available from the literature and none was
available for a UK population. This problem was
anticipated at the outset of the study and data
were collected using the EQ-5D questionnaire
from a sample of people with glaucoma as part of
another ongoing study (Kilonzo M, University of
Aberdeen: personal communication, 2006). These
data, however, were not specific to people with
OAG and the sample included some people with
other forms of glaucoma. Nevertheless, these data
were used as it was felt that the impact on quality
of life of the different types of glaucoma would be
similar. The data used to provide utilities data
were collected from respondents with a mean age
between 69 and 70 years. It is unclear how these
utilities might vary for lower age groups. As a
consequence, it is not clear whether the results of
the model would be influenced by utility data from
a younger age group. It should also be noted that
for the purposes of decision-making it has been
argued that utilities reflecting the preferences of
the general population rather than a specific
subgroup (e.g. by age or presence of OAG) should
be used.
Of greater concern is that these utilities are based
on people receiving treatment. Utility data are not
available for untreated glaucoma cases. In the
analysis it has been assumed that the utility
associated with treated and untreated glaucoma is
the same. This is justifiable in the sense that
treatment does not remove the symptoms of
glaucoma. However, this approach fails to reflect
any loss of utility associated with the side-effects of
treatment. Ideally, further data should be collected
in people whose glaucoma has not progressed,
both before and after treatment has started. This
Health Technology Assessment 2007; Vol. 11: No. 41
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effects of treatment to be determined.
The quality and usefulness of the economic model
is dependent not only on the quality of the data,
but also on the way in which the data are used.
The data requirements and the use of the data
were determined by the structure adopted for the
model. The development of the economic model
was, as described in Chapter 4, based on
discussions with a number of key stakeholders. It
then underwent a prolonged period of refinement
during which the care pathways were critically
examined and refined. The model structure
applies to a UK context, and may not be relevant
to other country settings, although other strategies
could be developed and readily added to the
model. As described in Chapter 4, the model
structure was developed so that the assumptions
made in the base-case analysis could be explored
in future work. For example, in the base-case
analysis it was assumed that the ophthalmologist
would make a perfect diagnosis. The model
structure has allowed for the possibility that this
will not be the case and that the ophthalmologist
might possibly initiate treatment when it is not
required (a false positive) and fail to diagnose
some cases of OAG (a false negative). Nonetheless,
since the test characteristics of the diagnostic tests
were all based on the assumption that
ophthalmologist assessment is the gold standard,
the sensitivity and specificity of those tests should
be adjusted for the fact that they are based on an
imperfect gold standard. It should be mentioned
that it is not possible to do this unless there is
another gold standard to get all tests’ sensitivity
and specificity (and ophthalmologist assessment)
adjusted for. The model is a simplification of the
care pathways that may follow. For example, the
diagnostic performance of the tests performed by
the glaucoma optometrist has been represented by
a single value for sensitivity and specificity of a
test. In reality, a battery of tests would be
performed, each with its own values for sensitivity
and specificity. This simplification was made as
there is a plethora of tests that may be used and
the values for sensitivity and specificity used in the
model appeared to be consistent with the
estimates from the literature. A second
simplification made in the model was the relatively
small number of stages used to reflect the
progression of this chronic condition. This
assumption may fail to represent the subtleties of
disease progression. Owing to limitations of the
primary data, estimates of the risk of progression
between health states are based on data from one
eye, and do not necessarily represent the
definition of the heath states in the model, which
is based on binocular visual field loss. This is a
limitation as the second eye may not have such
advanced disease as the study eye so may be
overestimated, but equally studies may have used
the better eye for analysis and may underestimate
the risk of progressive binocular visual field loss.
Furthermore, there were insufficient data to
determine whether many of the parameter values
varied between the stages of disease, for example
whether diagnostic performance of the tests or
rate of progression would vary by severity of
disease. The model was, however, structured in
such a way that should such data become available
in the future they could be readily incorporated. 
A further simplification in the model structure is
that rather than modelling the full variety of
treatments available for OAG it has been assumed
that the effect of treatment can be represented by
a single relative effect size for treatment compared
with no treatment.
Finally, when interpreting the results of the
economic evaluation it should be borne in mind
that the estimates of cost-effectiveness relate to a
male cohort. Gender-specific data were not
available for any of the parameter estimates except
for annual all-cause mortality. Had the analysis
been repeated with estimates of female all-cause
mortality it might be expected that, so long as the
other parameters are unchanged, screening would
be more likely to be considered cost-effective. This
is because, on average, females have a longer life
expectancy and are therefore more likely to gain
the benefits from earlier detection of OAG.
Conclusion
Screening for OAG is associated with an ICER that
society might be willing to pay for particular
cohorts of patients. A particular cohort of interest
was 40 year olds who might be expected to have a
prevalence of OAG of between 6 and 10%
(depending on society’s threshold willingness to
pay for a QALY) when screening is conducted at a
3-year interval. As the screening interval increases
the cost-effectiveness of the screening strategies
improves. 
The results should be treated with some caution
and further data are required to confirm the
findings. Such data relate to both improving the
estimates available for some of the parameters in
the model, and also from a well-designed controlled
study comparing viable screening strategies in the
cohorts of patients for whom this research has
indicated that screening may be cost-effective.
Economic analysis
134Potentially relevant target groups
for screening
The results of the economic evaluation reported in
Chapter 8 suggest that screening is most likely to
be cost-effective for people who have a family
history of OAG and people of black ethnicity, with
a 10-year screening interval. Assuming that
screening might commence at 40, 50 or 60 years
of age, Table 63 shows the percentage of people
from the UK population who would be in the
target age, the prevalence of OAG and the
percentage of these who might be described by the
target risk factors. Although people with myopia
or diabetes who fall within a similar age range are
less likely to be considered cost-effective because
of their lower prevalence of OAG, extending the
invitation to screening to them might also be
considered. Table 63 also shows the estimated
proportions of the population with each of these
risk factors. 
Estimating the numbers eligible
for screening
The numbers of people eligible for screening and
the proportions of cases of OAG that might be
expected to be included or excluded from the
screened populations can be estimated from the
data reported in Table 63 (details of how these
estimates were derived are provided in
Appendix 25). It could be decided that people of
black race and/or with a family history of OAG are
the only groups where the prevalence of OAG is
sufficiently high to warrant screening. However,
when considering just the first cycle of screening,
these groups represent only an estimated 6% of
the age cohort for screening starting at 40, 50 or
60 years of age. Therefore, the majority of the age
cohort would not be eligible for screening. As a
consequence, this strategy would have the chance
to detect only 21% of all the expected cases in
these age cohorts (although this could be as high
as 29% when the extremes of confidence intervals
for prevalence of risk factors and relative risks of
OAG reported in Table 63 are considered). If the
eligibility criteria were extended to include other
at-risk groups (e.g. people with myopia or
diabetes) then, as myopia is common, screening
would cover at most approximately 40% of the 
40-year-old cohort (and 44% and 28% of the 50-
or 60-year-old cohorts) and would have the chance
of detecting 58% (although it might be as high as
85%) of all the expected cases in the 40-year-old
cohort (similar percentages are 66% and 36% for
screening at 50 and 60 years, respectively).
Although the precise way in which a screening
programme might be implemented is unclear,
over time it might be expected that all those
people with the target risk factors would be
eligible for screening. In Table 64 estimates are
provided on the basis that screening is limited to
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Chapter 9
Factors relevant to the NHS, other sectors of the 
economy and patients
TABLE 63 Characteristics of the groups for whom screening for OAG may be cost-effective
Age % of total  Prevalence of  % of target population with risk factor
(years) populationa OAG (95% CI)
Myopia301 Diabetes302 Black303 Family historyb
40 3.24 0.3 (0.1 to 0.5) 31 3 2 4
50 2.64 0.9 (0.6 to 1.3) 35 3 2 4
60 2.05 1.4 (0.9 to 1.8) 19 3 2 4
RR (95% CI) 1.88 (1.5 to 2.3) 2.08 (1.4 to 2.99) 3.8 (2.5 to 5.64) 3.14 (2.32 to 4.25)
a Based on a UK population aged 40 and above of 27,116,127 and the number of people of this age as reported in Table 8
(p. 31).
b Assuming that each case of OAG has two blood relations in the target age group.those aged 40 years and above of black race
and/or with a family history of OAG. Two sets of
estimates are provided in this table. The mean
estimates were derived using the point estimates
of prevalence and relative risk of OAG along with
the information of the percentage of people in the
population with the target risk factors. The high
estimates combined the upper values from the
95% confidence intervals for relative risks and
prevalence of OAG with information on the
percentage of people in the population with the
target risk factors.
If the criteria for screening were extended to
include those with myopia or diabetes then
approximately 37% of the 100,000 total cohort
would be eligible for screening. The screening
strategy would also have the chance to detect
approximately 80% of all the expected cases in the
total cohort. 
When considering the data presented in this
section it is essential to remember that all the
estimates presented are associated with
considerable uncertainty. Although they have been
calculated using the best available data their
calculation has required some very strong
assumptions to be made. Furthermore, it should
also be borne in mind that although a
considerable number of cases of OAG will be
missed because they occur in people who are not
part of the eligible cohort it is still possible that at
least some of these cases will be detected within
the community by case finding. 
Consideration of screening
performance
Performance of the strategies in terms
of diagnosis
The relative performance of the screening
programmes considered has been estimated from
the economic model reported in the section
‘Economic evaluation of screening for OAG’ 
(p. 106). These estimates have been provided for
the comparison of a technician strategy with
current practice (no-screening strategy) for
100,000 people with a prevalence of OAG of 
5% at the start of screening (Table 65).
In the first year in which a screening programme
would be initiated, approximately 0.6% and 3.5%
of the whole cohort would be referred to the
ophthalmologist with the no-screening strategy
and technician strategy, respectively. This would
enable approximately 49% of the total cases of
OAG within the 100,000 cohort of 40 year olds to
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TABLE 64 Estimate of the number of people eligible for screening as well as the estimated number of cases in the eligible and
ineligible population
Overall population figures Mean High
Total cohort 100,000 100,000
Eligible cohort (with a risk factor) 6,200 6,200
Number eligible with glaucoma 437 437
Number with glaucoma in total cohort 2,100 2,500
Cases not called for screening, but may be picked up by case finding 1,663 1,772
TABLE 65 Performance of the tests in a 100,000 cohort at 5% prevalence of OAGa
Technician No screening
(1) Number of people referred to the ophthalmologist 3,535 611
(2) Number of cases identified by the ophthalmologist as positive 2,456 376
(3) Number of cases identified by the ophthalmologist as negative  1,079 235
(i.e. false positives of screening)
(4) Of those judged as negative by the ophthalmologist in (3) above this number  464 101
will be kept under observation by the ophthalmologist
(5) Number of true negativesb 93,698 94,542
(6) Number of false negatives after the first yearb 2,283 4,363
a Numbers presented do not include the 485 people with each strategy who would be expected to die of natural causes
within the first year.
b Includes people not presenting for screening or to the community optometrist.be detected by the technician strategy compared
with approximately 8% with the no-screening
strategy (Table 65). It has been assumed within the
model that treatment will be initiated in all these
individuals identified by the ophthalmologist as
having OAG and that treatment would slow the
progression of the disease (treated cases of OAG
have a relative risk of progression of 0.65
compared with untreated OAG). 
In screening strategies not all those referred to the
ophthalmologist would have OAG. Of those
referred to the ophthalmologist approximately
38% and 30% of people would have been
incorrectly identified as positive for OAG (false
positives) with the no-screening strategy and
technician strategy, respectively (Table 65). This is
equivalent to approximately 800 more false
positives following technician screening. Within the
economic evaluation the extra cost of investigating
the false positives by the ophthalmologist has been
considered. What has not been considered is the
anxiety that this may cause to someone who is
incorrectly identified as having OAG. The
magnitude of this effect is uncertain, but in total it
will be greater for the technician strategy than for
the no-screening strategy.
Of the people referred to the ophthalmologist as
positive for OAG but for whom the
ophthalmologist does not make a diagnosis of
OAG (i.e. false positives), a proportion will still be
considered as at risk and kept under further
observation. In the model it has been assumed
that these people will be followed up annually for
a maximum of 5 years or until OAG is diagnosed
(at which point treatment is commenced). Given
the assumptions used within the model, in
particular the assumption of perfect diagnosis,
none of the suspect cases actually has OAG when
they start observation. They would, however, have
a chance of developing OAG during the period of
observation. Should this happen, the model
assumptions mean that any new cases of OAG that
develop will be identified (and treated). In the first
year of screening approximately 0.4% of people in
the technician strategy arm and 0.1% of people in
the no-screening strategy arm would go into an
observation state (Table 65). 
Even with the unrealistic assumption that the
diagnostic performance of the ophthalmologist is
perfect, these estimates illustrate the number of
people who would be held under observation by
the ophthalmologist with the technician strategy
(further details of the numbers of people held in
an observation state are reported in Appendix 26,
and further implications to both the NHS and
those people considered as suspect are considered
below). 
The data presented above represent estimates for
the first year of screening. In the model used to
derive these estimates it has been assumed that
screening will be repeated every 10 years and that
people in both the technician and the no-screening
strategy can be identified as having OAG by case
finding. Given that a high proportion of the cases
of OAG is detected in the first year of screening
with the technician strategy, the performance of
the technician strategy would compare less
favourably with the no-screening strategy in
subsequent years because there would be fewer
cases of OAG to detect. Further details of the
performance of the alternative strategies over the
duration of follow-up considered by the economic
model reported in the section ‘Economic
evaluation of screening for OAG’ (p. 106) are
shown in Appendix 27. This appendix reports the
number of people referred to the ophthalmologist,
the number of these who are either true or false
positives and the number of true and false
negatives. From these data it is possible to
calculate the positive predictive value, the negative
predictive value and the sensitivity and specificity
of the strategies for each year of follow-up
(reported in Appendix 27). Consideration of these
data may also help to inform a decision about the
maximum age at which screening once initiated
should continue (something that the evaluation
has not otherwise explicitly considered, but is
worthy of further consideration).
Information on the diagnostic performance
predicted by the model can also be used to
provide estimates of the cost-effectiveness of the
different strategies in terms of incremental cost
per case detected. Table 66 reports the average
cost of diagnosis and probability of correctly
detecting OAG over the lifetime of a cohort of 
40-year-old individuals for whom there is a 5%
prevalence of OAG and for whom screening is
repeated every 10 years. Further details of the
number of cases detected for both the technician
and the no-screening strategy are supplied in
Appendix 28.
In the calculations that form the basis of the data
presented in Table 66 the cost of ophthalmologists
had been omitted. It should be noted that over
the remaining lifetime of a 40 year old there is
approximately a 17.6% chance of seeing an
ophthalmologist with the no-screening strategy
and a 21.5% chance with the technician strategy.
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include cases of OAG that occur among people
who are held by the ophthalmologist in
observation. Given the assumptions within the
model of perfect diagnosis of OAG by
ophthalmologists, there is only a 6% and an 8%
chance of a 40-year-old person entering an
observation state over their lifetime for the 
no-screening and technician strategy, respectively.
The likelihood of OAG being detected in this state
is equal to the likelihood of a new case of OAG
developing. 
Performance of the strategies in terms
of visual impairment
One indication of the importance of detecting
cases of OAG is to consider both the number of
people who enter the state of severe OAG (i.e.
losing vision to below the standard required for
driving) or visual impairment and the mean time
spent in these states. Figure 49 describes the
cumulative number of cases of visual impairment
that are predicted by the model to occur over time
for both the technician and the no-screening
strategy. These estimates are based on a 40-year-
old cohort which has a 5% prevalence of disease
and is invited for screening every 10 years. It
should be noted that it has been assumed that out
of a total cohort of 100,000 a small number of
people will already be visually impaired. Hence, in
the figure the two curves for the number of people
with visual impairment cross the x-axis at
approximately 250 cases. 
In addition to the estimates of the cumulative
number of people with visual impairment it may
be important to consider how long people who
have visual impairment spend in this state
(Table 67). In this table data have also been added
on the number of people with severe OAG, as this
is the stage where the OAG greatly affects activities
of daily living (e.g. people may have to give up
driving).
Fewer people develop severe OAG with the
technician strategy, but they spend longer in this
state compared with the no-screening strategy.
This is because cases of severe OAG progress more
Factors relevant to the NHS, other sectors of the economy and patients
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TABLE 66 Incremental cost per case detected for a 40 year old with a 5% chance of having OAG and assuming a 10-year screening
interval
Strategy Cost (£) Incremental  Average  Incremental  Incremental 
cost (£) cases detected cases detected cost per case 
detected (£)
No screening 123 0.05351
Technician 203 80 0.06255 0.0090 8823
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FIGURE 49 Cumulative number of cases of visual impairment occurring over time for the initial cohort of 100,000rapidly to becoming visually impaired, as is
indicated by the greater number of people
becoming visually impaired with the no-screening
strategy (Table 67). 
A consequence of fewer and later cases of visual
impairment is that the estimated number of total
years spent visually impaired on average is less for
the technician strategy than for the no-screening
strategy. The average time spent visually impaired
is on average also less with the technician strategy. 
Implications for service provision
Screening, at least in the way in which the
screening strategies have been defined, is likely to
result in significant increases in the workload of
ophthalmology departments. In part, this will be
because more people will be correctly identified as
having OAG. However, ophthalmologists may also
have to deal with more people who have been
referred to them as being potentially positive.
Ophthalmologist departments may also have an
increase in their workload due to the increased
number of people considered as suspect.
One aspect of service provision not included in
the economic model, which may also be affected
by a screening strategy, is the provision of services
to those people who are visually impaired.
Although the costs of these services may fall
outside the health service (notably local authorities
and the voluntary sector) they may be of sufficient
magnitude to change a decision about the cost-
effectiveness of screening. Updating the estimates
from Meades and Hyde to 2006 UK pounds gives
a cost of the first year of blindness of £7851 and a
cost for subsequent years of £7657 (the cost of
vision aids and rehabilitation were only incurred
in the first year).299 As illustrated by Figure 48
(p. 132), this is sufficient for the technician
strategy to be considered both less costly and more
effective (i.e. dominant) compared with no
screening for a cohort of 40 year olds with a 5%
prevalence of OAG. It is not, however, large
enough for the glaucoma optometrist strategy to
be associated with an incremental cost per QALY
of less than £30,000 when compared with the
technician strategy. It is clear that expanding the
perspective of costs beyond the NHS will increase
the cost associated with visual impairment and
hence improve the cost-effectiveness of screening.
However, it is unclear whether improvement in
cost-effectiveness will be of sufficient magnitude
for society to consider screening to be worthwhile
for older age groups at risk of OAG.
A further implication for the provision of services
not considered by the economic model is the
capacity of screening to detect other significant
eye disease. Such disease may be identified either
by the community or glaucoma optometrists, or by
the ophthalmologist. Given the potentially larger
numbers of people seen by these groups of
healthcare professionals within the technician
strategy, it might be expected that more cases of
other significant eye disease will be detected
compared with the no-screening strategy. Should
this occur there would be a consequent increase in
workload and healthcare costs in order to manage
these conditions (as well as, hopefully, an
improvement in health).
Implications for patients and their
families
The economic model has not taken into account a
number of intangible benefits and disbenefits
associated with the process of diagnosing OAG.
These benefits and disbenefits may include
anxiety following either a true or a false positive,
reassurance following a true negative and the
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TABLE 67 Estimated time spent with severe OAG or visually impaired
Technician No screening Difference
Total individuals visually impaired 3,981 4,154 –173
Total individuals with severe OAG  6,477 6,777 –300
Total number of years visually impaired 81,690 87,652 –5,963
Total number of years with severe OAG 52,043 50,780 1,263
For people who are visually impaired the average years spent as  20.5 21.1 –0.6
visually impaired
For people who have severe OAG the average years spent with  8.0 7.5 0.5
severe OAGanger and despair following a false negative. 
With respect to anxiety following a true positive,
some of this may be considered worthwhile if
detection prevents or delays the onset of visual
impairment. However, for some people correctly
diagnosed as having OAG the anxiety may not be
worthwhile. This may be because of the
importance they attach to the health consequences
of OAG or because the diagnosis of OAG will not
result in any health benefits in that person’s
lifetime.
In addition to the intangible benefits relating to
diagnosis, earlier diagnosis may help to alleviate
the fear of becoming blind, which may be
especially acute for people with experience of
someone close to them becoming blind, such as
those with a family history of OAG.
There may also be an intangible effect on those
excluded from the screening programme. For
example, people excluded from the target
population for an active screening strategy may
Factors relevant to the NHS, other sectors of the economy and patients
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TABLE 68 Balance sheet comparing the factors favouring screening or no screening (current practice)
For screening Comment Against screening
More cases of OAG detected resulting in: Unclear; probably,  More cases of OAG detected and treated, 
• Better health on average on balance, favours  resulting in:
• Fewer cases of severe OAG and VI screening • More suffering from the side-effects of 
• Delay in onset of severe OAG and VI on average treatment
• Fewer years of life spent with severe OAG and VI  • More people experiencing the dislike of 
on average continuing treatment
• Lower costs to other sectors of the  • Increased costs of monitoring of cases
economy of managing VI • Increased costs of treatment
• Lower costs to patients and their families  • Increased anxiety due to a diagnosis of 
of managing VI OAG
Avoiding the false positives caused by no-screening,  Favours no screening  Large number of false positives identified at 
resulting in: as there are more every screen, resulting in:
• Reduction in anxiety caused false positives with  • Increase in anxiety among those
• Reduction in the costs of diagnosis to the NHS screening incorrectly diagnosed as positive
• Reduction in the costs of diagnosis to the patient • Increase in the costs of diagnosis
• Increase in the costs of diagnosis to the
patient
Avoidance of false negatives, resulting in: On balance, favours  Avoidance of false negatives, resulting in:
• Less loss of health due to untreated OAG screening • More anxiety as previously unaware of 
• Less regret and despair caused by late diagnosis diagnosis
• More side-effects of treatment
Screening involves the selection of at-risk groups,  Unclear; probably,  Screening involves the selection of at-risk 
resulting in: on balance, favours  groups, resulting in:
• Reassurance gained from knowing they have  no screening • Anxiety among at-risk groups on being 
access to screening informed they are at risk
• Feelings of exclusion in those not eligible for
screening
• Adverse health consequences and costs for
those not eligible for screening
More cases of other significant eye disease  Unclear; probably,  More cases of other significant eye disease 
detected and treated, resulting in: on balance, favours  detected and treated, resulting in:
• Better health on average screening • More suffering from the side-effects of 
• Fewer cases of VI treatment
• Delay in onset of VI on average • More people experiencing the dislike of 
• Fewer years of life spent with VI on average continuing treatment
• Lower costs to other sectors of the economy  • Increased costs of monitoring of cases
of managing VI • Increased costs of treatment
• Lower costs to patients and their families of  • Increased anxiety due to a diagnosis of OAG
managing VI
VI, visual impairment.have strong feelings about the fact that they are
excluded. 
Further implications to patients and their families
not otherwise included in the analyses relate 
to the costs and worries (both to the individual
and to the people providing informal care) of
visual impairment. Although not measured or
valued, it would be expected that as the number 
of cases of visual impairment falls, the total 
costs and disbenefits associated with visual
impairment would fall. Furthermore, as the
number of years spent with visual impairment
falls, the costs and disbenefits of suffering 
visual impairment to the individual and carer
would also fall.
As indicated in the section ‘Implications for
service provision’ (p. 139), screening may lead to
the identification and treatment of other
significant eye disease. Treatment of such
conditions may improve the health of the
individual (at extra cost to the health service), but
it may also result in similar sorts of intangible
benefits and disbenefits as described above.
Furthermore, it may also reduce the costs and
worries to both the individual and any carers for
those who may otherwise have gone on to develop
some degree of visual impairment caused by other
significant eye disease that affects the activities of
daily living.
Summary
In this chapter an attempt has been made to
highlight the consequences of alternative
screening strategies based on selected groups. An
attempt has also been made to consider the
implications for the health service, other sectors of
the economy and the individuals who may be
considered eligible or ineligible for screening.
Within the evaluation conducted as part of this
study not all of these implications have been
explicitly measured and valued. This does not
necessarily mean that such potential effects should
be ignored. Table 68 summarises the implications
for the NHS, other sectors of the economy and
the potential recipients of screening. This has
been presented as a balance sheet where an
attempt has been made to consider the likely
direction of effect, even if the magnitude of the
effect has not been measured and valued. In this
balance sheet those factors not explicitly measured
or valued are shown in italic. It is a matter for
decision-makers to consider whether any or all of
these issues are pertinent to the decisions they
have to make.
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he UK NSC assesses proposed new screening
programmes against a set of internationally
agreed criteria covering the condition, the test,
the treatment options, and effectiveness and
acceptability of the screening programme.
Assessing programmes in this way is intended to
ensure that they do more good than harm at a
reasonable cost. This chapter assesses whether
screening for OAG in the UK would meet the NSC
criteria based on the evidence presented in the
previous chapters.
The authors’ views on the extent to which each
criterion is satisfied is appended after each
criterion.
The condition
The condition should be an important
health problem
Glaucoma is second to age-related macular
degeneration as the most common cause of
blindness in adults in the UK. Glaucoma blindness
is particularly disabling as navigational vision is
impaired and severely restricts independent
mobility and the ability to self-care.
The major risk factor for developing glaucoma
blindness is late presentation with advanced
disease. Currently, an estimated 67% of cases of
OAG are undetected by the current practice of
opportunistic case finding. Thus, it is likely that
improving detection strategies for population
groups at risk of sight-threatening OAG would
reduce the incidence of visual impairment due to
OAG. This review has addressed whether a
screening programme for OAG is effective and
cost-effective in preventing severe disease and
visual impairment. Severe disease refers to
sufficient visual loss such that one is not able to
drive, and visual impairment means being blind
or partially sighted.
Best estimates suggest that 3108–3138 people
aged over 50 years were newly registered with
visual impairment (blind and partial sight) due to
glaucoma in England and Scotland in 2002/03. Of
these, at least 1192 new registrations were due
to OAG as the main cause, but the true number
may be higher than this, as some OAG cases
would have been registered as glaucoma 
non-specified.
Criterion met? Yes.
The epidemiology and natural history of
the condition, including development
from latent to declared disease, should
be adequately understood and there
should be a detectable risk factor,
disease marker, latent period or early
symptomatic stage
The systematic review of the epidemiology
identified risk factors for developing OAG. These
are: increasing age, higher levels of IOP, African
ethnicity, diabetes, myopia and family history in a
first-degree relative. Insufficient data were available
to estimate the prevalence of OAG in other ethnic
minority groups in the UK. Further research is
required to quantify these risks at different ages.
In early glaucoma, structural changes at the optic
nerve may precede functional visual loss and this
potentially identifies a latent period before
glaucomatous visual field loss. The visual loss in
early glaucoma is in the mid-peripheral field of
vision and individuals may not perceive a visual
difficulty or incorrectly attribute symptoms to a
normal ageing process. In the late stages of
disease the visual field loss impacts on central
vision and reduces HRQoL. Treatment at an early
stage can prevent serious visual impairment, as
presenting late with already advanced disease is a
major risk factor for blindness. 
Criterion met? Yes.
All the cost-effective primary
prevention interventions should have
been implemented as far as practicable
OAG is not amenable to primary prevention. The
only potentially modifiable risk factor is diabetes
mellitus, but this is unlikely to have an impact as
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Chapter 10
Does screening for open angle glaucoma meet 
the National Screening Committee criteria?the proportion of cases in the population that are
attributable to diabetes is low.
Criterion met? Yes.
If the carriers of a mutation are
identified as a result of the screening,
the natural history of people with this
status should be understood, including
the psychological implications
Genetic screening is not indicated, as only a small
number of cases have an identifiable gene
mutation. Research is ongoing looking for
causative gene mutations that may be implicated
in adult-onset OAG, and also for mutations that
are a determinant of raised IOP. If a gene
mutation is identified that is a major determinant
of adult OAG, a case for genetic screening could
be considered.
Criterion met? Not currently relevant.
The test
There should be a simple, safe, precise
and validated screening test
There are numerous potentially suitable screening
tests for OAG. The systematic review of screening
tests found that all tests perform reasonably well
and no single test (or strategy) is clearly better
than the others. Furthermore, within the range
observed, the performance of the screening
programme (as judged by its cost-effectiveness)
was not particularly sensitive to test accuracy.
However, data were of limited quality and it
remains unclear what the optimal testing strategy
should be.
Criterion met? No.
The distribution of test values in the
target population should be known and
a suitable cut-off level defined and
agreed
Appropriate cut-offs are available for standard
optic disc photography and visual field testing.
There are widely used cut-offs for IOP and the
appropriate choice depends on how IOP testing is
combined with other screening tests. More recent
technologies (e.g. HRT, SLP, OCT and FDT) have
the advantage over subjective assessments in that
‘machine classifiers’ have been developed to
define abnormal results, but these cut-offs may not
be appropriate for a screening situation. Further
research is required to determine suitable cut-offs
and test accuracy in a screening setting.
Criterion met? Partially met.
The test should be acceptable to the
population
Overall, the tests are safe. There are potential
minor risks with some of the tests. IOP testing
using applanation may have a potential for cross-
infection, but disposable tips can be used to
eliminate the risk. Rarely, incorrect applanation
tonometry may result in a corneal abrasion. This
would be unacceptable and painful, although it
usually heals in 24 hours. NCT avoids these risks.
Ophthalmoscopy and photography require
dilation of the pupil, which is associated with some
short-term discomfort (1–2 hours) such as light
sensitivity and glare. Rarely, pupil dilation can
precipitate angle closure glaucoma, but if
appropriately warned of the symptoms the
condition is easily treated. Objective tests of
structural damage and functional tests do not
require pupil dilation.
These potential concerns were discussed with
representatives from a patient organisation (the
IGA). In the opinion of all five participants, these
were potential risks and discomfort that if
explained at the time of screening were acceptable.
Criterion met? Yes.
There should be an agreed policy on
the further diagnostic investigation of
individuals with a positive test result
and on the choices available to those
individuals
Diagnostic investigation of the positives on
screening would be best placed in a community
optometric setting. The evaluation has evaluated
the costs and benefits of using a care pathway
whereby optometrists, who have received additional
training in glaucoma assessment, examine screen
positives, with positives from the optometrist
assessment referred to an ophthalmologist. This
pathway fits with current initiatives by the
Department of Health, the Scottish Executive and
the Wales Eye Care Initiative in their reviews of
general ophthalmic services.51–55,296
Criterion met? Partially met.
If the test is for mutations the criteria
used to select the subset of mutations
to be covered by screening, if all
possible mutations are not being
tested, should be clearly set out
Criterion met? Not relevant.
Does screening for open angle glaucoma meet the National Screening Committee criteria?
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There should be an effective treatment
or intervention for patients identified
through early detection, with evidence
of early treatment leading to better
outcomes than late treatment
Evidence from two RCTs of treatment compared
with no treatment suggests that treatment in early
disease slows the rate of progression.
Extrapolating from this, and assuming accelerated
progression with advancing disease severity, it can
be estimated that, without treatment, the mean
time to blindness in at least one eye is 23 years,
and with treatment this is approximately 35 years.
The extrapolation from medium- to long-term
outcome is supported by evidence from
retrospective, observational studies of the risk of
blindness from glaucoma, although results from
these studies should be interpreted with caution,
as selection bias is likely. Data from prospective,
long-term cohort studies are required to confirm
these findings. 
From the limited data available, a patient’s
valuation of their health status (utility value)
decreases, as expected, as glaucoma becomes more
severe. The modelling of a screening strategy and
treatment effectiveness to long-term outcome
suggests that earlier detection and treatment
improves health status compared with no
screening. Further research is required to develop
valid and reliable measures of visual disability and
quality of life in glaucoma, and to determine how
early detection and treatment impact on patient-
reported health outcomes.
Criterion met? Yes.
There should be agreed evidence-based
policies covering which individuals
should be offered treatment and the
appropriate treatment to be offered
Clinical guidelines for the treatment of OAG
exist.3,5,7,304 Evidence-based guidelines for the
management of OAG are in development as part
of the clinical guidelines programme of NICE.305
Criterion met? Yes.
Clinical management of the condition
and patient outcomes should be
optimised in all healthcare providers
prior to participation in a screening
programme
In the UK, various healthcare practitioners are
involved in the detection and management of
glaucoma: optometrists, nurse practitioners and
ophthalmologists. Overall responsibility rests with
the consultant ophthalmologist. There are
concerns that, with an ageing population and
improved detection of OAG, the current hospital
eye service for managing detected cases will
become overloaded. Initiatives to define and
develop a glaucoma clinical care pathway are
underway. These, together with a review of general
ophthalmic services and a connected information
technology system in the NHS, provide the basis
for a standardised diagnostic and treatment
service for glaucoma.
Criterion met? Yes, in principle.
The screening programme
There should be evidence from high-
quality randomised controlled trials
that the screening programme is
effective in reducing mortality or
morbidity
No RCTs of the effectiveness of screening for OAG
were identified.
Criterion met? No.
There should be evidence that the
complete screening programme (test,
diagnostic procedures,
treatment/intervention) is clinically,
socially and ethically acceptable to
health professionals and the public
No studies on the social and ethical acceptability
of screening were identified, but in view of the
safety and non-invasive nature of the tests, major
concerns on acceptability would not be
anticipated. It is likely that if screening were to be
considered it would be targeted at higher risk
groups, such as people with a family history of
glaucoma or of African ethnicity, covering about
6% of the UK population. This might be
considered unacceptable for the majority of the
population not called for screening. 
Currently, the only identifiable risk factor for
identifying people to attend for screening is age.
It is feasible that specific age cohorts could be
identified and invited to complete a questionnaire
of risk factors, and then those at risk could be
invited for screening. However, self-reporting of
risk factors other than ethnicity is likely to be
unreliable. Ethnic minority groups may be less
likely to attend for screening, and campaigns to
improve communication and awareness of
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of attending for testing would be needed.
Discussion with representatives from a patient
group (the IGA) highlighted the fact that a
screening programme would be very welcome, and
no concerns were raised about harms of screening.
However, this was a very small sample and the
views of this select group are likely to be in favour
of screening.
Further research is required on patient preferences
for screening compared with no screening, and a
patient-based valuation on the benefits and harms
of screening.
Criterion met? No.
The benefit from the screening
programme should outweigh the
physical and psychological harm (caused
by the test, diagnostic procedures and
treatment)
Potential harms of screening include concerns
regarding overdetection (i.e. identifying OAG at a
stage that is not likely to cause significant
impairment in a person’s lifetime), anxiety and
inconvenience associated with being falsely
identified as positive, being a missed case, and
adverse effects that may be associated with
treatment of a condition that is asymptomatic at
detection. 
Even in higher risk groups, the prevalence of OAG
is low, and this evaluation suggests that 30% of the
test positives would be falsely identified as OAG
(although 43% of these would be suspect and
require observation), and thus have the consequent
anxiety and inconvenience associated with this.
However, the balance of this is that screening
detects more cases, but this may also be associated
with more anxiety and side-effects of treatment.
No adverse effects of screening tests were reported
in the systematic review. The potential
psychological harms of screening, being a false
positive or a false negative, were not reported.
Medical treatments for OAG can have adverse
effects; these may be local eye discomfort, or
systemic, particularly with topical  -blocker agents.
Alternative medications, for example with
prostaglandin analogues, have better safety and
effectiveness profiles. 
Any harmful effects of screening should be
considered as important outcomes in an RCT of
screening for OAG compared with no screening.
Criterion met? Partially met. 
The opportunity cost of the screening
programme (including testing, diagnosis
and treatment, administration, training
and quality assurance) should
economically balance in relation to
expenditure on medical care as a whole
(i.e. value for money)
The economic evaluation suggests that screening
is cost-effective in a cohort of people aged 40, 
and possibly aged 50, if OAG prevalence is 4%
with a screening interval of 10 years. At 60 years
the prevalence would need to be 6% to be
considered cost-effective. The evaluation has
identified certain target groups (black ethnicity,
family history of OAG in a first-degree relative)
where screening may be cost-effective. Other
groups at risk are people with myopia and
diabetes, but the prevalence is lower and it is
unlikely to be cost-effective to screen these 
groups.
The economic evaluation has identified how a
screening service might be organised in that a
technology-based screening test for OAG is more
cost-effective than a full ophthalmic assessment by
a specialist optometrist. The evidence on cost-
effectiveness should be treated cautiously, as the
estimates used in the model are associated with
considerable uncertainty. 
Criterion met? No.
There should be a plan for managing
and monitoring the screening
programme and an agreed set of
quality assurance standards
This would need to be instituted. 
Criterion met? Not yet. 
Adequate staffing and facilities for
testing, diagnosis, treatment and
programme management should be
available prior to the commencement
of the screening programme
This is potentially feasible, but additional
technical staff would need to be trained, and
testing sites in primary care equipped and
established. It is possible that a screening
programme for OAG could use the same
infrastructure as the National Screening
Programme for sight-threatening diabetic
retinopathy.
Criterion met? Not yet.
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condition should have been considered
(e.g. improving treatment, providing
other services), to ensure that no more
cost-effective intervention could be
introduced or current interventions
increased within the resources available
In the absence of screening, an improved
attendance rate for a sight test and an improved
performance of the community optometrist at
detecting glaucoma would improve the
effectiveness of current case detection. However, if
this improved performance of the community
optometrist involved an increased cost of
providing this eye examination, at levels
approaching the cost of an assessment by a
specialised optometrist, then improving the
performance of current practice might not be a
cost-effective approach to improved case
detection. The economic modelling suggests that,
although screening by a glaucoma optometrist is
more effective, it is more costly than a technician
strategy. 
Awareness campaigns, aimed at improving the
uptake of sight testing and earlier detection,
might be effective at preventing late presentation
with severe disease and improve health outcome.
Further research is required on the effectiveness
and cost-effectiveness of such an approach. 
Criterion met? No.
Evidence-based information, explaining
the consequences of testing,
investigation and treatment, should be
made available to potential participants
to assist them in making an informed
choice
This evaluation provides evidence-based
information on the consequences of testing,
investigation and treatment such that guidelines
could be produced, although more robust
evidence is required on the long-term health
outcomes and any potential harmful effects of
screening to inform patients fully of the
consequences of screening. 
Criterion met? Partially met. 
Public pressure for widening the
eligibility criteria for reducing the
screening interval, and for increasing
the sensitivity of the testing process,
should be anticipated. Decisions about
these parameters should be
scientifically justifiable to the public
The economic model provides scientifically
justifiable evidence for the optimal screening
interval and the performance of the screening
programme. However, there are uncertainties in
the parameter estimates in the model, in
particular regarding the uptake of screening,
disease progression, utility and costs associated
with screening particular patient groups where
screening may be most relevant. Further research
to improve these parameter estimates is required.
Criterion met? Yes.
If screening is for a mutation the
programme should be acceptable to
people identified as carriers and to
other family members
Criterion met? Not relevant.
Summary
Screening for OAG meets the UK NSC criteria
regarding the condition and treatment, but does
not meet most of the criteria for the test or a
screening programme. Population screening
appears not to be cost-effective, but targeted
screening of high-risk groups may be. However, if
a societal perspective on the costs of visual
impairment is taken screening is more likely to be
considered cost-effective. Measures to identify
systematically those at risk and quality assure the
programme would be required. Adequate service
provision for the screen positives would need to be
established. 
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The purpose of this evaluation was to assess
whether screening for OAG met the UK NSC
criteria for a screening programme. In the absence
of any evidence from RCTs of screening, a Markov
modelling approach was used, informed by a
series of systematic reviews, which compared the
clinical and cost-effectiveness of screening for
OAG with the current practice of case finding.
Given the perspective of the analysis, the data on
the effectiveness and more especially the cost-
effectiveness may be of limited transferability to
other countries.
An evaluation against the NSC criteria was a
valuable tool to identify areas where the evidence
was inadequate to make a judgement on whether a
screening programme should be initiated.
Screening for OAG met the criteria regarding the
condition and the treatment, but did not meet
most of the criteria for the test or a screening
programme. 
Screening using a strategy of inviting the at-risk
cohort to a primary care setting for a measure of
IOP, and a second test for people with IOP below
26 mmHg (the technician strategy), was more
effective but more costly than a no-screening
strategy. Screening by invitation to attend a highly
trained optometrist for an ophthalmic assessment
was more effective but more costly than the
technician screening strategy. The main
determinant of cost-effectiveness was the
prevalence of disease: the higher the prevalence
the more likely screening would be cost-effective.
With screening, fewer people become visually
impaired (defined as partial sight and blind) and
spend less time with visual impairment. Likewise,
fewer people lose vision to below driving standard,
although with screening, time spent in this severe
state is longer, as progression to the state of visual
impairment is less likely to occur.
Taken at face value, the economic evaluation
suggests that general population screening for
OAG is not cost-effective at any age. The
prevalence level would have to be in the region of
3–4% in 40 year olds with a screening interval of
10 years to approach what might be considered
cost-effective. The prevalence of OAG in a 
40-year-old cohort is around 0.3%; at this
prevalence level there is very little likelihood that
any screening strategy would be considered cost-
effective compared with current practice. 
Similarly, in a 60-year-old cohort the prevalence of
OAG would have to be about 6% to be considered
cost-effective at screening intervals of 5 or 10
years: the prevalence of OAG in this age group is
about 1.4%. 
An important factor in assessing cost-effectiveness
was the cost of visual impairment. The costs of
visual impairment in the model were based on
treatment costs, from an NHS perspective. If a
wider societal perspective of costs is taken, then it
is likely that the NHS cost of visual impairment
used within the model is an underestimate. This is
because it does not include the costs falling on
individuals, carers and society in terms of loss of
independence, and the need for social support.
The threshold analysis conducted as part of the
economic model suggests that, for a 40-year-old
cohort with a 1% prevalence of OAG, the
technician strategy would be associated with an
incremental cost per QALY of £30,000 compared
with current practice should the annual costs of
visual impairment be £8800. This is
approximately £1000 per year higher than the
annual cost estimated by Meads and Hyde.299
Should the prevalence of OAG be 5%, then the
technician strategy would be more effective and
less costly than current practice if the annual cost
of visual impairment was £5700 per year.
Recognising higher personal and societal costs of
visual impairment makes screening considerably
more likely to be cost-effective even at lower
prevalence levels.
The results of the model indicate that even though
the prevalence is lower, screening younger people
appears to be the more cost-effective option. This
is because the risk of developing visual disability
and reduced quality of life is more likely over a
longer lifetime. Screening high-risk groups (black
ethnicity and family history) might be worthwhile,
but for these groups at 40 years the prevalence of
OAG is in the region of 1–2% and therefore not
high enough to consider screening. At 50 years,
the prevalence is higher, estimated as between
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Discussion2 and 5%, and approaches levels where screening
might be considered. The model has not explicitly
considered screening a 50-year-old cohort.
Interpolating from the results of the model on 
40-year-old and 60-year-old cohorts, one would
predict that screening every 10 years might be cost-
effective in a 50-year-old cohort at a prevalence of
4%. Targeted screening of those groups with the
highest risk of having OAG would, however, only
cover a small proportion (6%) of the population
and this might be considered unacceptable.
Extending the target population to include other
higher risk groups (myopia and diabetes) would
give greater population coverage (37%), but the
prevalence estimates in 40–60 year olds are most
likely to be 0.6–3.6% and, as such, not sufficiently
high to be considered cost-effective.
At the first screen for a cohort with a 5%
prevalence of OAG, using a technician strategy
gave a positive predictive value of screening of
52% compared with 62% for case finding. The
negative predictive value was 98% and 96%,
respectively. Screening detects more cases, but with
a consequent increase in false-positive referrals,
which has considerable implications for service
provision. Initiatives to develop glaucoma care
pathways are underway in the UK,51–55,296 and the
implications of screening, if it is to be considered,
would need to be incorporated into any future
reconfiguration of eye care services. 
The only readily identifiable risk factor currently
available for inviting people to screening is age. It
is feasible that specific age cohorts could be
identified and invited to complete a questionnaire
of risk factors, and then at-risk people invited for
screening tests. However, self-reporting of risk
factors other than ethnicity is likely to be unreliable.
Inviting people with a family history of OAG for
screening also poses considerable problems. A
national register of all newly diagnosed cases of
OAG would be required. This should be possible,
but the initial costs of setting up this surveillance
have not been incorporated into the economic
model. The review has identified that people of
black ethnicity have a higher risk of OAG. There
were insufficient data to estimate the risk of OAG
in other ethnic minority groups in the UK.
Restricting screening to select minority groups is
likely to be socially unacceptable. Future research
should examine prevalence according to ethnicity
and the acceptability of offering glaucoma testing
to only selected at-risk groups. 
In the absence of screening, an improved
attendance rate for an eye test among at-risk
groups and an improved performance of the
community optometrist at detecting OAG would
improve the effectiveness of current case
detection. However, if the improved performance
of the community optometrist involved an
increased cost of providing the eye examination, at
levels approaching the cost of a glaucoma
optometrist test, then improving the performance
of current practice might not be a cost-effective
approach to improve case detection. The results of
the economic modelling indicate that a
technology-based screening test, rather than
screening by a full optometric examination, is
more likely to be cost-effective; as only those with
suspect pathology go on to a more costly but
effective full assessment, the feasibility of
introducing automated testing into a primary care
setting merits consideration. One high-risk group,
namely people with diabetes, is already included
in a screening programme for diabetic
retinopathy, and this programme could be
modified to include testing for glaucoma.
Similarly, myopes, another higher risk group, are
likely to be attending for eye tests and
consideration should be given to improved
awareness and case detection in these individuals.
When considering interventions to improve uptake
current eye care services an understanding of the
barriers to attendance for eye testing is required.
Improved communication and awareness
campaigns on the importance of attending for
regular eye examinations would be required to
improve uptake. An ongoing study in
Birmingham, UK,306 is assessing attitudes and
beliefs related to eye disease and factors associated
with presenting late to the eye-care services. This
study will provide insight and estimates of how
likely it is that high-risk groups would attend for
screening. 
Assumptions, limitations and
uncertainties
A series of systematic reviews was undertaken and
a language restriction was applied (except for the
reports on effectiveness of screening). This
restriction is a potential source of bias; however it
was felt that studies reported in English were most
likely to be relevant to the UK context. Despite a
systematic search of the literature, data on the
sensitivity and specificity of current optometric
practice were not identified and assumptions had
to be made. Data were available on the positive
predictive value of testing, but details on the
number of false negatives were not reported or,
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examination were not assessed by a reference
standard to ascertain whether they were true or
false negatives. 
The decision to use a cut-off of IOP of 26 mmHg
was based on expert opinion. Although the IOP
distribution in the population is known, the
systematic review found only two studies that
reported the risk of OAG according to IOP in
newly detected cases. Although IOP does not
define OAG, a higher risk of progressive disease at
higher levels of IOP is reported,25,27 and more
severe disease at presentation is associated with
higher levels of IOP.28 In the systematic review of
screening tests (Chapter 6), there were insufficient
data to determine what IOP cut-off would give the
best balance between sensitivity and specificity.
Most studies reported a cut-off of above
21 mmHg. In the economic model, results from
one population-based study in the USA were used
to estimate the proportion of people with an IOP
of 26 mmHg or above who did or did not have
glaucoma, and similarly for people with an IOP
below 26 mmHg. Data from this study were used
to create a beta distribution around this estimate
to reflect its considerable imprecision, but there
are concerns that these data may not be applicable
to the UK. The model only looked at two out of
many possible screening strategies; in particular
IOP measurement was used and GAT specified as
part of the technician-based screening pathway.
The model structure is such that other tests of
IOP, such as NCT, could be considered, and based
on the results of the sensitivity analyses on costs
and test performance the decision regarding cost-
effectiveness would not be expected to change.
Within the whole economic model-based analyses
it was assumed that the ophthalmologist
assessment was the gold standard. In terms of the
model this means that ophthalmologist assessment
sensitivity and specificity are equal to 1. In other
words, these professionals have perfect
information and do not make mistakes in their
patient management decisions. While this might
not be the case, all test characteristics were
calculated against ophthalmologist assessment.
Should this perfect information assumption be
relaxed, another reference standard should be
chosen against which every test sensitivity and
specificity within the model, as well as
ophthalmologist assessment, should be tested. 
The results of the deterministic economic analysis
presented do not take into account the
imprecision around the data used to derive
estimates of cost-effectiveness. This imprecision
was reflected in the probabilistic sensitivity analysis
in the model; it was shown that the prevalence of
OAG would have to be 5% in a 40-year-old cohort
for technician-based screening to have a 55%
chance of being considered cost-effective. For a
60-year-old cohort and at this prevalence level the
model suggests that screening is unlikely to be
cost-effective. 
Extensive sensitivity analyses explored the effects
of changing the parameter estimates used in the
model. The important drivers of estimates of cost-
effectiveness were considered to be the attendance
for sight tests in current case finding, the rate of
glaucoma progression, the utility estimates
associated with each stage of glaucoma and the
costs of visual impairment.
One of the findings of the economic model was
that more frequent attendance for eye testing in a
no-screening strategy may affect the cost-
effectiveness results; this higher rate of attendance
for sight testing is likely to apply to people with
myopia or diabetes and those aged 50–60 years,
prompted by the need for reading glasses. This
may also apply to family members of known cases
of OAG, as they are more likely to be aware of the
significance of OAG and the risk to vision. Other
high-risk groups may attend less frequently for
sight testing, making screening more cost-effective,
although it might be expected that such groups
would also have a lower uptake of screening. In the
UK, if an African-derived population were to be
invited for screening the attendance could be
expected to be as low as 40%.120 In the economic
model an uptake of screening of 78% has been
assumed, with a minimum of 66% and a maximum
of 92%. The net effect of lower uptake rates in
ethnic minority groups on the cost-effectiveness of
screening is uncertain. 
A sensitivity analysis around screening a 
40-year-old cohort, using a technician-based
strategy, at an OAG prevalence of 5% with a
rescreen every 10 years, found that, as expected,
cost-effectiveness increased as the sensitivity and
specificity of the screening test used in the
technician-based strategy increased. However, the
sensitivity analysis found that the sensitivity and
specificity of the screening test over the ranges
considered did not greatly alter the estimates of
cost-effectiveness. The specificity of the test does
affect the impact that screening would have on
diagnostic services; a highly specific test is
required to reduce the large numbers of false-
positive referrals from any of the screening
strategies.
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screening tests found that no test, or combination
of tests, was clearly superior as a screening test.
For the potential tests on which data were
available, the sensitivity was at least 50%, apart
from IOP measurement, and all tests had
specificity above 80%, apart from one test, FDT 
C-20-5, which had a specificity of 75%. There is
uncertainty around all the estimates as the results
are based on indirect comparisons and, as such,
are prone to bias due to differences in the
populations studied. In a screening situation it is
important that the majority of people to be
screened are able to perform the test and have
results that can be read. In general, across all the
tests 80–99% of the people tested were able to
perform the test adequately. For some tests that
were considered as potential candidate tests for
OAG screening, no studies met the inclusion
criteria for the accuracy review. As a result, this
research has not been able to provide estimates for
the test accuracy of SLP (the GDx VCC), OCT or
the RTA.
The review of treatment effectiveness suggests that
with treatment at an early stage of disease, the risk
of progressive visual loss is reduced by
approximately 35%, delaying time to blindness on
average by 12 years. The treatment effect on long-
term outcomes may be better or worse than this
average effect. There was insufficient evidence to
determine the rate of progression for different
stages of OAG severity or different at-risk groups,
and thus the rate of progression in higher risk
disease is uncertain. A higher rate of progression
would make screening more likely to be
considered cost-effective. 
There were limited published data for estimating
the utility loss associated with different severities of
OAG.298,307 The populations used in these studies
were not necessarily representative of a UK
population, and as a result this evaluation used
utility estimates as measured by the EQ-5D, in 264
people with glaucoma in whom severity was self-
reported, apart from a subset (63 people) in whom
disease severity was validated based on binocular
visual field loss. This generic measure of health
status may not adequately capture the utility loss
due to glaucoma. However, the generic health state
utilities were estimated using the EQ-5D based on
UK population tariffs and such an approach has
recently been advocated as being a necessary part
of the reference case for health technology
assessments conducted on behalf of NICE.297
The utility estimates used in the base case may
also be imprecise as they were based on a small
sample of glaucoma patients with validated disease
severity. Using estimates based on the subjective
assessment of disease severity led to both the
technician and the glaucoma optometrist
strategies being more likely to be considered cost-
effective. For example, the likelihood for the
technician strategy being considered optimal rose
from less than 50% to about 61% and over 70%
when society’s willingness to pay for a QALY was
£20,000 and £30,000, respectively. 
The costs of visual impairment in the model were
based on treatment costs, from an NHS
perspective. If a wider perspective of costs is
taken, then it is likely that the cost of visual
impairment is an underestimate, and does not
recognise the cost on individuals, carers and
society in terms of loss of independence, and the
need for social support. Recognising higher
personal and societal costs of visual impairment
makes screening considerably more likely to be
cost-effective.
The model has not taken into account other
potential benefits of screening for OAG, mainly
the possibility of detecting other treatable eye
disease. Both screening strategies are likely to
detect other eye pathology. This is an additional
benefit, but may be a negative consequence of
screening in that referrals to ophthalmology
services will be increased, and some of these will
be false-positive referrals. It is unclear what effect
the inclusion of costs and other effects of detecting
other eye disease would have on the relative cost-
effectiveness of screening. It might be expected
that a glaucoma optometrist strategy would detect
more cases of other significant eye disease, but
would result in increased costs of diagnosis and
treatment. How this might affect the relative cost-
effectiveness of the ‘glaucoma optometrist’
strategy compared with the ‘technician’ strategy is
also uncertain.
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Based on the available evidence derived from 
the economic model, population screening of 
age cohorts between 40 and 75 years is not
considered to be cost-effective. The model was
particularly sensitive to estimates of prevalence
and costs of visual impairment. Selective screening
of groups with higher prevalence, such as those
aged between 50 and 60 years with a family
history of OAG, or of people of black ethnic origin
may be worthwhile. Selective screening of these
groups covers 6% of the population cohort and
therefore would only have the chance to detect
20–30% of all the expected cases in the 50- or 
60-year-old cohorts. Moreover, systematically
identifying those at risk is not currently feasible in
the UK. 
The positive predictive value of the more cost-
effective screening strategy, based on a screening
test that does not require skilled interpretation, is
about 52%, with a negative predictive value of
98%, and as such detects more cases but also
results in a large number of false-positive referrals.
This has implications for the ophthalmology
services.
Based on the results of the model there are two
strategies that will improve current case detection,
namely improving the attendance rate for eye
examination generally, particularly in high-risk
groups, and improving the performance of current
optometric assessment, either by refining
optometric practice or by adding in a technology-
based first assessment, the latter being the more
cost-effective option. This has implications for any
future organisational changes in community eye-
care services in that if, in the absence of screening,
recommendations are made to improve case
finding, then recommendations that at-risk people
require a full assessment by a specialised
optometrist may not be the best use of healthcare
resources, and the feasibility of improving case
detection by an initial automated test strategy in a
community setting should be explored. The
economic evaluation suggests that the diagnostic
skills of the optometrist are best utilised for
people testing positive on an initial technology-
based examination for OAG. 
These recommendations that population screening
is unlikely to be cost-effective are based on the
results of an economic model; the parameter
estimates are associated with considerable
uncertainty and should be interpreted with
caution. In particular, if the rate of progression
and the costs of visual impairment are higher than
estimated then screening is more likely to be cost-
effective. For example, the annual cost of visual
impairment would need to be £8800 for the
technician strategy to have an incremental cost per
QALY of £30,000 for a 40-year-old cohort with a
1% prevalence of OAG. At a 5% prevalence level
of OAG, technician screening would be dominant
(more effective and less costly) when the annual
cost of visual impairment is £5700 or greater. 
Priorities for further research
An RCT of screening is considered to be the
optimal design to determine the benefits of
screening. However, before initiating a trial,
further research should aim to develop and
provide quality data to populate the economic
model. The model only considered a limited set of
screening and case-finding strategies, and further
research is required to determine what an optimal
screening or case-finding strategy could be. 
Priority 1: feasibility of screening strategies
This research has several components and would
involve input from qualitative researchers, health
psychologists, health economists and trialists. The
main requirements are:
● to establish how the risk groups could be
identified; multiple identification strategies
would be required according to risk factor
● to determine the optimal test strategy in a
community setting; this study should explore
how a technician strategy might be
incorporated into existing visual assessments,
for example, as part of the diabetic retinopathy
screening programmes
● to explore the acceptability of interventions to
improve attendance for glaucoma testing and
the acceptability of subsequent testing using
established models of behaviour change from
health psychology
● to value any potential harms and benefits
associated with screening (or targeted case
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Conclusionsdetection) by exploring the strength of
preferences of potential users of the service
using established health economics
methodology.
Priority 2: identifying weaknesses in the model,
and improving parameter estimates
There is considerable uncertainty regarding
parameter estimates used in the model as the
available data were considered to be too limited
and of too poor quality to provide reliable
estimates. Prospective data collection on the costs
of detection, management and costs of visual
impairment could be collected in the context of
current service provision. Improved monitoring of
health outcomes in large populations using
registers of blindness by cause would provide
surveillance for the estimation of the impact of
prevention strategies over time. Surveillance
systems should explicitly consider how to ensure
completeness of ascertainment. Improved
estimates of health status, both patient reported
and estimates of the risk of progressive loss of
visual function, are required. As further data,
including new information as to how a screening
strategy might be organised, become available
these should be used to refine the model. 
A value for information analysis is indicated to
determine which data have most impact on the
model results and hence where future primary
research should be directed to inform decision-
making. 
Priority 3: improving uptake of glaucoma testing
An RCT of interventions to improve the uptake of
screening, or enhanced case detection, informed
by the results of the prior feasibility studies is
indicated. 
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